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Abstract 
Photodynamic therapy (PDT) is an approved but under-development modality for cancer 
therapy. Conventional, non-targeted PDT consists of administration of a photosensitiser to the 
patient, passive accumulation in the tumour, localised photosensitiser activation using visible 
light and subsequent cellular destruction via reactive oxygen species (ROS) and/or free radicals. 
A major limitation of PDT is its poor selectivity for tumours and a suboptimal pharmacokinetic / 
biodistribution profile. This leads to low potency and patient photosensitivity. This is being 
addressed with the development of antibody targeted PDT; the conjugation of multiple 
photosensitisers to a tumour-specific antibody. For effective antibody conjugation 
photosensitisers are preferable if highly water soluble. PPa (Pyropheophorbide-a) is an effective 
photosensitiser and more soluble versions have been prepared to aid in its conjugation.  The 
work presented in this thesis explores the differences these novel, soluble photosensitisers 
exhibit in terms of toxicity, cell death mechanisms and uptake in an in vitro model of traditional 
PDT and also in terms of improvements in their bio-conjugation. Data presented shows chemical 
manipulation of PPa significantly affects the biochemical properties important for effective PDT. 
PEG-modified PPa (PS-1, with enhanced solubility over PPa) as an un-conjugated drug exhibits 
similar overall toxicity to PPa, along with similar hallmarks for caspase-independent apoptosis, 
however this equivalent toxicity is achieved despite a significantly reduced cellular uptake. Its 
toxicity therefore is higher per internalised molecule than its parent compound. This is 
hypothesised to be due to enhanced retention of photo-physical properties in a cellular 
environment. Cationic PPa (PS4, with even greater enhanced solubility over PPa) exhibits a loss 
in cytotoxicity in comparable levels of free 
photosensitiser studied; this is hypothesised to be due to 
decreased uptake in addition to an altered cellular 
localisation. Derivatives of PS1 activated for conjugation 
showed greatly enhanced reaction with antibody 
compared to PPa showing its promise for improved 
targeted PDT, PS4 proved too difficult to chemically 
activate in the time frame of this project. 
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In the Microscope 
Here too are dreaming landscapes, 
lunar, derelict. 
Here too are the masses, 
tillers of the soil. 
And cells, fighters 
who lay down their lives 
for a song. 
 
Here too are cemeteries, 
fame and snow. 
And I hear murmuring, 
the revolt of immense estates. 
 
Miroslav Holub (1923 – 1998) Czech poet and Immunologist. 
Translation by Ian Milner 
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Abbreviations 
1
O2   Singlet Oxygen 
3
O2   Molecular Oxygen 
A490  absorbance at 490nm  
Ab  Antibody 
Abs  Absorbance 
ADC  Antibody Drug Conjugate 
ADCC  Antibody-dependent cell-mediated cytotoxicity  
ADP   Antibody directed phototherapy 
AE  Active ester 
AIPcS4  Aluminum phthalocyanine tetrasulfonate. 
ALA   5-aminolevulinic acid 
AMD   Age-related macular degeneration 
ATP   Adenosine triphosphate 
BCA   Bicinchoninic acid  
bp   Base pairs (measure of DNA size) 
BPD-MA Benzoporphyrin derivative monoacid 
BSA  Bovine serum albumin 
CD20  B-lymphocyte antigen CD20 
CDK   Cyclin-dependent kinases 
CDR   Complementarity-determining region 
CDC  Complement-dependent cytotoxicity 
Ce6-PVP  Chlorin e6-polyvinylpyrrolidone 
CEA  Carcinoembryonic antigen 
CMC  Critical micelle concentration 
DAMP  Damage-Associated Molecular Pattern 
DCM  Dichloromethane] 
DFF   DNA fragmentation factor  
DMEM  Dulbecco's modiﬁed Eagle's medium 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DT  DMSO/ Triton-X114 lysis solution 
EGFR  Epidermal growth factor receptor 
EndoG   Endonuclease G  
ER   Endoplasmic reticulum 
EtBr  Ethidium Bromide 
EtOH  Ethanol 
FC  Flow Cytometry 
FcRn   Neonatal Fc receptor 
FCS  Foetal Calf Serum 
FcγR   Fc-gamma receptors 
FITC  Fluorescein isothiocyanate 
FL1/FL2/FL3/FL4 Fluorescent Filter/Detection channel for the FACSCalibur flow cytometer. 
g/L  Grams per Litre 
G0   Quiescent state (Cell cycle phase) 
G1   Gap1 Phase (Cell cycle phase) 
G2   Gap2 Phase (Cell cycle phase) 
GFP  Green fluorescent protein 
H2O   Water 
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H2O2   Hydrogen peroxide 
Hb(H2O) Deooxyhemoglobin 
Hb(O2)  Oxyhemoglobin 
HCl  Hydrochloric acid 
HeNe  helium–neon  
HER2  Human Epidermal Growth Factor Receptor 2 
HPD   Hematoporphyrin derivative 
HPLC   High-performance liquid chromatography 
HPMA  N-(2-Hydroxypropyl)methacrylamide 
HPPH   2-(1-hexyloxyethyl)-20devinyl pyropheophorbide-a 
Hrs   Hours (unit of time) 
HSA   Human serum albumin 
IC10   Concentration required for 10% inhibition (10% cell kill) 
IC50   Concentration required for 50% inhibition (50% cell kill) 
IC90   Concentration required for 90% inhibition (90% cell kill) 
IgG  Immunoglobulin G 
ITC   Isothermal titration calorimetry 
IUPAC International Union of Pure and Applied Chemistry/ 
J  Joules (unit of energy) 
JNK   c-Jun N-terminal kinase 
kb   Kilobase (measure of DNA size) 
kDa / Da  Kilodalton / Dalton (Dalton = atomic mass unit) 
L (µl / ml / L) microliters / millilitres / litres (a unit of volume) 
Laser  Light amplification by stimulated emission of radiation 
LD50   Lethal dose required for 50% cell kill 
LDL   Low density lipoprotein 
Log D  Log of the distribution (D) coefficient. 
Log P  Log of the partition (P) coefficient. 
LUMO  lowest unoccupied molecular orbital  
M (pM / nM / µM / mM / M) picomolar / nanomolar / micromolar / millimolar / molar (a unit of concentration) 
M phase  Mitosis (Cell cycle phase) 
M0   Stress-induced senescence (Mortality phase)  
M1   Cellular aging or telomere-initiated senescence (Mortality phase) 
M2   Mitotic catastrophe (Mortality phase) 
MACE   Mono-(L)-aspartylchlorin-e6 
MAPK  Mitogen-activated protein kinases  
MeCN  Acetonitrile 
MOMP  Mitochondrial outer membrane permeablisation 
mTHPC  M-tetrahydroxyphenylchlorin 
MTS   3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. 
Mv  Millivolts 
Mw  Molecular weight 
MWCO Molecular weight cut-off 
NaCl  Sodium Chloride 
NADH  Reduced nicotinamide adenine dinucleotide 
NaOH  Sodium Chloride 
NF-κB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NHS   N-hydroxysuccinimide 
NIR   Near infrared (certain wavelengths of light) 
nm  nanometers (unit of length) also used for wavelength of electromagnetic radiation. 
Page | 16  (Hayley Pye 2012) 
 
 
o
C  Degree celsius (unit of temperature) 
OG  n-Octyl-β-D-Glucopyranoside 
OH  Hydroxyl  
PAGE  Polyacrylamide gel electrophoresis 
PBS   Phosphate buffered saline 
PCI   Photochemical internalization 
PDT   Photodynamic therapy  
PEG   Polyethylene glycol 
PES  Polyethersulfone 
PGA   Polyglutamic acid  
pH   −log10  a(H
+
) (the negative logarithm of the activity of hydrogen ions in solution) 
pI  Isoelectric point 
PI  propridium iodide 
PICs  Photoimmunoconjugates 
pKa.   −log10 Ka (the negative logarithm of the equilibrium constant for acid dissociation) 
PPa   Pyropheophorbide-a 
PPa-ether Pyropheophorbide a-ether 
PPME  Pyropheophorbide a methyl ester 
PS   Photosensitiser  
PTFE   Polytetrafluoroethylene 
PVA  Polyvinyl acetate 
PVDF  Polyvinylidene fluoride, 
QSAR   Quantitative structure-activity relationship  
R2NH  Secondary amine 
RFU  relative fluorescence values  
RNH2  Primary amine 
ROS   Reactive oxygen species 
S phase  DNA Synthesis (Cell cycle phase) 
S0   Ground singlet state, (atomic/electronic energy level) 
S1   Excited singlet state, (atomic/electronic energy level) 
scFv   Single-chain variable fragment (antibody fragment) 
SDS   Sodium dodecyl sulfate 
SDT   Sonodynamic therapy 
SH   Sulfhydryl 
SIP   Small Immunoprotein (antibody fragment) 
SnEt2   Tin ethyl etiopurpurin 
Stauro  Staurosporine 
T1   Excited triplet state. (atomic/electronic energy level) 
TLC   Thin layer chromatography 
TNF-α  Tumour necrosis factor alpha 
UV  Ultraviolet (certain wavelengths of light) 
UV-VIS Ultraviolet-Visible (certain wavelengths of light) 
VDss   Steady state volume of distribution  
VEGF  Vascular endothelial growth factor 
υ/J   Vibrational/rotational levels (atomic/electronic energy levels) 
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Chapter One 
1.1 Introduction 
1.2 Photodynamic therapy for cancer 
1.2.1 Cancer and its clinical treatment. 
 
The standard clinical treatment of cancer involves a combination of both cancer specific and 
non specific treatments. These include chemotherapy, radiotherapy, hormone therapy and 
immunotherapy (King and Robins, 2006) Not all cancer patients respond well to treatment and 
even those with non-metastatic cancers will show signs of relapse; during a study of over 2000 
females being treated for various stages of non-metastatic, invasive breast cancer, 18% of these 
patients had local, regional or distant relapse, 79% of these occurring within the first 5 years after 
primary treatment (Elder et al., 2006). 
 
The resistance of cancer cells to current treatment is thought to be both an endogenous and 
acquired characteristic and in some cases treatment induced. There is an inherent genetic and 
morphological instability of cancer cells, allowing adaptation and survival at a rate beyond that 
of a normal cell. Research has discovered multiple elements with the potential to contribute to 
this resistance of cancer, including defects in apoptosis pathways, superior detoxification 
mechanisms, acquired desensitisation, cell cycle status, hypoxia and poor vascularisation of the 
tissue mass (Agarwal and Kaye, 2003; Gottesman et al., 2002; Igney and Krammer, 2002; King 
and Robins, 2006; Trédan et al., 2007). In addition by the time of treatment variable progression 
of the tumour has led to a heterogeneous cell mass, this is reflected in a heterogeneous response 
of the cancer mass to treatment. The discovery of specific cells in solid tumours that exhibit self-
renewal capacity has created the ‘cancer stem cell hypothesis’, this discovery has implications 
for both the origin or cancer and its resistance to therapy (Dean et al., 2005; Zhou and Zhang, 
2008). All the above elements confer differing resistances to the various therapies and this has 
caused an increased interest in new and/or combinational approaches to treating cancer. This 
project will be exploring a promising new treatment for cancer; targeted photodynamic therapy.  
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1.2.2 Clinical photodynamic therapy. 
 
Conventional, non-targeted photodynamic therapy (PDT) involves intravenous or topical 
administration of a photosensitiser (PS) to the patient, followed by its activation using visible 
light. The photosensitiser is transformed from its singlet state into its triplet state which can react 
both with cellular components directly, or with molecular oxygen to produce various radicals and 
reactive oxygen species which mediate cellular destruction (Palumbo, 2007; Robertson et al., 
2009; Wilson and Patterson, 2008). 
 
The first photodynamic therapy of cancer was carried out with a standard white light lamp  
around 100 years ago, since then, great advances have occurred and PDT is now an approved 
clinical modality for various types of cancer, (Agostinis et al., 2011; O’Connor et al., 2009; 
Triesscheijn et al., 2006). Table 1 lists selected approved photosensitisers for oncology and their 
indications. Now championed by some to be preferable to classical treatments options, it has 
been shown to be cost-effective, have superior cosmetic outcome along with equivalent or 
improved results, and provides the chance of a cure for some patients who would have limited 
treatment options, for those unsuitable for the classical treatments options or those who have 
previously failed with radiotherapy, surgery or systemic chemotherapy. (Hopper et al., 2004; 
Nyst et al., 2009). 
 
In addition to anti-cancer applications PDT has the potential to be a platform technology over 
a wide spectrum of applications (Celli et al., 2010; Choudhary et al., 2009; Dai et al., 2009; 
Maisch, 2007; Tandon et al., 2008; van der Snoek et al., 2008; Wilson and Patterson, 2008; 
Wormald et al., 2007): 
 Current clinical indications for PDT that have been approved or are in active clinical trials 
include; solid tumours, dysplasias, warts, rheumatoid arthritis, age-related macular 
degeneration, actinic keratosis, cosmetic application, psoriasis, endometrial ablation, 
localised infection, coronary atherosclerosis and prophylaxis of arterial restenosis.  
 Current non-clinical indications include; diagnostic and prognostic imaging or as a 
sterilisation / antimicrobial agent for synthetic materials or donated human samples. 
  
Page | 19  (Hayley Pye 2012) 
 
 
Clinical progression of PDT has in part been driven by the development of multiple branches 
of so-called ‘second generation’ photosensitisers; researchers have produced a vast toolbox of 
new synthetic and/or chemically modified photosensitisers with a range of specified 
photophysical and pharmacokinetic properties. This extension in photosensitiser repertoire 
expanded alongside a growth in the understanding of the mechanisms behind the structure-
activity relationship of photosensitisers in all areas from photophysics to clinical application.  
Clinical progression is reviewed in (Agostinis et al., 2011; Huang, 2005; Mang, 2004; Mitton 
and Ackroyd, 2008). 
 
1.2.3 Benefits and limitations of traditional PDT. 
 
PDT lacks a specific cellular target and has multiple mechanisms of biological effect, this 
helps against the inherent variability of tumours and means treatments can be repeated without 
inducing significant resistance in the tumour, although a range of cell sensitivities to PDT has 
been shown (Casas et al., 2011). Additionally, it has the dual specify of preferential tumour 
localisation and laser directionality, and it has influence on the immune system that could be 
very important as discussed below in 1.2.4. Other advantages of PDT include: It can be 
minimally invasive as the drug is given intravenously or topically and illumination is carried out 
at the surface or via endoscope or hollow needle. PS have low systemic toxicity when inactive, 
and treatment is low scarring as damage only occurs in target tissue- sparing tissue structures like 
collagen. Treatment time is low and has a rapid effect with the potential in some cases to be 
limited to a single treatment. The mechanism of action also means it is compatible with many 
other cancer treatments such as chemotherapy or immunotherapy allowing concurrent use.  
 
PDT also has some limitations, some fundamental but others only limited by current 
technology and knowledge; they are outlined in Table 2. (Allison et al., 2008; Z. Huang et al., 
2008; Walker and Andrew Maiden, 2009; Whitehouse and Rapley, 2012; Wilson and Patterson, 
2008)  
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Table 1 : Selected approved PDT photosensitisers in oncology  
Re-produced from  (Agostinis et al., 2011). 
 
Photosensitiser Structure Wavelength Approved Trials Cancer Type 
Porfimer sodium 
(Photofrin) (HPD) 
Porphyrin 630 Worldwide   
Lung, Esophagus, Bile duct, 
Bladder, Brain, Ovarian 
ALA 
Porphyrin 
precursor 
635 Worldwide   
Skin, Bladder, Brain, 
Esophagus 
ALA esters 
Porphyrin 
precursor 
635 Europe   Skin, Bladder 
Temoporfin (Foscan) 
(mTHPC) 
Chlorin 652 Europe 
United 
States 
Head and Neck, Lung, 
Brain, Skin, Bile Duct 
Verteporfin Chlorin 690 
Worldwide 
(AMD) 
United 
Kingdom 
Ophthalmic, Pancreatic, Skin 
HPPH Chlorin 665   
United 
States 
Head and Neck, Esophagus, 
Lung 
SnEt2 (Purlytin) Chlorin 660 
  
United 
States 
Skin, Breast 
Talaporfin (LS11, MACE, 
NPe6) 
Chlorin 660 
  
United 
States 
Liver, Colon, Brain 
Ce6-PVP (Fotolon), Ce6 
Derivatives (Radachlorin, 
Photodithazine) 
Chlorin 660 
  
Belarus, 
Russia 
Nasopharyngeal, Sarcoma, 
Brain 
Silicon Phthalocyanine 
(Pc4) 
Phthalocyanine 675 
  
United 
States 
Cutaneous T-Cell 
Lymphoma 
Padoporfin (TOOKAD) Bacteriochlorin 762 
  
United 
States 
Prostate 
Motexafin lutetium 
(Lutex) 
Texaphyrin 732 
  
United 
States 
Breast 
 
Abbreviations: ALA (5-aminolevulinic acid), AMD (age-related macular degeneration), Ce6-
PVP (chlorin e6-polyvinylpyrrolidone), HPD (hematoporphyrin derivative), HPPH (2-(1-
hexyloxyethyl)-20devinyl pyropheophorbide-a), MACE (mono-(L)-aspartylchlorin-e6), mTHPC 
(m-tetrahydroxyphenylchlorin), SnEt2 (tin ethyl etiopurpurin) 
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Table 2: Selected shortcomings in PDT. 
 
Disadvantage Reason 
Poor selectivity / Skin 
photosensitivity 
Although many PS exhibit significant tumour localisation, PDT drugs 
do not have high selectivity, in part due to their high hydrophobicity. 
Many PS-drugs remain in the body for weeks and accumulate in the 
skin; patients have to stay out of direct sunlight to prevent skin damage/ 
inflammation. This is being addressed by the development of 
specifically targeted PS, like in antibody directed phototherapy (ADP). 
Lack of approved 
drugs 
Clinical development of new drugs is hindered by poor understanding 
and/or an unwillingness of pharmaceutical companies to explore the 
area. Complicated dosimetry and a requirement for equipped PDT 
centres has led to a lack of robust, randomised clinical trials. 
Limited light 
penetration into 
tissues 
Light propagation through tissues is heavily limited by refraction, 
reflection and scattering processes and the absorption patterns of tissue 
chromophores. This is being addressed by the continual improvement 
of laser and light delivery technology including interstitial PDT under 
image guidance, light diffusing fibres and use of near infrared (NIR) or 
ultrasound absorbing drugs. 
Not being as 
immediately 
applicable to systemic 
diseases 
PDT is not as immediately applicable to systemic/disseminated disease 
This is being addressed by the development of the specific targeting of 
PS, like in ADP, and the development and further understanding of 
PDT-induced immune responses in particular antitumor-specific 
immunity  
A degree of oxygen 
dependence 
Many of the effective mechanisms of PDT depend on the availability of 
molecular oxygen in the target tissue during light irradiation. This is 
being addressed as some PS can preferentially initiate oxygen 
independent pathways, and light-dose fractionation can allow time for 
tissue re-oxygenation 
Difficult patient 
dosimetry 
Due to the range of different PS available, its multiple applications and 
multiple factors involved in its administration, there are difficulties in 
prescribing the correct patient dosimetry for each situation. Over-
illumination of some drugs can also lead to drug inactivation 
(photobleaching). 
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1.2.4 PDT and manipulation of the immune response 
 
The ability of a patients own immune system to recognise and manage cancer is backed up 
by many reported cases of spontaneous regression, often seen after an infection. This is 
especially important when you consider most of the commonly used cancer therapies; high dose 
chemotherapy, major surgery and high dose radiation are all immunosuppressive. The ability of 
PDT to manipulate both the innate and adaptive immune systems in an immune stimulatory way 
is of particular interest because if understood, it will challenge the idea that PDT cannot be used 
to treat disseminated disease. The potential for PDT-activated mechanisms to recognise 
remaining or disseminated cancer in the body after specific eradication of the main solid tumour 
mass is very appealing. Even more so when it is also suggested that PDT could provide future 
protection from relapse with the same cancer. The work is briefly discussed below and reviewed 
in (Ana P Castano et al., 2006; Firczuk et al., 2011; Korbelik, 2011; Mroz and Hamblin, 2011; 
Nowis et al., 2005; van Duijnhoven et al., 2003).  
 
In vivo experiments in mice have shown not only that an intact immune system can improve 
the efficacy of PDT but when cured of their cancer via PDT mice can develop a resistance to any 
re-challenge with the same tumour, mice with the same intact immune system but cured of 
cancer by surgery did not survive the same re challenge (Canti et al., 1994). In addition, studies 
in mice have also shown that the immune response produced by PDT treatment of a tumour 
transplanted on one leg of a mouse (with the additional post PDT intra-tumour injection of 
autologous dendritic cells) can also cause regression in a distant and completely untreated 
tumour (Saji et al., 2006). Excitingly (Kabingu et al., 2009) presents clinical work carried out in 
human patients with basal cell carcinoma in which lesions were either treated with PDT or 
surgically removed, they showed that in humans too, local tumour PDT can induces a systemic 
immune response to the tumour in the patient. The balance between apoptosis and necrosis is 
thought to be important in the type and extent of immune activation after PDT, and can be 
manipulated by many factors including the clinical dosimetry method as well as the type and 
delivery method of the PS. Pyropheophorbide-a (PPa), the photosensitiser under study in this 
thesis, and its related molecules show this capability to enhance immune response. (Li et al., 
2006).  
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1.2.5 PDT in combination with other therapies 
 
In addition to the combination of PDT with the classical cancer treatments including 
chemotherapy (Khdair et al., 2009) and hormone therapy (Bhuvaneswari et al., 2007), there are a 
range of combination therapies based on immune modulation alongside PDT including co-
administration of microbial adjuvants, cytokines or moieties to regulate T cell or other leukocyte 
balance. (Kwitniewski et al., 2008; Qiang et al., 2008; St Denis et al., 2011). Other combination 
therapies with PDT (Agostinis et al., 2011; Verma et al., 2007) include vascular manipulation 
(Ferrario et al., 2000) or changes in the tumour microenvironment (Gomer et al., 2006), co-
administration of antioxidant inhibitors (Kimani et al., 2012) or conversely antioxidants (Jakus 
and Farkas, 2005). 
 
1.2.6  ‘State of the art’ in PDT  
 
One of the most successful variations from classical PDT is two photon PDT, this is listed 
below alongside other variations of note: 
 
 Two photon PDT uses sub-picosecond pulsed lasers for simultaneous delivery of two photons 
in quick succession to a fluorophore, the package of energy delivered is additive, providing a 
way of accessing an excited state by using photons of half the energy / twice the wavelength of 
the corresponding one-photon transition. Two photon PDT can penetrate deeper into tissues as 
well as being incredibly spatially specific. Two photon PDT has been used to selectively close 
a single blood vessel (Collins et al., 2008; Khurana et al., 2007; Pawlicki et al., 2009). 
 
 Sonodynamic therapy (SDT) involves the use of ultrasound to activate sonosenitisers, these 
sonosensitive molecules are often the same photosensitive molecules as used in PDT (Kuroki et 
al., 2007; Ma et al., 2009; Mitragotri, 2005; Yamaguchi et al., 2011).  
 
 Gold containing photosensitisers or nanoparticles can also produce heat in response to light  
activation damaging tumour tissues via a different method to PDT (El-Sayed et al., 2006; 
Huang et al., 2007; X. Huang et al., 2008). 
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 The development of nanomaterials linked to photosensitisers that work as energy transfer 
molecules, including the development of systems that use ionising radiation for example X-rays 
or gamma rays which can penetrate much deeper in order to activate the photosensitiser. (Chen 
and Zhang, 2006; Juzenas et al., 2008; Liu et al., 2008; Samia et al., 2006).  
 
 Specifically modified PS used as combined magnetic resonance imaging probes and PDT 
agents (Huang et al., 2011; Vaidya et al., 2008). 
 
 Laser independent-PDT using chemiluminescence strategies to active PS (Laptev et al., 2006) . 
 
 The development of a genetically encoded photosensitser, named killer red, (Bulina et al., 
2005; Vegh et al., 2011). This work was particularly influential on the field of bioconjugation 
as classical PS conjugation reactions that require harsh conditions and subsequent purification 
are completely negated if the PS can be encoded and expressed as a fusion protein. Work by 
(Serebrovskaya et al., 2011, 2009) produced such photo- immunoconjugates with killer red and 
showed specific photo activity and cell killing in vitro although currently this is not as potent as 
traditional PDT. 
 
 The manipulation of photosensitisers to make them activatable at certain times or in certain 
environments, for example; after the exposure of  a protease site to an enzyme, or a sequence of 
deoxyribonucleic acid (DNA) to its complementary partner, or an environmental induced 
conformational change, these effects can be made to initiate or relieve quenching of a PS. 
(Lovell et al., 2010; Zheng et al., 2007).  
 
 Photosensitisers have also been used as ‘genetic switches’ using light activation (and the 
subsequent oxidative mediators) to switch off or inactivate selected proteins or pathways in 
living cells (Mitra et al., 2003; Yogo et al., 2008). 
 
 PS also make excellent moieties to include in delivery vehicles in a technique called 
photochemical internalization (PCI), a well studied and established technique that uses 
photosensitisers which are known to preferentially localise in endosomal membranes. Once 
taken up and upon irradiation of the cell with light, the activated photosensitiser causes rupture 
of endosomal membranes and delivery of the payload which is normally a drug or a toxin. 
(Adigbli and Macrobert, 2012; Norum et al., 2009a, 2009b).  
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1.3 Important physiological factors in the efficiency of PDT 
 
Currently there is a wealth of knowledge in the literature about the effectiveness of specific 
photosensitisers in various specific situations but there is a lack of any clear unifying model of 
photosensitiser clinical or in vivo efficiency; if such a thing is indeed possible. Progress in 
clinical effectiveness of PDT would surly benefit from the existence of such models; however it 
is likely there are two major reasons for the lack of any umbrella models: 
 
 The first being the complex influences of systemic factors and pharmacokinetics on 
the delivery of the PS to cancer; factors including photosensitiser distribution, 
aggregation, absorption, specificity and localisation, metabolism, excretion, and the 
properties of the tumour itself (Caldwell et al., 1995; Castano et al., 2005a; Ferrari, 
2010; Iyer et al., 2006; Ochsner, 1997; Smith et al., 2010; Trédan et al., 2007).  
 
 
 The second being how clinical use of PDT can effect outcome; understandably the 
method of injection can effect outcome (Bachor et al., 1994), but interestingly also 
photosensitiser dose, total light dose, fluence rate (laser energy delivered over time), 
change of the drug–light interval, fractionation of the dose over different time points, 
and even temporal characteristics of the light (i.e. pulsed vs. continuous irradiation), 
can all show remarkable effects on overall efficiency (Henderson et al., 2004; Wilson 
et al., 1997).  
 
The ability to modulate PDT efficiency using dosimetry in the clinic means that, with 
sufficient knowledge, treatment can be patient optimised, and if models can be developed for the 
consistent optimised delivery of PDT its therapeutic potential is massive. Some mathematical 
models are already being designed to help with various aspects of clinical dosimetry.  
(Grossweiner, 1997; Hu et al., 2005; N. Huang et al., 2008; Kogan, 2005, 2004, 2003). 
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1.3.1 How clinical use of PDT can effect outcome 
 
Optimal dosimetry methods can be complicated and there are many factors that can change 
the effective light dose beyond manipulation of laser application, many of these are well 
discussed in (Wilson et al., 1997) and include:  
 Intrinsic tissue sensitivity to oxidative damage.  
 Variation in concentration and micro-distribution of photosensitiser in the tumour 
target and adjacent normal tissues. 
 The range of absorption and scattering coefficients of different tissues as well as the 
spatial distribution of the light in the tissue volume, before and any changes during 
treatment. 
 The variability in initial tissue oxygenation and any changes during treatment. 
 Possible self shielding or quenching with highly absorbent PS.  
 PS photo-bleaching and loss of efficiency of the PS during treatment.  
 The vascular status before and during treatment. 
However despite these variables it has been well documented that clinical manipulation of 
laser application can affect outcome significantly, in particular fluence rate modification and the 
dose light interval. 
 
1.3.1.1 The drug-light interval 
 
The drug- light interval can be a very important factor in therapy design because of the effect 
it can have on the location of the PS during irradiation and subsequently the type of tissues that 
are damaged. (Andrejevic-Blant et al., 1997; Borle et al., 2003; Chen et al., 2001; Dolmans et al., 
2002; Ris et al., 1993). A highlighted paper from Chen et al (Chen et al., 2005) studied the PS 
VisudyneTM in an in vivo rat prostate tumour model and showed that 15 minutes after dosing the 
PS predominantly localised in tumour vasculature but by 3 hours it was predominantly in the 
tumour parenchyma. They carried out combination light dose experiments and showed the best 
anti tumour response when achieved when they irradiated at first 3 hours and then 15 minutes 
when compared to all other regime options. The inverse (15minutes then 3 hours) was shown to 
be less effective due to increased hypoxia in the tumour tissue by the second irradiation.   
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1.3.1.2 Fluence rate modification 
 
In some systems, but not all, maintaining the light dose but lowering the fluence (laser 
energy delivered over time) can produce significant beneficial effects on overall PDT efficiency. 
The current explanation for this is that extended irradiation at lower laser doses causes 
significantly less oxygen depletion in the tissues, increasing the power of the laser can also 
increase the heat in the tissue, but this can occur with prolonged irradiation as well as high power 
irradiation. Photosensitiser type along with light dose will also affect the oxygen consumption 
through its photophysical characteristics, i.e. PS with higher extinction coefficients or higher 
quantum yields for singlet oxygen production will cause more rapid oxygen depletion. (Angell-
Petersen et al., 2006; Babilas et al., 2003; Coutier et al., 2002; Ericson et al., 2004; Henderson et 
al., 2006, 2000; Xue et al., 2011).  
 
Tissue oxygenation is of particular importance as solid tumours are often themselves hypoxic 
before any treatment (Freitas and Baronzio, 1991). Evidence for reduced PDT efficacy in 
hypoxic conditions are available (Henderson and Fingar, 1987; Istomin et al., 2006) and 
expression of HIF (hypoxia inducible factors) was correlated with a low PDT response rate in 
patients with early-stage oesophageal cancers (Koukourakis et al., 2001). However (Busch et al., 
2004) looked at tumour hypoxia and PS uptake in human patients and showed no correlation. 
Because of this it is important to investigate the switch from Type II to Type I reactions in 
hypoxic areas of the tumour.  
 
As well as prolonged fluence rate, fractionated fluence rate, a pulsed light delivery and also a 
lower total PS doses have all been used to also facilitate the recovery of tissue oxygenation. 
Wang and colleagues (Wang et al., 2007) showed changes such as these, in cases where they 
may not have any direct effect on therapeutic efficacy, can still be changing the mechanism of 
action and even the type of tissue damaged. The manipulation of other factors important to the 
mechanism of tumour cell death are also mirrored in papers that show inflammation or immune 
suppression can also be manipulated by light dose (Frost et al., 2011; Henderson et al., 2004). 
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1.3.2 Monitoring treatment before or during PDT 
 
PDT has the specific advantage of utilising an inherently fluorescent drug and this has been 
used for fluorescence imaging and diagnosis as well as treatment, this is reviewed in Celli et al 
(Celli et al., 2010). In addition to PS fluorescence, other measurable endpoints from the PDT 
process have been widely investigated to try and provide a direct way to monitor treatment 
before or during therapy. (Dysart et al., 2005; Gill et al., 2009; Stefflova et al., 2006; Wilson et 
al., 1997; Yu et al., 2006; Z. Zhang et al., 2004; Zhu et al., 2005). Some of these endpoints are 
listed below, however their use has proving complicated, for example; the most popular 
endpoint, photo-bleaching, has been shown experimentally be both effective by (Dysart et al., 
2005; Sheng et al., 2007) and ineffective by (Dysart and Patterson, 2006; Iinuma et al., 1999). 
 PS fluorescence / photo-bleaching,  
 Singlet oxygen production,  
 Photoproduct formation (i.e. a chemical modified by the PDT reaction/singlet oxygen), 
  Uptake of PS into tissue.  
 PS triplet-state concentration and lifetime. 
 Tissue parameters such as temperature, optical properties or oxygenation, pH or redox 
potential. 
 Changes in vascular permeability or tumour blood flow.  
 The addition of fluorescence 'reporter' molecules for example for apoptotic activation  
 
1.3.3 Tumour micro-environmental pH 
 
Poor perfusion and high metabolic rates in tumour tissues leads to the acidification of the 
extracellular medium by about 0.5 pH units creating a typical pH of around 6.9, the intracellular 
pH remains normal and between pH 7-7.2. (Gerweck and Seetharaman, 1996; Zhang et al., 
2010). This can significantly change cellular uptake of molecules with a carboxylic acid group or 
other ionisationable group within the right range (Gerweck et al., 2006) (Raghunand and Gillies, 
2000) changes in pH can effect PS cellular membrane partition and/or  self-aggregation 
(Bonneau et al., 2004a).   
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1.3.4 Serum proteins can influence drug uptake 
 
Highly dividing cells like tumours have a high demand for cholesterol and there are two 
ways for them to supply this demand; either by higher uptake of low density lipoprotein (LDL) 
(major carrier of cholesterol in blood) or by increasing endogenous synthesis via HMG-CoA 
reductase (rate limiting enzyme). Many tumours have been shown to have increased levels of 
LDL receptor (Firestone, 1994; Gal et al., 1981; Vitols et al., 1992). Particularly hydrophobic 
photosensitisers, are often injected in a solubilising transport vehicle, e.g. liposomes, oil in water 
emulsions or lipid nanoparticles, and the nature of this delivery vehicle can also affect the 
relative transfer of the drug to other elements within the blood or target tissue. (Kongshaug et al., 
1989; Sobolev et al., 2000a). 
 
In terms of PDT, research has shown the extent and mechanism of tumour uptake can be 
changed by the presence of albumin, LDL or other serum factors in the media. Although most PS 
show they can interact with both various lipoproteins (including LDL) and albumin, there is a 
general rule that states; hydrophobic PS tend to associate with LDL and hydrophilic PS tend to 
associate with serum albumin, for PS that contains an asymmetric charge its serum distribution 
will favour LDL-binding above what is predicted based on its lipophilicity.  Both LDL and 
albumin can interact with cellular membranes and can be taken up by receptor mediated 
endocytosis, albumin can also be taken up in liquid phase endocytosis. Changes in the tumour 
environment can cause release of the PS near the cell surface, this seems to be dependent on PS 
structure and it response to changing pH. LDL or albumin binding can alter cellular uptake and 
localisation as well as effect PS photo efficiency and/or PS aggregation.  (Alarcón et al., 2010, 
2009; Bonneau et al., 2004b; Brandis et al., 2005a; Guelluy et al., 2010; Mojzisova et al., 2007b, 
2007c; Rinco et al., 2009; Siboni et al., 2002)  
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1.3.5 Cancer and its effect on drug bio-distribution. 
 
Reviewed by (Ferrari, 2010) and others there are many transport differences between cancer 
and normal tissue, a field sometimes called ‘transport oncophysics’, and the drug development 
field has started to design macromolecules to manipulate this. Cancer tissues exhibit these 
changes most often alongside the progression of tumour angiogenesis, during which the presence 
of atypical vessel morphologies or endothelial gaps are thought to make pores with sizes ranging 
from tens of microns to hundreds of nanometers. Changes do not only effect direct extravasation 
but the dynamics of the blood flow. Together with unregulated proliferation of the tumour the 
insufficient co-development of lymphatic drainage can help to generate imbalances in 
hydrostatic, osmotic and interstitial fluid pressures in cancer. Changes toward tissue invasion and 
metastasis also drive changes in cell size, shape, and mechanical properties, as well as cell 
surface and vasculature biomarker changes in protein expression and modifications of the 
endothelial barrier all likely affecting any potential drug uptake. These factors can also be key 
players in drug resistance mechanisms. All this has to be manipulated for effective drug 
(including antibody) delivery. Depending on the properties of the drug in question these changes 
in tumour micro-environment and transfer processes can help to inhibit or promote non targeted 
drug uptake. In traditional PDT many of the PS accumulated non-specifically in the tumour in 
this manner.  (Danhier et al., 2010; Iyer et al., 2006; Thurber et al., 2008; Trédan et al., 2007).  
 
1.4 Photochemical factors in PDT  
1.4.1 The photophysics behind PDT. 
 
Photosensitisers are chromophore-containing compounds that can harness the energy in a 
photon of light for energy transfer reactions in biological systems. Photosensitiser photophysics 
is explained by the principles of molecular orbital theory. In terms of light absorbance, it is the 
wavelength, and hence the ‘quantum of energy’, that is absorbed by the molecule that is 
important as this will correlate with the energy difference between available ground and excited 
state energy levels within the molecule. It is because photosensitisers have extended regions of 
delocalised electrons that this correlates to areas of the spectrum uncluttered by more common 
bond energy transitions.  
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Absorption of a photon produces a short lived excited singlet state (excitation), the excited 
state reached depends on the energy contained in the light absorbed. (Transition between states 
corresponds to the movement of one electron from one orbital to another. ) The transition back to 
ground state (relaxation) can then go via numerous paths, a modified Jablonski diagram, shown 
in Figure 1, can be used to detail some of the important excitation and relaxation paths of a 
photosensitiser. Absorbed photon energy of the singlet state can be lost through radiationless 
transition (a transition between two states of a system without photon emission or absorption) 
including vibrational and rotational motions of a molecule, or re-emitted as a photon 
(fluorescence). Certain molecules, including PS, can undergo intersystem crossing to a triplet 
excited state (when an electron changes its spin state). This triplet state has a longer lifetime than 
the singlet and the energy of the triplet state can also be lost through vibrational and rotational 
motions of a molecule or re emitted as a photon (phosphorescence). However it is the 
radiationless transfer of energy from this triplet state to other molecules that is crucial for 
effective PDT. (Bonnett, 2000; Macdonald and Dougherty, 2001; Plaetzer et al., 2009) .  
 
The path of radiationless transitions that occur in PDT can be classed as either Type I or 
Type II transfer reactions. In PDT both type I and II reactions can be occurring in the same 
system but may occur to varying extents. The energetic choice of relaxation path for a 
photosensitiser depends on the chemical characteristics of the photosensitiser itself, the local 
concentration of specific targets, as well as other environmental factors. Type II energy transfer 
refers to the transfer of energy, specifically the transfer of energy from the triplet excited state of 
the photosensitiser to the triplet ground state of molecular oxygen, causing the excitation of 
oxygen into its singlet state. Singlet oxygen can cause significant damage to key cellular 
components for example by direct oxidation of proteins and lipids. Type I energy transfers refer 
to the transfer of electrons, i.e. the reaction of the triplet state photosensitisers upon collision 
with other molecules. Energy is transferred via electron exchange creating free radicals within 
both photosensitiser and target molecule; these radical species can include the creation of 
superoxide as well as other more reactive chemical species. Radical production has a propagative 
nature in that reaction of radicals with non radical substrates creates an escalating number of 
highly reactive radicals throughout the cell (Bonnett, 2000; Plaetzer et al., 2009).  
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Figure 1: Photosensitisation processes in PDT illustrated by a modified Jablonski diagram. 
Adapted from (Agostinis et al., 2011)  
 
Absorption of a photon of light converts a PS from S0 = ground singlet state, to S1 = excited singlet state, 
it can then undergo intersystem crossing to a T1 = excited triplet state. From either the S1 or T1 energy 
can be lost as emission of a photon of light (orange arrows) or various paths of radiationless transition 
(not all shown). The paths of radiationless transition that are important in PDT are shown as purple 
arrows and are characterised as either Type II reactions; the transfer of energy to the triplet ground state 
of 
3
O2 = Molecular Oxygen, causing excitation into its excited singlet state, 
1
O2 = Singlet Oxygen. Or 
Type I reactions; the electron or hydrogen transfer of the triplet state photosensitisers upon collision with 
other molecules. υ/J = vibrational/rotational levels, loss of energy by movement between these 
vibrational/rotational levels are what cause light to be emitted at a lower energy, this is called the Stokes 
shift, energy transfer arrows are not associated with any discreet υ/J level.  Singlet Oxygen can also lose 
energy via phosphorescence (not shown on this diagram). 
 
1.4.2 Reactive Oxygen Species (ROS) 
 
Reactive Oxygen Species (ROS) is a phrase used to describe a number of reactive molecules 
and free radicals derived from molecular oxygen. Many are free radicals as they can be defined 
as molecules containing a single unpaired electron in atomic or molecular orbits. ROS can 
readily interconvert between themselves and all have different redox potentials and reactivity. A 
species with particular importance to PDT is singlet oxygen (1O2), see 1.4.1. (Redmond and 
Kochevar, 2006; Winterbourn, 2008). During PDT oxidative damage occurs to a range of bio-
molecules due to the relatively non specific type of oxidation reactions carried out by the mixture 
of ROS that are found in different microenvironments within the cell. (Davies, 2003; Ott et al., 
2007; Valko et al., 2006).Work presented by (Sakharov et al., 2003) used these oxidized markers 
left behind after PDT to look at which proteins are most effected and trace the path of cell death 
through the cell. 
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In eukaryotic cells the mitochondria are a major source of endogenous ROS, where they play 
important roles as subcellular signalling molecules (Esposito et al., 2004). An imbalance toward 
the pro-oxidative state and accumulation of ROS within the cell is often referred to as ‘Oxidative 
stress’. This is kept in balance by the numerous cellular antioxidant defences in place to remove 
excess ROS (Kohen and Nyska, 2002; Turrens, 2003; Valko et al., 2006; Winterbourn, 2008). 
Through PDT one is attempting to overcome this balance with the introduction of excessive 
singlet oxygen and other ROS. In cancer the levels of basal oxidative stress are already found to 
be higher in tumours over normal tissue where it has been implicated in the pathology and 
progression of cancer (Behrend et al., 2003; Valko et al., 2006). 
 
Due to the highly reactive nature of ROS its lifetime within the cell and subsequent diffusion 
distance is transient and decreases with more reactive ROS. Distances can range from <10nm 
(1O2) to ~1.5 mm (H2O2). Singlet oxygen as it is an excited state molecule will always return to 
the ground state so its reactivity within the cell is given an upper limit by its inherent excited 
state lifetime. Many attempts have been made to model its intracellular maximum lifetime and 
spherical diffusion range but it has proved difficult as it can encompass a range of environments 
within the cell and the different compartmentalisation of any scavengers. Estimates have been 
made ranging from <10 nm to 125 nm, (125nm is the upper limit assumed if in aqueous solution 
and without reaction with any other bio-molecules). For reference a typical whole cell diameter 
is 10 to 30 µm, a mitochondria around 500 nm, and a lipid membrane or average globular protein 
is around 10 nm across. Any secondary ROS beyond singlet oxygen will have a greater and more 
variable range of diffusion paths to propagate the signal.(Kuimova et al., 2009; Redmond and 
Kochevar, 2006; Winterbourn, 2008). The behaviour of singlet oxygen can also change 
dependent on where it is produced, and as changes occur in the cell during the PDT process (da 
Silva et al., 2012). 
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1.4.3 Light for PDT 
 
Light propagation through tissues is heavily affected by refraction, reflection, absorption and 
scattering processes. Diffusion and loss of light energy in refraction and reflection can minimised 
by perpendicular light application, scattering however is harder to minimise. Mathematical 
models have shown that over 4/5ths of the fluence can be lost in the first 0.5 cm, and cancerous 
tissue can present different optics than normal tissue (Jacques, 2010; Salomatina et al., 2006; 
Wilson and Patterson, 2008). Another contributing factor to loss of light intensity is light 
absorption by tissue chromophores. Levels of chromophores vary dependent on tissue type but 
the most relevant are water, oxyhemoglobin, deooxyhemoglobin and melanin. When plotted as 
seen in Figure 2 the absorption spectra of these chromophores show an optimum window for 
PDT which diminishes tissue absorbance, this window corresponds to outer limits of 650-1200 
nm this range is further reduced since PS triplet-state molecules excited by light >850 nm are 
predicted to have a low triplet energy level so be unable to produce singlet oxygen efficiently 
(Plaetzer et al., 2009), however alternative type I processes could still occur. 
 
Porphyrins, Chlorins and Bacteriochlorins have proven widely popular as photosensitisers 
because alongside a good singlet oxygen quantum yield, (defined as the average number of 
molecules of singlet oxygen produced per photon of light absorbed, 100% efficiency is defined 
as 1), they also have inherent spectral properties suitable for PDT applications; i.e. absorption 
bands in the red. These sorts of photosensitisers have a characteristic absorption pattern 
consisting of a strong Soret band around 400nm and a series of weaker satellite Q bands between 
600 and 800nm, it is these Q bands that are used for PDT treatment (Macdonald and Dougherty, 
2001). Below in Figure 3 is the absorption spectrum of Pyropheophorbide-a, the Chlorin based 
photosensitiser used in this thesis, it is presented here to show its typical spectral bands and the 
standard spectral nomenclature for Porphyrins and related molecules as discussed above. There 
is a significant body of work on interpreting spectral pattern shifts in relation to molecular orbital 
theory, including the effect of chemical addition of new groups onto the core ring structure, 
particularly those with electron withdrawing or donating properties that would affect the 
conjugated electron system and have a pronounced effect on the intensity and wavelength of the 
Q bands (Bonnett, 2000).   
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Figure 2: The ‘optical window’ for PDT. 
Taken from (Plaetzer et al., 2009) Absorption spectra of common tissue chromophores. H2O = 
water, Hb(H2O) = deooxyhemoglobin, Hb(O2) = oxyhemoglobin. 
 
 
Figure 3: Absorption spectrum of PPa and its standard spectral nomenclature 
The absorption spectrum of Pyropheophorbide-a in Dimethyl sulfoxide (DMSO). 
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1.4.4 Photosensitisers for PDT. 
 
Many of the classical photosensitisers were originally derived from natural substances. For 
example pheophorbides, like the one used in this thesis, were originally derived from 
chlorophyll-a. The first photosensitiser to achieve regulatory approval in 1993 was 
hematoporphyrin derivative or HPD, derived from haemoglobin. A partial purification from 
HPD, PhotofrinTM is one of the most commonly used and studied photosensitisers to date, but its 
research and application was hindered by the fact it is in fact an impure mixture of porphyrin 
oligomers of varying lengths, linkages and stereo-chemistries. (Allison and Sibata, 2010; Detty 
et al., 2004). 
 
New photosensitisers are developed via chemical synthesis techniques with preferred 
photophysical or pharmacokinetic characteristics designed into them. Preferable characteristics 
can vary upon application of PS but can include (Ochsner, 1997; Plaetzer et al., 2009): 
 Photosensitisers that absorb in the red as tissue penetration of light is optimal with red 
/ NIR light, aiding activation of photosensitisers in deeper tissue. See 1.4.3. 
 Emission photophysics that favour more efficient radiationless transition to molecular 
oxygen or other specified cellular targets. Optimised triplet state excitation energy 
(110-130 kJ.mol-1) being the theoretical triplet state energy required to promote 
oxygen transfer mechanisms, a lower energy however can still promote transfer to 
other molecules.  
 Increased triplet state quantum yield (defined as the average number of times that 
photosensitiser triplet state formation occurs per photon of light absorbed, 100% 
efficiency is defined as 1). 
 Triplet state lifetime (the average time a molecule spends in its first excited triplet 
state, optimum time is 500ns or longer). 
 
Among such a wide repertoire of natural or synthetic photosensitisers and the numerous 
chemically-modified derivatives that have been produced from them, scientists and clinicians 
have a great deal of choice. This means theoretically, suitable photosensitisers could be chosen 
for the best possible applications based solely on their individual photophysical or 
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pharmacokinetic properties (Allison et al., 2004; Palumbo, 2007; Plaetzer et al., 2009). However 
ideal, having just one photosensitiser that will fit all applications looks less achievable than 
having a toolbox of different photosensitisers, tuneable with clinical endpoints (dose, light etc) to 
different patients and disease states. For example one photosensitiser; a monoacid 
benzoporphyrin derivative called verteporfin, branded clinically as VisudyneTM, has a half- life in 
the body too short for tumour accumulation. However the half- life is ideal for the treatment of 
neovascularisation in the eye during treatment of the wet- form of age related macular 
degeneration (Macdonald and Dougherty, 2001).The effect of any specific chemical modification 
on a PS is hard to predict and not always synergistic for all the important factors that influence in 
vivo efficiency, although many labs do carry out quantitative structure-activity relationship to try 
and predict this (QSAR) studies (Banfi et al., 2006; Gryshuk et al., 2007; Henderson et al., 1997; 
MacDonald et al., 1999).  
 
1.4.5 Chemical modifications of PPa 
 
Pyropheophorbide a (PPa) is the PS under investigation in this thesis. One QSAR study 
(MacDonald et al., 1999), looked at a molecule very similar to PPa, Pyropheophorbide a-ether 
(PPa-ether) the same molecule as PPa but with a ether group in place of the vinyl group. PPa-
ether was then modified with side chains with increasing alkyl carbon chain length from propyl 
(n=3) to dodecyl (n=12). Increasing chain length increased hydrophobicity. The intracellular 
localisation of these PS showed the octyl, decyl and dodecyl derivatives localised to the 
lysosomes at extracellular concentrations below the LD50 (PS concentration required to kill 50% 
of the cells). At extracellular concentrations equal or greater than LD50, the compounds localised 
mainly to mitochondria. The propyl, pentyl, hexyl and heptyl ether derivatives localised mainly 
to the mitochondria at all concentrations studied. This change in localisation correlated with the 
change in cell kill efficiency, (mitochondrial localisation being more lethal than lysosomal). 
They concluded an inverse relationship between the aggregation state and the LD50 
concentration, compounds were shown to have a higher tendency to aggregate at low 
concentrations with increasing alkyl chain length, hence effecting their mechanism of uptake, 
sequestering aggregated PS in the lysosomes after endocytosis while monomeric PS were 
internalised by some other pathway.  
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Two molecules from this same group of PPa-ether molecules above were further investigated 
to examine whether the PS that aggregated could disaggregated once inside tumour cells 
(Kelbauskas and Dietel, 2002). They looked in particular at the hexyl and nonyl derivatives 
which were both shown to aggregate and accumulate in lysosomes. Over time, both hexyl and 
nonyl derivatives underwent disaggregation in the cell interior, the extent of disaggregation was 
faster and more complete for the more hydrophilic hexyl derivative which corresponded with its 
potency as a more effective photosensitiser. 
 
As in this thesis Guelluy and colleagues (Guelluy et al., 2010) were trying to improve the 
solubility of a similar molecule to PPa, PPME (Pyropheophorbide a methyl ester), which differs 
from PPa in the replacement of the carboxylic acid group on the propionic acid side chain to a 
methyl ester. They chose a liposomal delivery method to aid PS solubilisation. Free PPME 
dissolved in phosphate buffered saline (PBS) exhibited spectra designated to be typical of 
aggregates, with a strongly reduced fluorescence and absorbance efficiency, whereas PPME 
dissolved in a liposomal formulation (Lipo-PPME) retained high fluorescence and absorbance 
efficiency comparable to monomeric PS (observations from the PS in Ethanol). The use of a 
liposome improved cellular uptake in HCT-116 cells by a factor of 5 but over time both reached 
the same maxima, interestingly all the internalised molecules (delivered either way) showed a 
fluorescence lifetime measurement that matches monomeric PPME. When they looked at 
subcellular localisation they found that in both cases PPME located to many intracellular 
organelles including endoplasmic reticulum, Golgi, lysosomes and mitochondria (although levels 
were limited in mitochondria to only when the higher concentrations of extracellular PS were 
used). They then showed the liposomes themselves did not enter the cells by internalisation or 
fusion mechanisms but they released PPME at the plasma membrane by inter-membrane contact. 
Other work by this group showed they could alter the balance from apoptotic cell death to 
necrotic cell death by changing concentration of PPME; propensity for necrotic cell death varied 
from 8% (1 mM) to 79% (5 mM) for PPME alone, and from 10% (0.25 mM) to 68% (1 mM) for 
Lipo-PPME. After irradiation of cells incubated with both forms of PS, they also characterised 
the types of ROS generated inside the cell via ESR spin trapping. Their experiments revealed 
that 1O2 is the major ROS detected after activation of both forms of intracellular PPME. Others 
types of ROS (H2O2, O2
.-, OH.) represented only 30% of the ROS detection.  
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1.4.6 Addition of a positive charge or Polyethylene glycol chains to a PS 
 
In this thesis the novel PS under investigation have been modified either by the addition of a 
positive charge and/or small Polyethylene glycol (PEG) chains in order to try and improve their 
aqueous solubility.  
 
Cationic porphyrin molecules often show improved cellular uptake; for example Ball and 
colleagues (Ball et al., 1999) investigated 3 substituted zinc phthalocyanines, one anionic, one 
cationic and one neutral. They showed increased aqueous solubility for both the anionic and 
cationic PS over the neutral PS. Quantified levels of cellular uptake after 2 hours was as follows; 
cationic > neutral >anionic, and the concentration of each PS needed to kill 50% tumour cells 
(LD50) showed cationic to be by far the most potent at 0.028 µM, the anionic and neutral PS were 
similar at 2.1µM and 2.6µM respectively. In terms of localisation all showed an initial punctuate 
distribution indicative of lysosomes that under low light conditions (1000 lower than cell kill 
irradiation) re- localised to different places depending on the charge of the PS, the neutral PS 
stayed punctuate, the anionic PS showed a more diffuse mostly nuclear pattern, and the cationic 
showed a more diffuse but cytosolic pattern.  
 
PEGylation is a popular choice to improve water solubility; for example Grahn and colleagues 
(Grahn et al., 1999) synthesised a PEGylated PS where they modified the clinically licensed PS 
FoscanTM. Four PEG chains were either attached by carbonate (liable linker) or triazine (stable 
linker) linkages via the 4 phenol hydroxyl groups of the FoscanTM. They noted however that 
preparations did contain some un-reacted (free) FoscanTM and a range of incompletely 
conjugated FoscanTM (1–3 PEG chains per FoscanTM). Their work showed FoscanTM PEG had a 
longer circulating half- life than free FoscanTM, but potency was not improved over the original 
molecule. The stable linker showed better bio-distribution but insufficient potency in tumours 
and the liable linker showed increased non specific toxicity at early dose light intervals and an 
equivalent profile to FoscanTM at later time points. Continuation of this work (Krueger et al., 
2003; Reuther et al., 2001) further developed the linkages of FoscanTM to the PEG and did show 
some improvements in in vivo effectiveness.  
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A different group PEGylated a series of Chlorin e6 photosensitisers which were loaded onto 
to a Poly L-Lysine polymer (Hamblin et al., 2001), they showed PEGylation changed the 
mechanism of PS deactivation from majority type II (singlet oxygen) to majority type I (radicals 
or electron transfer) and that PEGylation increased the selectivity and potency in vitro, showing 
it had an increased tendency to disaggregate, an altered cellular localisation and a more apoptotic 
mechanism of action. When injected intra-peritoneally into mouse tumour models the PEGylated 
PS-Poly Lysine conjugates also gave a higher photosensitiser tumour uptake and higher tumour 
to normal tissue ratios as well as increased depth of penetration into the peritoneal wall. 
 
 
1.5 Antibody targeted PDT 
1.5.1 Antibodies in modern medicine 
 
Cancer cells exhibit altered and/or unregulated expression profiles of numerous genes, 
proteins, carbohydrates and lipids compared to the endogenous cells in their surrounding 
environment. These have become useful markers in aiding diagnosis, treatment and research. 
Antibodies against these molecules can be raised and recombinant antibody therapy for cancer is 
well established; four of the top ten cancer therapy drugs are antibodies including Trastuzumab 
(Herceptin®), and Bevacizumab (Avastin®). (Adams and Weiner, 2005; Deonarain, 2008; Scott 
et al., 2012). In terms of antibody engineering the field has expanded exceptionally since its 
beginnings (Carter, 2006; Nelson et al., 2010; Sidhu and Fellouse, 2006).  
 
Humans express five isotype forms of antibodies which are designated IgG, IgA, IgM, IgD, 
and IgE, they differ in their physicochemical properties, i.e. charge, size, and solubility as well as 
their behaviour and interaction with antigens and other bio-molecules. The IgG (Immunoglobulin 
G) constitutes about 80% of the antibodies in the serum, and as such is the ‘classic’ antibody. 
Many of the current therapeutic antibody drugs are of this format or a fragment thereof (Elgert, 
2009). The influence of selecting the most suitable Isotype is discussed well by Salfeld et al 
(Salfeld, 2007).  
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Antibodies are typically made up of a series of repeating immunoglobulin units that are 
roughly 110 amino acid residues in length and share significant structural homology, each 
domain has the characteristic tertiary structure consisting of two β-pleated sheets. Layers are 
covalently linked by a disulfide bridge near the centre of the domain. All proteins that exhibit 
this structural motif belong to the immunoglobulin gene super family (Elgert, 2009). A 
schematic representation of an IgG molecule is shown in Figure 4 next to the structure of an 
intact IgG solved by X-ray diffraction. The IgG molecule consists of two heavy and two light 
chains linked by disulfide bonds and non-covalent interactions. The light chain of IgG has two 
domains called VL and CL. The heavy chain of IgG has four domains: one VH and three in the 
CH region numbered 1 to 3. When the VL and VH chain framework residues assume their native 
arrangement, three loops from each domain come together and are held out into the solvent, 
these loops are called complementarity determining regions or CDRs. The size and shape of the 
loops are defined by their amino acid residues. It is these CDRs that form the antigen-binding 
site of the antibody. An antibody can also be designated in terms of its Fc portion or its Fab 
portion, an IgG is made up of one Fc and two Fab portions (Elgert, 2009). 
 
Each immunoglobulin domain contributes different properties to the molecule, whether it is 
intra or inter-dimerisation, binding to cellular molecules or encoding regions for glycan 
extension. Each domain folds independently of each other into a compact globular structure so 
can be ‘cut up’ and rearranged like biological Lego bricks. These isolated fragments of the 
original antibody molecule or novel multimeric antibody formats all have their own properties, 
and can be adapted to fulfil a chosen role. Figure 5 shows a schematic representation of some of 
the antibody formats used. Antibody fragments such as these are fast replacing monoclonal 
antibodies in the preclinical pipeline providing a much greater potential for intelligent design and 
engineering toward both diagnostic and therapeutic applications. (Holliger and Hudson, 2005; 
Nelson and Reichert, 2009).  
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Figure 4 : Structure and nomenclature of an IgG antibody  
Reproduced from  (Carter, 2006) and structure file taken from http://www.rcsb.org/pdb. 
 
IgG molecules comprise a pair of identical heavy (purple) and light (orange) chains linked 
by interchain disulphide bonds (green bars). Selective binding of antigen (light blue) is mainly 
mediated by six loops three of which are present in each of the VH and VL domains. Effector 
functions require the presence of the Fc-region and its glycosylation (dark blue bars) and are 
crucially influenced by its structure. The structure of an actual immunoglobulin was taken from 
the RCSB protein databank at http://www.rcsb.org/pdb (PDB number 1IGT) and recoloured in 
Pymol www.pymol.org/ . Abbreviations: FcRn = neonatal Fc receptor, FcγR = Fc-gamma 
receptors, ADCC = Antibody-dependent cell-mediated cytotoxicity, CDC = complement-
dependent cytotoxicity 
 
Figure 5 : Schematic representation of selected antibody formats 
Adapted from (Holliger and Hudson, 2005) and (Carter, 2006) 
 
Schematic representation of an intact ‘classic’ IgG molecule and a variety of antibody fragments 
and novel multimeric formats including Fab, F(ab’)2, F(ab’)3, ScFv-Fc, Minibody, ScFv, 
Diabody and Tandem ScFv. Sizes given in kDa are approximate. Abbreviations: ScFv = single-
chain variable fragment, IgG = Immunoglobulin G, kDa = Kilodaltons. 
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1.5.2 Considerations for antibody selection 
 
The target to which the antibody is raised will affect its efficiency, despite more than 30  
different antibodies already approved worldwide for therapeutic use. More than 80% of these are 
against only five main targets (TNF-α, HER2, CD20, EGFR, and VEGF) (Shim, 2011). The 
choice of target will not only effect therapeutic considerations but also pharmacokinetic ones 
because it can affect retention and distribution throughout in the tissue. 
 
Inclusion of the Fc domain has significant influence on many important biological properties 
including binding of the neonatal Fc receptor (FcRn) which extends the half- life (Roopenian and 
Akilesh, 2007), and Fc mediated activation of the immune system by antibody dependent 
cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) (Golay and Introna, 2012). 
 
Bacterial expression systems for recombinant antibody expression will produce non 
glycosylated antibodies while a mammalian expression system will produce a range of 
glycoforms (Raju, 2003). Inclusion of glycans can provide useful conjugation handles or 
physiological properties however the lack of glycans will produce a more standardised product 
(Arnold et al., 2007). 
 
Stability of the fragments is important (Quintero-Hernández et al., 2012; Röthlisberger et al., 
2005) as well as domain order (Carmichael et al., 2003; Kipriyanov et al., 2003) and the 
inclusion of any linkers. In particular with scFv; molecules with a linker of 3–12 residues cannot 
fold into a functional scFv domain and instead associate with a second scFv molecule to form a 
divalent dimer, called a diabody. Reducing the linker length below 3 residues can further force 
scFv association into trivalent triabodies, or tetravalent tetrabodies, depending on composition 
and domain orientation (Todorovska et al., 2001) Interestingly even scFv with the traditional 
(Gly4-Ser)3 peptide linker, such as used in this work, often thought to produce scFv in a fully 
folder monomeric form, can also allow reversible formation of domain swapped dimers in 
solutions above 1mg/ml. (Lee et al., 2002). 
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1.5.2.1 The effect of antibody size  
 
The effect of antibody size on its pharmacokinetics can both be modelled mathematically 
(Schmidt and Wittrup, 2009) and has repeatedly been shown experimentally (Batra et al., 2002; 
Kenanova and Wu, 2006; Yuan et al., 1995), including for anti HER2 antibodies like the one 
used in this thesis (Deyev and Lebedenko, 2008).  
 
Smaller antibody fragments are able to penetrate the tumour quickest and achieved peak 
uptake early within the first few hours, the blood clearance of these molecules is also relatively 
quick, so in terms of the tumour to blood ratio the best ratios are normally found with these 
smaller fast clearing fragments. However the highest tumour uptake levels are normally always 
seen for the full IgG, the increase over all other fragments even those of similar size is due to Fc 
interactions and FcRn mediated salvage. Evidence that it is the increased rate of serum clearance 
that is limiting small fragment tumour uptake is in part backed up by (Adams et al., 1998) who 
showed that in a standard mouse tumour model, tumour retention of an scFv was of a sufficient 
but predictably much lower level when compared to the equivalent molecule in its IgG format. 
However when they looked at a mouse model in which renal clearance was blocked by surgically 
nephrectomisation the peak tumour retentions for scFv were similar to the tumour retention 
levels achievable by full IgG molecules in the normal model.  
 
A general rule is that larger fragments such as the IgG fragments are retained at high levels in 
human tumours over longer time periods (days) but with a lower degree of specificity while 
smaller fragments such as scFv are taken up into the tumour more rapidly (hours) and with 
greatly improved specificity but at comparatively lower levels and will show quicker clearance 
times both from the serum and the tumour.  
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1.5.2.2 The effect of affinity and avidity  
 
Properties inherent in vascular or tumour tissue as well as the endogenous properties of the 
antibody such as size, shape, lipophilicity and charge can all have an impact on localisation and 
bio-distribution of the antibody. Of particular importance are the affinity and avidity of the 
binding interactions especially in reference to any engineered increased valency (Cuesta et al., 
2010) and the idea of a ‘binding site barrier’ (Rudnick and Adams, 2009). Another factor of 
importance in tumour penetration related to antigen binding is the influence of antigen 
expression, density and the rates of internalisation and any subsequent antibody catabolism. 
(Ackerman et al., 2008).  
 
Heterogeneous antibody (Ab) distribution within a tumour can arise in part from 
heterogeneous antigen expression, vasculature, or necrosis but it can also be affected by the 
‘binding site barrier’. This is a model which predicts that diffusion of high-affinity antibodies 
into a tumour is limited because slow rates of dissociation decrease the local concentration of 
diffusible, free antibody. As the strength of the bond between the Ab and its target increases, the 
amount of Abs available to diffuse into tumour decreases, leading to a reduction in penetration 
into the tumour. This effect is made even more pronounced in a tumour microenvironment where 
the lack of draining lymphatics hinders further the diffusion of macromolecules (Rudnick and 
Adams, 2009; Rudnick et al., 2011; Zuckier et al., 2000). This ‘binding site barrier’ has been 
shown with the antibody used in this thesis; C6.5 in both the scFv and IgG formats, (Adams et 
al., 2001; Rudnick et al., 2011) as well as for the clinical competition HerceptinTM (Baker et al., 
2008). 
  
Page | 46  (Hayley Pye 2012) 
 
 
1.5.3 Photo-Immunoconjugates  
 
Many academic and industrial researchers are now developing antibody targeted PDT for 
treatment and tumour detection by conjugating either whole antibodies or antibody fra gments to 
photosensitisers. As antibody conjugation delivers photosensitisers to the tumour via tumour-
associated cell receptors it is hypothesised to improve both specificity and efficiency, removing 
the some of the current limitations of non-targeted PDT see 1.2.3, including the prolonged 
sensitisation and non specific uptake of PS into the skin, and the problem with complicated 
dosimetry in the clinic. The antibody targeting of PS to well characterised disease state epitopes 
will hopefully provide a more predictable, more specific and hopefully more effective clinical 
outcome.  
 
The first work carried out with photo- immunoconjugates (PICs) was in 1983, inspired by the 
recent development of monoclonal antibody technology- this technology was to grow to 
represent the realisation of the ‘magic bullet’ hypothesis proposed by Paul Ehrlich back at the 
beginning of the 20th century. Mew and colleagues (Mew et al., 1983) synthesised 
Hematoporphyrin (HPD) / IgG conjugates via creation of an amide bond between an acid group 
of the photosensitisers and amine groups on the antibody. Their hypothesis was antibody 
conjugation would lower the effective dose of PDT required in cancer therapy, reducing the 
current problematic side effects caused by low tumour specificity.  When compared to equivalent 
concentrations of free Photosensitiser (PS) or Antibody (Ab) in antigen positive over antigen 
negative tumour lines they were indeed able to demonstrate both superior specificity and 
efficiency in tumour targeting and reduction in tumour growth both in vitro tumour cell lines, 
(efficiently killing 95% of tumour cells compared to 0%) and in vivo mouse tumour models, 
(significantly increasing mean time for tumour development). 
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In between the first steps and today, significant scientific developments have helped shaped 
the field of PIC production, both in terms of antibody engineering and photosensitiser 
development. The vast toolbox of new synthetic and/or chemically modified photosensitisers 
with a range of specified photophysical and pharmacokinetical properties has improved 
alongside a growth in the understanding of the important aspects of mechanisms behind effective 
PDT. Interest in the application of these photo-immunoconjugates is growing and recently work 
has been published in some well recognised journals; e.g. Nature Medicine, (Mitsunaga et al., 
2011) and PNAS (Serebrovskaya et al., 2009). 
 
Antibody photosensitiser conjugates have now been proven to increase the rate of cellular PS 
uptake and prolong cellular PS retention, along with an ability to be more selective and more 
effective at cancer destruction than free PS both in vitro and in vivo producing complete cures in 
a number of different mouse models of cancer. More detail of the scientific work carried out on 
PICs is discussed further in a later chapter see 5.1.4. 
 
Despite these successes the only PIC studied at a clinical level is an old feasibility study to 
determine whether immune-photodiagnosis could be applied in the clinic; a FITC conjugated 
human-mouse chimeric IgG directed against carcinoembryonic antigen (CEA) was studied in six 
patients with primary colorectal carcinoma, (Folli et al., 1992) in which they showed some 
promising results. Another small piece of PIC clinical work is a short communication by 
(Schmidt, 1993) in which they used Anti-CA125 and Anti-TAG 72 Phthalocyanine-zinc(II) 
conjugates alongside surgical techniques. The delay in clinically successful PICs is likely due to 
the fact that despite the substantial increase in the scientific understanding of PDT processes, 
funding for clinical trials is much harder to find for complex drugs and there are still PIC 
production problems, namely non specific toxicity and impurity of the product due to non 
covalently bound hydrophobic PS, alongside incorrect or un-reproducible dosimetry calculations, 
both things resulting in an inability to always produce a reliable well-characterised product. 
These problems are discussed further see 5.1.4. 
 
  
Page | 48  (Hayley Pye 2012) 
 
 
1.5.3.1  ‘State of the art’ with photoimmunoconjugates. 
 
Most PICs are produced against solid tumour antigens but the use of PIC to manipulate other 
systems includes: the targeting and shutdown of tumour vasculature (Palumbo et al., 2011), PICs 
against non solid-tumours for example lymphomas, (Mew et al., 1985; Oseroff et al., 1986), 
induction of immune regulation and induced cancer immunity (Palumbo et al., 2011), the 
targeted removal of one cell population from a mixture i.e. ex vivo in bone marrow transplants 
(Berki and Németh, 1998), or in vivo manipulation of wound healing (Strong et al., 1997). PICs 
have also been developed for infectious disease (Berthiaume et al., 1994; Bhatti et al., 2000) 
including against drug resistant bacteria like MRSA, (Embleton et al., 2004), as well as being 
manipulated to target on a much smaller scale to destroy specific intracellular structures while 
sparing the rest of the cell (Conlon and Berrios, 2001; Conlon et al., 2002). 
 
1.5.3.2 Targeted PDT without the antibody 
 
Other targeting methods or methods that improve the level and/or specificity of delivery 
include (Bechet et al., 2008; Chatterjee et al., 2008; Konan et al., 2002; Sharman et al., 2004; 
Solban et al., 2006): 
 The encapsulation in other carrier systems such as liposomes, oil-dispersions, dendrimers, or 
polymers to facilitate drug delivery. 
 The pre-association or direct conjugation with serum protein carrier molecules or serum 
protein binding moieties. 
 Conjugation to peptides, glycans or lipids that mimic the natural ligands or mitogens of over 
expressed tumour receptors.  
 Conjugation to substrates for metabolic pathways altered in tumours, e.g. some steroids, 
amino acids, or sugars.  
 Conjugation to chemicals with signals for specific cellular uptake and localisation, e.g. 
signals for scavenging macrophages, nuclear localisation sequences, or cell penetrating 
peptides.  
 Conjugation to non endogenous moieties such as some bacterial toxins, viral peptides or 
plant lectin molecules that have been shown to selectively bind tumour associated targets.   
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1.6 Previous work with C6.5-k targeted PPa. 
 
The work presented in this thesis is based on original work from this lab (Bhatti et al., 2008; 
Kuimova et al., 2007). This work was recently extended by Stamati et al (Stamati et al., 2010).  
 
For the original body of work an scFv fragment of medium affinity for good tissue 
penetration and rapid clearance was chosen for conjugation to PS. Bhatti and colleagues (Bhatti 
et al., 2008) showed that the conjugation of PPa to available lysine resides on the surface of a 
number of different scFv antibody fragments led to effective PICs. Conjugation ratios of 2-8 PS 
per scFv molecule were obtained, and final PDT cytotoxicity was hypothesised to be influenced 
by the number and position of these lysines. The most successful PIC was with C6.5-k, a scFv 
that binds HER2. This PIC was tested in vitro against cell lines positive and negative for HER2, 
results demonstrated improved specificity and potency over free PPa, again this was proposed to 
be due to the optimal lysine spacing and therefore PS loading of this antibody. This enhanced 
potency was rare in the literature at a time where it was becoming common to see a loss in 
potency once PS were conjugated at this level to antibodies, see 5.1.4. They also looked at blood 
clearance in mice of the conjugates compared to scFv and PPa alone, scFv clears rapidly and PPa 
very slowly, the conjugate was found to clear at a rate intermediate to these two parent 
compounds – providing a therapeutically more attractive profile over free PPa. The serum half 
life calculations from this work are reproduced in Table 3 below. The PIC was also effective in 
vivo at eradicating tumour burden in mice.  
 
Kuimova and colleagues (Kuimova et al., 2007) looked in more detail at two of these 
conjugates, both C6.5-k as either a PIC with PPa or with the clinically licensed PS VisudyneTM. 
They used fluorescent spectroscopic techniques to confirm that there was ~20% non-covalently 
bound PS associated with the PICs. Interestingly there was a difference in the fluorescent 
profiles of VisudyneTM conjugates and PPa conjugates, PPa becoming twice as florescent 
(emission intensity) once bound to C6.5-k where as VisudyneTM became 3 times less emissive. 
Confocal fluorescent microscopy experiments were also carried out on these conjugates in cell 
lines positive and negative for HER2, the results showed specificity for PIC over free PS and 
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significantly different rates of uptake and leaching for the free PS vs. the PIC – the PIC 
exhibiting faster initial uptake and prolonger retention in the cells. 
 
The conclusions of this work was that although promising, there were still some problems 
with solubility of the PS PPa, it was thought to be affecting PIC pharmacokinetics, conjugation 
efficiency and driving the non-covalent contamination of free PS after conjugation. Work 
initiated by these two papers was therefore followed by Stamati and colleagues (Stamati et al., 
2010), in the characterisation of two new water soluble photosensitisers, based on PPa and 
synthesised with either 3 Polyethylene glycol (PEG) chains, called PS1, or with a small single 
PEG and a permanent positive charge, called PS4. The structures of these compounds are shown 
below in Figure 6. Fluorescence quantum yields and singlet oxygen quantum yields were 
calculated for the new PS and these are reproduced in Table 4 below. The results show that in 
toluene PPa and PS1 share similar fluorescence quantum yields, PPa (0.3) and PS1 (0.26) 
whereas PS4 is lower (0.15). The pattern for singlet oxygen quantum yields in toluene show that 
PPa and PS1 are again similar; PPa (0.50) and PS1 (0.56) but PS4 this time shows an increase 
(0.75). An indication of water solubility is also demonstrated in this data; when fluorescent 
quantum yield is examined in water compared to toluene, PPa quantum yield drops dramatically, 
PS4 shows a slightly better quantum yield retention between toluene and water but it is PS1 that 
shows a the greatest retention of quantum yield, inferring that both PPa and PS4 extens ively 
aggregate in water, whereas this is reduced in PS1 formulations. Also presented are cell kill 
experiments comparing the new PS to their parent molecule, the demonstrated potency of the 
new photosensitisers was PS1 > PPa >>> PS4. IC50 values for this work are reproduced in Table 
4 below. They also looked at confocal fluorescent microscopy co- localisation of all three PS in 
SKOV-3 cells, and concluded PS4 likely had a more lysosomal localisation compared to the co-
localisation of PPa and PS1, which included mitochondria, ER and Golgi. 
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Table 3 : Serum half life calculations for PPa, C6.5-k and their PIC. 
Taken from (Bhatti et al., 2008)  
Molecule 
half life                
α phase* 
(hrs) 
half life              
β phase* 
(hrs) 
IgG 1.1 76.2 
PPa 1.6 20.9 
C6.5-k ScFv 0.14 4.1 
C6.5-k PPa PIC 0.17 12.3 
*fit to a Bi-phasic exponential clearance curve 
 
Table 4 : Quantum yields and IC50 values for PPa, PS1 and PS4 
Taken from (Stamati et al., 2010).  
Molecule 
Fluorescent 
quantum yield 
(toluene) 
Singlet oxygen 
quantum yield 
(toluene) 
Fluorescent 
quantum yield 
(water) 
Potency;               
IC50 SKOV-3 
cells (μM) 
Potency;              
IC50  KB cells 
(μM) 
PPa 0.3 0.5 4x10-3 14.5 +/- 3.2  1.2 +/- 0.4  
PS1 0.26 0.56 0.01 1.1  +/- 0.2 1.2  +/- 0.5 
PS4 0.15 0.73 2x10-3 259.6 +/- 31 24.7 +/- 11.7 
 
Figure 6: Chemical structure of PPa, PS1 and PS4 at pH 7.4 
 
Major Species at pH 7.4 of all three Photosensitisers under investigation in this thesis, produced 
using MarvinSketch Freeware Version: 5.7.0, (ChemAxon Ltd.) 
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1.7 Key aims and objectives 
 
During this project the aim is to investigate the effect of increased PS solubility on efficiency 
to induce cytotoxicity in cancer cells in vitro and the molecular mechanisms behind any changes 
seen. This project will have a focus on elucidating the molecular mechanisms behind any altered 
potency, particularly in respect to the processes of intracellular trafficking and the mechanism of 
the cell death. Another aim is to investigate the potential of these new PS for antibody 
conjugation, and how this further affects its properties. The work aims to explore the possibilities 
of targeted PDT while improving understanding of the influence of PS solubility on PDT cell kill 
mechanisms. This knowledge will hopefully help make the development of PDT and targeted 
PDT agents for cancer therapy more informed and hopefully help modulate current cancer 
treatment modalities around the endogenous and treatment induced resistance seen in patients. 
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1.8 Work presented in each of the results chapters 
 
Chapter 3: Chemical characterisation of PS and testing of PDT in an in vitro model of cancer  
Characterisation and evidence for the increased solubility of novel PPa based photosensitisers, 
alongside further development of a traditional non-targeted PDT cancer cell model in vitro, 
and testing of the new PS compounds within this model. 
 New PS modifications are hypothesised to make the new PS more water soluble. 
Presented are studies to check this hypothesis that also give an insight into PS 
photophysical efficiency in physiological conditions. 
 Initial testing of the cytotoxicity of new PS compounds is presented to show if the 
enhanced solubility affects the potency of the PS as a free molecule for PDT. 
 
Chapter 4 : The effect of increased PS solubility on cellular mechanisms important for PDT 
Analysis of the effect on PS on cellular uptake and localisation and the mechanism of cell 
death induced upon irradiation. 
 Experiments are presented that investigate why changing the solubility can alter the 
potency of the free PS. For example looking in more detail at some of the factors 
beyond photophysical efficiency that can impact potency in vitro. 
 
Chapter 5: The conjugation of novel photosensitisers to the antibody fragment C6.5-k 
Optimisation of the conjugation of photosensitisers to the antibody fragment C6.5-k and 
attempts made toward a consistent purification and analysis of conjugates. 
 New PS modifications are hypothesised to make the new PS more water soluble and so 
have improved conjugation efficiency and purity, presented is work carried out to 
investigate the extent of any such improvements. 
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Chapter Two 
2 Materials and Methods 
2.1.1 Equipment 
 
2.1.1.1 Laser System 
HPD 7401 laser system, (High Power Devices Inc) 
Model HPD5325-HHLF-TEC (High Power Devices Inc) 
Semiconductor laser diode light, Wavelength 671.6nm FWHM 0.6nm.  
PMax  = 2.05 Watts, Imax = 5.00 Amps, Vmax = 2.95 Volts 
Laser temperature = 15-30oC 
Fibre Optic Cable  
SMA to SMA Patch Cable: 600µm/0.39 NA FT600EMT Fibre ( M29L01 ThorLabs)  
Length = 1meter 
Collimating lens 
λ=633nm SMA Collimation Package, NA 0.25, F=11.0mm (F220SMA-B ThorLabs) 
1/e2 Output beam diameter = 2.2mm 
Full angle beam divergence = 0.021 o 
Aligned at 633nm 
 
2.1.1.2 Microplate Spectrophotometer (Absorbance) 
SPECTRAmax 340PC Microplate Spectrophotometer (Moleculardevices) 
340-850nm Monochromator tuneable in 1nm increments. 5nm FWHM 
5Watt Xenon Flash Lamp,  
Photodetectors = Silicon photodiode  
 
2.1.1.3 Microplate Spectrophotometer (fluorescence) 
Cary Eclipse Fluorescence Spectrophotometer (Varian) 
Excitation monochromator (Czerny-Turner) 190-900nm +/- 1nm 
Emission monochromator (Czerny-Turner) 190-900nm +/- 1nm 
15W Xenon pulse lamp (pulse width 2-3us), Power 60-75kW 
Photodetector = photomutiplier (X2) 
 
Fluroskan Ascent FL; Type 374. (Labsystems)  
Fluorometric filters :  
Excitation = 320nm HBW 40nm / 390nm HBW 20nm / 485nm HBW 14nm.  
Emission = 405nm HBW 50nm / 510nm HBW 10nm / 538nm HBW 25nm / 555nm HBW 25nm 
Quartz-halogen lamp (30W) 
Photodetector = photomutiplier  
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2.1.1.4 Cuvette Spectrophotometer (Absorbance) 
Agilent 8453 UV Visible Spectrophotometer (Agilent Technologies) 
Combined deuterium-discharge lamp  (190-800nm) and tungsten lamp (370-1100nm) 
Photodetector : photo diode array, 190nm-1100nm , nominal spectral slit width= 1nm 
 
2.1.1.5 Luminescent image analyse 
Las-3000 (Fujifilm) 
CCD camera of 3,200,000 pixels with cooling function 
Incident light source: Blue LED (460nm) / White  
Transmitted light source 312nm UV  / White  
Filters: 605DF40 detection between 565 and 645 nm / Y515 for detection over 515 nm 
 
2.1.1.6 Inverted confocal laser scanning microscope  
LEICA TCS SP5 (LEICA) 
Lasers : Argon (max30mW): 458, 476, 488, 496, 514 / Diode: 405 / HeNe1: 543 / DPSS 561 
HeNe2: 633. 
Objectives: 10x Air (HC PL APO 10x 0.40 CS) 20x Air (HC PL APO 20x 0.70 CS) 20x Imm Corr (HC PL APO 20x 0.70 
IMM CORR CS) 40x Oil (HCX PL APO 40x 1.25-0.75 OIL CS) 63x Oil (HCX PL APO 63x 1.40-0.60 OIL CS) 63x 
Water (HCX PL APO 63x 1.20 W CORR CS) 
Detectors : 3 x normal PMT detectors / 1 x FLIM PMT detector / 1 x PMT detector (bright- field) 
/ NDD1: FITC (BS RLD + TLD/RLD) / NDD2: TRITC (BS RLD + TLD/RLD) 
 
2.1.1.7 Flow Cytometer 
FACSCalibur flow cytometer (BD Biosciences) 
Laser : 15 mW 488 nm, air-cooled argon-ion laser / optional red diode laser 635 nm  
Forward Scatter Detector and Filter: solid-state silicon detector; 488 nm bandpass filter  
Side Scatter Detector : Photomultiplier using Brewster-angle beam splitter 
Fluorescence Detectors and Filters : photomultipliers with bandpass filters 
 FL-1 = 530/30, FL-2 = 585/42, FL-3 = 650/LP, FL-4  = 661/16 
 
2.1.1.8 SDS-Page Gels / Western Blot Equipment 
Various short and spacer glass plates and combs for Hand Cast Gels (BioRad) 
Mini-PROTEAN Tetra Electrophoresis System (BioRad) 
Trans-Blot SD Semi-Dry Transfer Cell (BioRad) 
ECL Hybond nitrocellulose membrane (GE Healthcare RPN203D)  
Blotting paper (BioRad 170-3965) 
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2.1.2 Buffers 
(dH20 = deionised water) (RT = room temperature) 
 
10X TG buffer (2L) Store at RT 
 Fw Final; To make; 
Tris 121.14   0.25M 60.4g 
Glycine 75.07 2.5M 376g 
dH2O   Up to 2L 
 
1X SDS-PAGE Running buffer (2L) Store at RT 
 Stock Final; To make; 
TG buffer 10X 1X 200ml 
SDS 20% 0.1% 10ml 
dH2O   Up to 2L 
 
1X Transfer buffer (2L) Store at RT 
 Stock Final; To make; 
TG buffer 10X 1X 200ml 
SDS 20% 0.04% 4ml 
methanol 100% 20% 400ml 
dH2O   Up to 2L 
 
10X PBS (10L) Store at RT  
From this make 1 X PBS and 1 X PBS+0.1% Tween 20  
 Fw Final 10X; To make up;  
NaCl 58.44 1.37M 800g 
KCl 74.55 0.027M 20g 
KH2PO4 138.08 0.018M 24g 
Na2HPO4 141.96 0.101M 144g 
dH2O   Up to 10 Litres 
 
TE buffer (pH 8) (100ml) Store at RT 
 Stock Final; To make; 
Tris 100mM 10mM 10ml 
EDTA 0.5M 1mM 0.2ml 
dH2O   Up to 100ml 
pH to 8.0 with HCL 
NB: when making up 0.5M EDTA warm slightly and continually pH >pH8 with NaOH during dissolution  
 
FC buffer 
 Final  Supplier and Cat no 
FBS 2% Gibco 10108-165 
EDTA 1mM Sigma E7889 
PBS(-Mg-Ca)  PAA HIS-002 
Make up under sterile conditions with sterile stocks  
 
  
Page | 57  (Hayley Pye 2012) 
 
 
12%  Acrylamide SDS Gels  
(mixed in the order listed below, APS then TEMED last) 
Acrylamide and TEMED have to be stored in the toxic cabinet at RT. APS is only stable for a few months at 4
o
C, re 
–make if not used within this time. Tris and SDS buffers can be stored at RT for longer periods of time. 
 
Coomassie (and de stain) 500ml 
 
 
 
 
 
 
 
Laemmli Loading buffer 50ml (for reducing and denaturing conditions) 
 
 
 
 
 
 
 
 
2TY media 
 Make up 2.5L in dH20 and send to autoclave, aliquot at 500ml plus 3 X 20mls  
(storable at RT unopened for a couple of months) 
 
 
 
 
 
 
2TY agar 
Make 1L 2TY agar in dH20 and send to autoclave, aliquot at 200ml  
(around 10 plates, ~10ml per plate) 
(storable at RT unopened for a couple of months) 
 
 
 
 
 
 
 
NB doesn’t completely go into solution at RT so heat it up on stirrer for a bit to get as much in as possible and try to 
pour evenly for aliquots. Re heat in Microwave until all in solution before pouring plates under flame. NB wait to 
cool until it’s just bearable to touch before adding antibiotic. 
  
 Resolving Gel  Stacking Gel 
 1 Gel 2 Gel 3 Gel  1 Gel 2 Gel 3 Gel 
dH2O 1.7ml 3.4ml 5.1ml dH2O 1.5ml 3.0ml 4.5ml 
1.5M Tris pH 8.8 1.25ml 2.5ml 3.75ml 1.0M Tris pH 6.8 0.25ml 0.5ml 0.75ml 
30% Acrylamide 2.0ml 4.0ml 6.0ml 30% Acrylamide 0.3ml 0.6ml 0.9ml 
10% SDS 50ul 100ul 150ul 10% SDS 20ul 40ul 60ul 
10% APS 50ul 100ul 150ul 10% APS 20ul 40ul 60ul 
TEMED 2ul 4ul 6ul TEMED 2ul 4ul 6ul 
Ingredient (stock) FINAL Coomassie  De-Stain 
Methanol (100%) 40% 200ml  200ml 
Acetic acid (100%) 10% 50ml  50ml 
De-Ionised water Made up to 500ml 250ml  250ml 
Brilliant Blue R (Sigma B0149) 0.1% 0.5g  / 
Ingredient (stock) FINAL (1x) FINAL (5x)  For 50ml 
Tris pH6.8 (Fw 121.14) 0.0625 M 0.3125 M  12.5 ml of 0.3125 M pH’d to 6.8 
SDS (solid) 2% 10%  5g 
Glycerol (100%) 10% 50%  25 ml 
Brilliant Blue R (Sigma B0149) 0.01% 0.05%  0.025g 
β-mercaptoethanol 5% 25%  12.5 ml 
 Amount (g in 1L) Supplier and Cat no 
Tryptone 16g Merck 1.11931.1000 
Yeast 10g Merck 1.11926.1000 
NaCl 5g BDH 102415K 
 Amount (g in 1L) Supplier and Cat no 
Tryptone 16g Merck 1.11931.1000 
Yeast 10g Merck 1.11926.1000 
NaCl 5g BDH 102415K 
Agar 15g Merck 1.01614.1000 
Page | 58  (Hayley Pye 2012) 
 
 
2.1.3 Computation Based Methods 
2.1.3.1 Curve fitting and equations  
Where fitted used  = SigmaPlot for Windows Version 11.0 (Systat Software, Inc.) 
Name Equation Constraints Figure 
4 parameter logistic 
curves 
y = min +      (max-min)       . 
                   1+(x/EC50)
-Hillslope
 
 
Figure 11 
Figure 14 
2 parameter power curve y = aX
b
 b<0 
Figure 15 
Figure 31 
Exponential Decay, 
Double, 4 Parameter y = ae
(-bx) 
+ ce
(-dx)
  Figure 12 
Sigmoidal, Sigmoid, 4 
Parameter 
y = y0  +         a          . 
                1 + e 
–((x-x0)/b)
 
 Figure 12 
Exponential rise to 
maximum y = a (1- e
-bx
) b>0 
 
Figure 30 
 
2.1.3.2 Computational pKa prediction  
The programme used to present data in 3.2.3.3 is: 
MarvinSketch Freeware Version: 5.7.0, (ChemAxon Ltd.) www.chemaxon.com  
It utilizes a QSPR method the details to which can be found at: 
http://www.chemaxon.com/marvin/help/calculations/pKa.html  
 
Models for computational pKa 
Different algorithms have been developed to calculate the pKa. Standard methods for pKa. 
prediction can be purely empirical and based on observation or experimentation; or based on 
quantum methods which utilize 3D structure determinants and calculated quantum mechanical 
properties. The more commonly used empirical methods include 1) linear free-energy 
relationships (LFER), based on the Hammett and Taft equations which a im to correlate atomic 
properties to biological activity.  2) Quantitative structure-property relationships (QSPR), based 
on correlating calculated structural groups with predefined pKa values. Or 3) Database similarity 
relationships, methods that search for similar whole structures in a database of molecules with 
known experimentally measured pKa. values. It is still not clear which of these is best and often 
different methods favour the chemical type upon which they were originally developed. (Liao 
and Nicklaus, 2009)  
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2.1.3.3 Computational Log P Prediction 
The programmes used to present data in 3.2.3.4. are: 
 
ACD/Log P  
Calculated with ADC/Chemsketch Freeware, Version 11.02, (Advanced Chemistry 
Development Inc. ACD/Labs) www.acdlabs.com  
Uses a fragmental based method details to be found at 
http://www.acdlabs.com/resources/freeware/chemsketch/logp/  
 
ALOGPs, AC LogP, KOWNN, XLOGP2 and XLOGP3  
calculated with the ALOGPS 2.1 freeware  (Virtual Computational Chemistry 
Laboratory, VCCLAB)  www.vcclab.org 
Use various methods, details to be found at  http://www.vcclab.org/lab/alogps/ 
 
VG, KLOP, and PHYS   
Calculated with MarvinSketch Freeware Version: 5.7.0, (ChemAxon Ltd.) 
www.chemaxon.com. 
All uses atomic level fragmental based methods utilising 3 databases published by 
Viswanadhan et al (VG), Klopman et al (KLOP) and the PHYSPROP database (PHYS) 
details to be found at http://www.chemaxon.com/marvin/help/calculations/logPlogD.html  
 
Models for computational LogP 
Computational Log P predicting software is readily available as freeware online, there have been 
multiple algorithms designed over the years but all are being continually improved, many can 
provide some impressive correlations with experimental data (Xing and Glen, 2002a) The 
standard methods can be grouped as either substructure methods or property based methods. 
Substructure methods will break a molecule into fragments or single atoms and assign each a 
contribution value which are then summed, most fragmental methods also apply additional 
correction factors to compensate for intermolecular interactions. Property based methods use 
structural features and various considerations of the entire molecule to calculate its predicted 
behaviour in a solvent. It is normally suggested that one uses multiple programmes. (Faller and 
Ertl, 2007; Mannhold and van de Waterbeemd, 2001; Mannhold et al., 2009; Xing and Glen, 
2002b). 
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2.1.3.4 Protein Homology modelling  
Protein fold recognition server used =  PHYRE  Version 0.2 Structural Bioinformatics 
Group, (Imperial College, London) (http://www.sbg.bio.ic.ac.uk/~phyre/)  
 
More information on PHYRE can be found within the case study published in Nature Protocols 
(Kelley and Sternberg, 2009). 
 
The amino acid sequence was trimmed to remove tags and linker regions and the heavy and light 
variable regions put through independently. The top models for the two domains were 
downloaded, heavy chain top model was based on SCOP code d1n0xh1; (Immunoglobulin heavy 
chain variable domain, VH from Human (Homo sapiens), cluster 1) with 50% amino acid ID and 
an E value of 4.4 x 10 -18, Estimated precision was 100%. The top model for the light chain was 
based on SCOP code d1rzfl1; (Immunoglobulin light chain lambda variable domain, VL-lambda 
from Human (Homo sapiens), cluster 2) with 77% amino acid ID and an E value of 3.3 x 10 -16, 
Estimated precision was 100%. (NB high-confidence homologs have E values < 0.001). These 
two models were then aligned to the variable heavy and light chains in an endogenous IgG with a 
known structure taken from the RCSB Protein Data Bank or PDB 
(http://www.rcsb.org/pdb/home/home.do) structure ID =1IGT, which is of a intact IgG2a 
monoclonal antibody refined to Resolution of 2.80 Å and an R value of 0.209. (Harris et al., 
1997).  
 
The results from this modelling work for C6.5-k were manipulated in The PyMOL 
Molecular Graphics System, Version: Open-Source PyMOL 1.1eval. Schrödinger, LLC. 
(http://pymol.org/)  
 
The 3D model was also put through the PROPKA 3.0 server (Jensen Research Group, 
Department of Chemistry, University of Copenhagen) (http://propka.ki.ku.dk/). 
 
PROPKA calculates the predicted pKa. values of ionisationable residues (including lysines) 
taking into consideration extra information from the 3D structure file such as spatially 
neighbouring residues and solvent exposure (Bas et al., 2008). 
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2.1.4 Cell Based Methods 
2.1.4.1 Cell culture 
SKOV3 cells (human ovarian adenocarcinoma)  
ATCC number = HTB-77TM  (http://www.lgcstandards-atcc.org) 
Cells were cultured in DMEM media (PPA E15-883) or phenol red free DMEM media 
(PAA E15-877) supplemented with 10% FBS (Gibco 10108-165) , incubated at 37oC / 
5%CO2 and split twice a week along standard cell culture techniques for an adherent cell 
line. 
 
U-87 cells (human brain glioma) 
ATCC number = HTB-14 TM (http://www.lgcstandards-atcc.org) 
Cells were cultured in DMEM media (PPA E15-883) or phenol red free DMEM media 
(PAA E15-877) supplemented with 10% FBS (Gibco 10108-165) and 1% NEAA (SIGMA 
M7145), incubated at 37oC / 5%CO2 and split twice a week along standard cell culture 
techniques for an adherent cell line. 
 
Jurkat E6-1 cells (human acute T cell leukaemia) 
ATCC number TIB-152 TM (http://www.lgcstandards-atcc.org) 
Cells were cultured in RPMI media (PPA E15-885) or phenol red free RPMI media (PAA 
E15-848) supplemented with 10% FBS (Gibco 10108-165) and 1% NEAA (SIGMA 
M7145) 1mM Sodium Pyruvate (SIGMA 58636) and 50uM β-mercaptoethanol, incubated at 
37oC / 5%CO2 and split twice a week along standard cell culture techniques for a suspension 
cell line. 
 
Initially all cell lines were grown up and multiple stocks made and stored in 20 % DMSO in FCS 
under liquid nitrogen along standard cell culture techniques. Cell used in all experiments 
presented in this thesis were of passage numbers no more than 15 more than this original stock. 
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Genetic abnormalities in SKOV-3 cells 
 
It is worth noting that SKOV-3 are a hypoploidy cell line, information taken from ATCC 
(http://www.lgcstandards-atcc.org) states the modal chromosome number for this cell line is 43, 
occurring in 63.3% of cells with a range from 42-45.  
 
Listed are the coding gene mutations mentioned on the Wellcome Trust/Sanger Institutes  
COSMIC database: SKOV-3 COSMIC I.D. = 905959. (Forbes et al., 2006), Care has to be taken 
using such databases as they can contain both cancer causing mutations and passenger mutations. 
Additionally due to the complexity of signalling pathways post gene transcription, these 
mutations in single genes, although interesting, are currently unlikely be unable to tell us 
everything about how our cell line will behave. 
 
 Homozygous mutation in both p53 genes. (triggers cell cycle arrest and apoptosis 
in response to diverse stress stimuli)  
 
 Homozygous deletion mutations in the gene coding for Cyclin-dependent kinase 
inhibitor 2A (negative regulator of proliferation of normal cells)  
 
 Heterozygous substitution missense mutation in the gene coding for 
Phosphoinositide-3-kinase (PI3K), (Involved in the generation of PIP3 in the 
cellular membrane which activates signalling cascades involved in cell growth, 
survival, proliferation, motility and morphology)  
 
 Homozygous whole gene deletion of the gene coding for mismatch repair protein 
Mlh1, (a component of the post-replicative DNA mismatch repair system).  
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2.1.4.2 Control compounds  
Staurosporine (Merck 569397)  
(Mw = 466.5 )Stock solution made up at 1mM in DMSO and stored at -80oC 
A small molecular weight compound (466.5 Da) that is a cell permeable promiscuous kinase 
inhibitor (Karaman et al., 2008). Due to the promiscuous nature of staurosporine- it can 
induce apoptosis in a wide range of cell lines, and has an ability to initiate apoptosis via 
different mechanisms, both caspase dependent and independent (Belmokhtar et al., 2001; X. 
D. Zhang et al., 2004). This means inherent mutations within cancer cell lines that convey 
protection from apoptosis will be less influential. Staurosporine at sub apoptotic doses can 
induce cell cycle arrest at various points; relatively low dose can cause G1 cell cycle arrest 
and subsequent accumulation at this phase and relatively high dose can induce G2/M arrest 
(Bernard et al., 2001). 
 
Triton X 141, (Sigma X114)  
(Av Mw =537) Stock solution made up at 10%  in Water and stored at room temperature. 
Triton X 114 is an non-denaturing non- ionic detergent and for cell lysis is used at levels 
sufficient to break open cellular membranes and form mixed cell lipid/detergent micelles, 
i.e. above the critical micelle concentration (Koley and Bard, 2010), the CMC for Triton X 
114 is approx 0.2mM or 0.009% in water), below CMC triton has been shown to be able to 
induce an apoptotic like phenotype including DNA laddering (Strupp et al., 2000) . 
 
Cisplatin  (Sigma P4394) 
(Mw = 300.05 ) Stock solution made up at 10mM in DMF and stored at -80oC 
A platinum containing clinical chemotherapy compound (Mw 300), thought to induce 
apoptosis primarily via its ability to form cross links between DNA bases (Jamieson and 
Lippard, 1999; Siddik, 2003). The influence of additional protein adducts is also suggested, 
and like staurosporine, a number of different cell death mechanisms can be initiated 
(Berndtsson et al., 2007). Cisplatin at low doses is also known to be able to induce cell cycle 
arrest at various points in particular an S phase block that in some cases appears to be 
transient and leads to a delayed G2 block (Qin and Ng, 2002; Siddik, 2003) 
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2.1.4.3 Photodynamic therapy;  
Pyropheophorbide-a (PPa) (Frontier Scientific Inc 24533-72-0) 
PS4 and PS1 synthesised in house. (Dr G. Yahioglu and Dr. I. Stamati) 
PS stored in 100% dry DMSO at 4oC in a dark dry environment. 
HPD 7401 laser system 
 
Cells were plated in black 96 or 6 well plates, replicate plates were set up for +/- laser. The 
day after plating, media was replaced with new media containing PS. PS was diluted into 
supplemented phenol red free cell culture media (PS stock in 100% DMSO, PPa 18.7mM, PS1 
24.52mM, PS4 25.11mM) and final DMSO made up to 2%, DMSO vehicle and compound 
controls were also plated. Plates were protected from ambient light with foil and where necessary 
assays were carried out in subdued lighting. Cells were incubated for a further 2 hours the n 
washed twice with PBS, media re-added then cells were lasered.  
 
Calibration of laser power:  
The laser power output over the whole beam was measured and optimised to deliver 33 mW/cm2 
in both microplate formats, see below. The standard laser dose was 10  seconds of 670nm laser 
light at a final fluence of 0.33 J/cm2.  
(1 Watt = 1 Joule / Second) 
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2.1.4.4 MTS assay 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (PROMEGA G3580). 
Read on : SPECTRAmax 340PC Microplate Spectrophotometer 
 
Cells were plated in a 96 well plate at 2500 cells/well in 200 µl supplemented DMEM phenol red 
free media (phenol red interferes with absorbance readings at 490nm.) After treatment 20 µl 
MTS assay reagent was added directly to each well and the plate incubated at 37oC / 5%CO2,  
protected from light, for a further 2 hours. The absorbance at 490nm was then read. 
 
What the MTS assay measures 
The MTS assay is a well used stardard end point for the in vitro cyto-toxicity assay. It is an 
adaptation of a relativilty old technique used to measure cell viability via metabolic capacity (the 
MTT assay) (Mosmann, 1983). It is based on the fact that metabolism in viable cells produces 
reducing equivalents- these will indirectly reduce the MTS reagent into a soluble coloured 
formazan product. At death, cells rapidly lose this ability to reduce MTS, and so the production 
of the coloured formazan product is proportional to the number of viable cells in culture. 
Reduction occurs at various locations throughout the cell (Bernas and Dobrucki, 2002). Key 
reducing agents thought to be responsible for the change include the reduced pyridine 
nucleotides NADH and NADPH (Takahashi et al., 2002; Vistica et al., 1991). 
 
2.1.4.5 Confocal fluorescent microscopy  
Image management:  LAS AF Lite: Version 2.6.0 (Leica Microsystems CMS GmbH) 
Cells were plated in a Lab-Tek 8 well chambered borosilicate cover glass (NUNC 155411) at 
10,000 cells/well in 200 µl supplemented DMEM phenol red free media, replicate wells were set 
up for dye free cell controls for endogenous fluorescence (negative control). After treatment and 
depending on experimental set up, cells were either; imaged directly, washed once in PBS prior 
to imaging, or washed with PBS, fixed with 4% methanol free formaldehyde in PBS (Thermo 
Scientific 28906)  for 10 minutes at room temperature, washed again and then imaged. Lasers 
and detector set up was optimised for each experiment so no fluorescence was seen from 
negative control and the control predicted to have the highest fluorescence was not saturated. See 
individual experiment details for the objectives, laser and detector settings used. Be tween 
comparable images, laser parameters and detector gain and offset were not adjusted.  
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PS fluorescent spectra overlaid with the available lasers   
Fluorescence spectra of equivalent concentrations of photosensitisers read in 100% DMSO 
on Cary Eclipse Fluorescence Spectrophotometer. Due to its lower fluorescent efficiency PS4 is 
plotted on a different axis to PPa and PS1 to show the optimal spectral pattern. 
 
 
LASERS = NearUV: 405, Argon: 458/476/488/496/514, DPSS: 561, HeNe: 543/633 
 
Quantification of confocal fluorescent microscopy image  
SOFTWARE   = Image J, Version 1.45s, (Wayne Rasband, National Institutes of Health) 
http://rsbweb.nih.gov/ij/  
 
To quantifying the images for fluorescent intensity a mask was made from the brightfield 
image to cover the area of the image not covered by cells. One of the macros written for this in 
Image J software and examples of what is happening to the image is shown over the page. 
Average fluorescent intensity can then be measured from the fluorescence images but restricted 
to the area prescribed by the brightfield mask. The fluorescent image is opened alongside the 
brightfield binary image in image J. The fluorescent image needs to be converted to an 8-bit 
greyscale image and if actual cell area is required the scale can be set to µm with the known 
image width (found in original image information in LAS AF Lite software). Using Image Js 
analyze particles plugin the measurements need to be re-directed from the binary image to the 
fluorescent one and the mean grey value for each independent ‘particle’ on the binary image  is 
calculated, this can then be averaged relative to particle size to obtain average fluorescence 
intensity for the cell only area.  
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Macro for brightfield image conversion to a binary image: 
run("8-bit"); 
//run("Brightness/Contrast..."); 
run("Enhance Contrast", "saturated=0.35"); 
run("Apply LUT"); 
run("Find Edges"); 
setAutoThreshold("Default"); 
//run("Threshold..."); 
setThreshold(40, 255); 
run("Convert to Mask"); 
run("Dilate"); 
run("Median...", "radius=5"); 
run("Remove Outliers...", "radius=6 threshold=50 which=Dark"); 
 
What is happening during macro  
 
Below is a representation of the binary image above converted to an outline and overlaid with the 
original cell images.  
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Recognising patterns of intracellular localisation  
 
Identification of intracellular localisation was based on fluorescent images of proteins with 
prescribed localisations, in particular images from the work by both the Pepperkok lab and the 
Wiemann lab in their GFP-cDNA Localisation Project. Example images from this are shown in 
below or can be found online (http://gfp-cdna.embl.de/). or in papers such as (Simpson et al., 
2000). Examples of such images produced using GFP tagged proteins are shown below 
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2.1.4.6 PS Uptake experiment  
Read on : Cary Eclipse Fluorescence Spectrophotometer 
 
Uptake experiment in a 96 well microplate 
Cells were plated in 96 well plate at 8000 cells/well, cell containing plates were also set up 
for the standard curves. The day after plating, media was replaced with new media containing 
PS. PS was diluted into supplemented phenol red free cell culture media (PS stock in 100% 
DMSO, PPa 18.7mM, PS1 24.52mM, PS4 25.11mM) and final DMSO made up to 2%, DMSO. 
For the standard curves known dilutions of PS in 100µl DT lysis solution (DT=0.25%triton x 
114 in DMSO) were plated directly over the cells. Plates were protected from ambient light with 
foil and where necessary assays were carried out in subdued lighting. Cells were incubated at the 
desired condition for the chosen time and then washed twice with PBS before adding 100ul DT 
lysis solution (DT=0.25%triton x 114 in DMSO) to each well and the plates read alongside the 
standard curve plates. The fluorescence was read using Excitation at 410nm and Emission at 
680nm.  
 
Uptake experiment in cell culture flask 
Adaption to a larger cell number; cells were grown in small flasks covering an area of 25cm2, 
exposed to PS in cell culture media as before and then (as quickly as possible and under subdued 
lighting) washed twice, harvested with trypsin (via normal cell culture technique), and washed 
with PBS again, all via centrifugal wash steps, the cell pellet was then lysed into 350ul DT lysis 
buffer. This was then divided into 100ul aliquots over 3 wells in a 96 well microplate and the 
fluorescence read from the 96 well plate as before. For the standard curves known dilutions of 
PS in 100ul DT lysis solution (DT=0.25%triton x 114 in DMSO) were plated in empty 96 well 
microplates to be read at the same time as the sample plates 
  
Page | 70  (Hayley Pye 2012) 
 
 
2.1.4.7 Protein assays 
Micro BCA Protein assay kit – Thermo scientific (23235) 
Coomassie (Bradford) Protein assay kit – Thermo scientific (23200) 
 
Additional information BCA Assay 
Bicinchoninic acid (BCA) is the detection reagent for Cu+1, which is formed when Cu+2 is 
reduced by protein in an alkaline environment A purple-coloured reaction product is formed by 
the chelation of two molecules of BCA with one cuprous ion (Cu+1). This water-soluble complex 
exhibits a strong absorbance at 562nm that is linear with increasing protein concentrations. The 
macromolecular structure of the protein, the number of peptide bonds and the presence of four 
amino acids (cysteine, cystine, tryptophan and tyrosine) have all been reported to be responsible 
for colour formation with BCA http://www.piercenet.com 
 
Additional information Bradford Assay 
When coomassie dye binds protein in an acidic medium, an immediate shift in absorption 
maximum occurs from 465nm to 595nm with a concomitant colour change from brown to blue. 
NB: Differences in amino acid sequence, isoelectric point, structure and the presence of certain 
side chains or prosthetic groups can alter the protein’s colour response 
http://www.piercenet.com. 
 
2.1.4.8 Trypan Blue assay. 
Trypan Blue (Sigma T8154).  
 
Cells were plated in a 96 well plate at 8000 cells/well, and the day after cells are treated. 
After treatment media is removed, and cells washed in PBS, Trypan blue was added in PBS at a 
final concentration of 0.2% and left at room temperature for 5 minutes, cells were then washed 
again and then fixed with 4% methanol free formaldehyde in PBS (Thermo Scientific 28906) for 
10minutes room temperature, solution was then removed and 50 µl PSB added. Cells could then 
be stored at 4oC until they could be imaged on an inverted light microscope at x63 objective 
under white light from a mercury bulb.  
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2.1.4.9 Caspase assay. 
Apo-ONE Homogeneous Caspase-3/7 Assay(PROMEGA G7790). 
Read on : Cary Eclipse OR Fluroskan Ascent FL Fluorescence Spectrophotometer. 
 
Cells were plated in a black 96 well plate at 8000 cells/well. During treatment final volume 
was adjusted to 100 µl. After treatment 70 µl media was removed from each well and 25 µl 
caspase reagent added, the plate was incubated in foil at 37oC / 5%CO2, protected from light for 6 
hours. The fluorescence was read using Excitation at 500nm and Emission at 520nm. 
 
The caspases detected in the caspase assay 
To measure caspase 3 and 7 activation cells are permeabilised and a profluorescent substrate 
specific for caspase 3 and 7 is delivered, any active caspase 3 and 7 that is present can then 
cleave the assay substrate into its fluorescent form – this can then be measured. The main 
caspases that participate in apoptosis can be divided into the initiator caspase group, which 
includes caspases 2, 8, 9 and 10; usually activated by dimerisation, and the effector caspase 
group to which caspases 3, 6 and 7 belong; usually activated by cleavage. Effector caspases can 
be activated by a number of different upstream apoptotic signalling pathways (traditionally by 
cleavage by initiator caspases) and so the presence of activated effector caspases is a convenient 
way to look for activation of a number of apoptosis pathways in parallel. (Huai et al., 2010; 
Kroemer and Martin, 2005; Pop and Salvesen, 2009). 
 
2.1.4.10 DNA fragmentation assay 
For each condition cells were plated in an entire 6 well plate at 80,000 cells per well. After 
treatment cells were trypsinised and pooled, the cell pellet obtained from both well supernatant 
and trypsinised cell layer was snap frozen in a 100%EtOH/Dry ice mixture and stored at -80oC. 
Subsequently genomic DNA was extracted using a Phenol/Chloroform extraction technique 
detailed over the page. After extraction DNA (4 µg) was made up in DNA loading dye 
(Fermentas R0611) and loaded into a 1.5% agarose gel and ran slowly at 60V for 1 hour. The gel 
was then stained in either ethidium bromide (SIGMA E7637) or GelRedTM (Biotium) in TE 
buffer at 0.5 µg /ml EtBr or 1X GelRedTM respectively. Gels were visualised under UV light. If 
necessary used two 8 well combs stuck back to back to widen the well so it could take a capacity 
of ~50µl, (single comb was only ~15µl.)   
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Detailed method: Extraction of Genomic DNA from Cells  
Note: Do all of the following transfers of the DNA-containing supernatant with a wide-bore 
pipette tip or a tip with the end cut off. This is because the DNA will be viscous, and it can be 
easily sheared.  
 
Extraction buffer (pH8) =10mM Tris-Cl  / 0.1 M EDTA / 0.5% SDS / MilliQ Water  
Just prior to experimentation supplement extraction buffer with final concentration 20µg/ml 
RNAse (SigmaR5125) and 100µg/ml  Proteinase K (SigmaP2308).  Resuspend cells (from frozen 
pellet) in 1ml extraction buffer. Detach cell pellet by carefully flicking tube with finger or gentle 
pipetting  Incubate at 55oC for 3 hours or until pellet is dissolved.  Cool to room temp. Add 1ml 
of phenol equilibrated to pH 8.0 (SigmaP4557) to each eppendorf. Mix two phases by slowly 
turning tubes over for 10 minutes. Centrifuge at 2000rpm for 2mins to separate the phases on a 
bench top centrifuge. Transfer the top aqueous phase (DNA-containing) to new tubes. Repeat the 
extraction using 1ml of phenol+chloroform(1:1). Again save the top phase. Repeat extraction 
using 1ml of chloroform. Again save the top phase.  Divide the top phase into 2 (~500ul/eppi) 
into 2ml eppendorfs Add 1ml 100% Cold EtOH (-20oC) and 100ul 5M NaCl to each. Put at -
20oC for at least two hours (overnight also ok).  Spin on high (~14,000rpm) at 4oC in microfuge 
to precipitate DNA for 15minutes. Remove EtOH and resuspend pellet in 700ul 70% ethanol. 
Spin on high (~14,000rpm) at 4oC  for 5 minutes. Remove as much EtOH as possible and invert 
on tissue and allow any remaining EtOH to evaporate (can put on 37oC heat block with lid open 
for 10/20min to help.) Add 100ul TE buffer (pH8) to all tubes and 
resuspend pellet, recombine split samples as one here. 
 
QUANTIFICATION 
Take a 10ul sample of DNA and mix with 190ul TE buffer 
(1:20 dilution) and measure absorbance on UV-VIS spec 
reader over 190-400nm and record values for A260. 1 x A260 
unit of double stranded DNA = 50ug  DNA/ml so use the 
following equation to calculate DNA concentration of 
sample. 
A260(1cm) X50 Xdilution factor =  DNA in ng/µl 
DNA marker  (Fermentas SM0313)    
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2.1.4.11 Cell cycle assay 
FACSCalibur flow cytometer (BD Biosciences)  
Software = FlowJo. Version: 7.6.5 (Tree Star, Inc.) http://www.flowjo.com/  
 
For each condition cells were plated in an entire 6 well plate at 80,000 cells per well. Include 
additional conditions exposure to control compounds (positive controls) and an untreated control 
for endogenous fluorescence (negative control). Replicate plates were set up for each condition 
for a saponin free PI stained cell control to check for any cell death. After treatment cells were 
removed with Accutase solution  (PAA L11-007) and pooled, the cell pellet obtained from both 
well supernatant and cell layer was resuspended and washed once in PBS then resuspended in 
200ul PBS+5%FCS. For negative control leave unsupplemented, for cell death controls 
supplement with 50ug/ml Propridium Iodide (Sigma P4864), for cell cycle analysis supplement 
with 50ug/ml Propridium Iodide and 0.05% Saponin (Sigma S7900). Store on ice and run 
directly on a flow cytometer, readjusting detection channels between cell death analysis and cell 
cycle analysis. For cell cycle analysis set up to include FL-2 as the DDM (see below) 
  
Background information -Cell cycle assay 
To identify what part of the cell cycle a population of cells are in one of the most established 
methods involves cell permeablisation and subsequent staining of genomic DNA with 
propridium iodide, multi-parametric analysis by flow cytometry can then determine the 
difference in fluorescence between individual cells with 1 set of chromosomes (cell cycle 
position G1), 2 full sets of chromosomes (cell cycle position G2) or mid synthesis of the second 
set, i.e. somewhere in between G1 and G2 (cell cycle position S) NB: any cells actively 
undergoing Mitosis (M) will appear with G2 and any cells in quiescence (G0) will occur with 
G1. Each cell is measured independently and so can be assigned to a cell cycle position 
depending on the amount of DNA they contain (the intensity of their fluorescence). Any 
apoptotic or necrotic cells with partially degraded or fragmented DNA will be shown within the 
DNA histogram as a sub-G1 peak (Ormerod, 2002) . 
 
Fluorescence of propridium iodide bound to DNA    
http://www.invitrogen.com/site/us/en/home/support/Prod
uct-Technical-Resources/Product-Spectra.1304dna.html   
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PS Fluorescence spectra of PS overlaid with BD FC Calibur setup options. 
 
Data manipulation for cell cycle analysis 
Fluorescence intensity is detected in channel FL-2 as the DDM parameter (doublet 
discrimination mode), DDM means it will record FL2- W (width of fluorescent pulse, i.e. time 
taken to travel through detector) FLA-H (height of pulse, i.e. maximum fluorescence intensity) 
and FL2-A (area, i.e. total fluorescence of pulse, area*height/2). FL2-H which is recorded on a 
log scale normally is sufficient to see shifts positive and negative between populations, but as 
cell cycle data requires a greater sensitivity it is recorded on a linear scale and so 2 cells which 
are in G1 travelling together will give the same signal as 
one cell in G2 travelling alone. For this reason it is 
important to separate artefacts such as these. To do this, as 
well as separating signal from larger aggregates or cell 
debris, data can be gated out by plotting FL2-A vs. FL2-W 
and gating out all outliers as shown on the right. (Taken 
from : http://www.ucl.ac.uk/wibr/services/docs/cellcyc.pdf)  
 
After gating FlowJo was used to fit a Watson Pragmatic 
model to the FL2-A histogram in order to define the G1, S, and G2 phases of the cell cycle. This 
model fits G1 and G2 with Gaussian curves and no assumptions are made about the shape of the 
S-Phase distribution. When cell cycle curves were modelled in all cases G2 was constrained to 
be twice the fluorescence of G1 – the centres of these peaks at the constrained distance are 
marked as lines in the figure. More information on the software can be found at: 
 http://www.flowjo.com/home/tutorials/TN/cellcycleweb2010.pdf   
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2.1.5 Protein Based Methods  
 
2.1.5.1 Cloning of C6.5-k 
C6.5 is a fully human anti-HER2 single-chain Fv isolated from a filamentous phage antibody 
library, first described by (Schier et al., 1995), see 5.1.1. The original paper by (Schier et al., 
1995) presented the full amino acid sequence of the heavy chain and light chain (without any 
tags or linkers, the linker they used was a ‘single chain linker’ (G4S)3 like ours). Later work 
produced a range of higher affinity versions by light chain shuffling, heavy chain shuffling, and 
molecular evolution of the VL CDR3 region (Schier et al., 1996a, 1996b). 
 
Previous work within this lab had cloned the full length scFv antibody fragment C6.5 
(obtained from Prof J. Marks (University of California, SanFrancisco) with an N terminal pelB 
secretion sequence, C terminal His and Myc tags into a PUC119 vector under control of the lac 
promoter. An annotated sequence confirmed by recent sequencing for the inserted antibody is 
shown in section 2.1.5.2. Various mutations to the amino acid sequence were carried out 
including: The lysine in CDR3 was changed to an alanine (K111A) and two leucine to valine 
mutations were introduced at the N terminal - it was then was termed C6.5-k. This sequence 
compared to the sequence of the original C6.5 antibody is shown below. (Mutagenesis, 
expression and Biacore analysis for kinetic constants (see 5.1.1.) were carried out at within the lab 
of M.P.Deonarain at Imperial College) 
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2.1.5.2 Annotated amino acid and DNA Sequence of C6.5-k 
KEY  
Start /Stop 
His Tag (HHHHHH) Myc Tag (EQKLISEEDL) 
pelB leader sequence (MKYLLPTAAAGLLLLAAQPAMA)  
Nco1(C/CATGG) Not1 (GC/GGCCGC)  
Linker region  
Heavy chain framework regions (1,2,3 and 4)     /    Light chain framework regions (1,2,3 and 4)      
Heavy chain CDR  (1,2, and 3)                            /    Light chain CDR  (1,2, and 3)                       .      
 
      ATG  AAA  TAC  CTA  TTG  CCT  ACG  GCA  GCC  
      Met      K        Y        L        L        P        T        A        A         
        PelB leader Sequence 
GCT  GGA  TTG  TTA  TTA  CTC  GCG  GCC  CAG  CCG  GCC  ATG  GCC  CAG  GTG   
  A        G        L        L         L         L        A       A        Q        P         A        M        A      Q        V 
            Nco1 
CAG  CTG  GTG  CAG  TCT  GGG  GCA  GAG  GTG  AAA  AAG  CCC  GGG  GAG  TCT   
   Q        L        V        Q        S        G        A        E        V        K        K        P        G        E        S   
 
CTG  AAG  ATC  TCC  TGT  AAG  GGT  TCT  GGA  TAC  AGC  TTT  ACC  AGC  TAC   
   L        K        I         S        C        K        G        S        G        Y        S        F        T        S         Y   
 
TGG  ATC  GCC  TGG  GTG  CGC  CAG  ATG  CCC  GGG  AAA  GGC  CTG  GAG  TAC   
   W        I        A       W        V        R        Q       M        P        G        K        G        L        E       Y 
 
ATG  GGG  CTC  ATC  TAT  CCT  GGT  GAC  TCT  GAC  ACC  AAA  TAC  AGC  CCG   
   M       G        L        I        Y        P        G        D         S        D        T        K        Y        S         P  
 
TCC  TTC  CAA  GGC  CAG  GTC  ACC  ATC  TCA  GTC  GAC  AAG  TCC  GTC  AGC   
   S        F        Q        G        Q        V        T        I         S        V        D        K        S        V         S 
 
ACT  GCC  TAC  TTG  CAA  TGG  AGC  AGT  CTG  AAG  CCC  TCG  GAC  AGC  GCC   
   T        A        Y        L        Q        W        S        S        L        K        P        S        D        S        A 
 
GTG  TAT  TTT  TGT  GCG  AGA  CAT  GAC  GTG  GGA  TAT  TGC  AGT  AGT  TCC   
   V        Y        F        C        A        R        H        D        V        G        Y        C        S        S        S 
 
AAC  TGC  GCA  GCG  TGG  CCT  GAA  TAC  TTC  CAG  CAT  TGG  GGC  CAG  GGC   
   N       C        A        A        W        P        E        Y        F        Q        H       W        G        Q       G 
 
ACC  CTG  GTC  ACC  GTC  TCC  TCA  GGT  GGA  GGC  GGT  TCA  GGC  GGA  GGT   
   T        L        V        T        V        S        S        G        G        G        G        S        G        G        G 
            Linker region 
GGC  TCT  GGC  GGT  GGC  GGA  TCG  CAG  TCT  GTG  TTG  ACG  CAG  CCG  CCC   
   G        S        G       G        G        G        S        Q        S        V        L        T        Q         P         P 
 
         (continued over page......) 
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(......continued) 
 
TCA  GTG  TCT  GCG  GCC  CCA  GGA  CAG  AAG  GTC  ACC  ATC  TCC  TGC  TCT   
   S        V        S        A        A        P        G        Q        K        V        T        I         S        C         S 
 
GGA  AGC  AGC  TCC  AAC  ATT  GGG  AAT  AAT  TAT  GTA  TCC  TGG  TAC  CAG   
   G        S        S        S        N         I        G        N        N        Y        V        S        W        Y       Q 
 
CAG  CTC  CCA  GGA  ACA  GCC  CCC  AAA  CTC  CTC  ATC  TAT  GGT  CAC  ACC   
   Q        L        P        G        T        A        P        K        L        L        I         Y        G        H         T 
 
AAT  CGG  CCC  GCA  GGG  GTC  CCT  GAC  CGA  TTC  TCT  GGC  TCC  AAG  TCT   
   N        R        P        A        G        V        P        D        R        F        S        G        S        K        S 
 
GGC  ACC  TCA  GCC  TCC  CTG  GCC  ATC  AGT  GGG  TTC  CGG  TCC  GAG  GAT   
   G        T        S        A        S        L        A        I          S         G        F        R        S        E        D 
 
GAG  GCT  GAT  TAT  TAC  TGT  GCA  GCA  TGG  GAT  GAC  AGC  CTG  AGT  GGT   
   E        A        D        Y        Y        C       A        A        W        D        D        S        L        S        G 
 
TGG  GTG  TTC  GGC  GGA  GGG  ACC  AAG  CTG  ACC  GTC  CTA  GGT  GCG  GCC   
   W       V        F        G        G        G        T        K        L        T        V        L        G        A        A 
                 Not1 
GCA  GAA  CAA  AAA  CTC  ATC  TCA  GAA  GAG  GAT  CTG  AAT  GGG  GCC  GCA   
   A        E        Q        K        L        I         S        E        E        D         L        N        G        A        A 
     Myc Tag 
CAT  CAC  CAT  CAT  CAC  CAT  TAA  TAA   
  H        H        H        H       H        H      stop     stop 
         His Tag 
 
 
 
2.1.5.3 C6.5-k Predictions via EXPASYS ProtParam service 
http://web.expasy.org/protparam/ 
For more information and for information  on how calculations are done  
see (Gasteiger et al., 2005).  
 
Number of amino acids: 278 
Molecular weight: 29185.1 
Theoretical pI: 6.52 
Extinction coefficients: 
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient    65235 
 Abs 0.1% (=1 g/l)   2.235, assuming all pairs of cysteine residues form cystines  
Ext. coefficient    64860 
 Abs 0.1% (=1 g/l)   2.222, assuming all cysteine residues are reduced 
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2.1.5.4 Expression of antibody fragment C6.5-k 
 
Stocks of transformed HB2151 E.Coli bacterial cells containing the antibody vector were 
stored in 10-15% Glycerol in 2TY Media at -80oC. NB all work carried out using full bacterial 
sterile technique as standard. Single colonies from this were picked for carbenicillin selection 
(Melford C0109)  and plated on 2TY agar plates (recipe in 2.1.2) supplemented with 
carbenicillin 0.1mg/ml. A single colony was subcultured into 10ml  2TY media (recipe in 2.1.2) 
then grown up at 370C / 250rpm for ~16hours under high (2%) glucose and carbenicillin 
(0.1mg/ml) conditions overnight until it reached stationary growth phase. At this point bacteria 
were resuspended in 10ml fresh 2TY, and 5ml subcultured into 500ml fresh 2TY + 0.1% Glucose 
+  0.1mg/ml Carbenicillin + a drop of Antifoam 204 (Sigma A8311). Bacteria were cultured at 
37oC 250 rpm until O.D 600nm was 0.6-0.8 then expression was induced by introduction of 
1mM IPTG (Isopropyl-β-D-thio-galactoside) (Melford MB1008) and temperature reduced to 
30oC and left to shake for no more than 16 hours 
 
Inclusion of the PelB leader sequence should direct the protein to the periplasmic space 
where a membrane anchored peptidase will cleave the sequence completely (after “PAMA”) 
(Hauser and  Ryan 2007) (Lei et al 1987). Previous work in our lab (also supported by other 
work in the literature), show that the majority of the protein produced escapes the periplasm and 
accumulates in the extracellular culture media. Therefore supernatant was collected and 
concentrated 10X using a 200 cm² 10,000 MWCO PES crossflow cassette (VIVAFLOW 200, 
Sartorius Stedium VF20P0) with a SciQ 323 bench top pump system (Watson Marlow). 
Supernatant was then dialysed into PBS through MWCO 8 kDa cellulose dialysis tubing (Fisher 
scientific BID-030-040K). From this fully folded C6.5-k was purified via its Myc tag using 
columns pre-prepared with an Anti Myc antibody (9E10 IgG) isolated on Protein G activated 
sepharose beads ( an anti Fc Protein), elution from column was carried out with 0.2M Glycine 
buffers of decreasing pH (pH 5, pH 3 and pH 2.5). Column was previously prepared by Dr 
Antony Constantinou (Imperial College). 
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Analysis of expression  
Various short and spacer glass plates and combs for Hand Cast Gels (BioRad) 
Mini-PROTEAN Tetra Electrophoresis System (BioRad) 
Trans-Blot SD Semi-Dry Transfer Cell (BioRad) 
ECL Hybond nitrocellulose membrane (GE Healthcare RPN203D)  
Blotting paper (BioRad 170-3965) 
 
Samples taken from all wash and elution fractions from the purification process were mixed 
with Laemmli Loading buffer (recipe in 2.1.2)  and separated via SDS PAGE. Gels were cast of 
0.75mm thickness, with resolving and stacking gel made up to the 12% Acrylamide SDS Gels 
recipe above (recipe in 2.1.2). Gels were run under1X running buffer made up as (recipe in 
2.1.2) at constant current (40mA per gel) or a constant voltage (180V) for ~40 minutes or until 
dye boundary is ~1cm from the bottom of the gel.  Two sets of samples were run alongside each 
other and one gel subsequently stained with coomassie (recipe in 2.1.2) and the second gel was 
transferred to nitrocellulose via transfer buffer (recipe in 2.1.2) and a semi-dry transfer blotter. 
The membrane was subsequently blocked (5% Marvel in PBS) for at least an hour then blotted 
with a peroxidase-conjugated anti-polyHistidine IgG used at 1:5000 for 1 hr in 1% Marvel in 
PBS  (AntiHis HRP Sigma A7058) Washed membrane could then be imaged using an ECL 
detection reagent (Amersham ECL plus RPN2132) and chemiluminescence detected and imaged 
on the Las-3000 system. See 2.1.1.5 
 
Protein marker  (Fermentas SM1811) 
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Final protein preparation  
 
The purified fractions containing C6.5-k alone were collected, dialysed into PBS  through 
MWCO 8 kDa cellulose dialysis tubing (Fisher scientific BID-030-040K), concentrated via a 
5000 MWCO polyethersulfone membrane using centrifugal pressure (Vivaspin 20, Sartorius 
Stedium VS2012) and clarified through a 0.2 µm PVDF membrane (Generon # GEN-MSF500) 
before storage at -20oC. 
 
QUANTIFICATION 
Sample was diluted into PBS and absorbance was measured on a UV-VIS spec reader over 
190-400nm and values recorded for A280. The molar extinction coefficient (ε ) is 65235  M-1 
cm-1, at 280 nm measured in water, see 2.1.5.3. The Beer–Lambert law states : 
Aλ = ε c L  (Thermo Scientific, 2008) so when the cuvette used has a path length of 1cm the 
following equation can be used to calculate C6.5-k concentration of sample:  
 
(A280 / 65235) X dilution factor = concentration of protein in Molar 
 
NOTE:. The extinction coefficient was chosen assuming all pairs of cysteine residues form 
cystines because predicted tertiary structure for immunoglobulin type structures such as the VH 
and VL domain have two cystine bridges, this accounts for the 4 cysteine residues in the 
framework regions, another 2 cysteine can be found in the CDR 3 region of the heavy chain, this 
is a solvent accessible flexible loop region important for antigen recognition so it is likely these 
other cysteine also form a bond to help give specific structure and therefore specific recognition. 
(Cystine is the name given to the dimerisation of two cysteine residues via oxidation, the bond is 
referred to as a disulfide bond, and can contribute to absorbance at 280nm.) 
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2.1.5.5 C6.5-k binding via Flow cytometry 
FACSCalibur flow cytometer (BD Biosciences)  
Software = FlowJo. Version: 7.6.5 (Tree Star, Inc.) http://www.flowjo.com/  
 
Cells were grown as usual and on the day of the experiment Accutase (PAA L11-007) was 
used  to remove cells from flask. Cells were counted and aliquoted at 300,000 per eppendorf / 
per condition. Include conditions for unstained and secondary/tertiary only controls. Cells were 
subjected to centrifugal force and washed in PBS then resuspended in 50µl FC buffer plus the 
primary antibody. For C6.5-k it was determined to be optimal at 60nM C6.5-k final 
concentration, for FC buffer (recipe in 2.1.2) and for details on the titration experiment to 
determine this see 5.2.1.1. Cell were stained on ice in the primary staining solution for 1 hour 
before washing twice in FC buffer before re-suspending in 50ul FC buffer plus the secondary 
antibody at  3 times molar excess over primary. (180nM anti-c-Myc monoclonal mouse IgG 
(9E10) (Sigma M4439)) or (180nM anti- Penta-His monoclonal mouse IgG (Qiagen 34660 made 
up to 100ug/ml)). Cell were stained on ice in the secondary staining solution for 1 hour before 
washing twice in FC buffer before re-suspending in 50ul FC buffer plus the tertiary antibody at  
3 times molar excess over secondary. (540nM goat anti mouse IgG (whole molecule) FITC 
conjugate Sigma F2012). Cell were stained on ice in the tertiary staining solution for 30 minutes 
before washing twice in FC buffer and re-suspended in 300µl FC buffer. Signal from the FITC 
fluorophore was then detected through channel FL-1 on the BD FACSCalibur machine. See 
2.1.4.11. 
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2.1.6 Chemical Based Methods  
 
2.1.6.1 Spectral analysis  
Absorbance spectra carried out using Agilent 8453 UV Visible Spectrophotometer  
Fluorescent spectra carried out using Cary Eclipse Fluorescence Spectrophotometer  
 
2.1.6.2 Experimental Log P 
Photosensitisers were diluted 1:1000 into either 1-Octanol or PBS pH7.4 and then added to 
the opposite solvent. Alongside photosensitisers were also mixed under the same conditions and 
concentrations in either purely PBSpH7.4 or 1-Octanol. Experiments were carried out in glass 
vials and solvent mixtures were upturned over 24 hours before layers were separated and UV 
spectra read of each partition and peak values compared to extinction coefficients previous 
calculated for each PS in the relevant solvent. Data was calculated utilizing the equation; 
Apparent LogD = Log10([Organic]/[Aqueous]) 
Where square brackets correspond to absolute concentrations calculated from both the 
Octanol and PBS fractions using their extinction coefficients.  
 
2.1.6.3 Cy5.5 AE structure and fluorescent spectra 
Amersham Cy5.5 Mono NHS Ester (GE healthcare PA15605) Images and information taken 
from the product booklet 
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2.1.6.4 PS Acid and AE structure and Mw 
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2.1.6.5 Photo-Immunoconjugate production  
Amersham Cy5.5 Mono NHS Ester (GE healthcare PA15605) 
NHS Ester forms of PPa, PS1 and PS4 synthesised in house. (Dr G. Yahioglu and Dr. I. Stamati) 
Reconstituted in small batches in 100% dry DMSO and stored at -20oC in a dark environment 
and tested periodically via TLC for the extent of any hydrolysis (see2.1.6.8). 
 
The reaction conditions previously used within this lab (Stamati et al., 2010) were; C6.5-k at 
10µM in PBS at pH8, PPa AE (active ester) at 16 times molar excess over C6.5-k with additional 
DMSO added to make the final DMSO 2% of total reaction volume, and MeCN at 6% of total 
reaction volume. MeCN then PS/DMSO was added to the C6.5-k drop wise in a 15oC water bath 
over one hour, all the while stirred and protected from light.  Conjugation conditions changed 
throughout the work presented in this thesis but a general method is described below. See main 
text for more details. The main changes were an increase in the antibody concentration to help 
encourage interactions between reactants, and changing the buffer in order to raise the pH was so 
more of the lysine amine groups would be reactive for conjugation, although the rate of 
hydrolysis of the active ester is also increased which could compromise reactivity. 
 
General method: 
C6.5-k  was buffer exchanged and concentrated to 160µM in Carbonate buffer at pH 10.5 (buffer 
made with varying ratios of 0.1M Na2CO3 and 0.1M NaHCO3) (Delory and King, 1945). PS AE 
(active ester) dissolved in 100% dry DMSO at a stock of 25.11mM was added at 1/10th of the 
volume of the C6.5-k solution along with the same volume of 100% DMSO. (For example: 
100µl C6.5-k + 10µl DMSO + 10µl PS AE) The final molar ratio of PS:C6.5-k was 16:1 with 
145mM C6.5-k in the final conjugation mixture and the final DMSO concentration was 16.67%. 
Mixtures were added immediately and reaction was left shaking and protected from light at RT 
for 2-3 hours then left overnight at 4oC before analysis and purification. 
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2.1.6.6 Analysis of photo-immunoconjugate: 
 
Spectral analysis  
Spectral analysis of the absorption spectra was undertaken in various different buffers.  
Absorbance of the conjugate from its peak absorbance in the red (for PS this is Q band I 
~680nm) should be solely due to the absorbance of the dye – this can be used to calculate final 
concentration of dye in the conjugate, the extinction coefficient of the dye at 280nm (as it also 
absorbs in this part of the spectra) can be used to calculate the contribution to the absorbance at 
280nm from the PS and so therefore also from the protein and therefore also the protein 
concentration. Before spectra could be used to calculate conjugation efficiency, extinction 
coefficients for 280nm and the peak absorption were calculated for the free dyes in the relevant 
solution. See figure Figure 51 for Cy5.5 and Figure 57 for PPa and PS1. 
 
Gel analysis  
Conjugates were separated on SDS Page gel as described before in 2.1.5.2 the only exception 
being the protein loading buffer used was made without the blue dye (recipe in 2.1.2) as this 
travels at the dye front along with any free PS and interferes with the fluorescent signal from the 
PS. Directly after the run had ended gels were directly imaged under UV light in the Las-3000 
see 2.1.1.5, using a filter to remove light below 515nm, the gel was then stained in coomassie. 
 
Image J software has macros designed to calculate band intensity on SDS page gels 
SOFTWARE   = Image J, Version 1.45s, (Wayne Rasband, National Institutes of Health) 
http://rsbweb.nih.gov/ij/ . 
 
The gel is manually divided into equally sized wells and the intensity of each band converted 
into a graphical format with the X axis of each well representing the distance travelled down the 
gel, and the Y axis for the fluorescent intensity of that distance down the well. The areas of these 
curves can then be calculated and correspond to the total intensity of the band, see 5.2.10.2. 
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The effect of using a filter to image gels under UV 
Unfiltered light shows a seemingly more heavily conjugated sample but also a ‘banding’ 
pattern from detection of the UV bulbs themselves; shown right, and shows how manipulation of 
the equipment can change how conjugation effectiveness is perceived. All other conjugate gels 
presented in this thesis are imaged with filtered light to avoid this banding.  
 
 
2.1.6.7 Purification of photoimmunoconjugate 
 
Many different methods were tried for PIC purification, see main text for a full discussion. 
Listed here are the source information for selected pieces used.  
 
 Dialysis tubing : MWCO 8 kDa cellulose (Fisher scientific BID-030-040K),  
 Vivaspin 20 ; 5000 MWCO polyethersulfone membrane /centrifugal pressure - (Sartorius 
Stedium VS2012) 
 Vivapure Ion Exchange centrifugal Spin Columns -Q mini H. (Sartorius Stedium 
VS1X01QH24) 
 Ion exchange chromatography columns – HiTrap CaptoG 1ml (GE healthcare 11-0013-02) 
 
  
UV transmitted light source, Exposure 1/15th Second
a) Unfiltered light
b) Filtered light for over 515nm,
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2.1.6.8 TLC plates of free PPa and PS1  
PS samples were cleaned in a H20/DCM mixture, so any DMSO would partition to the H20 
and PS to the DCM. This was important to prevent the PS running inside a DMSO solvent 
bubble up the plate. Separation obtained by using Silica gel 60 glass TLC plates with F254 
indicator (Merck) in a 10% Methanol in DCM solvent system and once removed the solvent 
front was marked by a pencil line before it evaporated. Images of the plates were taken on a 
standard computer scanner and RF values were calculated from the plate image in Image J 
software according to the equation below:  
 
RF value = distance travelled by the compound / distance travelled by the solvent front 
 
SOFTWARE   = Image J, Version 1.45s, (Wayne Rasband, National Institutes of Health) 
http://rsbweb.nih.gov/ij/  
 
NB PS4 requires a different solvent system; 80 % MeCN plus 10% H2O and 10% K2NO3. 
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Chapter Three 
3 Chemical characterisation of PS and testing of PDT in an in vitro model of cancer 
3.1 Introduction 
3.1.1 Considerations for an effective PDT model. 
 
Chapter 0 introduced some clinical factors that influence PDT. This thesis however will 
mostly focus on the influences on a chemical and cellular level. Cellular processes that are well 
validated in the literature to be important for effective PDT include cellular uptake rates,  the 
uptake mechanism, the final intracellular localisation and the type of cell death mechanisms 
induced. These processes are discussed in more detail in chapter 0.  
 
3.1.1.1 The end point 
 
Drugs in preclinical use are often compared in their efficacy by an in vitro cytotoxicity 
measurement, in many cases this is described as its IC50 value. To calculate this parameter, in 
vitro cytotoxicity assays are set up using an appropriate cell line and the drug is tested for the 
concentration required to kill 50% of the cells. IC is actually the ‘inhibitory concentration’, here 
it is used in the context that it ‘inhibits  proliferation or viability’, so for example an IC90 is the 
dose required for 90% of cells to have died. A parameter that is possibly more relevant but 
essentially the same is LD50 (lethal dose required for 50% cell kill) but it is perhaps not so 
ubiquitous in the literature so IC values will be used instead. The MTS assay is a stardard end 
point for an in vitro cytotoxicity assay, it is an adaptation of a technique used to measure cell 
viability via metabolic capacity (the MTT assay) See (2.1.4.4). 
 
3.1.1.2 The cell line 
 
The cell line chosen to carry out this work is SKOV-3, a cell line originally derived from a 
sample of human ovarian adenocarcinoma tissue. The choice of cell line is worth prior-
investigation as all have inherent sensitivities and bias, especially in pathways involving cell 
death (X. Li et al., 2001; Marcelli et al., 2000). SKOV-3 cells have non-functional p53 due to a 
homozygous mutation in both genes causing a complete lack of detectable mRNA or protein 
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(Berglind et al., 2008; Yaginuma and Westphal, 1992). p53 is a tumour suppressor protein that is 
mutated in up to 50% of cancers and its most famous role is that it can trigger cell cyc le arrest 
and apoptosis in response to diverse stress stimuli including DNA damage and hypoxia  (Stegh, 
2012). Other genetic aberrations are listed in 2.1.4.1. SKOV-3 have also been shown to have low 
levels of FAS receptor cell surface expression making them more FAS resistant (FAS induces 
apoptosis) than endogenous ovarian tissue (Baldwin et al., 1999). They have also been shown to 
over express Notch 1 intracellular domain, (an important role in cellular differentiation and 
proliferation) (Rose et al., 2010), and have relatively low level Bcl-2 expression, an anti-
apoptotic protein from the Bcl-2 family of proteins (Beale et al., 2000). 
 
3.1.1.3 The light dose 
 
PDT is able to be dosed in two ways, the dose of drug and the dose of light. The standard 
light dose used in our laboratory is 33mW/cm2 which over 10 seconds corresponds to a power 
delivery of 0.33 J/cm2. The choice to use almost the lowest power setting available on the laser, 
(which is of the type and power that would be used in a clinical setting), is deliberate. Cells in a 
dish will be exposed to a lot more of the laser light than one could deliver in vivo due to tissue 
absorbance factors, see 1.4.4. The light dose used in vivo and in the clinic commonly ranges 
between 50-100 J/cm2. In previously published work (Bhatti et al., 2008; Stamati et al., 2010), 
the photosensitiser was left on the cells for two hours at 37oC/5%CO2 before removal and 
subsequent immediate irradiation of the cells. This timepoint was originally designed so to be 
sufficent for most mechanisms of cellular uptake in vitro, but not so prolonged as to create a 
situation irrelevent to the in vivo situation where cells are unlikly to experience the prolonged 
exposure to such high levels of drug. As mentioned in 1.3.1.1, the drug- light interval can be a 
very important factor in therapy design and have significant impact on overall effectivness of the 
therapy, however the main factors that drive the influence of the drug-light interval on toxicity, 
i.e drug presentation to a target site and systemic clearance processes, are not likly to have any 
effect in our in vitro assay.  
 
 
 
Page | 90  (Hayley Pye 2012) 
 
 
3.1.1.4 Other considerations 
 
An example of the differences seen between in vitro and in vivo data in PDT include work by 
Kessel (Kessel et al., 1997) who looked in vitro with two photosensitisers, both structurally 
similar with similar absorbance profiles, however one had an amine side chain and the other 
carboxyl. In vitro the PS with the amino group demonstrated a much more efficient and quick 
apoptotic cell kill however in vivo they both had a similar efficacy. Other work by Moore 
(Moore et al., 2007) looked at the PDT susceptibility of endothelial cells vs. tumour cells in vitro 
compared to in vivo. They saw in vitro no differences in susceptibility to PDT however in vivo, 
the endothelial cells routinely appeared to be more heavily targeted.   
 
The use of 3D structures made from mixtures of in vitro cell lines (multi-cellular tumour 
spheroids) are designed to better represent the a tumour environment, however one problem with 
structures like this, particularly tumour spheroids is that they can only grow to a certain size 
since there is no vasculature inside the spheroids to provide tissue oxygen, this also means that 
PDT can easily deplete oxygen and so PDT experiments can show much lower toxicities o n cells 
in the spheroid centre. Models such as these can show us factors important for PDT not seen in a 
monolayer cell culture, for example the balance between apoptotic and necrotic cell death in a 
population and PS intra-tumour distribution (Marchal et al., 2005; Obrigkeit et al., 2009b; Xiao 
et al., 2005). 
 
Even in vivo tumour models can show bias, Chen et al (Chen et al., 2005) looked at the same 
tumour model implanted ectopically in subcutaneous space or orthotopically in the prostate and 
showed differences in PS uptake, even at time points where uptake was similar in the two models 
they showed different responses to PDT.  
 
Despite all the care in setting up a comparable in vitro assay, all the cells within an actual 
tumour are going to be exposed to different levels of drug and light as well as factors that include 
possible levels of de-differentiation, areas of hypoxia or local pH change, and differential supply 
of nutrients and removal of waste. All these things are capable of changing how, and to what 
extent, a cell will respond to PDT. The bystander effect will also play a role in vitro. Various 
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experiments have shown that when cells die they often die in groups, independent of the location 
of the death source and beyond the probability of the group all dying independently by chance. 
This bystander effect indicates that communication between neighbouring cells plays a role in 
the induction of cell death, in both apoptosis and necrosis, (although evidently to a larger extent 
in necrosis). This has been shown to be particularly relevant for PDT (Dahle et al., 2000; Rubio 
et al., 2009). 
 
3.1.2 Making Drugs more soluble 
 
Solubility as a term is dependent on its context. The IUPAC Gold Book definition for 
solubility (IUPAC, 2011) defines its use linked intrinsically to the solution in which you are 
trying to dissolve said component in and the fact that the solute should be at saturation to infer 
any information about its solubility. In the context of this project however the term solubility is 
taken in a much broader sense to fit its application to clinical ‘pharmacokinetic solubility 
parameters’ and in these the solvent is the human body.  
 
One of the most common solubility terms when studying pharmacokinetic and 
pharmacodynamic properties of drug molecules is a term better used to describe a molec ules 
lipophilicity; the log of a partition coefficient- LogP. It sees prolific use in both bench 
experiments and computational analysis. Experimentally it is most commonly measured as the 
Log of the ratio of the distribution of solute in a aqueous-organic / liquid- liquid biphasic system, 
(commonly 1-octanol and water) under conditions in which the unionised species is both in a 
saturated and non aggregated condition (Sangster, 1989). Also available are computational 
approaches of LogP calculation (Faller and Ertl, 2007), which try to improve upon bench made 
predictions via the sheer number of structures that can be put through the system while avoiding 
difficult un-biased experimental set-ups. As important as Log P is in giving an indication of the 
molecules intrinsic lipophilicity, when this is related to its use in the clinic, information about a 
molecule in its ionised form (for example at the pH of blood plasma), has encouraged the 
additional use of a LogP derivative LogD (D for distribution coefficient) which takes into 
account its degree of ionisation at given pHs. Other ‘LogP like’ systems that utilise biological 
Page | 92  (Hayley Pye 2012) 
 
 
solvents are also common; including replacing the octanol partition with lipid systems that model 
biological membranes (Avdeef, 2001). 
 
Solubility forms a key aspect of the Biopharmaceutics Classification System and there have 
been many attempts by pharmaceutical companies to design wish lists of physiochemical 
parameters to help predict and therefore produce drugs with ideal pharmacokinetic profiles;  
Pfizer (Lipinski et al., 2001) GlaxoSmithKline (Veber et al., 2002) AstraZeneca (Waring, 2009). 
LogP is almost always included in some form and traditionally it is thought that the lower this 
can be the better (Leeson and Springthorpe, 2007). The average LogP of most approved drugs is 
~2.5 (Proudfoot, 2005), or 1.92 for intravenous drugs (Obach et al., 2008), and can vary from -2 
to +8 (Avdeef, 2001). Typical LogP values in the context of drug development are thought of as 
follows: very hydrophilic (LogP <0), hydrophilic (LogP 0-1), moderate (LogP 1-2), lipophilic 
(Log P 2-4), very lipophilic (>4), (Obach et al., 2008). 
 
The data of Obach (Obach et al., 2008) also shows a positive correlation with increased 
lipophilicity and higher distribution in tissues (as opposed to blood plasma) this was measured by 
steady state volume of distribution (VDss). High VDss levels are not always an indication that 
the drug is in the specific target tissue just that it is no longer in the blood plasma. Many papers 
argue that high lipophilicity promotes high promiscuity (Leeson and Springthorpe, 2007) but the 
role of lipoprotein-mediated drug transport from the blood to the tissues is also important, 
especially as metastatic tumours have an increased demand for the cholesterol contained within 
these lipoproteins (Wasan et al., 2008). The intelligent ‘formulation’ of medicines can help 
insoluble drugs fit the solubility parameters set out by the pharmaceutical industry but it is no 
guarantee of success, what happens to drug and formulation once inside the body can be two 
independent events. It is more sensible to be able to design intrinsic solubility into drugs via 
chemical manipulation methods. 
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3.1.3 Making Photosensitisers more soluble 
 
Solubility design with respect to PDT drugs needs to consider the inherent requirement of a 
photosensitiser for delocalised electrons -they often have large areas of conjugated planar ring 
systems  which contribute heavily to making the molecule more hydrophobic in character. It is 
also generally believed that strong hydrophobic interactions will drive toxicity- caused by high 
levels of unspecific binding and poor metabolic clearance. PDT itself is recognised to exhibit this 
problem through the commonly seen side effect of high skin accumulation and prolonged 
photosensitivity, see 1.2.3. Evidence suggests therefore that making PS more soluble will have 
significant influence on PDT efficiency.  
 
One reason to improve photosensitiser water solubility has been the desire to improve PDT 
by the conjugation of photosensitisers to proteins such as antibodies. This is the main driving 
force behind the work presented in this thesis. Two hypotheses are behind the theory that 
aqueous soluble photosensitisers will provide better photoimmunoconjugates (PICs): The first is 
physiological; the conjugation of too many heavily hydrophobic molecules to an antibody may 
disrupt its inherent pharmacokinetic and targeting properties. The second is chemical; the 
conjugation process to antibody has to be carried out in aqueous conditions as antibodies like 
most proteins can be irreversibly damaged if they unfold when exposed to organic solvents (Pace 
et al., 2004; Ugwu and Apte, 2004). 
 
There is a lot of research that looks at the relationship between changing a PS structurally, 
calculating its lipophilicity via LogD and LogP and comparing this to uptake, whether into cells 
or artificial cellular membrane models. There is a general trend between increased lipophilicity 
and increased cellular or liposomal uptake. Engelmann and colleagues (Engelmann et al., 2007) 
looked at a series of 20 cationic meso-phenyl(pyridyl)porphyrin derivatives and showed a 
general correlation between an increase in the number of positive charges introduced to the rings 
and an decrease in LogP with values ranging between -4 and 2. Other factors such as the type of 
positive charge and where it was on the molecule were also shown to be influential. They also 
looked at binding to negatively charged synthetic liposomes as a model of cell interaction and 
showed a positive correlation with an increase in LogP, the only outlier being a PS with an 
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asymmetric distribution of charges which showed enhanced binding above the trend predicted by 
its LogP. Meng and colleagues (Meng et al., 1994) measured LogP for a series of meso-
substituted porphyrins via sulfonation of the phenyl or methylation of the pyridyl groups, all 
derivatives had varying numbers of both positive and negative charges, and the LogP value 
correlated closely with data measuring increased uptake into HT-29 cells with increased 
lipophilicity. Kepczynski and colleagues (Kepczyński et al., 2002) also show a trend between 
increased lipophilicity and increased cellular uptake but suggested this relationship is much 
stronger within related groups of PS, for example modification of the same core as opposed to 
comparing different PS entirely. They also suggested a rule of thumb that a molecule should 
have a log P greater than 0 in order to bind cellular membranes minimally but larger than 3 for 
significant binding. 
  
It has however been suggested that there is an upper limit where PS that are too lipophilic 
will form aggregates in solution and that this will compete with cellular uptake. Ben-Dror and 
colleagues (Ben-Dror et al., 2006) investigated particularly hydrophobic porphyrins over a range 
of computationally predicted LopP values between 8.89 and 11.81, they showed a negative 
correlation between LogP and Liposome binding indicating the more hydrophobic molecules 
bound to liposomes less, their overall hypothesis was that for molecules with high 
hydrophobicity (in their experience LogP >7) the usual positive correlation becomes inverted due 
to a tendency of the molecules to aggregate.  
 
These rules may not correlate exactly with tumour uptake in vivo as they do not consider the 
effect lipophilicity will have on serum pharmacokinetics. Work by Henderson and colleagues 
(Henderson et al., 1997) is of particular relevance as it looked at a range of PPa derivatives, their 
C1 compound being very close to the PPa used herein. The rest of their panel differed from each 
other only in the number of carbon atoms in and the shape or flexibility of an alkyl ether side 
chain. To measure hydrophobicity they looked at retention times on a reverse phase HPLC 
column, computationally calculated LogD at pH 7.4, and for some compounds they attempted to 
measure an experimental logD. They then used this panel of PS to look directly at anti- tumour 
activity in mice: Upon treatment with PS, speed of tumour growth was fastest at the extreme 
ends of LogP (3 and 9) with a peak for slowest tumour growth around LogP 6 or 7, a similar 
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pattern was seen when they plotted LD50 , with the highest tumour cytotoxicity seen around LogP 
5.6-7. Interestingly they also looked at plasma and tumour PS levels 24hrs after injection (the 
time point used for irradiation in the above mentioned experiments), both tumour and plasma 
showed an increase in plasma PS with increasing LogP until a plateau around LogP=8. This 
doesn’t match the cytotoxicity observed as a distinct drop in toxicity is seen with the PS above 
LogP=6, that is not due to a lack of uptake into tumour tissue or sufficient blood retention times. 
They excluded molar extinction coefficients and quantum yields as a reason as they stated these 
were the same as the parent compound for all derivatives, they therefore concluded differential 
intracellular localisation is likely to blame, and hypothesised an optimal compound has midrange 
lipophilicity allowing it to readily enter and leave different cellular compartments on its way to 
the target compartment. 
 
3.1.4 Measuring the solubility of PS via spectral shifts 
 
In addition to experiments to determine logP, chromophore containing molecules like 
photosensitisers provide a more direct way to investigate their properties in a given environment 
- their absorption profiles. This relationship between absorbance profile and molecular orbital 
theory, see 1.4.1, gives us a way to visualise the effect various solvents have on PS atomic 
structure and can therefore give us important information about PS solubility (Lakowicz, 1999) . 
 
Shifts in spectral profile can be described by four common terms; Bathochromic or red-shift 
(shift to lower energies), Hypsochromic or blue-shift (shift to higher energies). Hyperchromic 
(increase in intensity of a spectral band) and hypochromic (decrease in intensity of a spectral 
band). Common factors that can cause solvent induced spectral shifts are the influence of 
polarity of a solution in the stabilisation of energy states (Solvatochromism), aggregation/ 
interaction of a molecule with itself or other moieties, an altered ionisation state of the molecule, 
metal ion co-ordination, or charge-transfer interactions (inter molecular or with solvent ions). 
Unfortunately spectral shifts are a complex phenomenon and often involve the interaction of 
multiple elements, also not all changes to molecular orbitals will result in visible spectral effects 
(Lakowicz, 1999). 
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3.1.5 Aggregation of Photosensitsers 
 
Aggregation is a solution phenomenon involving the non covalent interaction of solute 
molecules, in this case PS, to give assemblies of molecules, they can be dimers, trimers, 
multimers or mixtures of all these. In some cases the aggregates become so extensive they will 
precipitate out of solution. Aggregation arises when the intra-molecular interactions between 
solute and solute become more energetically favourable than the interactions between solvent 
and solute. Aggregates can be hetero-aggregation (with other solutes in the media) or homo-
aggregation (with other molecules of the same type within the solution). Aggregate formation is 
reversible with monomer and multimer formation reaching a point of equilibrium. The 
equilibrium point can be affected by various factors such as temperature, solute concentration, 
changing ratio of solvents in a mixed solvent system or manipulation of molecular conformation; 
for example via metal ion binding. Weak forces are responsible for the aggregative interactions 
for example hydrogen, electrostatic, van der waals, or hydrophobic interactions.  
 
For PS it is often the delocalised π electrons from the ring, with themselves or with electrons 
from σ orbitals that make a significant contribution to aggregative interactions. The molecular 
orientation of aggregation can in part determined by the various substituents made around the 
ring (Bonnett, 2000). Research by Kasha, Jelly and Scheibe over the years have all been 
important in the development of a model and subsequent nomenclature for different aggregative 
formations seen with Porphyrins. A basic interpretation of the model put forward here is that if 
two monomers aggregate, exciton splitting occurs and two energy levels are formed of different 
energies, one higher and one lower than the original energy level, the probability of each of these 
energy level being used is predicted by molecular orbital rules influenced by the spacial 
relationship of the two molecules to one another. Aggregates that form side by side aggregation 
exhibit a blue shift in their spectra and are termed J-aggregates. Aggregates that form face to face 
aggregation and exhibit a red shift in their spectra are termed H-aggregates (Bonnett, 2000). This 
model, alongside other methods, was used by Fabiano and colleagues to investigate the 
aggregation of cationic PPa molecules in aqueous buffer (Fabiano et al., 1997). 
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Both fluorescence quantum yield and singlet oxygen quantum yield of aggregated 
photosensitisers are often significantly lower than those of the monomeric form. This is predicted 
to be due to increased radiation-less energy transfer between the photosensitiser molecules 
within aggregates. This fast energy relaxation channel shortens the lifetime of the lowest excited 
level of the photosensitiser, thus reducing the probability of the molecule converting to the triplet 
level, the level from which most important photochemical processes for PDT start.  
 
Serum mediators are capable of monomerising PS in vivo and once intracellular the 
aggregated PS have also been shown to revert to a monomeric form. Some researchers have even 
carried out work to design molecules that are more photo-physically efficient when aggregated 
(Baba et al., 2007; Chang et al., 2012; Kim et al., 2007). 
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3.2 Results 
3.2.1 Further development of the in vitro PDT assay 
 
To check if the new, more water-soluble photosensitisers PS1 and PS4 retain their efficiency 
they were tested on cancer cells grown in vitro. Some changes to the earlier published method 
(Stamati et al., 2010) were made: 
 
Back cell culture plates were used instead of clear plates, and the lids are removed during 
irradiation. Previously when using clear plates during the irradiation process the scattering of 
laser light was observed both throughout the entire plate and through the lid. Control 
experiments were carried out and results show the change to a black plate and lid-off irradiation 
didn’t have any significant difference on final toxicity parameters (Data not shown).  
 
Laser calibration experiements were carried out, see 2.1.4.3; with a new slightly larger beam 
diameter than used previously to ensure the irradaiated wells were covered more evenly by the 
laser beam. The experimental method allows irradaition of 4 wells in a 96well plate 
simutaneously and to investigate if they were recieveing a similar energy, measurments were 
taken with an appature device to try to discover any ‘hotspots’ within the laser. This data is 
shown in Figure 7 and shows there are slight differences in the ammount of energy each well 
recieves. The method was also adapted for a larger beam diameter ideal for 6well plate formats 
(required to obtain enough irradiated material to analyse DNA and protein lysates). Calibration 
with a power meter ensured the same energy was delivered to the cells in this format as in the 
96well experiments. This calibraton is shown in 2.1.4.3.  
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Figure 7: Hot spots within the laser light effects the amount of energy delivered.  
 
 
Using an appature device power at different points within the projected beam of laser light were 
measured and plotted over area to show the off-centered hotspot from the laser. 
 
 
 
During the PDT of 96well microplates 4 wells are irraidated simultaneously and when power 
was measured over the area that would project onto each individual well in a 96 well plate setup 
differences in the ammount of light each would recieve was seen.  
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3.2.1.1 Interference of PDT with MTS assay relaibility 
 
MTS is not a direct measure of cell viability and can be reduced in the absence of cells 
(Ishiyama et al., 1997; Peng et al., 2005). It was important to have confidence in our endpoint so 
a few addtional PDT-specific checks were carried out.  
 
PS are promiscuous absorbers of light, so experiments were done to check that the 
photosensitisers didn’t interefere with absorbance at 490nm (end point absorbance of MTS). 
These are shown in Figure 8 and show that PS does not contribute to absorbance at 490nm below 
concentrations of 10µM, this should be sufficiant as wells containing this level of PS or above 
are washed prior to irradaition and subsequent MTS.  
 
Photosensitisers are chemicals that can carry out redox activities so there was potential for 
the PS to oxidise cellular NADH either directly or via its reactive oxygen products, this could  
reduce the signal seen on MTS without any actual cell death. Figure 8 shows an experiement in 
which a stardard curve of recombinant NADH in a suitable buffer produces a range of  
absorbance at 490nm when mixed with MTS, this was incubated with PS (at the maximum level 
that did not directly absorb at 490nm) with and without irradiation by laser  to see if any signal is 
lost. No signal loss was seen, from which one can conclude that PPa-based PS cannot directly 
oxidise NADH under these conditions. 
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Figure 8 : Potential interference of PDT with MTS assay reliability. 
 
Different dilutions of PS were mixed with and without MTS solution over a range of PS 
concentrations, when absorbance at 490nm (endpoint of the MTS assay) was read it shoed that 
PS does not contribute to absorbance at 490nm when below 10µM. 
 
 
A stardard curve of recombinant NADH in a suitable buffer can produce a range of absorbance 
at 490nm when mixed with MTS, when this was incubated with and without irradaition by laser 
to see if any signal is lost, no significant signal loss was seen. 
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3.2.1.2 Calibration of MTS assay for chosen cell line 
 
The only further calibration needed in respect to the MTS assay was that it would need to be 
of a suitable sensitivity to follow cell death over time; to obtain this an inital cell plating number 
was needed that would give a positive reading in the linear region of the MTS assay for both 
timepoints 0hr and 48hr with no saturation of signal or growth inhibition of cell lines. As shown 
in Figure 9 this was chosen to be 2500 SKOV3 cells per well. The data also considers un-washed 
cells vs washed cells because the PDT method requires a fair ammount of washing/media 
exchange steps. An additional cell line was required for a negative control (for later work) this 
presented some problems as many cell lines tested at this stage has insufficeint plate adherance  
for intensive wash steps and so couldn’t be used reliably, a few were tested (data not shown) but 
eventually a less adherant cell line was chosen (U87) and calibrated but with plate pre treatement 
with attachment factor (TCS cellworks ZHS-8949) (data not shown). Whilst carrying out this 
work it was noticed that the time between addition of MTS and the reading of absorbance was 
important, also shown in Figure 9, particuarily relevent as the plate reader available was not 
immediatly accessible, therefore all future data shown will be presented as a % of untreated 
control to make data more comparable, although care was taken to keep as close as possible to a 
2 hour incubation time. 
 
3.2.1.3 Effect of DMSO in the cell culture media. 
 
A final concentration of 2% DMSO was maintained in all the cell culture media solutions 
containing PS, this was included to help PS solubilisation. Any possible cytotoxic effects were 
investigated. This is presented in Figure 10, where 2% DMSO was shown to have no significant 
effect on SKOV-3 cell culture. For interest, spectral analysis was carried out and is also shown in 
Figure 10. Interestingly the only effects of DMSO on the PS that were visable via spectral 
change was with PS4, thought to be the most water soluble PS.  
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Figure 9 : Calibration of MTS assay for SKOV-3 cells 
 
 
Optimisation of the number of SKOV-3 cells that would produce a non saturated signal with the 
MTS assay at two timepoints within the ‘PDT assay’, these were 0hrs, around 24hours after 
plating, the time at which cells would be irradiated, and 48hrs, which was 48hrs after 
irradiation. 
 
 
Increasing the time between addition of MTS reagent to the well and subsequent reading of 
absorbance at 490nm increases the signal recorded. 
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Figure 10 : Effect of DMSO in the cell culture media. 
 
 
The toxicity of different amounts of DMSO contained within the cell culture media on SKOV-3 
cells, when exposed either transiently for two hours before leaving cells to grow for a further 
48hours or leaving the DMSO in for the entire 48hours. 
 
 
Spectra of PPa, PS1 and PS4 in cell culture media with and without 2% DMSO. 
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3.2.2 Potency of the new photosensitisers. 
3.2.2.1 Cyto-toxicity of the new photosensitisers in the in-vitro PDT model 
 
Cell kill experiments were carried out in the PDT in vitro model described above and in 
2.1.4.3 with PPa and each of the new photosensitisers alone and in parallel. Figure 11 shows a 
representative experiment of results obtained when running all PS in parallel. Cell viability 2 and 
48 hours after irradiation is shown. This data shows that PS4 exhibits no cytotoxicity at any of 
the examined doses under these experimental conditions, in a separate experiment the doses for 
PS4 were escalated to over 500µM but still there was no observed cytotoxicity. At 48 hours after 
irradiation PPa and PS1 both exhibited dose dependant cytotoxicity, PPa showing slightly higher 
potency than PS1. Two hours after irradiation high dose PPa can reduce cell viability levels to 
around 0% whereas PS1 showed only limited potency at the same high doses. Cell kills for each 
PS were carried out numerous times at 48 hours, and dose response curves were fitted see 
2.1.3.1. From all the collected values, averages were taken for the dose needed to kill 10%, 50% 
and 90% of cells, termed IC10, IC50 and IC90 respectively. These average values are shown in 
Table 5.  
 
No PS exhibited any ‘dark’ toxicity at any of the doses studied, i.e. toxicity independent of 
activation by laser but this data suggests that the new, more water soluble, photosensitisers 
exhibit a loss in potency compared to their parent compound PPa. Of interest is the differences 
seen between PPa and PS1 in the time they take to kill the cells, PPa seems capable of killing 
immediately with the dose response curve shifting slightly after a further 48 hours of time has 
passed, whereas with PS1 a much larger difference is seen between 2  hours, when very little 
toxicity is recorded, and 48 hours when it is almost as cytotoxic as PPa. This suggests that 
different mechanisms of cell death could be being initiated. Because the PS was washed off the 
cells after two hours and then cells immediately irradiated, only PS that was intercellular or cell 
associated at that point will have been contributing to potency, additionally the ‘dark’ data shows 
only activated PS is toxic.  
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Figure 11: Cell viability after PDT with PPa, PS1 and PS4 
 
 
PPa, PS1 and PS4 tested in the in vitro PDT assay on SKOV-3 cells. Viability measured 2 hours 
and 48 hours after PDT.  
 
Table 5 : IC10, IC50 and IC90 of PPa and PS1 
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3.2.2.2 Indirect evidence for uptake and leaching kinetics from cell viability studies  
 
In an in vitro model, although influential factors such as serum pharmacokinetics, tissue 
delivery and blood clearance are absent, it is their absence that allows cellular uptake and cellular 
leaching processes of PS to be studied. These cellular processes will of course still occur in vivo 
but the tissue level processes are likely to have an equally or more significant influence on 
outcome. In this section some initial work looking at cellular uptake and leaching of PS is 
presented which will be expanded in the next chapter. Figure 12 shows the standard cell kill 
experiment carried out at IC90 doses of PS but adapted to show cellular uptake by varying the 
amount of time PS was left over the cells before it was washed off and cells then immediately 
irradiated. It also shows a similar experiment but designed to look at cellular leaching: The PS 
were left over the cells for 2 hours, washed off and then the time before irradiation was varied.  
 
Results from the uptake experiment showed that by two hours both PPa and PS1 have 
reached a plateau at around 10% cell viability, but PPa reaches this point by around 1 hour, much 
quicker than PS1. Two different conclusions could be taken from this data, if one assumes a 
linear relationship between uptake of PS into the cell and its toxicity then it could be concluded 
that PPa is taken up quicker than PS1. However because this experiment does not look at uptake 
directly but rather final toxicity as an endpoint, this result could also be due to inherent toxicity 
differences between PS: For example, if both are taken up at the same rate but PPa is more toxic, 
at low doses it would seem more toxic than PS1. There are also additional factors such as a 
possible change in intracellular localisation of photosensitiser, if this occurred over time it could 
also affect toxicity over time. It will be important, as shown later, to try and answer these 
questions.  
 
Results from the leaching experiment showed that after PS was removed from the 
surrounding medium enough PS leached back out of the cells over two hours that it caused a 
complete loss in toxicity. This data was very influential in further assay design as when many 
plates are being processed, the time between initiation of washing and irradiation can easily stray 
into 10-15 minutes which according to this result can significantly reduce potential toxicity. This 
data also confirms that it is only internal PS that can induce cell kill. This is because the cells 
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were not re-washed after the first wash step, meaning any leached PS would still be in the well 
during irradiation. However it is also possible that other processes could be involved; for 
example if once PS is taken up it relocates or converts to a non toxic form, this would also cause 
a decrease in toxicity over time after cells are washed, something that wouldn’t be seen at 2 
hours in the standard cell kill experiments as the PS is continually replaced by PS in solution. 
This data may also explain the difference in standard deviations seen associated with the IC 
values in Table 5, PS1 has larger variation values than PPa, possibly a result of slight changes in 
the wash- irradiation interval having more of an influence in PS1 over PPa. This argument also 
fits to explain the general increase in standard deviation seen with IC10 < IC50 < IC90 as increased 
PS dose would show increased amounts lost in leaching.  
 
3.2.2.3 Cell kill with increasing light dose  
 
All of the standard cell kills above were performed at a relatively low laser dose, to see the 
full potential of these photosensitisers it was of interest to carry out cell kill experiments at the 
full range of light doses. There are two ways to increase the overall energy of light delivered to 
the cells, you can increase the power of the laser, or you can increase the amount of time spent 
lasering. Differences in this ‘fluence rate’, is of particular clinical relevance as discussed more in 
the introduction see 1.3.1.2. 
 
 Figure 13 shows an experiment carried out to see if our model was affected by a change in 
fluence. The top graph shows all the possible laser doses available on our laser, traced over the 
top are three blue ‘paths’ that cover the range of possible energies; one for changing time, 
another for changing power (amps) and the final for a combination of both. Standard cell kills 
were carried out with constant doses of PS whilst changing the energy delivered over each of 
these paths. The results show for both PPa and PS1 there is no significant difference in which of 
these paths are taken, it is only the final energy received by the cells that has an effect on 
toxicity. 
 
Changes in the PS drug dose response curve over a range of laser doses could then be 
studied. The results are shown in Figure 14. The data shows that PS4 has not lost its cyto-toxicity 
completely and at 23 J/cm2 can exhibit potent toxicity with an IC50 of 337nM. At this dose PPa 
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and PS1 have IC50 values of 61nM and 65nM respectively. PPa and PS1 are now only a factor of 
around 5 times more potent than PS4. At the laser doses used above in the standard assay 
(0.33J/cm2), if PS4 were simply 5 times less cyto-toxic, cell death would have been observed.  
Figure 15 shows this influence of light more clearly by plotting the IC50 value of each PS over 
increasing light dose. This graph gives an indication of the ‘rate’ at which PS4 becomes to xic 
compared to PPa and PS1. Each curve was fitted with a 2 parameter power curve following the 
equation (Y = aXb) see 2.1.3.1. The constants from this equation are a and b; constant a refers to 
a scaling factor, used to convert the units to the appropriate amount, but constant b corresponds 
to the slope or rate of change, (a higher value indicating a steeper slope or higher rate of c hange, 
the negative sign before the b shows it is a decay function not a growth function). PS4 has a 
higher value for b (2.7), than PPa (0.7) and PS1 (0.6), this could indicate the PS4 ‘population’ of 
PS within the cell is responding in a more sensitive way to an increase in light than PS1 or PPa, 
i.e. it is exhibiting more efficient photophysical behaviour. However what is still not known is 
how many molecules of PS are actually contained within this population , if this was known one 
could make a stronger conclusion about how effective each PS is relative to the amount of light 
delivered. This is discussed later in the thesis, see 4.2.3.5. 
  
Page | 110  (Hayley Pye 2012) 
 
 
Figure 12 : Indirect evidence for uptake and leaching kinetics from cell viability studies. 
 
 
The standard cell kill experiment carried out at IC90 doses of PS but adapted to show cellular 
uptake by varying the amount of time PS was left over the cells before it was washed off and cells 
then immediately irradiated.  
 
 
The standard cell kill experiment carried out at IC90 doses of PS but adapted to show cellular 
leaching by leaving the PS on the cells for 2 hours, washing it off and then the time before 
irradiation varied. 
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Figure 13 : Light dose delivery, and the importance of overall dose. 
 
 
All the possible laser doses available on our laser, traced over the top are three blue ‘paths’ that 
correspond to three ways to increase the overall light dose; one for just changing the time 
lasered, another changing the power (amps) and the final changing a combination of both. 
 
 
Standard cell kills were carried out with constant doses of PS whilst changing the total energy 
delivered over each of the paths shown above. The results show for both PPa and PS1 there is no 
significant difference in which of these paths are taken, it is only the final energy received by the 
cells that has an effect on toxicity. 
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Figure 14 : Cell kill with increasing light dose 
 
 
The standard cell kill experiment carried with PPa, PS1 and PS4 out over a range of increasing 
laser doses. IC50 values calculated from 4 parameter logistic curves fitted to each dataset. 
  
PS1 PPA PS4
 J/cm2 IC50 IC50 IC50
0.3301 3.8339 1.9729
2.8174 1.4195 0.4383 25.0555
7.4619 0.3051 0.2157 1.5516
14.2636 0.1808 0.1073 1.2522
23.2225 0.0652 0.0608 0.3374
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Figure 15 : IC50 value of each PS over increasing light dose 
 
 
 
The standard cell kill experiment carried with PPa, PS1 and PS4 out over a range of increasing 
laser doses. X axis = energy delivered, and Y= axis µM PS needed to kill 50% of cells. The IC50 
value from each experiment plotted over increasing light dose. Curves were fitted with a 2 
parameter power curves and the constants from each curve shown alongside the graph. 
  
IC50 vs light dose recieved
J/cm2
0 5 10 15 20 25 30
IC
50
 (u
M
)
0
5
10
15
20
25
30
PS1 
PPA 
PS4 
NonLinear Regression - Global Curve Fitting
Equation: Power, 2 Parameter 
f=a*x^b
Constraint = b<0
Global Goodness of Fit:Rsqr = 0.9976
Data Set  1: PS1
Rsqr  = 0.9699
a=1.9313
b=-0.6285
Data Set  2: PPa
Rsqr  = 0.9993
a= 0.8862
b= -0.7230
Data Set  3: PS4
Rsqr  = 0.9977
a= 400.1415
b= -2.6753
Page | 114  (Hayley Pye 2012) 
 
 
3.2.3 Investigating the solubility of the new PS.  
3.2.3.1 Spectral changes in different solvent environments. 
 
To get an initial indication of solubility, all 3 photosensitises were diluted to the same 
concentration into various solvents. The solvents were chosen to be relevant to future biological 
work and to cover a range of solvent polarity, osmolarity and protein content. Solvents properties 
as specified by supplier are tabulated below the spectra in Table 6. The dielectric constant (or 
relative permittivity) gives an indication of solvent polarity, an increase in polarity exhibits as an 
increase in permittivity. Osmolarity was chosen instead of molarity as it is more useful in the 
comparison of ‘salty’ solutions because it represents the number of moles of solute particles 
taking into account dissociation of any salts.  
 
It is the Q bands (in particular Q band I) that were of most interest because they are nearest to 
the relevant irradiation wavelengths that will be used to carry out PDT, however all wavelengths 
were studied. The PS concentration chosen gives between the values of 0 and 1 AU (absorbance 
units) to avoid saturation of signal often caused by particle shadowing in more concentrated 
solutions. Additionally as solid PS were initially solubilised in 100% DMSO the final DMSO 
concentration in other solvents was maintained at ≤0.1% at which was expected to have the same 
contribution, if any, to spectral shifts in each condition (Pan et al., 2001). 
 
In the spectra shown in Figure 16 all three photosensitisers showed notable changes in Q 
band I upon dissolution in different solvents, all three photosensitisers showed red-shifts and 
reductions in intensity when dissolved in water compared to the less polar aprotic solvent 
DMSO. Upon dissolution in PBS compared to water shifts of PPa and PS4 showed little change, 
perhaps a slight decrease in intensity, PS1 exhibits a more notable further red shift and an 
increase in intensity. Upon dissolution in foetal calf serum (FCS) supplemented media compared 
to PBS, this time PS4 and PS1 show little change but PPa exhibits a significant red shift and an 
increase in intensity. In all cases when in more aqueous solutions Q bands II-IV seem to flatten 
and red- shift appreciably as to make then difficult to distinguish.  
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A common way to determine if shifts are due to aggregative processes or solvation processes 
is to look at the shifts change over different concentrations. Aggregation is concentration 
dependant where as solvatochromatic effects are not. In theory if there is aggregation you should 
acquire a linear correlation between absorbance and concentration at low concentrations and the 
point at which this changes is seen as evidence of aggregation, care must be taken not to confuse 
a saturating signal with the effect of particle shadowing mentioned above. For the data shown in 
Figure 16 there are no major peak changes or changes to the linear relationship of absorbance 
with concentration suggesting effects are due to solvatochromism. Fluorescence is actually a 
more sensitive measure of this effect but that will be discussed later see 4.2.2.1. 
 
For analysis of this data the assumption was made that when a chromophore molecule is 
‘monomeric’ in a solvent, i.e. when it is fully dissociated and has less intra and inter molecular 
interactions that reduce photo efficiency, it will show a more intense and more distinct 
absorbance pattern. When interactions with the solvent aren’t favourable the molecule will 
undergo either normally unfavourable conformation changes or form interactions with other 
molecules in the solution more preferably than interactions with the solvent. These changes will 
often change the atomic orbitals available for the absorption of light and hence the absorption 
spectra. Most PS spectral solubility studies are done in reference to an assumed ‘monomeric’ 
conformation in an organic solvent like DMSO or Ethanol. As can be seen from the spectra in 
Figure 16 all PS in this study are most ‘monomeric’ in DMSO. As the shifts away from DMSO 
are less pronounced in PS4 over PS1, and both exhibit less shifts than PPa when they are 
dissolved into more physiological buffers, one can assume they also undergo less conformational 
changes / soluble aggregate formation, and therefore they are more soluble in these environments 
than their parent molecule.  
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Figure 16: Absorbance spectra of Q bands. PPa, PS1 and PS4 in various solvents 
 
Absorbance spectrums over 450nm to 750nm of PPa PS1 and PS4 dissolved in de-ionised water 
(red), PBS(yellow), DMEM media with phenol red and 10% FCS (green) and 100% DMSO 
(blue). All PS at a final concentration of 20µM. Spectrums of absorbance read over a blank of 
the relevant solvent and normalised to absorption at 900nm. Graphs overlaid with an indication 
of laser irradiation wavelength at 671.6nm shown more accurately alongside. 
 
Table 6: Solvent properties taken from details specified by supplier 
 
SOLVENT Supplier (Cat No) pH 
Dielectric 
constant (20oC) 
Osmolarity 
(mOsmol/kg) 
Protein content 
(g/100mL) 
Water Purite System 6.9 -7.2 78.4 0.1 0 
PBS PAA HIS-002 7.0 – 7.5 (as aqueous)* 240 – 320 0 
DMEM+10% FBS 
DMEM =PPA E15-883 
FCS=Gibco 10108-165 
DMEM =6.8 -7.5 
FCS= 6.90 - 7.80 
(as aqueous)* 
 
DMEM = 280 – 350 
FCS = 280 - 340 
DMEM = 0 
FCS = 3.50 - 5.50 
DMSO Sigma D2650 none 46.7 none none 
 
(DMEM = Dulbecco's modiﬁed Eagle's medium) 
(FCS = Foetal Bovine Serum) 
(PBS = Phosphate buffered saline)  
(DMSO= Dimethyl sulfoxide) 
*unknown - proteins and salts will increase it but not vastly  
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3.2.3.2 PS spectral changes over pH change 
 
To further extend the spectral investigation a set of photosensitiser solutions were prepared at 
different pHs. In chromophoric compounds with ionisationable groups, protonation or 
deprotonation of each group can affect the molecular orbitals within the co mpound as with 
solvation or aggregation. If you consider each ionisationable group will have a pKa., when pH is 
at this pKa. the species will be 50% ionised and 50% unionised, so this point should be at the 
mid-point of a spectrum changing between plateau areas where the majority species is either 
ionised or unionised and where you see no spectral changes (excluding speciation that doesn’t 
show viable spectral change). Spectrums themselves represent averages of the population and 
can show the range of species present in the broadness of a band, (note; even single species 
bands exhibit some broadness due various internal rotational and vibrational levels providing a 
range of energy levels available). 
 
PPa photosensitisers are multiprotic and two of the ionisation sites are within the delocalised 
electron system so likely to show visible spectral effects when altered. PS concentration was kept 
constant and pH was adjusted from a 0.2 M glycine solution with NaOH or HCl to prepare a 
range of solutions from pH 2 to pH 11. Figure 17 shows how the Soret band spectrum shifts with 
changing pH. The work could not be done with PS4 due to insufficient compound availability.  
Changes in species of PPa and PS1 over pH induces changes in intensity as well as shifts in 
wavelength. To make plateaus and transitions easier to visualise the ratio between peak 
absorbance at each pH extreme was plotted over pH and is also shown in Figure 17. However 
this method is biased to presenting shifts in wavelength over intensity; PPa seems to have 3 
species with transitions over pH 3-4 and pH 6-8. But PS1 seems to have only two species with a 
transition over pH 6-8. However when you look at the spectrums themselves there does appear to 
be a matching shift over lower pH with PS1 to match PPa however it shifts over intensity not 
wavelength. Identical shift patterns were also seen in Q band I (not shown). The shifts seen 
between the PPa species are more dramatic than in PS1, this is shown more clearly by the graph 
in Figure 17 which shows a plot of change in peak (nm) vs. change in absorbance at that peak. It 
also highlights the direction of the shift; as pH increases, PPa shows a blue shift and PS1 a red 
shift.  
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Figure 17 : PS spectral changes over pH. 
 
 
PS concentration was kept constant and pH was adjusted from a 0.2 M glycine solution with 
NaOH or HCl to prepare a range of solutions from pH 2 to pH 11 showing how the Soret band 
spectrum shifts with changing pH for PPa and PS1. 
 
 
The same data presented as a ratio of peak absorbencies at each pH extreme (left) and change in 
peak wavelength vs. change in absorbance at that peak (right) 
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3.2.3.3 .Computational prediction of pKa. values within PS 
 
To help understand the spectral data presented above some in-silico computer predictions of 
the pKa of PS ionisationable groups was done. The programme used here is Marvin, see 2.1.3.1. 
To carry out computational pKa calculations a lot of computer programmes are available,  
(McLaughlin and Fisk, 2007). It is normally suggested that you use multiple programmes, 
preferably one from each algorithm family. Unfortunately many could not provide pKa values for 
our compounds (ACD, SPARC, PHYSPROP, VCCLab), this is likely due to either the 
complexity of our compounds and number of possible sites, or lack of similar data in 
experimental databases. Additionally freeware options are more limited.  
 
Figure 18 shows all three structures with their predicted pKa Values, the ones that fall 
between pH 1 to 14 are in bold and underlined. In all three photosensitsers it is predicted to be 
the same groups that become ionised and the pKa do not vary to any great extent between PS, 
although it is important to remember pKa is a log scale so small changes will make big 
differences in the percentage of species that will be present. One should however also be wary of 
forming conclusions using computer prediction alone unless backed up with experimental data. 
The four ionisation atoms predicted are; two of the four nitrogens on the central pyroll rings (pKa 
~4.5), the oxygen on the propionic acid side chain (pKa~3.5) and the allylic carbon in the 
cyclopentanone ring (pKa ~12). 
 
Because all photosensitisers are predicted to show a similar ionisation pattern only the charge 
species distribution graph for PPa is presented, this graph shows the percentage of each ionised 
form that is likely to be found at each pH for each of these three sets of atoms (nitrogens, carbon 
and oxygen). If these predictions are accurate it is likely the spectral shifts seen in the spectra 
above over pH 3-4 may be due to central N ionisation but the shifts over pH 6-8 must be due to a 
different pH induced effect. The yellow area in the charge species distribution graph shows 
where the unionised photosensitiser is predicted to appear. Importantly for LogP the unionised 
form is not predicted to be present as a majority species at any pH, so LogP would 
experimentally always be compromised. A logD may be a more relevant and obtainable 
indication of solubility.  
Page | 120  (Hayley Pye 2012) 
 
 
Figure 18 : Computational prediction of pKa. values within PS. 
 
 
In-silico computer predictions of the pKa. of ionisationable groups on PPa, PS1 and PS4 was 
carried out with Marvin (see 2.1.3.1.). Structures are presented with their predicted pKa. values 
next to each ionisable group. The ones that fall between pH 1 to 14 are in bold and underlined. 
 
 
For PPa the charge species distribution graph for PPa is presented, this graph shows the 
percentage of each ionised form that is likely to be found at each pH for each of these three sets 
of ionisable atoms (nitrogens, carbon and oxygen).The yellow area in the charge species 
distribution graph shows where the unionized photosensitiser is predicted to appear. 
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3.2.3.4 Computational prediction of LogP values for PS 
 
Computational LogP predictive software is also readily available as freeware online, multiple 
algorithms have been designed over the years and all are being continually improved. Many can 
provide impressive correlations with experimental data. Again it is normally suggested that you 
use multiple programmes, here three programmes were used to make predictions of LopP, two of 
which provide results for multiple different algorithms. The results are presented in Figure 19 
individually in tables and as an average of all in graphical format. For more detail on the 
methods and software see 2.1.3.1. As can be seen in Figure 19 the range of calculated LogP 
values is large, (around 2 LogP units), this seems particularly unreasonable as in one report 
(Faller and Ertl, 2007) it was suggested as little as 0.5 would be the expected deviation. The 
apparent difficulty in computational prediction faced here is likely due to the number of 
ionisation group and the extensive delocalisation of electrons which will propagate interactions 
over longer distances than usually encountered by these computational models. The fact that 
these compounds are also unlikely to inhabit an completely unionised form, and that these 
compounds can also be prone to soluble aggregate formation when neutralised,  makes LogD a 
more relevant parameter for this work.  
 
Within the data the PS-1 predictions tended to appear more hydrophobic than their parent 
molecule, this does not agree with previous spectral data. PS1 was designed with short PEG 
chains; chains synonymous in the literature as a technique used to impart water solubility (Allen 
et al., 2002). One possible reason for the confusion of the computation software could be that 
PEG chains help to provide water solubility by helping to order the water molecules around the 
protein, creating a hydration shell, these complex global interactions may not be fully considered 
by the models employed by the various programs. Or perhaps because a majority of the 
prediction methods used to calculate LogP were of a fragmental method, the software is likely to 
work out all possible micro species (each micro species being a combination of possible 
ionisations) and PEG chains will provide lots of potential domains for ionisation, despite not 
being physiologically relevant ionisations to our work they could be altering the we ighting of 
influence from the physiologically relevant ionisations in the overall calculation.   
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Figure 19 : Computational prediction of LogP values within PS 
 
 
Three different programmes used to predict computational LogP of PPa, PS1 and PS4, two of 
which provide results for multiple different algorithms. Each programme is represented in its 
own table containing all the predicted LogP Values. Alongside an average of all these value is 
presented in graphical format. For more detail on the exact methods and software see 2.1.3.1. 
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3.2.3.5 Computational prediction of LogD values  
 
LogD combines predicted LogP and pKa information. For this reason Marvin see 2.1.3.1 was 
the only software that could be used to produce a predicted graphical LogD and this is presented 
in Figure 20. The peaks shown on the predicted LogD graph seems to match the experimental pH 
influenced spectral changes that were unexplained by predicted ionisation domains earlier 
3.2.3.2. Between pH 2 and pH 8 the LogP is predicted to increase with a peak around pH 4.5, 
likely due to the prevalence of neutral form, resulting in a dramatic drop in solubility. This 
means that the data shown in Figure 17 represents not just the effect of ionisation domains but of 
a molecule becoming less soluble in its chosen solvent and forming different species of soluble 
aggregates.  
 
3.2.3.6 Experimental prediction of LogD  
 
To attempt to provide more experimental evidence for any increased solubility of our new 
compounds an experiment like a LogP ‘shake flask’ experiment was carried out. As previously 
mentioned this sort of experiment requires a unionised form of the photosensitisers, which in 
isolation is unlikely, so an experiment was designed to predict LogD rather than LogP and the 
photosensitisers were partitioned in an aqueous-organic / liquid-liquid biphasic system consisting 
of 1-octanol and PBS at pH7.4 (Any ionisation of PS therefore will be physiologically relevant). 
Parallel experiments were carried out in which solute was diluted initially in either 1-octanol or 
PBS pH7.4 and then added to the opposite solvent, providing information on possible movement 
in both directions and hopefully reducing any bias to the solvent the PS was initially dissolved 
in. Photosensitisers were also diluted 1:1000 into the relevant solvent to try and avoid any 
influence of original preparatory solvent (DMSO) acting as a conduit where PS could exist in 
bubbles of DMSO as it travels between each solvent. 
 
Table 7 shows the average ‘apparent LogD’ value of the two vials, each with the chosen 
solute travelling in a different direction. Due to low absorbance values for the PBS fraction 
absolute concentrations of PS could not be accurately calculated for this fraction so the 
calculation shown in Table 7 involved using just the data taken from the 1-octanol solvent 
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partitions in which it was assumed all photosensitiser is in a non aggregated state and absorbance 
values were within an accurate range. Control vials of the same concentration of PS in purely 1-
octanol were calculated alongside and therefore any loss in the biphasic system could be 
calculated as a fraction of this and the corresponding hypothetical fraction that moved into the 
aqueous fraction also calculated. 
 
The experimental ‘apparent LogD’ data shows PS4 and PS1 exhibit lower values of LogD 
compared to PPa (PPa>PS1>PS4). However the errors are large and for this data to provide any 
useful indication of solubility one would need to carry out subsequent repeats of the experiment 
and at higher PS concentrations, the dilution factor meant very small volumes of stock 
photosensitiser were handled and absorption values low.  
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Figure 20 : Computational prediction of LogD values 
 
 
LogD combines predicted LogP and pKa. information. Previous predictions from Marvin for 
these two values were combined by the same software to provide a graphical LogD. 
Physiological pH (pH7.4)  is marked by a pink arrow, at pH 7.4 LogD is 3.92 (PPa) 6.01 (PS1) 
and 3.48 (PS4).  
 
Table 7: Experimental prediction of LogD. 
 
 
An experiment like a LogP ‘shake flask’ experiment was carried out in which PPa, PS1 and PS4 
were partitioned in a aqueous-organic / liquid-liquid biphasic system consisting of 1-octanol and 
PBS at pH7.4. See 2.1.6.2 for method details.  
0
1
2
3
4
5
6
7
8
9
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Lo
g 
P
pH
Log D
(weighted prediction VG:KLOP:PHYS) 
Ppa
PS1
PS4
pH 7.4
PPa 1.266 0.64
PS1 1.086 0.36
PS4 0.748 0.12
Standard deviation 
between vialsApparent LogD
Page | 126  (Hayley Pye 2012) 
 
 
3.3 Discussion 
3.3.1 Potency of the new PS in the In-vitro PDT model 
 
Changes were made to the methodology of the in vitro PDT cell kill assay used in previously 
published work (Stamati et al., 2010). When directly compared in the same assay, the altered 
conditions demonstrated no significant change to the cytotoxicity of PS, but when IC50 values 
from the new assay were compared to those previously published the PS have different 
potencies: Stamati et al : IC50 = PPa 14.5 µM, PS1 1.1 µM and PS4 259.6 µM, This Thesis; 
IC50 = PPa 2.1 µM and PS1 3.5 µM with PS4 non toxic even up to 500 µM. This could be due to 
unknown changes made in the protocol between researchers, changes in batches of PS, storage 
conditions or even an adaption of the cell line over time. The experiments we re repeated a 
number of times over the course of this thesis and the IC values were reproducible. The cells 
were divided into stock vials and kept within a limited passage for all experiments.  
 
A particular problem with the development of a successful in vitro assay for PDT is the 
increased number of variables over a standard drug toxicity model. This also makes it hard to 
compare PS cytotoxicity across the literature and to clinical standards. As demonstrated in this 
chapter; changing the light dose can change the cytotoxicity of a photosensitiser (PPa) from 2-
3µM to 60-70nM, and a PS (PS4) which could have been abandoned due to complete loss of 
cytotoxicity has been retained for further analysis because when light dose is increased it actually 
showed more potential for an improved relationship between toxicity and delivered light  over its 
parent molecule, a hypothesis backed up by PS4s increased singlet oxygen quantum yield in 
toluene (shown in 1.6).  
 
It will be of interest to investigate what changes the chemical manipulations of PPa (i.e. PS1 
and PS4) has had on cellular uptake, intracellular localisation and the mechanism by which these 
new photosensitisers initiate cell death. All these things will be investigated in the next chapter 
but it was initially desirable to also try to obtain an experimental demonstration of any increase 
in solubility of these new PS. 
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3.3.2 Spectral investigation of PS solubility. 
 
Stamati and colleagues (Stamati et al., 2010) designed two new photosensitisers to exhibit 
more water solubility than their parent compound PPa. In the work presented here an indication 
of the increase in solubility provided by these chemical modifications was investigated.  
 
PS contain chromophores which can function as inherent solubility indicators, shifts in their 
absorbance spectrums when dissolved in different solvents can help indicate how well the 
molecules interact with the solvent. In the data presented in this chapter larger shifts away from 
monomeric PS were seen with PPa than with its derivatives after dissolution in more 
physiological solvents such as water, PBS and supplemented cell culture medium. For reference 
a chromophore known to have good water solubility; Cy5.5 dissolved in the same solvents as PS 
is shown below in Figure 21. From the spectral data one could conclude that PS1 and PS4 are 
both more soluble in aqueous solution than their parent compound, PS4 more so than PS1. 
Another important thing to note from the spectral data is that some of the shifts in absorbance 
take the spectrum a significant distance, in some cases outside the range of the emitted light from 
the laser being used for therapy, if similar shifts occur intracellularly it would have an influence 
on the cytotoxicity of these compounds. 
 
The spectra for the new photosensitisers all show a notably lower intensity red-shifted 
spectra for Q band I when dissolved in water compared to the less polar aprotic solvent DMSO. 
An increase in the intensity of a band would be more preferable (as seen in Figure 21) because if 
the molecules are absorbing more photons and the deactivation pathways are unaffected it will 
increase the efficiency of photophysical processes. The impact of a red or blue shift is less 
predictable of photophysical efficiency unless the shift to the red is to such an extent that the 
energy level inhabited is now so low as to not be sufficient to be able to react with the preferred 
target molecules required for effective PDT induced toxicity.  
 
Similar work was carried out by Aveline and colleagues (Aveline et al., 1995) with 
benzoporphyrin derivative monoacid ring A (BPDMA), another chlorin-type molecule, they 
showed concentration dependent self association into non covalent aggregates in aqueous media, 
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this was exhibited through the absorbance spectra with a broadening of all bands along with a 
reduction in intensity, the Q bands were red shifted and the Soret band was blue shifted. Addition 
of BSA to the aqueous media returns the spectra (blue shifts) to that of a monomeric PS (i.e. 
similar to its spectra in organic solvent). Kelbauskas and Dietel (Kelbauskas and Dietel, 2002) 
conducted a study of pyropheophorbide-a ether (PPa-ether) and chlorin e6 derivatives possessing 
alkyl chains of 1–9 carbons. Lipophilicity of these compounds increased with increasing alkyl 
chain length. The PS which were shown to aggregate in aqueous solution (PBS) vs. 
monomerisation in organic solvent (methanol) also showed in their absorbance spectra a 
broadened Soret band and broadened and red shifted Q bands. 
 
Figure 21: Cy5.5 in different solvent systems 
 
A chromophore known to have good water solubility; Cy5.5 dissolved in the same solvents as PS 
presented in Figure 16. 
 
The spectral shift of PS in media-supplemented with FCS when compared to PBS is 
particularly intriguing; large changes were seen with PPa compared to much smaller changes 
with the new photosensitisers. The introduction of serum proteins (in FCS) could indicate the 
formation of non-specific interactions between serum protein and PS, visualised by shifts in the 
PS spectra, these would affect both any future antibody conjugation reactions and the PS’s 
pharmacokinetic behaviour in the blood. Nevertheless the introduction of PS to an environment 
as complicated as the human body can sometimes be unpredictable. . It is worth considering that 
there are other differences between media and PBS that could account for this change other than 
serum proteins, but there is a significant body of work that supports the observation that these 
molecules (PS) often form associations with BSA or LDL and that this can affect its spectra, 
these are discussed in part below and in more depth in 1.3.4.  
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Fluorescence emission profiles have previously been used to investigate the same thing in 
other PS however the data tends to show a return to a monomeric type spectra with the 
introduction of serum proteins: Rinco and colleagues (Rinco et al., 2009) looked at a range of 
different porphyrin molecules and their fluorescent emission profile in d ifferent solutions 
including toluene, methanol, 0.04M phosphate buffer (pH 7.4) and phosphate buffer 
supplemented with human serum albumin (HSA). Most showed a blue shift in their fluorescence 
spectra with increasing solvent polarity (toluene < methanol < phosphate buffer), and a red shift 
once HSA was added to the phosphate buffer solution. Mojzisova and colleagues (Mojzisova et 
al., 2007c) looked at Chlorin e6, a PS which is based on same macrocycle as PPa, is also derived 
from methyl-PPa but has three additional carboxylic acid groups on one side of the ring. Their 
work demonstrated PS fluorescent emission profiles showed a red shift and increased intensity 
with association with human serum albumin or LDL. 
 
Seemingly most papers that show a shift in PS spectra  will state aggregation of the molecule 
as its cause, but there are many other factors that can influence spectral shifts, see 3.1.4. 
Although no precipitates were seen in any of the solutions used in this work, it may be useful to 
carry out more work to confirm if the formation of soluble aggregates is indeed occurring. As 
aggregation is concentration dependant, aggregates will present a spectral shift back to a 
monomeric spectral pattern at lower PS concentrations. This was not seen in the work carried out 
for this thesis; however it could be that PS were not diluted sufficiently, (although absorbance 
was approaching the limit of detectability). To check this idea more thoroughly fluorescence can 
be used and is a much more sensitive measure of this aggregative effect, fluorescence has the 
additive sensitivity of measuring not just miss-absorption of laser light but the quenching of 
fluorescence due to the close interaction of another molecule. Quenching occurs as either the 
emitted light is re-absorbed or the energy transferredin non-radiative transition to the other 
molecule without any emission of light. Fluorescence as a result of changing PS concentration is 
looked at in the next chapter, see 4.2.2. Isothermal titration calorimetry (ITC) could also be used 
to confirm aggregation as it is able to detect the change in heat energy as aggregates or micelles 
form in a solution (Heerklotz and Seelig, 2000). This could be especially interesting in the case 
of PS-1 as its chemical structure suggests it could form micelles via its ‘soapy’ PEG-like tail.  
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3.3.3 The partition and distribution coefficient of PS (LogP and LogD). 
 
A well recognised measurment of solubility is the partition coefficient LogP, to calculate this 
an unionised form of our compound was needed but computational software predicted that this 
would be unlikely (see Figure 18). Another complication in carrying out a LogP partition 
experiment with a molecule like PPa is ion pair partitioning; where the charged species pairs 
with a reagent ion or even in certain cases itself. Instead LogD, an ionisation dependent form of 
LogP, was decided more suitable, in addition LogD has been shown to be a more physiologically 
relevant parameter for drug discovery and more predictive of pharmacological outcome than 
LogP (Bhal et al., 2007). 
 
As presented in this chapter the experimentally derived LogD values, see Table 7, agree with 
the spectral data that the order of aqueous solubility from least soluble to most soluble is, PPa 
(LogD=1.266), PS1 (LogD=1.086) then PS4 (LogD=0.748), but as discussed there were 
problems with data reliability. Problems seen with the reliability are echoed in work by 
Engelmann and colleagues (Engelmann et al., 2007) whom carried out a similar initial 
experiment but improved their data by carrying out the experiment in a butanol–water system. 
The results from the LogD experiment presented in this thesis were a lot lower than any values 
predicted by computation software. Published LogP and LogD values for similar molecules in 
the literature cover a large range so both numbers presented here could be in line with what 
would be expected. Other researchers too have seen variations between LogP/LogD values for 
the same molecule when they are calculated using different models, however most also show the 
trend between different molecules will be reliable when using the same model, see 3.1.3. 
 
It is often hard to match up computational data and experimental data becuase there are many 
elements not always easy to factor into computational calculations. For LogP/LogD values these 
can including ion pair interactions, interactions between the molecules themselves and 
consideration of the solvent molecules not just the structure of interest (McLaughlin and Fisk, 
2007; Xing and Glen, 2002b). This leads to both difficulties in prediction as well as the design 
and interpretation of experimental data.  
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Other simple methods to look at aqueous solubility beyond partitioning or spectral shifts also 
exist, for example Pan and colleagues (Pan et al., 2001) added a compound to aqueous solution 
and sieved it through nylon or PTFE filters to measure how much remained in solution via 
spectrometric analysis at 245nm (most organic compounds will have strong UV absorbance here) 
or you can measure turbidity using a Nephelometer.  
 
3.3.4 Spectral shifts with pH change 
 
The importance of looking at spectral shifts over pH may initially be overlooked but the 
work carried out in order to help design a LogP experiment (i.e. trying to visualise ionisation 
domains) may also have given us hints about pharmacokinetic behaviour. Computational 
prediction of ionisation domains showed very little difference between PS1 and PPa, but the 
spectral changes upon changing pH were markedly different: Both PPa and PS1 show 3 species 
with transitions over pH 3-4 and pH 6-8, but the shifts occur in opposite directions and to 
different extents. PS1 transitions were smaller and as pH increased, light of a lower energy was 
absorbed, i.e. it was red shifted. In comparison PPa showed a blue shift as pH increased and the 
changes that occurred were of a more dramatic nature.  
 
Other labs that have studied pH dependent changes in PS including Mojzisova and 
colleagues (Mojzisova et al., 2007c) who showed pH dependant spectral changes when they 
looked at Chlorin e6, a PS based on same macrocycle and also derived from Methyl-PPa. Their 
work examined its fluorescence emission spectra in PBS at pH 6.5, 7.4 and 8.0 and they showed 
a decrease of the fluorescence intensity and a small blue shift (3nm) when the pH was decreased. 
Bonneau and colleagues (Bonneau et al., 2004a) looked at membrane diffusion rates for an 
asymmetrical porphyrin with 2 carboxylic acid groups on the same side of the ring.  Dimerisation 
of the PS was shown to be pH dependent and accompanied by changes in absorption spectra and 
a strong inhibition of the fluorescence. The monomer and dimer forms could be identified by 
bands at 395 and 370 nm respectively, this shift was in keeping with the exciton theory that a 
blue shift is interpreted as the formation of dimers with face to face stacking, the structure of the 
PS also suggested this formation as the polar groups would be arranged in opposite directions to 
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reduce repulsion. This arrangement meant the distribution of polar chains in the dimer was 
roughly symmetrical this reduced its subsequent incorporation into cellular membranes. 
 
These pH dependant shifts, as with the shifts seen in different solvents, can also help predict 
behaviour in a cellular environment. PS1 shifted less than PPa over pH so it is more likely to 
retain optimum photophysics in the range of pHs found within cellular environments  see 4.1.2. 
Pharmacokinetics may also be affected as the pH of the environments a drug can be exposed to 
will vary considerably, some examples are as follows: blood plasma 7.4, tumour extracellular 
media 6.9, stomach 2.0, kidneys 4.2, small intestine (food 5.0; fasted 6.8), duodenal mucus 5.5,  
(Xing and Glen, 2002b). 
 
3.3.5 Chapter conclusions 
 
Key proposition put forward from work; 
PPa derivatives PS1 and PS4 were shown to be more water soluble than their parent 
compound and show less spectral shifts in a range of physiological environments which could 
suggest improved photo-physical characteristics for effective traditional PDT in a biological 
environment. However in an in vitro non-targeted PDT cancer cell model, initial data suggested 
these new more soluble PS became less potent. 
 
Main question raised from this work;  
Are there any other experiments looking in more detail at some of the factors beyond 
photophysical efficiency that can be carried out to find out why changing the solubility in this 
way has causes a loss in observed potency?  
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Chapter Four 
4 CHAPTER 4: The effect of increased PS solubility on PDT cellular mechanisms 
4.1 Introduction  
 
The work presented in this thesis on cell death mechanisms is being undertaken in order to 
see if changes to PS structure can modulate the type of cell death induced. However there are 
additional benefits to looking at cell death mechanisms: If one can identify the cell death 
pathway that is implicated, or the importance of particular biochemical cascades or molecular 
targets that are being inhibited or activated, this can allow prediction of possible in vivo effects, 
including any possible immune activation, any possible resistances that could be pre-determined 
in certain sets of patients or help in the design of combination treatments. 
 
Regulation of cell survival, cell division, and all the forms of cell death are highly 
interconnected. Manipulation of just one variable is sometimes enough to switch cellular fate 
between these paths. (King and Cidlowski, 1995; Maddika et al., 2007; Vermeulen et al., 2003). 
However the mechanism and rate of PS cellular uptake and any subsequent intracellular 
localisation will also have a significant effect on PDT efficiency and the type of cell death 
initiated. 
 
4.1.1 The different cell uptake mechanisms  
 
Mechanisms controlling the membrane transport and uptake of compounds into cells can be 
divided into passive mechanisms, (single molecule with concentration or electrochemical 
gradient), active mechanisms, (single molecule against the concentration or electrochemical 
gradient) or bulk flow mechanisms (multiple molecules via vesicle mediated transport). Passive 
mechanisms occur via direct diffusion or can be facilitated by protein channels or carriers. 
Active mechanisms are defined by the requirement of carriers or pumps that are coupled to a 
source of metabolic energy, for example adenosine triphosphate (ATP) hydrolysis or an ion 
gradient. Bulk flow can be categorised as active or passive; for example endocytosis as a process 
requires cellular energy but can at the same time take up specific molecules against their 
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concentration gradient or non specifically ‘drink’ molecules from the extracellular environment. 
NB these processes exist in two directions. 
 
Theoretically any molecule can diffuse across a lipid bilayer down a concentratio n gradient 
but for larger, more polar or charged molecules the rate of this becomes inhibitively slow. The 
extent of diffusion of molecules across the membrane is controlled by the interaction between the 
composition and structural arrangement of the membrane and the physicochemical 
characteristics of the molecule including its hydration and/or solvation. Passive facilitated 
transport of molecules through channels or carriers also follows this same gradient, but the 
facilitation lowers the activation energy for the transport process.(Brandl et al., 2007) . 
 
Passive and active transport can occur directly over the plasma membrane into the cell 
cytosol, but in bulk transfer vesicles containing patches of the cellular membrane, often 
containing a high concentration of protein or lipids acting as receptors for extracellular ligands 
are ‘budded off’ and invaginated forming a intracellular vesicle, this vesicle then travels on 
microtubules and links up to a pathway of vesicles and organelles that share membranes and 
cargo. This vesicle mediated transport can carry cargo in both directions between the cell surface 
and internal organelles including endoplasmic reticulum (ER), Golgi, Endosomes and 
Lysosomes. Endocytosis travels from the cell surface in, and exocytosis from intracellular 
organelles out. Cargo can be either part of the vesicle wall, (lipids themselves or lipid associated 
macromolecules), or soluble cargo carried in the aqueous centre of the vesicle. Organelles 
outside this system (inc mitochondria, peroxisomes, nucleus) have independent trans-membrane 
transport mechanisms between them and the cytosol for protein and other molecular movement, 
membranes for these compartments are not shared directly with other organelles as with the 
vesicle system mentioned above but phospholipid exchange proteins can moves lipids around 
specifically between organelles (Alberts et al., 2002). 
 
Endocytosis can be divided into phagocytosis, macropinocytosis, clathrin-mediated 
endocytosis, caveolae-mediated endocytosis, and the multiple remaining mechanisms that are 
clathrin- and caveolae independent. See Figure 22. Although cargo selection and uptake 
mechanistically is different, all pathways appear to feed into the same early endosome system, 
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but with differences seen on final locations and potential interactions occurring during the 
trafficking process. Cargo taken from the cell surface by endocytosis will be, if not otherwise 
directed, confined within the endocytic pathway. The default process follows transport of cargo 
through early endosome to late endosomes and finally the lysosome. (Conner and Schmid, 2003; 
Doherty and McMahon, 2009; Luzio et al., 2007; Maxfield and McGraw, 2004; Sorkin and von 
Zastrow, 2009). 
 
4.1.2 Cell uptake and drug design  
 
Although it has long been established that transporters across the plasma membrane exist for 
various endogenous compounds such as glucose, amino acids, nucleosides, water soluble 
hormones and neurotransmitters, cellular uptake for non endogenous drugs was traditionally 
thought to be exclusively via passive diffusion through the lipid bilayer, and many 
pharmaceutical processes designed drugs around this idea. Many novel techniques have been 
designed to overcome the cell membrane barrier and drive cellular uptake (Rajendran et al., 
2010a; Sobolev et al., 2000b). 
 
A series of opinion papers published relatively recently put forward the theory that successful 
membrane crossing could in fact be dominated almost solely by carrier-mediated cellular uptake 
via transporters, they argue what is thought to be uptake via passive diffusion is due to either 
unknown transporter interactions, transporters as yet unknown with uncharacteristic substrate 
specificity or due to the hitchhike of drugs on endogenous molecules. (Di et al., 2012; Dobson 
and Kell, 2008; Kell et al., 2011; Sugano et al., 2010).  
 
After endocytotic uptake, drug macromolecules designated for target organelles, i.e. nucleus, 
mitochondria can undergo what is called endosomal entrapment and end up stuck in the 
lysosome. There have been numerous methods designed to overcome this and free the drug to the 
cytosol (El-Sayed et al., 2009; Rajendran et al., 2010b; Torchilin, 2006). 
 
Particularly useful for manipulation in drug design is the trans-membrane pH gradients that 
exist between various organelles, covering a range from pH 8 to 5 for example : cytosolic and ER 
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(pH 7.1-7.2) golgi (pH 6.2-7) secretory granules (pH 6-5) cell surface (pH 7.2-7.4) endosomes 
(pH 5.5-6) lysosomes (pH 5.0) and mitochondria (pH 8). Changes in proton concentration 
between microenvironments therefore can cause changes in the physiochemical behaviour of 
drugs -especially those with groups with a pKa between 5 and 8.  For example; as pH decreases 
below the pKa of molecule containing a weak acid group the anionic charge is neutralised driving 
an increase in membrane partitioning of that group. A molecule with a weak base would show 
the opposite behaviour and membrane partitioning with the neutral species would occur as pH 
increases above the pKa. The different concentrations of other ions (e.g. potassium, sodium, 
calcium) between the inside and outside of the cell, as well as within different intracellular 
compartments, creates membrane potentials across cellular membranes (also called membrane 
voltages); the plasma membrane typically has a membrane potential of–60 to –80 Millivolts 
(mV) in amplitude, and for the mitochondria this membrane potential is thought to be between 
180 and 200 mV. Any molecules with a net positive charge are therefore favoured in their 
attraction for these slightly negatively charged membranes and should have improve uptake 
efficiency (Asokan and Cho, 2002; Rajendran et al., 2010b).  
 
Figure 22 : Mechanisms of Endocytosis 
 
Reproduced from (Conner and Schmid, 2003) The endocytic pathways differ with regard to 
the size of the endocytic vesicle, the nature of the cargo, the type of lipids and receptors in the 
vesicle, and the mechanisms of vesicle formation. (NB: monomeric PS is ~ 1-2nm) 
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4.1.3 Categorised cell death  
 
Cell death can be categorised into many forms. The field of cell death has however perhaps 
suffered from the rapid and un-controlled introduction of new terms for types of cell death, 
leading to confusion and incorrect generalisations. In the few years there have been various 
publications to try and re-address this, (Galluzzi et al., 2007; Golstein and Kroemer, 2007; 
Kroemer et al., 2009). Cell death categorisation is defined by observed morphology, this in turn 
is a reflection of the pathway taken to death. An official commentary from the ‘nomenclature 
committee on cell death’ in 2009 defined cell death into four distinct categories, Apoptosis, 
Autophagy, Cornification and Necrosis, and these are shown below in Table 8. Interestingly 
since their last commentary in 2005 this has reduced drastically from the eight categories 
presented then (Kroemer et al., 2005). This new categorisation of cell death vocabulary has made 
the process of carrying out experiments into cell death a little more challenging, no longer can 
one molecular end point such as caspase activation be sufficient to define cell death and many 
conventional assay interpretations now no longer stand (Galluzzi et al., 2009). 
 
4.1.4 Practical considerations 
 
Many of the key biological markers of cell death are transient and will occur at different time 
points so the timing of a cell death assay is an important consideration. The cell line in use is also 
important, as its immortality means it will likely have mutations or an altered phenotype that 
mean some cell death hallmarks or receptors for apoptotic stimulus will be missing or non 
functional. Also factors such as cell density, differences in cell cycle phases, passage number and 
the density to which the parental culture was grown can affect a cells ability to respond to a 
stimulus. Care also needs to be taken when comparing data from populations of cells vs. single 
cells (Sundquist et al., 2006) (Goldstein et al., 2000). Finally In vivo observations show the 
removal of the apoptosing cells by phagocytosis, with the absence of these immune cells in vitro 
apoptotic cells will continue through cell death after apoptosis into a state that more resembles 
necrosis, this transition is termed secondary necrosis. (Krysko et al., 2006; Silva et al., 2008).  
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Table 8: Modalities of cell death (nomenclature committee on cell death). 
Taken from  (Kroemer et al., 2009).  
 
Cell death mode Morphological features Notes 
Apoptosis 
Rounding up of the cell 
'Apoptosis' is the original term 
introduced to define a type of 
cell death with specific 
morphological features. 
Apoptosis is NOT a synonym of 
programmed cell death or 
caspase activation. 
Retraction of the pseudopodes 
Reduction of cellular and nuclear volume (pyknosis) 
Nuclear fragmentation (karyorrhexis) 
Minor modification of cytoplasmic organelles  
Plasma membrane blebbing 
Engulfment by resident phagocytes, in vivo 
Autophagy 
Lack of chromatin condensation 
'Autophagic cell death' defines 
cell death occurring with 
autophagy, though it may 
misleadingly suggest a form of 
death occurring by autophagy as 
this process often promotes cell 
survival 
Massive vacuolisation of the cytoplasm 
Accumulation of (double-membraned) autophagic vacuoles 
Little or no uptake by phagocytic cells, in vivo 
Cornification 
Elimination of cytosolic organelles  
'Cornified envelope' formation or 
'keratinisation' is specific of the 
skin to create a barrier function. 
Although apoptosis can be 
induced by injury in the basal 
epidermal layer (e.g., UV 
irradiation), cornification is 
exclusive of the upper layers 
(granular layer and stratum 
corneum).  
Modification of plasma membrane 
Accumulation of lipids in F and L granules  
Extrusion of lipids in the extracellular space 
Desquamation (loss of corneocytes) by protease activation 
Necrosis 
Cytoplasmic swelling (oncosis) 'Necrosis' identifies, in a 
negative fashion, cell death 
lacking the features of apoptosis 
or autophagy. Note that necrosis 
can occur in a regulated fashion, 
involving a precise sequence of 
signals. 
Rupture of plasma membrane 
Swelling of cytoplasmic organelles 
Moderate chromatin condensation 
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4.1.5 Molecular markers for apoptosis  
 
Popularly reported molecular markers for apoptosis include; initiator and effector caspase 
activation, mitochondrial membrane permeablisation and release of cytochrome c, 
externalisation of phosphatidylserine on the plasma membrane, and internucleosomal DNA 
fragmentation. Not all of these biochemical events are specific to apoptosis, and even within 
apoptosis may not always occur. 
 
Caspases consist of a family of proteases and activation of the ‘caspase cascade’ was a  
classical marker of apoptosis. This was until the discovery of types of caspase independent 
apoptosis and the involvement of some caspases in non lethal signalling pathways for 
inflammation, differentiation and migration. Caspase activation is now no longer a requirement 
for the categorisation of apoptosis but as effector caspase targets still include the various proteins 
important for the induction of cell death morphologies they are still a well respected marker 
(Earnshaw et al., 1999; Huai et al., 2010; Pop and Salvesen, 2009). Malfunction of apoptosis 
plays an important role in the pathogenesis of tumours therefore it is unsurprising that many 
cancers show mutations in one or more of the key caspases or regulatory proteins, these 
mutations are also often also a factor in the development of treatment resistance (Ghavami et al., 
2009). 
  
DNA fragmentation, unlike capsase activation is still a hallmark fundamental to the 
classification of apoptosis, and can be seen as a united endpoint for various different upstream 
apoptotic initiating pathways. During apoptosis, DNA fragmentation usually occurs in two 
stages: initial cleavage of chromatin loop domains (creates 50–300kb fragments) then subsequent 
cleavage of exposed internucleosomal DNA (creates fragments in approximate multiples of 
180bp) (Kitazumi and Tsukahara, 2011). Several nucleases have been shown to be able to induce 
degradation of DNA during apoptosis, (Counis and Torriglia, 2006; L. Y. Li et al., 2001; Nagata 
et al., 2003) but the two main ones are endonuclease G (EndoG) and DNA fragmentation factor 
(DFF) (Candé et al., 2002; Widlak and Garrard, 2005). DNA damage is fundamental to the 
progression of cancer and many cancers have been shown to lack aspects of the DNA damage 
response pathways (Aziz et al., 2012; Jackson and Bartek, 2009). 
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4.1.6 The cell cycle and cellular senescence 
 
Many cells in the human body are capable of cell division and proliferation but reside in a 
non-proliferative state, called G0, which despite its name is in fact quite an active phase in which 
cellular functions still occur as the cell awaits the stimulus to enter the cell cycle which commits 
a cell to a path resulting in cell growth and cell division. The cell cycle is divided into four 
phases (G1, S phase, G2,and M phase) and these are shown in Figure 23 (Alberts et al., 2002; 
Norbury and Nurse, 1992; Sherr, 2000). Progression through the cell cycle is monitored by 
checkpoints which will prevent or delay cell cycle progression if various criteria are not satisfied, 
they are also involved in the initiation of repair mechanisms. If cells aren’t able to re enter the 
cycle, cells can be induced to enter cellular senescence or undergo apoptosis. There are currently 
thought to be numerous checkpoints within the cell cycle, found in all parts of the cell cycle 
(Khodjakov and Rieder, 2009; Nyberg et al., 2002). 
 
Cellular senescence is in most cases an irreversible process during which cells acquire 
widespread changes in gene expression and can acquire certain resistances to apoptotic cell-death 
signals. Cells can undergo cellular senescence due to various cellular stresses including DNA 
damage and oxidative stress, this is termed stress- induced senescence or (M0) (M=mortality 
phase) and is independent of both telomere- initiated senescence (cellular aging  or M1) and 
mitotic catastrophe (M2). Cell cycle arrest can be hard to study in vitro as by necessity tumour 
cells have mutations in pathways thought to be responsible for normal cell ageing and cellular 
senescence, although many papers have shown many they retain the ability to undergo stress 
induced senescence and there is a long history of cell cycle regulation for cancer treatment 
(Campisi and d’ Adda di Fagagna, 2007; Malumbres and Barbacid, 2009, 2001; Schwartz and 
Shah, 2005). The cellular stresses responsible for the induction of cellular senescence are very 
similar to those that induce apoptosis. Importantly for PDT, ROS are thought to be able to play 
an active role in induction of cellular senescence in both prolonged exposure or short bouts of 
oxidative stress, (Colavitti and Finkel, 2005).  
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Figure 23 : The cell cycle 
 
 
The cell cycle can be separated into two major phases that alternate with each other: Interphase 
(shown in blue), during which the cell grows, prepares for mitosis and duplicates its DNA, and 
the mitotic (M) phase (shown in red), Interphase can be further divided into three phases: G1, S 
phase, and G2. G1 phase is the gap phase which leads to a cells commitment to entry into the cell 
cycle (the restriction point) and subsequent S phase, S phase is the synthesis phase in which 
chromosomal DNA replication occurs, G2 phase (gap 2) determines the time of entry into M 
phase, and M phase consists of the division of two cells into two daughter cells (Mitosis). It is in 
G1 phase in which cells can respond to cellular signals that determine exit (or entry) from the 
cell cycle into the quiescent state (G0)  
 
 
4.1.7 Cell death in PDT. 
 
There is a very fine balance within the cell, and PDT is capable of manipulating the balance 
between different cell pathways with only a small change in parameters. The original papers 
published back in 1996/1997 (Dellinger, 1996; Luo and Kessel, 1997) first showed that changing 
PS incubation time or dose can change the induced cell death from an apoptotic morphology to a 
necrotic morphology. Nowadays manipulation of this is regularly seen in PDT papers, even 
during clinical treatment. The preference of apoptosis vs. necrosis isn’t always clear, and  
although some argue for a preferably less immunogenic/inflammatory controlled cell death - 
recently the interest in the recruitment of immunogenic mediators to improve long term PDT 
efficiency has challenged this view.  
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PDT can induce cell death via a number of different routes and all the three main modalities - 
apoptosis, necrosis and autophagy have been linked to PDT. No single PDT factor is responsible 
for control over cell death mechanism, some of the responsible factors include photosensitser 
type, localisation and dose, PS physicochemical behaviour in specific microenvironments, light 
fluence/wavelength and timing, the oxygen concentration and the disease state itself. The process 
of intracellular signalling after PDT is complex but much work has been published on the 
subject. A review from (Almeida et al., 2004) tabulated major molecular events during 
specifically apoptotic death induced by PDT, this single table contained 181 references, covering 
20 different ‘major’ cellular events, each one investigating a different photosensitiser or tumour 
cell line. This example emphasises the difficulty in compiling a model molecular pathway for 
PDT. When large scale studies looking at proteome changes post PDT are carried out (Baglo et 
al., 2011; Tsaytler et al., 2008) the scale of the number of pathways involved is apparent. 
However attempts have been made and numerous in-depth reviews have been written on the 
subject (Almeida et al., 2004; Buytaert et al., 2007; Castano et al., 2005b; Moor, 2000; Nowis et 
al., 2005; Oleinick et al., 2002; Ortel et al., 2009).  
 
Pathways that are commonly manipulated by PDT alongside apoptosis, necrosis and 
autophagy, include the unfolded protein response, calcium homeostasis, lipid metabolism/ 
ceramide signalling, transcriptional regulation including NF-κB signalling, tyrosine kinase 
signalling including mitogen-activated protein kinases (MAPK), Cyclin-dependent kinases 
(CDK) and cell cycle control, heat shock protein expression, ROS and antioxidant pathways, 
hypoxia induced pathways and DNA-damage associated signalling. These are just some of the 
examples of known and well studied intracellular events that can occur after PDT. Extracellular 
signalling processes will also have an effect on cell survival, whether via the direct effect of PDT 
or via a secondary response of neighbouring cells and tissues. Reviews on extracellular effects 
such as these include the effect of PDT on the extracellular matrix, the immune syste m, 
surrounding vasculature, including effects on cell adhesion, cytokine expression, and 
angiogenesis. (Ana P Castano et al., 2006; Castano et al., 2005a, 2005b; Pazos and Nader, 2007).  
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4.1.8 PPa specific cell death mechanisms  
 
Although  changeable using experimental parameters, some common pathways of cell death 
are upregulated in more comparable cases. Work on examination of the specific upregulation of 
cell death pathways after PDT with PS derived from or similar to PPa, are reviewed in part by 
Piette et al (Piette et al., 2003) and briefly discussed below. 
 
Li and colleagues (Li et al., 2007) present the induced cell death response from PPa PDT as a 
mixture of necrosis and apoptosis with cytochrome c release from the mitochondria into the 
cytosol alongside caspase-9 and caspase-3 activation.. Matroule and colleagues (Matroule et al., 
2001, 1999) also show a mixture of necrosis and apoptosis, but focus on the involvement of 
reactive oxygen species and NF-kB activation, interestingly they also identify the lysosomal 
release of ceramide. Cytochrome c release is frequently observed by others (Choi et al., 2004) 
alongside involvement from p38 and c-Jun N-terminal kinase (JNK) pathways  and subsequent 
activation of caspase-3 (Lee et al., 2004). Li and colleagues (Li et al., 2006) show a release of 
cytochrome c alongside the collapse of mitochondrial membrane potential,  the up-regulation of 
endoplasmic reticulum stress proteins (calnexin, Grp 94 and Grp78), and the activation of 
caspases-3 and -9. Interestingly this paper also shows up-regulated gene expression of pro-
inflammatory cytokines and beta-chemokines. Collapse of Mitochondrial membrane potential is 
common (Tan et al., 2009), and possibly related to evidence for the direct deactivation of the 
mitochondrial electron transport chain (Kim et al., 2004). 
 
4.1.9 Intracellular localisation and PDT 
 
As mentioned in section 1.4.2 the reactive oxidative mediators in PDT have a short lifetime 
due to their inherent instability and reactivity. This means that the intracellular localisation of the 
photosensitiser will have a big influence on the type of photo-damage that occurs. This 
subcellular localisation can be influenced by; the chemical nature of the PS (inc size, 
lipophilicity, amphiphilic character, ionic charge, structural symmetry), macromolecule binding 
characteristics (inc protein albumin, LDL), the local and serum concentration of the PS, 
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incubation time or time after injection, even the phenotype of the target cell and state of lipid 
bilayer (inc presence of cholesterol).  
 
Different PS have been found to localise in a wide range of intracellular localisations and 
different cell death pathways can be induced from these various intracellular sites. Most 
organelles can be targeted and PS have been seen to locate in the plasma membrane, nucleus, 
mitochondria, ER, Golgi, Endosome/Lysosomal, and Cytosol. PS at all localisations are capable 
of killing but at varying efficiencies, this is due to the range of reactive mediators that can be 
induced by PS and their promiscuity and highly reactivity capability..  
 
There are some good reviews on PS subcellular localisation and uptake (Boyle and Dolphin, 
1996; Castano et al., 2004; Mojzisova et al., 2007a), these reviews aim to pull together some 
rules for a collection of molecules that are incredibly structurally variable from the mass of data 
available. Some of these rules include: The main factors for PS structural changes affecting 
intracellular localisation are hydrophobicity, ionic charge, and structural asymmetry. 
Mitochondria and endosomes/lysosomes are the most common PS localisation sites and 
apoptosis prevails over necrosis when death is induced from these sites. The localisation of PS in 
the Golgi apparatus and endoplasmic reticulum is less frequent and more likely related to a non-
specific solubilisation of the photosensitiser in the membranes of intracellular organelles. 
Compounds that localise in the plasma membranes or nucleus are possible but relatively 
uncommon. Plasma membrane localisation has been linked with inducing a quick, necrotic style 
death. Lysosomal localised PS can lead to cell killing upon illumination, however the relative 
efficacy is significantly lower than that seen with PS localised in mitochondria and other 
organelles. It is often seen that highly aggregated PS are internalised by endocytosis and remain 
sequestered in the lysosomes, while PS that remain as (or are induced to be) monomers can be 
internalised by other pathways. PS that accumulate in mitochondria are usually hydrophobic with 
an asymmetric cationic charge (this rule is less exclusive). PS which are hydrophobic and have 
two or less negative charges can likely freely diffuse across the plasma membrane, and then 
relocate to other intracellular membranes. Those PS which are less hydrophobic and have more 
than 2 negative charges tend to be too polar to diffuse across the plasma membrane, and are 
taken up by endocytosis. PS which are hydrophilic or have many positive or negative charges 
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also tend to be too polar to diffuse across the plasma membrane, and are therefore also taken up 
by endocytosis. (Boyle and Dolphin, 1996; Castano et al., 2004; Mojzisova et al., 2007a). 
 
Intracellular localisation can change over time (Fabris et al., 2001) and it is also worth noting 
that the process of irradiation itself can cause not only photo-modification and photo-degradation 
of the PS but has been shown to cause photo-relocalisation of some photosensitisers, often 
thought to be either due to photodynamic permeablisation of the various membranes and release 
of PS or the lysosomal autophagy of damaged organelles (Moan et al., 1994; Scully et al., 1998; 
Wood et al., 1997).  
 
Localisation is also important in a multi-cellular model, Xiao and colleagues (Xiao et al., 
2005) compared commonly used photosensitisers, and looked at the intra-tumour distribution in 
tumour spheroids. All PS showed concentration-dependent, diffusion driven penetration and 
accumulation and all showed greater accumulation at the spheroid rim than the spheroid centre. 
Contrary to single cell studies in which higher lipophilicity often means increased cell uptake 
(see 3.1.3), here they showed better distribution with the more hydrophilic PS, hypothesised to 
be because a lipophilic PS would have higher affinity for the network of hydrophilic extracellular 
matrix found on a spheroid surface and not seen in monolayer cell culture, this could slow its 
penetration into the spheroid centre. However PS size too was also an important factor in their 
results.  
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4.2 Results 
4.2.1 Intracellular localisation by confocal fluorescence microscopy 
 
To visualise the localisation of the intracellular photosensitiser, cells were exposed to 20µM 
photosensitiser over two hours in conditions matching those used in the in vitro cell kill assays. 
Confocal fluorescence microscopy images were taken from the br ightest part of the cell 
(generally found to be the centre). A laser excitation wavelength helium–neon (HeNe) laser at 
633 nm was used instead of the 405 nm diode laser. This was because with the 405nm laser, even 
at the lowest useable settings, irradiation of the image would initiate cell morphology changes 
over the whole plate. For example one saw cell shrinkage and/or what seemed to be the 
development of intracellular vesicles (data not shown). It is likely cells were undergoing 
conformational cell death changes.  
 
Cells were imaged directly and not fixed, although fixing was shown to reduce irradiation 
induced morphology change (data not shown) the introduction of formaldehyde can compromise 
images in other ways: For example it can introduce artefacts from precipitated salts or 
paraformaldehyde, formaldehyde can have endogenous auto fluorescence, it can also cause 
morphological changes, loss of immuno-recongition, and the re-localisation of unfixable 
molecules. Its presence also has the potential to change the fluorescent efficiency of any 
neighbouring fluorophores in its vicinity by changing their immediate environment (Ganguly et 
al., 2011; Grizzle, 2009; Meade et al., 2010; Schmiedeberg et al., 2009; Tate and Cooper, 2008). 
 
In the set of confocal fluorescent microscopy images shown in Figure 24 all images were 
taken using the same camera sensitivity, however PS4 staining required higher laser intensity 
settings than used for PPa and PS1 due to lower fluorescent yield (Stamati et al., 2010). 
Presented are images of cells containing the three PS at their optimal laser settings, in these 
images PPa and PS1 are imaged using the same laser settings but PS4 at a higher laser intensity. 
For interest included at the bottom of the figure is an image of PS4 containing cells taken at the 
same settings as used for PPa and PS1 and an image of cells in just media alone demonstrating 
no cellular auto-fluorescence at these camera settings. 
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In all the images obtained PS1 and PPa both show the same localisation pattern; dotted 
throughout the cell but concentrated in an area around the nucleus, this peri-nuclear localisation 
seems most similar to that of an Endoplasmic Reticulum (ER) localised protein. ER is an area of 
dense membranes within the cell and its most recognised function being protein folding, sorting 
and modification. PS4 displays a different localisation pattern, more punctuate and less centred 
close to the nucleus, perhaps of a more endosomal or lysosomal pattern. Conclusions on 
localisation were based on fluorescent images of proteins with prescribed localisations; for more 
information and example images see 2.1.4.5. 
 
Throughout this work it was also noticed that upon leaving the PS containing media in with 
the cells during imaging, no difference would be seen between these images and images taken 
where PS containing media was removed and cells washed prior to imaging (data not shown). 
Due to this and the decrease in imaging induced morphological changes with the HeNe laser, it 
was possible to image the same cells 4-5 times before any morphological changes were seen. If 
the same image was taken every few minutes after PS addition in the media one could see the 
cells over time start to fluoresce over their background. PPa demonstrated this to a greater extent 
than PS1, (data not shown). This raises questions over whether the pattern of fluorescence 
observed is only an artefact of the change in fluorescent efficiency in different 
microenvironments within the cell, for example the PS could be in other compartments to those 
seen but reduced fluorescent efficiency will make it invisible, as it is the surrounding cell culture 
media.  
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Figure 24 :Intracellular localisation of PPa, PS1 and PS4 with new laser system 
PPa PPa (Zoom) PPa (Zoom) 
   
PS1 PS1 (Zoom) PS1 (Zoom) 
   
PS4 (higher laser) PS4 (higher laser) (Zoom) PS4 (higher laser) (Zoom) 
   
PS4 (same laser settings) Media only Control  
  
 
SKOV-3 cells exposed to supplemented cell culture media containing 20µM photosensitiser 
solution, after 2 hours cells imaged directly. Confocal fluorescent microscopy imaging carried 
out under irradiation of 633nm laser at 20% (PPa and PS1) or 49% (PS4), through a X63 water 
objective with detection channels for brightfield and fluorescence between 660-770nm. 
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4.2.2 PS fluorescent spectral profiles 
4.2.2.1 Extracellular fluorescent spectral profiles 
 
PS fluorescent spectra outside the cell was studied, particularly PS emission spectral changes 
over concentration in DMSO (in an assumed non aggregative and optimal photophysical state) 
and in cell culture media containing FCS and 2% DMSO. As mentioned in 3.2.3 this will also 
give a better indication of the existence of any aggregation induced spectral shifts and at what 
concentration they occur. The data is shown in Figure 25 and shows that for none of the PS in 
DMSO are any shifts or losses in intensity to the spectra seen as concentration changes, peaks 
occur in DMSO at PPa (675nm), PS1(678nm) and PS4 (684nm). When in supplemented cell 
culture media however all PS show some change in spectra between 3µM and 6µM: At 
concentrations below 3µM all PS show similar peaks to that of PS in DMSO, for PS4 the peak at 
all concentrations is the same as in DMSO and it is only a gradual drop in fluorescence intensity 
after 3µM that is seen. PPa exhibits increasing peaks at 675 nm until between 3µM and 6µM 
where it begins to decrease in intensity at 680 nm and increase at 718 nm, at around 25µM the 
peak at 718 nm is the dominant peak. PS1 also exhibits increasing peaks at 678 nm until between 
3µM and 6µM where it begins to shift over to 694 nm but unlike PPa and PS4 it continues to 
increase in fluorescence intensity as concentration increases. The extent of the fluorescent shifts 
to lower energy wavelengths (red-shifts) tell us that the lowest unoccupied molecular orbital 
(LUMO), the one responsible for the amount of energy released in both fluorescence and non 
radiative processes important for PDT induced toxicity, is also at a lower energy level. The 
extent of shifts in spectra are as follows; PS4 (684nm684nm), PPa (675nm718nm), PS1 
(678nm694nm). It is thought photosensitisers that absorb above 850nm cannot efficiently 
excite oxygen (Plaetzer et al., 2009), and so the energy contained within even the aggregated red 
shifted states of each PS should still be sufficient to excite molecular oxygen if relevant 
deactivation processes are still maintained, however in some cases type II dissipations of energy 
could become less favourable. 
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4.2.2.2 Intracellular fluorescent spectral profiles 
 
Within the confocal fluorescence microscopy system a lambda scan can read the emissive 
profile of the fluorophore coming from within the cells under irradiation. Lambda scan results 
are shown in Figure 26. The data has been represented in two different ways; one graph shows 
the raw relative fluorescence readings of all three PS under the same laser intensity and camera 
detection settings. The values have been normalised to take into account for the cell covered area 
of the image via a method described in 2.1.4.5. Another graph shows comparative optimal 
spectra normalised to 1 for peak emission, for this PS4 was imaged under increased laser power 
conditions as to get a more comparative signal range. PPa and PS1 show similar emissive spectra 
with peaks at around 680 nm whereas PS4 shows a broader red shifted spectra when compared to 
PPa and PS1, with a peak around 685 nm. When compared to the ‘optimal’ emission spectra of 
the three PS in DMSO (see 4.2.2.1) and considering the accuracy of the Lambda scan (band 
width = 10 nm, overlap = 5 nm), the spectra match well, suggesting the PS detected in their 
cellular environment are suitably dis-aggregated and in an optimal photophysical state.  
 
Although the imaged cells exhibit much lower fluorescence with PS4 than with PPa and PS1, 
seen quantifiably on the lambda scan, this cannot be directly correlated with the level of 
internalised PS for a number of reasons including a differences in inherent PS fluorescence 
efficiency as well as the influence the cellular environment can have on fluorescent efficiency, 
also dense packing in organelles could cause self quenching of PS.  
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Figure 25 :Extracellular fluorescent profiles of PPa, PS1 and PS4 
 
 
PS emission spectra measured with excitation at 410nm over changes in concentration of PS in 100% DMSO  
 
 
PS emission spectra measured with excitation at 410nm over changes in concentration of PS in cell culture media containing FCS and 2% 
DMSO. 
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Figure 26 :Lambda scans of intracellular PS spectral profiles 
SKOV-3 cells exposed to supplemented cell culture media containing 20µM photosensitiser 
solution, after 2 hours cells were imaged directly. Confocal fluorescent microscopy imaging 
carried out under irradiation of a 633nm laser at 69% or 100%, through a X63 water objective 
and with the lambda scan reading the emissive profile of the fluorophore within the cells 
between ~640-780nm in 30 sections of 10nm bandwidth. 
 
 
Graph showing the raw relative fluorescence readings of all three PS under the same laser 
intensity and camera detection settings. The values have been normalised to take into account 
for the cell covered area of the image via a method described in 2.1.4.5. 
 
 
Graph showing comparative optimal spectra normalised to 1 for peak emission, for this PS4 was 
imaged under increased laser power conditions as to get a more comparative signal range. 
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4.2.3 A quantifiable measurement of PS uptake and leaching 
4.2.3.1 Assay design 
 
An assay was designed to measure absolute PS uptake. SKOV-3 cells were cultured in a 
microplate and exposed to PS containing cell culture media before being washed with PBS and a 
solution added to lyse the cells and release the PS into the solution, fluorescence could then be 
read and compared to a standard curve of PS in the same solution. As seen earlier in Figure 25 
PS in cell culture media does not provide a linear relationship between concentration and 
fluorescent intensity, therefore the lysis solution used was DMSO supplemented with 0.25% 
Triton X 114, see 2.1.4.6. As well as providing a linear relationship, PS in DMSO fluoresces 
more brightly than in aqueous buffers so allowing greater sensitivity within the assay. This is of 
particular importance for PS4 as the sensitivity of any fluorescence based assay will be reduced 
for PS4 compared to the other PS due to its inherent lower fluorescent efficiency.  
 
The lysis solution was tested with the MTS assay to confirm complete cell destruction 
occurred before 5 minutes (data not shown). Photosensitiser dilutions in the DT lysis solution 
(DT = 0.25% Triton X 114 in DMSO) were shown to be linear over concentrations of PS 
required for this assay, these dilution series were exposed to regular  laser irradiation and then re-
measured but no loss in signal that would indicate photo bleaching was observed (data not 
shown). Standard curves in DT were also left sealed at 4oC for a few days and re-read and no 
significant loss in intensity was seen (data not shown). Standard curves of PS in DT were also 
plated with and without 8000 cells per well to see if the presence of cell debris had any effect, a 
small decrease in signal was seen with PS1 at higher PS concentrations but not PPa or PS4 (data 
not shown), because of this all experimental standard curves were set up on the day of the 
experiment over cell debris and read at the same time as the data plates. The main source of error 
was the correction for how much PS was left in the wells after washing; two PBS washes was 
shown sufficient to reduce the background to manageable levels (<10 RFU) (data not shown). In 
addition; for all assays a washed standard curve was included alongside the normal standard 
curve to monitor PS levels left after washing. It is important to carry out this control and work 
highlighting this problem has recently been published by (Engelhardt et al., 2011).  
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4.2.3.2 Uptake of PPa, PS1 and PS4 into cells and the effect of serum depletion. 
 
Experiments were carried out to look at the uptake of PS over two hours, mirroring the time 
used in the in vitro assay. Additionally as this experiment is relatively high throughput, 
dissolution of the PS in cell culture media containing varying amounts of foetal calf serum (FCS) 
was also studied. This is of interest because as discussed in 1.3.4 PS are known to bind serum 
proteins and this can have an effect on cellular uptake. Previous work carried out within this lab 
(Kuimova et al., 2007) showed the addition of bovine serum albumin (BSA) to a PPa solution 
did exhibit a BSA concentration dependant increase in PPa fluorescence intensity which was 
suggested to be an indication of the association of the PPa with the hydrophobic pockets on a 
BSA molecule. If PS favourably interact with serum proteins or other elements in the FCS this 
interaction could both compete against or help encourage cellular uptake.  
 
The results of this experiment are shown in Figure 27,  raw relative fluorescence units (RFU) 
have been converted to ‘concentration of PS in 100µl lysed cell solution’ using the standard 
curves also shown in the figure. On each graph the relevant ‘left from washing’ curve is also 
plotted. Results show the amount of internalised PPa increases with the amount of PS added,  the 
relationship is not linear and the rate of this increase slows as concentration of PS added 
increases. PS1 and PS4 both show cellular uptake levels barely above the values measured for PS 
‘left from washing’. PS1 shows slightly higher increase over ‘left from washing’ compared to 
PS4 but it is at the limit of detectability. With respect to decreasing the FCS concentration in the 
media, this didn’t increase uptake of PS4 or PS1 above baseline, suggesting it is not 
sequestration of PS by serum proteins preventing detectable uptake. PPa does show some 
increased uptake at low FCS but only at 0% FCS and only at higher PS levels. This experiment 
was carried out at least twice on two independent occasions with the same result. 
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Figure 27 : Uptake of PPa, PS1 and PS4 into cells and the effect of serum depletion. 
 
 
 
SKOV-3 were incubated for 2 hours in supplemented cell culture media containing PS with 
varying amounts of FCS. Cells were washed twice in PBS then lysed into 100µl DT solution. 
Fluorescence was read at Ex410Em680 and values converted to concentration in µM with 
standard curves seen alongside. ‘left from washing’ controls are shown on each graph. 
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4.2.3.3 Uptake and leaching of PPa and PS1 over time and the effect of temperature. 
 
This assay was also used to look at the uptake of PPa and PS1 over time at 4oC compared to 
37oC. The results of these experiments are shown in Figure 28. PS4 was not tested due to lack of 
material. This experiment was carried out at least twice on two independent occasions with the 
same result. Again the assay was too insensitive to pick up any internalised PS1 at any time point 
(data not shown), meaning that PS1 must be taken up at a much lower level than PPa or is 
rapidly degraded once internalised, although degradation would be surprising considering the 
results obtained by confocal microscopy 4.2.1 and 4.2.2.  
 
With PPa, the signal is again strong enough to be detected and uptake over time is seen to 
saturate between 2 and 3 hours, this is later than was seen in via confocal microscopy in which 
the quantified fluorescent signal saturated within 1 hour for both PPa and PS1 (data not shown). 
The saturation seen in this assay occurs with all concentrations of PPa around the same time. 
When the temperature is reduced, the uptake of PPa is drastically reduced, to just above an un-
detectable level. In the same model leaching of PPa over time was also investigated, this is also 
shown in Figure 28. PPa leaching occurred at a slower rate than uptake and after two hours levels 
had only reached around half of what they were originally. Again this is not what was seen 
previously via confocal where leaching reached undetectable levels within 2 hours (data not 
shown). Reducing the temperature to 4oC slowed leaching rates slightly but not by much.  
 
An explanation for this data not correlating with the confocal fluorescent microscopy data is 
explained because in confocal microscopy fluorescent detection is of intracellular PS within 
different cell microenvironments, this can effect PS photophysical efficiency for example PS 
could be in an aggregated or densely packed form,however once released in the 96 well plate 
assay PS can monomerise and/or recover comparable photophysics in the lysis solution. As the 
confocal system is also measuring single cells (compared to thousands in the 96 well plate 
assays) it may also be less sensitive. Despite the fact sensitivity levels were kept below pixel 
saturation on the confocal, intracellular PS quenching and fluorescent saturation could still have 
occurred, a fact controlled in the 96 well plate assays using standard curves.   
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Figure 28:Uptake and leaching of PPa and the effect of temperature 
 
 
UPTAKE: SKOV-3 were incubated for varying amounts of time at either 37oC or 4oC in 
supplemented cell culture media containing PPa. Cells were washed twice in PBS then lysed into 
100µl DMSO.  
LEACHING: SKOV-3 were incubated for 2 hours in supplemented cell culture media 
containing PPa at 37oC then media was removed and replaced with media only, plates were then 
left for varying amounts of time at either 37oC or 4oC. Cells were washed twice in PBS then 
lysed into 100µl DMSO.  
Fluorescence was read at Ex410Em676 and values converted to concentration in µM with 
standard curves seen alongside. ‘left from washing’ values taken from equations fitted to a 
washed standard curve were subtracted from the data presented.  
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4.2.3.4 Increasing the cell number to increase sensitivity 
 
To extend this work to be able to detect PS1 and PS4, experiments on a much larger scale 
were attempted; see 2.1.4.6 for the adapted method. For this experiment an additional control 
was required; after reading the plates 50µl was taken from each well and the BCA assay was 
used to calculate how many cells were in originally in each well, the fluorescence data could 
then be normalised to any fluctuations in the BCA values to make it more accurate. Add itionally 
after harvesting and before lysis a small sample was taken from some of the samples to count via 
haemocytometer, this allowed a rough calculation of the estimated number of cells plated – the 
average count from this was around 25,000-30,000 expected cells per well, which matched the 
values obtained from the BCA assay (AV=28072 +/-11084 (2xSD)). 
 
Both the BCA and Bradford assays were investigated for their sensitivity in DT lysis buffer, 
see 2.1.4.7. The background for the Bradford assay went up unsuitably high with DT solution 
and so was deemed unsuitable, whereas the BCA assay showed alteration in signal only at higher 
levels of protein while the linear relationship still seemed intact, albeit less sensitive. (Data not 
shown). Direct PS interference with the end point of the BCA assay (absorbance at 562nm) was 
also checked and results showed that PS do exhibit concentration dependent absorption at 562nm 
but it was of a sufficiently low level that it was below the variability of the assays itself. (Data 
not shown).  
 
As cell number is increased in this assay the amount of cell debris that is required to interfere 
with PS fluorescent signal in DT buffer was investigated, and over 100,000 cells were required 
to cause interference in fluorescent signal of 5μM PS in 100μl DT lysis buffer (the highest PS 
concentration obtained from previous uptake experiments) (data not shown). 
 
Data obtained from this higher sensitivity uptake assay is show in Figure 29, the data is 
presented after normalisation with the BCA assay and after conversion using standard curves to a 
value for final concentration of PS in 100µl lysis solution. The experiment showed a similar 
relationship to the original lower sensitivity uptake assay in that uptake increased with 
concentration, at a rate which slowed over higher PS concentrations. The signal is about double 
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what was detected from the original uptake assay that used only 8000 cells, as calculated cell 
number from this assay was about 3 to 4 times that amount, signal is surprisingly low. This is 
most likely due to additional PS lost in leaching as it takes longer to prepare the cells in the 
higher sensitivity experiment. It is unlikely caused by PS saturation as results are still within the 
linear range. Despite this, values from PPa PS1 and PS4 from within this  experiment should still 
be comparable with each other. PPa again shows greatly enhanced signals compared to PS1 and 
PS4 which show some signal but still very low, PS1 and PS4 show similar uptake levels.  
 
Figure 29 : Higher sensitivity cellular uptake assay for PPa, PS1 and PS4. 
 
 
 
SKOV-3 were incubated for 2 hours in supplemented cell culture media containing PS. Cells 
were washed twice in PBS then lysed into DT solution. Fluorescence was read at Ex410Em680 
and values normalised to cell number and converted to concentration in µM with standard 
curves. see 2.1.4.6 for full method. 
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4.2.3.5 Using absolute uptake values to re plot cyto-toxicity graphs 
 
In Figure 30 the data from Figure 29 on absolute PS uptake into cells in was plotted against 
the concentration of PS that was added externally to the experiment. These graphs could be fitted 
with a 2 parameter exponential rise to maximum curve see 2.1.3.1. From this equation 
parameters a and b can be derived for each PS and used to calculate predicted internalised PS 
from external PS added. The parameters derived from Figure 30 were used to re plot the cell kill 
data from Figure 15. This is shown in Figure 31 and shows the IC50 value of each PS, which has 
now been converted to the concentration of PS that will be found internalised, plotted over 
increasing light dose. As in Figure 15 each curve is fitted with a 2 parameter power curve and as 
before constant b can give an indication of the ‘rate’ at which PS becomes toxic as light dose is 
increased. PS4 has a higher value for b (2.3) than PPa (0.7) and PS1 (0.6), these values are very 
similar to the values obtained with external IC50 in Figure 15 but now the data uses the 
internalised PS concentration it validates the conclusion that PS4 is responding in a more 
sensitive way to an increase in light than PS1 or PPa. The values for this sensitivity match with 
the increase in singlet oxygen quantum yield with PS4 compared to similar values for PPa and 
PS1, see 1.6.  
 
Despite similar curve gradients when you compare the two graphs in Figure 15 and Figure 
31, the changes in the placement of the curves on the X axis do change dramatically. In Figure 
15 it was shown that PPa and PS1 sat close to one another and close to the Y axis with PS4 
sitting much further to the higher end of the X-axis. Now internalisation has been taken into 
account, PPa has shifted to join PS4 on the right had side, and it is only PS1 retaining its toxicity 
at very low laser doses. In fact at higher light doses PS4 exhibits more cyto-toxicity than PPa in 
terms of internalised PS levels. 
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Figure 30: Predicted internalised PS from external PS added to cells. 
 
 
 
 
Data from Figure 29 on absolute PS uptake into cells was plotted against the concentration of 
PS that was added externally to the experiment. These graphs could be fitted with a 2 parameter 
exponential rise to maximum curve see 2.1.3.1. From this equation parameters a and b can be 
derived for each PS (shown in the table) and used to calculate predicted internalised PS from 
external PS added. 
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Figure 31 : Internalised IC50 of each PS over increasing light dose. 
 
 
 
Parameters derived from Figure 30 used to re plot the cell kill data from Figure 15.  
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4.2.4 Mechanism of cell death, cell viability over time. 
 
The data presented in 3.2.2.1 indicated there may be some differences in the type of cell 
death initiated by PPa and PS1: In the standard in vitro MTS assay model presented in chapter 0 
PPa caused significant loss of cell viability within two hours whereas PS1 required longer to 
exhibit a similar final toxicity. To investigate this further cell viability was measured at various 
time points after irradiation when concentrations of PS required for 10% 50% and 90% cell death 
(at 48hrs) were used. In Figure 32 the data is presented in raw 490nm absorbance (A490). For 
both PPa and PS1 the IC50 dose shows no change in A490 over time suggesting cell growth 
arrest, if the data had been presented as % viability as previously this would have been 
interpreted as a slow decrease over time. The IC90 dose for PPa confirms that a high proportion 
of the cell population death occurs within 2 hours, whereas for the IC90 dose PS1 the amount of 
cells dead within 2 hours is much lower and the majority of the population will die at various 
points over the 48 hours. This suggests a more necrotic style of death for PPa and a more 
apoptotic style of death for PS1 with the final same potency. This experiment was carried out at 
least twice on two independent occasions with the same result. 
 
In these experiments new controls have been introduced (see 2.1.4.2), these include 0.25% 
TritonX114 which provides a reading for immediate 100% cell death and 1µM staurosporine 
(Stauro) which was chosen for its ability to induce an apoptotic style death. Prior to its inclusion 
in this assay a dose response cell kill experiment was carried out in SKOV-3 cells, this is 
presented in Figure 37. It should be mentioned at this point that for two reasons cell death 
mechanisms induced by PS4 was not investigated in the following part of the chapter: Firstly to 
try and control variables in this work it was desirable to limit the work to looking mainly within 
the confines of the already introduced in vitro cell model, for example 2 hours PS incubation, 
laser irradiation at 0.33 J/cm2 and so on. Within these constraints PS4 is not cytotoxic enough. 
Changing PDT assay variables are known to be able to have significant impact on the toxicity 
and even mechanism of death and to modulate them all would, at this point in time, make the 
experiment unreasonably large. Secondly the mechanism of synthesis for PS4 involved a 
particularly labour intensive purification step so there was limited material.  
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Figure 32 : Cell viability over 48hours post PPa and PS1 PDT. 
 
 
 
The standard cell kill experiment carried out with concentrations of PPa or PS1 required for 
10% 50% and 90% cell death by 48hours. At various points over the 48hours post irradiation 
cells were assayed for cell viability via the MTS assay; viable cells contribute to absorbance at 
490nm. 
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4.2.5 Trypan blue staining of high dose PPa-PDT 
 
Trypan blue (Mw 960.81) is a blue acid dye containing two negatively charged chromophore 
groups. The dye is taken up into cells upon membrane damage and binds cellular proteins. It is 
used routinely as a marker of cell death. To confirm the immediate cell death seen with PPa PDT 
was in fact cell death and not an artefact of the PDT process, cells were exposed to 10 µM PPa 
for 2 hours, lasered and subsequently stained with Trypan blue, this is shown in Figure 33 next to 
a photograph of cells exposed to 10µM PS but not lasered. Positive staining of the cells treated 
with PPa PDT confirmed the MTS assays result. The experiment was carried out at least twice 
on two independent occasions with the same result. 
 
 
Figure 33 :Trypan blue staining of high dose PPa-PDT. 
 
 
 
SKOV-3 cells exposed to supplemented cell culture media containing 10µM PPa solution, 
underwent PDT as normal, 2 hours after irradiation cells were washed, stained with Trypan 
Blue, fixed with formaldehyde and a photo taken (RIGHT), cells that underwent the same 
treatment but not lasered are also shown (LEFT). 
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4.2.6 Caspase 3/7 activation post PDT. 
 
As mentioned in 4.1.5 a key hallmark of apoptosis is caspase activation. An assay to measure 
the activation of effector caspases 3 and 7 via cleavage of a pro-fluorescent substrate, (see 
2.1.4.9) was calibrated in a similar way to the MTS assay (see 3.2.1.2), to obtain a suitable cell 
number and incubation time to get a detectable linear signal range (data not shown). Additionally 
as PS are fluorophores themselves a control was carried out in which cells were incubated with 
PS for 2 hours, washed to remove PS but not lasered and then induced into apoptosis with 
staurosporine – this should reflect the amount of PS that would be present inside the cells and 
could possibly interfere with the assay. Results show PS at this level does not significantly 
interfere with the assay (data not shown).  
 
Caspase activation is transient so has to be studied over time at frequent intervals; 
staurosporine at 1µM was used as a positive control. The effect on caspase activation of PPa 
PDT or PS1 PDT at concentrations required for 10% 50% and 90% cell death at 48 hours was 
measured at various time points throughout 48 hours after irradiation. The results are presented 
in Figure 34 and show no detectable caspase activation with PPa or PS1 at any dose, MTS assays 
were carried out alongside to confirm cells died to the extent expected (data not shown), and 
different plate readers were used for the two figures – this accounts for the differences seen in 
RFU and sensitivity. The experiment was carried out at least twice on two independent occasions 
with the same result. 
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Figure 34 : Caspase 3/7 activation post PDT 
 
 
The standard cell kill experiment carried out with concentrations of PPa or PS1 required for 
10% 50% and 90% cell death by 48hours. At various points over the 48hours post irradiation 
cells were assayed for activation of caspase 3 / 7. Staurosporine is used alongside as a positive 
control for activation of caspases 3 / 7. 
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4.2.7 DNA fragmentation post PDT 
 
Another important hallmark of apoptosis is DNA fragmentation, see 4.1.5. An established 
method for visualisation of DNA fragmentation is by running isolated cellular DNA through an 
agarose gel so separating it by size and subsequent staining to visualise a ‘DNA Ladder’ under 
UV light. 
 
In order to extract enough DNA for visualisation the standard cell kill model had to be 
adapted to a 6 well format. The predicted increase in laser electric current required to maintain 
J/cm2 intensity when the beam is used over a larger area is shown in 2.1.4.3. In order to verify 
the predictions, 96 well plates were set up in the standard cell kill assay and irradiated with either 
the small beam or the larger beam at different laser power settings, the amount of cell death 
resulting from each laser setting is shown in Figure 35. Both beams show a positive correlation 
between increased laser power and increased cell death, the smaller beam (96 well plate height) 
showing increased cell kill over the larger beam at the same laser settings because the same laser 
energy is concentrated over a smaller area. Ringed in yellow are the two settings predicted to be 
equivalent J/cm2 for each of the beams. When data is plotted over J/cm2 as opposed to laser 
electric current (amps) all points fall on the same line and the two settings predicted to be the 
same overlap – this indicates that the predictions made are correct and the two beams are 
delivering the same amount of energy per cm2. 
 
To visualise DNA fragmentation after treatment with either PDT or staurosporine (the 
positive control) DNA was isolated from cells as detailed in 2.1.4.10. The data from this set of 
work is presented in Figure 36. DNA laddering is seen with staurosporine controls as well as 
IC90 levels of PS for both PPa and PS1 treatments. The experiment was carried out at least twice 
on two independent occasions with the same result. 
  
Page | 169  (Hayley Pye 2012) 
 
 
Figure 35 : Large and small laser beams deliver the same amount of energy per cm2. 
 
96 well plates were set up in the standard cell kill assay and irradiated at different laser power 
settings with either the small or large laser beam; for 6 and 96 well plates respectively. The 
amount of cell death resulting from each laser setting is presented. When plotted over predicted 
energy delivered over the laser area (J/cm2) all points fall on the same line indicating that the 
two beams are indeed delivering the same amount of energy per cm2. 
 
Figure 36 : DNA fragmentation post PDT. 
 
The standard cell kill experiment carried out with concentrations of PPa or PS1 required for 
10% 50% and 90% cell death by 48hours. After 48hours DNA was extracted as detailed in 
2.1.4.10 and ran through an agarose gel to visualise any DNA Ladders under UV light. 
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4.2.8 Cell cycle arrest after mid dose PDT 
 
An aspect of interest from the data presented in 4.2.4 was the ability of IC50 levels of PS to 
induce cell growth arrest in both PPa and PS1. In order to confirm this cells undergoing this 
arrest were examined to see if they exhibited accumulation in any stage of the cell cycle – this 
would suggest that it was stress induced checkpoint controlled cell cycle arrest and not an 
artefact.  
 
As a control for chemically- induced cell cycle arrest, staurosporine was used at sub apoptotic 
doses as it can cause either G1 or G2/M cell cycle arrest, see 2.1.4.2. The dose chosen was 
0.25µM, which as seen in Figure 37 shows evidence of cell growth arrest in our cell line SKOV-
3. An alternative compound was Cisplatin which at sub apoptotic doses can induce an S phase 
block that can be transient and lead to a further G2 block, see 2.1.4.2. A dose response cell kill 
experiment for cisplatin was carried out to calculate the correct dose for SKOV-3 cells, which 
was chosen to be 40µM. This data is shown in Figure 38. 
 
To identify which part of the cell cycle a population of cells are in, one of the most 
established methods involves cell permeablisation and subsequent staining of genomic DNA 
with propridium iodide, analysis by flow cytometry can then determine the cell cycle position of 
individual cells, see 2.1.4.11 for more information. Before running this experiment it was 
important to check that fluorescence from any residual intracellular PS wouldn’t interfere with 
analysis, especially as the propridium iodide (PI) fluorescent spectra overlaps with that of the PS. 
The work was carried out with Jurkat E6-1 cells (see 2.1.4.1) a suspension cell line useful for 
setting up flow cytometry (FC) assays due to ease of handling. The data presented in Figure 39 
shows channels FL3 and FL4 are unusable as the background from internalised PS is 
unacceptably high, unfortunately these are the also the best channels for PI detection, however PI 
is also detectable in FL2 and in this channel PS doesn’t have as much ‘bleed through’. To check 
if the bleed through from the PS would be enough to effect the distinction of different cell cycle 
positions in the cell cycle assay Jurkat were pre- incubated with either PPa or cell culture media 
and stained with PI for cell cycle analysis, results showed no difference between pre incubation 
with PS or not as PI staining is very bright (data not shown).   
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Figure 37 : Dose response cell kill with staurosporine 
 
 
SKOV-3 cells were exposed to different amounts of Staurosporine in supplemented cell culture 
media over 48hours and at various points assayed for cell viability via the MTS assay; viable 
cells contribute to absorbance at 490nm. 
 
Figure 38 :Dose response cell kill with Cisplatin. 
 
 
SKOV-3 cells were exposed to different amounts of Cisplatin in supplemented cell culture media 
over 48hours and at various points assayed for cell viability via the MTS assay; viable cells 
contribute to absorbance at 490nm. 
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Figure 39 : Interference of internalised PPa with flow cytometry analysis. 
 
 
Jurkat cells were incubated with different amounts of PPa for 2 hours then washed and ran 
directly on the FC machine to see what channels the internalised PS was detectable in and to 
what extent.  
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Experiments were carried out to determine the cell cycle position of cells 48hrs after 
treatment with IC50 levels of PPa or PS1, as well as low dose staurosporine or c isplatin. The 
results are shown in Figure 40. Data manipulation specifically for cell cycle analysis was carried 
out as described in 2.1.4.11. Results from this experiment show untreated cells distributed 
between G1 (62%), S (27%) and G2 (14%). Compared to this; staurosporine causes  
accumulation of cells in G2 as predicted from the literature (Bernard et al., 2001), and cisplatin 
caused an accumulation in S phase, also as has been predicted in the literature (Qin and Ng, 
2002). IC50 levels of PPa and PS1 showed a distribution between the cycles similar to that 
induced by cisplatin; cells seemed to have accumulated in the S phase. The pattern showed some 
slight difference in that there seemed to be an increase of cells with an amount of DNA that was 
close to but not exactly at the G2 level, however this could be seen as a transition to G2 arrest as 
can occur upon cisplatin treatment and as described in (Siddik, 2003). On some traces there was 
also the presence of a small sub G1 peak, likely apoptotic cells.  
 
It is worth noting that SKOV-3 are a hypoploidy cell line, (see 2.1.4.1) their modal 
chromosome number is 43 occurring in 63.3% of cells with a range from 42-45. Normal 
chromosome number for human diploid cells is 46. Chromosome imbalance (aneuploidy) in 
cancer is not an unusual occurrence, in fact chromosome aberrations have been found in 90% of 
all solid human tumours (Fröhling and Döhner, 2008; Manchado and Malumbres, 2011) but this 
variation in chromosome number could have some impact in the interpretation of signals from a 
cell cycle study, the doubling of intensity from G1 to G2 should however still remain. For 
comparison Jurkat E6-1 cells are only pseudodiploid with the modal chromosome number being 
46, occurring in 74% of cells.  
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Figure 40 : Cell cycle arrest after mid-dose PDT. 
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4.3 Discussion  
4.3.1 Modulation of cellular uptake or localisation by novel photosensitisers 
4.3.1.1 Intracellular PS localisation 
 
Work presented in this chapter showed the visualisation of endogenous PS fluorescence 
under a confocal microscope to determine PS localisation within cells. The data suggested the 
localisation of both PPa and PS1 into membrane rich areas of the cell such as the endoplasmic 
reticulum. PS4 localisation was also centred close to the nucleus but displayed a different, more 
punctuate, localisation pattern, it was suggested to be more of an endosomal/lysosomal 
localisation. Other work within the lab (Stamati et al., 2010) looked into this further by co-
localising commercial ‘tracker’ dyes for the mitochondria and lysosomes with these PS. Their 
data showed PPa and PS1 co-localised with but not exclusively to mitochondria whereas PS4 did 
not, and PS4 and PS1 co-localised with but not exclusively to lysosomes but PPa did  not. It 
seems likely that the PS are associating with multiple areas within the cell. This matches other 
published work for PPa based PS which have been shown to localise membrane rich areas 
including Endoplasmic Reticulum/Golgi, Mitochondria, and Endosomes/Lysosomes. (Li et al., 
2006; Matroule et al., 2001; Sun and Leung, 2002; Tan et al., 2009). 
 
From ideas presented in the literature it is thought that a PS that localises in membrane rich 
environments, particularly the mitochondria and other key cellular organelles, will be more cyto-
toxic than those in a less lipid environment for example PS contained within endosomes or in the 
cytosol (see below). This could explain why PPa and PS1 are more cytotoxic than PS4, despite 
PS1 and PS4 being taken up into the cell to the same level.  
 
PS have been shown to be capable of inducing death from almost all subcellular 
localisations. Discussed briefly below are those relevant to this work: 
 The mitochondria is often stated as the most important site for induction of apoptosis as 
either a primary or secondary target. Although also capable of inducing necrosis, for 
apoptosis the mitochondria forms the convergence and amplification point for a number of 
signalling pathways. ROS are formed as a natural part of mitochondrial action, and 
endogenous levels are managed for cellular function. Excessive levels however have been 
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linked to membrane permeablisation and release of various apoptotic factors. (George, 
2002; Morgan and Oseroff, 2001).  
 The Endoplasmic Reticulum (ER) is also linked to apoptosis via its ability to modulate 
calcium levels within the cytosol as well as containing various members of the Bcl-2 
family. (Buytaert et al., 2006; Ogata et al., 2003; Oleinick et al., 2002).  
 Lysosomal leakage of enzymes has been shown can initiate apoptosis via mitochondrial 
damage. Lysosomal damage by oxidative stress, in particular the Fenton reaction, will be 
enhanced by a low internal pH (~4–5) and high level of Fe(II) found within the organelle 
(Gèze et al., 1993; Kurz et al., 2008; Rodriguez et al., 2009).  
 
Although relatively closed to protein the ER membrane has been shown to be more 
permeable to small molecules than other cellular organelles. A paper by Le Gall and colleagues 
(Le Gall et al., 2004) showed the energy independent permeation of ER by multiple small 
molecules of a similar size to PPa that were unlikely to have endogenous  transpor ters, they 
hypothesised this was via either by protein conducting channels that are kept open by the 
association with non-translating ribosomes or a more leaky membrane due to its high protein 
content and the low level of cholesterol, known to fill “gaps” in lipid bilayers. The mitochondrial 
outer membrane is also thought to be permeable to all small molecules under 5 kDa in size due to 
the presence of membrane spanning proteins called porins, the inner membrane however is 
relatively impermeable for a cellular membrane as the membrane polarity is important for 
mitochondrial function (Malhi and Murthy, 2012). 
 
One of the difficulties encountered with confocal fluorescent microscopy when studying 
localisation was its un-wanted ability to induce cell death. This in some cases can be used to an 
advantage in the direct use of the confocal laser to irradiate and monitor cell death or look at 
ROS production post PDT (Alexandratou et al., 2005; Rollan et al., 1996).  
 
There were some observations during confocal fluorescent microscopy that raised questions 
over whether the pattern of fluorescence seen was artificially simulated in some way by the 
change in PS fluorescent efficiency in different microenvironments within the cell. This 
argument has further implications for potency. On one hand it could be said that increased 
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fluorescent efficiency in a particular microenvironment could indicate a more efficient 
absorptive processes or a reduction in energy dissipation processes such as aggregative induced 
quenching either with itself or other molecules within the cell, therefore indicating that a more 
fluorescent PS will be a more cytotoxic PS. Yet one could also make a similar counter-argument 
that a loss in fluorescence quantum yield could indicate an increase in the non radiative transfers 
important for PDT for example an increase in singlet oxygen quantum yield of PS in that 
microenvironment. 
 
It also may be interesting to look at intracellular localisation at more time points than the 
arbitrarily chosen two hours (chosen to match in vitro data). There is a chance the data presented 
here is not showing a change in final localisation of PS but a change in uptake mechanism and 
given time PS4 could re- locate itself to represent the same as PPa or PS1 or visa-versa. This has 
in part already been answered in the work by other colleagues within the lab (Stamati et al., 
2010) as their localisation experiments were carried out twenty hours after addition of PS and 
look similar to the ones presented here. Questions still remain however about once inside the 
cell, can the PS move around freely or is it fated to a destination prescribed by the uptake 
mechanism, in particular is it trapped within the protein trafficking pathway? It is generally 
thought that once inside the cytosol, i.e. via direct plasma membrane transport or endocytic 
escape, the PS are free to associate with their preferred compartment. Using this theory then PS1 
and PPa have at some point then travelled through the cytosol as they exhibit some 
mitochondrial localisation and this cannot be reached by endosomal transport alone. These ideas 
will also have implications once an antibody is used to deliver the PS. 
 
4.3.1.2 Intracellular and Extracellular fluorescent spectral profiles of PS 
 
As part of this work PS fluorescent profiles were investigated in DMSO vs. supplemented 
cell culture media. In 3.2.3.1 the absorbance profiles of PS in these same solutions were 
presented and although shifted, the relationship between absorbance and concentration was of a 
linear nature. Fluorescent curves in supplemented cell culture media however exhibited dramatic 
changes over concentration, especially PPa and PS1. Differences between absorbance and 
fluorescence spectra can occur for a number of reasons and many solvation effects are 
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exaggerated in fluorescent emission profiles compared to absorption profiles. Excited state 
molecules can encourage different interactions in the solvent than the ground state, this is 
because the time required for solvent relaxation is longer than the time needed to absorb a photon 
and excite a molecule but shorter than the excited state lifetime, solvent interactions can 
therefore move to accompany the excited state and will change respective energy levels before a 
photon is emitted (Lakowicz, 1999). 
 
Because of this fluorescence is also a much more sensitive measure of the aggregative effect 
than absorbance. Concentration dependent shifts that are only visible in the fluorescence profile 
and not the absorbance profile suggest a change in the excited state, and when shifts are  caused 
by an increase in the concentration of the molecule itself it is likely indicating PS self-
aggregation. The extent of the fluorescent shifts, like seen with absorbance, are less dramatic 
with PS1 and PS4 than with PPa and although the extent of the shifts varied between the 
different PS, they all occurred at a similar concentration (between 3µM and 6µM) with all three 
PS. So although modification of the PS may have made the new PS more soluble in aqueous 
solution, shown by the retention of electronic configuration more effectively in aqueous solvent,  
multimerisation still occurs. This extent of aggregation is unknown and still may vary between 
PS, no extensive precipitate forming aggregates were visualised in any solutions. 
 
Looking at extracellular PS in different solvents gives a good idea of how a molecule 
behaves in different environments, but it is worth remembering that these solvent environments 
are not completely comparable to intracellular environments. The principle of ‘macromolecular 
crowding’ (Ellis, 2001a, 2001b; Verkman, 2002) should always be kept in mind.  
 
Confocal fluorescent microscopy also produced fluorescent emission spectra from 
intracellular PS. The spectra for PPa and PS1 matched that for disaggregated and relaxed PS (i.e. 
in DMSO or at low concentrations in supplemented cell culture media),  this was particularly 
obvious for PPa and PS1 as they exhibit shifts upon aggregation. PS4 however only showed a 
loss in fluorescent intensity at higher concentrations and not a shift, this means the data is less 
conclusive on whether PS4 exists in a disaggregated form or not within the cell. It is possible that 
as these lambda scans were averages of whole images containing a number o f cells, more 
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information on environment specific shifts could be deduced from this data if lambda scans were 
taken from different areas within the cell, but for this, laser intensity would have to be increased 
and spectral changes could occur in the dying cell during irradiation.  
 
To support the suggestion PS becomes monomeric once internalised by cells, there are many 
examples in the literature, including a paper by Sun and Leung (Sun and Leung, 2002) that 
present evidence of this idea with PPME using simple spectra techniques. Spectra of our PS 
within a lipid environment have not been studied here but it would be possible to mix synthetic 
lipid vesicles in with PS solutions in order to study this. Experiments like this are often carried 
out with PS to model uptake and it is usually seen that lipid vesicles or serum proteins will 
induce a more monomeric spectra. 
 
PS1 and PS4 modifications were made outside the main ring and when structures were 
analysed with computer software to predict lowest energy conformers (data not shown) they 
were all shown  to have groups projecting above or below the ring; for PPa and PS4 this was the 
propionic acid side chain and for PS1 it is the PEG-like chains. This would have steric influence 
on the way the molecules arrange during aggregation and could explain the spectra which 
suggests side by side aggregation (J aggregates / red shifted) and not face to face stacking (H 
aggregates / blue shifted) NB In different solvent environments molecules can interconvert 
readily between a number of conformers.  
 
4.3.1.3 PS uptake into cells 
 
Although the data presented in this chapter suggests cellular uptake is unaffected by serum 
protein binding, it does not remove the possibility of serum protein binding occurring. PPa has 
already show evidence for binding in work presented from this lab previously (Kuimova et al., 
2007) and presented in this thesis are significant spectral shifts induced with the introduction of 
FCS to an aqueous buffer, see 3.2.3.1. In a similar assay to the one used in this thesis Siboni and 
colleagues (Siboni et al., 2002) saw differences in uptake of their PS with 10% serum, however 
for Brandis and colleagues (Brandis et al., 2005b) their in vitro assay levels of FCS had to be 
50% to show any significant loss in cytotoxicity even though they had already shown shown 
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significant albumin binding with their ‘water soluble’ PS. It could therefore be of interest to 
study further this relationship of the new PS with different isolated serum or cellular 
components. It may also be interesting to see if changes seen in the fluorescent spectra are 
translated into effects on singlet oxygen quantum yield.  
 
 
The data produced by the PS uptake experiments can give us an insight into what type of 
uptake mechanism is in use: Saturation of a receptor-driven process can be seen typically as an 
increase in intracellular concentrations with increasing incubation concentrations before reaching 
a plateau as available sites on the cell surface are saturated. (NB some mechanisms of 
endocytosis can also show this as there are limited numbers of sites for endocytosis on the cell 
surface.) If at high dosing concentrations in which these processes exhib it saturation some 
continued increased uptake is observed but at a lower rate, this indicates there may also be some 
passive diffusion of the complex across the cell membrane. If uptake is occurring only by a 
passive diffusion mechanism, uptake would be expected to increase linearly with concentration 
for all dosing concentrations. Additionally cell uptake by passive diffusion is most likely to show 
rates that mirror trends in logP (Sugano et al., 2010).  
 
Looking at the PPa data presented it is most likely visualisation of a system like the one 
described above with contribution from two mechanisms; a saturable process evident at low 
concentrations driving the majority of the uptake, but once this is saturated another mechanism 
continues to show its relationship between extracellular PS concentration and uptake. Uptake of 
PPa shows saturation of uptake much more prominently with time, rather than concentration. 
Saturation being dependent on time can infer a depletion of a requirement for uptake; this is 
unlikely to be ATP as the cells should be growing healthily in the provided cell culture 
conditions, it could be an indication the external PS source is running low – but as it is in high 
excess this is also unlikely. It is most likely an indication that flow in, flow out and internal 
degradation of the PS are in balance at the point of saturation and therefore no longer providing a 
change in internal PS concentration.  
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The data presented on PPa shows the leaching rate and the uptake rate to be different 
(leaching < uptake) and reducing the temperature to 4oC almost completely prevents uptake and 
barely effects leaching – this suggests that the mechanisms for these two paths are different. Due 
to the reduced uptake at 4oC compared to 37oC the most likely mechanism of uptake that could 
be responsible for PPa uptake is an active mechanism (i.e. one that requires ATP). Attenuation of 
uptake by reduction in temperature to 4oC is a common and well established method to 
determine the presence of an active mechanism of uptake. However there is also evidence in the 
literature that a reduction in temperature can induce stiffening of cellular membranes so will also 
to some extent reduce cellular uptake that is controlled by simple membrane diffusion processes 
(Poirier et al., 2008; Sugano et al., 2010). As there are reductions at 4oC in both leaching and 
uptake but the extent is very different, this indicates that the slight reduction seen with leaching 
is due to membrane stiffening -suggesting the PS are removed out by a non-active mechanism, 
and with uptake the almost complete reduction is due to the presence of an active mechanism for 
uptake like endocytosis. As suggested above a slower non-active mechanism of uptake is also 
likely occurring alongside endocytosis as uptake remains above-baseline even at 4oC.  
 
A similar PS to PPa, PPME was shown to cross the membrane passively by Guelluy and 
colleagues (Guelluy et al., 2010). PPME alters from PPa only by the exchange of a carboxyl 
group for a methyl ester on the propionic acid side chain, it is probably the presence of this 
carboxyl group (at pH 7.4 predicted to be in the ionised form) that is reducing the passive 
diffusion capability of PPME and instead be forcing PPa to rely more exclusively on 
endocytosis.  
 
The chemical modification of PPa into its more soluble forms PS1 and PS4, causes a 
significant reduction in cellular uptake, this would fit into a model describing the  loss of 
recognition by a specific receptor , but as PPa is not an endogenous molecule and at the moment 
has no known specific receptor it is more likely that it is endocytosis that drives its uptake, either 
by passively being taken up as part of the solvent surrounding cells or as piggyback on another 
molecule.  
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The literature primarily suggests that with less aggregative PS you achieve increasing uptake 
due to the higher proportion of monomeric PS in the solution which can then undergo passive 
diffusion across the membrane (Guelluy et al., 2010; Kelbauskas and Dietel, 2002). However 
with our less aggregative PS (PS1 and PS4) less uptake is seen. The predicted pKa. data 3.2.3.3 
also shows a neutral species cannot exist in any of these molecules as an independent species and 
neutral species are usually the driving force for both PS aggregation and membrane integration. 
Alongside the evidence above for endocytosis playing a dominant role in PPa uptake this  
suggests that the reduction in uptake of PS1 and PS4 is not likely being driven by a change from 
monomerised passive diffusion to aggregative endosomal uptake.  
 
The levels of PPa taken up into the cell at 4oC is a reduction to a similar level of PS1 or PS4 
at both 37oC and 4oC. A hypothesis could then be provided that PS1 and PS4 have significantly 
reduced ability to get as involved with an active form of endocytosis compared to PPa, and 
passive diffusion mechanisms for example pinocytosis are responsible for the baseline uptake for 
all three PS. For endocytosis, having a more hydrophobic character, i.e. like PPa, can increase 
levels of endocytosis in two main ways. Firstly, it can lead to increased PS interaction with 
serum proteins which are taken up more favourably, although for the PS studied here this is 
unlikely to be the reason as when FCS is removed completely the uptake relationship doesn’t 
change. Secondly; via increased direct PS interaction of hydrophobic PS with the cellular 
membrane and so a subsequently higher local concentration at the cell surface. PS1 has a few 
Polyethylene glycol (PEG) chains and PS4 has a small one. PEG is widely used for drug in vivo 
applications because it has been shown to prolong blood circulation time and decrease 
nonspecific interaction with the reticuloendothelial system, but, as shown by El Sayed and 
colleagues (El-Sayed et al., 2009), PEG chains can also decrease cellular uptake by prevention of 
direct cell membrane interaction by steric hindrance. PS4s additional positive charge, although 
predicted to increase membrane interaction may with the addition of the carboxyl be making the 
molecule carry too many charges to encourage any membrane integration.  
 
To make a more definite conclusion on uptake mechanism there are a lot of tools available to 
assess the contribution of various endocytotic pathways to PS uptake that could be used to look 
at this further, for example this paper by New and colleagues (New et al., 2010) used a diverse 
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panel of chemical inhibitors or activators of the various endocytotic processes and showed 
despite the differential localisation seen within a panel of different dyes, a common uptake 
mechanism of macropinocytosis was in place for all. Also Isothermal titration calorimetry (ITC) 
with lipid vesicles in particular, can be used to measure direct interactions/ integration into the 
membranes allowing easier measurement of kinetic calculations (Heerklotz and Seelig, 2000; 
Tsamaloukas et al., 2007), this can be very useful in understanding uptake mechanisms and 
would be hopefully more sensitive than the fluorescence based method used in this thesis. 
Another way to dissect data obtained from the uptake experiments could be by the application of 
a mathematical model. This can help separately address passive vs. active reaction kinetics 
providing such parameters for active transport processes such as Michaelis-Menten (Vmax and 
Km), and for passive diffusion processes (Pdif). One such model that could possibly be applied 
to my data is described here (Poirier et al., 2008). 
 
4.3.1.4 Possible endosomal escape mechanisms 
 
If the hypothesis above that PS are entering the cell via endocytosis and/or pinocytosis can be 
accepted the question still remains about final localisation of PS : PS1 and PPa seem able to 
escape and travel to the cytosol where they then partition into all sorts of cellular membranes 
whereas PS4 cannot.  
 
The computational prediction of pKa. groups in our PS are shown in Figure 18, and this along 
with data looking at fluorescence over pH (3.2.3.2) suggests the following: The pKa. values 
predict that at pH 7.4 the major species shows an ionised carboxylic acid and deionised pyrollic 
nitrogens. The pH of the cytosol (pH7.1-7.2) vs. endosomes (pH5.5-6) and lysosomes (pH5.0) 
means endosomal escape could be mediated by the nitrogens in the tetrapyrrole ring becoming 
protonated on a higher proportion of the PS population in lysosomal pH. Protonation would take 
free H+ out of solution and cause an imbalance, possibly causing more protons to be pumped 
into the lysosome and subsequent osmotic imbalance making the lysosome more leaky. However 
there is no significant difference in predicted pyrollic nitrogen pKa. between PPa, PS1 and PS4, 
so the difference in PS4s inability to escape could be that PS4 cannot pass through the membrane 
due to its additional  constant positive charge. For all PS once protonated there will be positive 
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charges on the ring so it could be that one proportion of the population causes the leakiness 
(protonated PS) and the rest that are able to leak out (un-protonated), PS4 however has a constant 
positive charge so none of its population are able to cross the membrane. 
 
The importance of the ionisation of PS in cellular transit is emphasised in work carried out by 
Bonneau and colleagues (Bonneau et al., 2004a) who looked at membrane diffusion rates for an 
asymmetrical porphyrin with 2 carboxylic acid groups on the same side of the ring. Small 
unilamellar vesicles were used to simulate membranes and they looked at PS transition into them 
at different pHs. Interestingly they found that whatever the pH of the initial solution membrane 
incorporated porphyrins in the membranes were not protonated on their ring nitrogens. They also 
observed a decreased rate of entry with decreasing pH, this decrease of the entry rate was 
thought to be due to dimerisation of neutral porphyrins. They also observed the movement of 
these molecules from a moderately acid to a neutral aqueous compartment was found to be 
strongly favoured kinetically, mirroring the tumour environment in vivo.  
 
4.3.1.5 Conclusions for cellular PPa, PS1 and PS4 uptake and localisation 
 
Quantified images of cell fluorescence from the confocal fluorescent microscopy showed cell 
fluorescence with PS has a relationship as follows PPa > PS1 >>> PS4 but when this was 
compared to actual uptake data it was seen that cellular uptake actually follows the relationship 
PPa >> PS1 = PS4. Potency in an in vitro assay follows the relationship PPa > PS1 >>> PS4, 
matching the confocal fluorescent microscopy data almost exactly, intracellular PS fluorescence 
in this case then could be used as a more accurate indicator for potency than cellular uptake. 
 
When considered together and in the context of toxicity it seems clear that despite massively 
reduced cellular uptake PS1 actually exhibits improved death per dose effects than its parent 
molecule PPa, this is hypothesised to be due to enhanced intracellular photophysics reflected in 
its enhanced fluorescence seen in confocal fluorescent microscopy and in extra cellular studies 
with PS in aqueous solution. What is still not known is if this enhanced photophysical retention 
is actually directly responsible for increased toxicity per dose, it could be that the increased 
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fluorescence per dose is in fact an artefact and not causative and is it instead through the 
induction of an alternative cell death mechanism that PS1 increases in potency. 
 
4.3.2 Modulation of cell death by novel photosensitisers 
4.3.2.1 Changes seen in the cell death induced by PPa and PS1 
 
Earlier in the chapter it was discovered that much lower levels of PS1 were responsible for 
the same toxicity at forty-eight hours as higher levels of PPa. Localisation experiments showed 
that PPa and PS1 seem to be localised in similar parts of the cell, so the question addressed in 
this part of the chapter asked could an altered mechanism of cell death be responsible for 
improved PS1 toxicity once inside the cell.  
 
Doses of PPa and PS1 that caused 90% cell death over 48 hours were used to look at two 
popular hallmarks of apoptosis, caspase 3/7 activation and DNA fragmentation. Neither PPa or 
PS1 seemed to induce any caspase 3/7 activation in SKOV-3 cells but there was evidence for 
DNA fragmentation for both PS. Could it be possible then, that both PPa and PS1 have similar 
mechanisms of action even though cell death occurs much quicker for PPa than PS1? The cell 
death that was observed within two hours with PPa was confirmed by the loss of outer membrane 
integrity at this point, i.e. cells were trypan blue positive. Despite this, the DNA fragmentation 
data suggests death is still of an apoptotic mechanism as opposed to necrosis, necrosis being the 
more likely mechanism to cause such sudden loss in membrane integrity and reducing ability 
(MTS). DNA damage when seen with necrosis results in non-specifically degraded DNA 
visualised as a smear rather than a ladder of DNA. Two hours, although incredibly quick, could 
still be sufficient time for apoptosis to initiate, however it is more likely that a population of cells 
is being measured in which both necrosis and apoptosis are occurring and there has been some 
bias in each experiment to one type of cell death. For example in the DNA fragmentation 
experiment, cells and cell debris are recovered after 48 hours and the DNA subsequently 
isolated, if some cells underwent necrosis 2 days previously there may not be much DNA left to 
collect and so when DNA is loaded on the gel it is only representative of a few of the cells that 
were in the PDT treated population. (Although during collection care was taken to collect both 
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floating and dead cells and debris but if cells were completely degraded DNA would have been 
lost).  
 
The idea of a heterogeneous population of cell death mechanisms is backed up by data 
presented in Figure 7 in which the laser profile was shown not to be evenly distributed in that it 
delivered a range of energy doses through the irradiated area. Additionally with both PPa and 
PS1 the cell kill profiles via MTS show some evidence of a ‘gradual’ decrease in cell viability 
over time, although a smaller proportion of the cell population in PPa that shows this some cells 
still take longer to die. This gradual slope is not a direct measure of the cells dying slowly, i.e. 
losing reducing ability slowly but more likely a representation of cells dying at different times 
over the period of analysis as this experiment measures an average of a population, not single 
cells. 
 
Some work was initiated to address this bias in the development of a  flow cytometry assay 
utilising a dual Annexin V / Propridium iodide staining technique (van Engeland et al., 1996), 
that can distinguish on a single cell level the difference between apoptotic, necrotic and living 
cells, assigning all individual cells within a population to one of these categories simultaneously 
within the same experiment. This experiment was successfully set up for control compounds but 
once PS were introduced to the cells the compensation between channels became too convoluted 
and it had to be manipulated to such an extent that the data lost any significance or relation to the 
original data (data not shown).  
 
4.3.2.2 Possible cell death mechanisms initiated 
 
There is a significant body of work investigating mechanisms of cell death that are caspase 
independent and still cause DNA fragmentation, some are reviewed here (Kitazumi and 
Tsukahara, 2011; Kroemer and Martin, 2005). A favoured contender for our model is perhaps 
EndoG/AIF mediated DNA fragmentation. (L. Y. Li et al., 2001; Susin et al., 2000; Widlak and 
Garrard, 2005). This would fit with the slightly smearyness of the higher Mw DNA 
fragmentation seen because it is known that there is higher internucleosomal DNA background 
upon Endo G digestion compared to CAD.  
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The first figure presented in a review paper by Kitazumi and Tsukahara (Kitazumi and 
Tsukahara, 2011) describes well the main regulation pathways for DNA fragmentation. From it 
you can see mitochondrial permeability linking both EndoG/AIF mediated DNA fragmentation 
alongside activation of the caspase cascades, however in our model these pathways are not both 
activated- despite the predicted mitochondrial damage caused by both PS1 and PPa. This result 
may be SKOV-3 specific, SKOV-3 cells have non functional p53 mutations, see 2.1.4.1, and p53 
is responsible for relocating BAX and formation of the mitochondrial pore that releases 
cytochrome c, if this isn’t properly formed it would prevent apoptosome formation and 
subsequent effector caspase activation. Cellular pathways however are very complicated and this 
brief description is merely of a selection of the pathways potentially involved.  
 
Mitochondrial permeability, an independent process to membrane permeablisation (MOMP), 
is often associated with a number of apoptotic pathways, and is linked to EndoG release. A paper 
on PDT by (Kessel and Luo, 1998) describes various PS that initiate different rates of cell death 
but all initiate mitochondrial permeability at some point. They hypothesise that this 
mitochondrial permeability can occur either as direct and rapid radical damage during irradiation 
or a subsequent delayed permeablisation after the initiation of apoptosis. Something similar 
could be happening with PPa and PS1, both initiating mitochondrial permeability and release of 
EndoG but at different times. 
 
To confirm the influence of this pathway in both PPa and PS1 induced cell death one could 
use the assay set up for DNA fragmentation but instead of isolating DNA from the cell pellet, the 
pellet could be resuspended in fractionation buffers and nuclear, mitochondrial and cytosolic 
fractions separated. Standard western blot techniques can then be used to look for relocalisation 
of EndoG from the cytosol to the nucleus. Looking for evidence of mitochondrial outer 
membrane permeablisation (MOMP), or the distinct mitochondrial permeability transition could 
also prove interesting. It would also be interesting to repeat this work in another cell line exposed 
to its own IC90 doses of PPa and PS1.  
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4.3.2.3 Theories on difference in cell death between PPa and PS1 
 
The intracellular localisation of PS is very influential on the type of cell death mechanism 
induced upon irradiation but PPa and PS1 were shown to have a similar localisation. There was 
no sufficient evidence from this work that suggests a change in apoptotic mechanism for PPa vs. 
PS1, only an apparent shift in balance between apoptosis and necrosis and/or how soon cell death 
is initiated. It has been shown that PS1 has more effective intracellular fluorescent photophysics 
than PPa, and that there are more molecules of PPa than PS1 contained within the cell; based on 
this a few alternative theories are presented below: 
 
 Although the localisations look similar by confocal microscopy, it could be a matter 
of orientation in the lipid bilayer that could change either the type of reactive species 
produced or the lifetime of the singlet oxygen produced. 
 As there are more PPa molecules they could be spread wider throughout the target 
organelle. PS1 will take longer to initiate cell death as it has to work via other 
reactive mediators to spread throughout the organelle via oxidative stress pathways. 
 As could be predicted by its hydrophobic nature PPa is forming aggregates inside 
membranes and these localised regions of PS are able to make larger holes in the 
membranes, inducing a more sudden necrotic death. 
 There is a pH difference between the cytosol/ER (pH7.1-7.2) and Mitochondria 
(pH8). Back in chapter 3, Figure 17 it was shown that between pH 7 and pH 8 PPa 
shows a decrease in absorbance and PS1 an increase. Since mitochondria are a 
particularly sensitive spot for inducing an apoptotic cell death this could be providing 
PS1 with a greater ability to induce apoptotic cell death compared to PPa. 
 That although the enhanced fluorescent photophysics suggest PS1 may be more 
effective at producing PDT mediators within the cell, because there are less 
molecules of PS1 the rate at which they are produced may be slower (a lower number 
of molecules can be excited at one time), favouring an apoptotic mechanism of death. 
 
It is an inherent benefit of PDT that it produces reactive oxidative mediators that can kill in a 
multitude of non-specific ways. This idea, alongside the fact that SKOV-3 cells are ‘uniquely 
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different’ along with all other cancer cell lines, and therefore inherently biased to certain cell 
death mechanisms and its markers, means that this work is perhaps not worth chasing without a 
more specific hypothesis in mind. Alongside this are the additional two ideas that a) it is possible 
that as soon as one changes variables in the in vitro kill assay everything could change and b) 
cells in a real tumour are subject to far more variations in light and drug dose than one would 
currently have the ability to accurately model.  
 
4.3.2.4 Cell cycle arrest with mid-dose PDT 
 
An additional investigation was undertaken to confirm the observation that IC50 levels of PPa 
and PS1 induced cell cycle arrest. This experiment confirmed that cells were arrested in the S 
phase similar to treatment with low dose cisplatin. Cell cycle arrest induced by low level PDT 
isn’t unusual (Sacková et al., 2006; Vantieghem et al., 2002) and has been seen with PPa (Tian et 
al., 2006), low level ROS are also known to induce cellular senescence (Esposito et al., 2004). . 
 
The question remains whether cell cycle arrest is a desired side effect of PDT? Staurosporine 
has the potential for cell cycle arrest at low dose, and has anticancer properties with a number of 
analogues undergoing clinical trials (Gescher, 2000). Cisplatin, a proven successful 
chemotherapeutic drug, also has this effect at low dose. Potential may rest on whether one is 
seeing a transient cell cycle quiescence that can lead to apoptosis or a more permanent cellular 
senescence, which has been shown to provide cells with resistance to apoptosis and a reduction 
in non-specific drug uptake (Wang, 1995). It may also be useful to try PDT and Cisplatin and/or 
staurosporine together as a combination therapy. A paper by Duska and colleagues (Duska et al., 
1999) has previously used full dose PDT to successfully re-sensitise cisplatin resistant cancer 
cells to cisplatin. 
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4.3.3 Chapter conclusions 
 
Key proposition put forward from work ; 
Investigation into the mechanism of cellular uptake and localisation of the modified PS 
showed that despite being as potent as PPa, PS1 intracellular concentrations were much lower 
suggesting PS1 actually exhibits improved death per dose over PPa, this was hypothesised to be 
due to its enhanced intracellular photophysics. Despite showing significantly different uptake 
kinetics, PPa and PS1 at lethal doses seem to be able to initiate similar mechanisms of apoptotic 
action, likely due to their similar intracellular localisations but the balance is shifted between the 
time and type of cell death that is initiated. PS4s reduced potency over PPa seems to be driven by 
both the substantially reduced cellular uptake, and an altered cellular localisation, although the 
potential for PS4 upon antibody conjugation still remains high.  
 
Main question raised from this work;  
If the cellular uptake of PS1 and PS4 were re-established on a similar level to PPa, for 
example by conjugation to an antibody fragment and subsequent utilisation of different uptake 
pathways (antibody internalisation), would this make them significantly more toxic than PPa? 
Other questions will arise over whether the PS or the antibody would provide the dominant 
determinants in uptake and localisation, and would antibody conjugation be able to change the 
cell death mechanism? 
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Chapter Five 
5 CHAPTER 5: The conjugation of novel PS to the antibody fragment C6.5-k 
5.1 Introduction 
5.1.1 HER 2 as a target  
 
The protein HER2 (Human Epidermal Growth Factor Receptor 2), also known as ErbB-2, 
Neu, CD340 or p185 is encoded by the ERBB2 gene. It is a member of the epidermal growth 
factor receptor (EGFR/ErbB) family and although thought to have no natural ligand, (an orphan 
receptor), it has a constitutively exposed dimerisation arm and through its role as a binding 
partner for itself and other members of the family can initiate downstream signalling important in 
many cellular pathways including proliferation, differentiation, angiogenesis and cell survival. 
Its ability to homo-dimerise is limited but it is the preferred hetero-dimerisation partner for all 
the other family members. (Gutierrez and Schiff, 2011; Hynes and Lane, 2005; Roepstorff et al., 
2008) HER2 is expressed in clusters on the cell surface (Kaufmann et al., 2011) and exhibits 
more resistance to down regulation than other members of the family. Due to the binding 
between family members the influence of the expression level of different members of the same 
family is also important. (Emlet et al., 2006; Roepstorff et al., 2008; Sorkin and Goh, 2009). 
 
First shown by Slamon and colleagues (Slamon et al., 1989) the amplification of the HER2 
gene and / or overexpression at the messenger RNA or protein level occurs in about 20% of 
patients with breast cancer and correlates with poor patient prognosis. HER2 is also implicated in 
other cancers including bladder, pancreatic, lung, ovarian, endometrial, colorectal, renal, head 
and neck, gastric, oesophageal, and prostate cancers (Ménard et al., 2001). It has provided and 
continues to provide a basis for many targeted therapeutics. (Arteaga et al., 2012; Yarden and 
Pines, 2012). 
 
Trastuzumab, also known as HerceptinTM (Roche), is the most successful anti HER2 therapy 
and is a humanised monoclonal immunoglobulin G (IgG) antibody against the extracellular 
region of HER2. Alone and in combination therapies it has shown significant success as a 
therapeutic agent in treating breast cancer. The lack of down regulation of HER2 after binding of 
antibody means cell populations will not develop a loss in sensitivity as often seen with other 
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targets when receptors are down regulated after prolonged antibody binding. Despite this, some 
resistance (treatment acquired and endogenous) has been observed, the reason for this resistance, 
seen in patients with HerceptinTM, is still unknown, but it is usually ascribed to modulation of 
intracellular downstream signalling pathways or the initiated ADCC response (Bailey et al., 
2011; Wong and Lee, 2012). 
 
C6.5-k is the chosen fragment for antibody conjugation in this thesis and is based on C6.5, 
see 2.1.5.1, a fully human anti-HER2 scFv isolated from a filamentous phage antibody library, 
first described by Schier et al in 1995 (Schier et al., 1995). C6.5 targets an epitope on the 
extracellular region of HER2, distinct from that bound by HerceptinTM (Reddy et al., 2011) 
Initial studies (Schier et al., 1995). showed C6.5 exhibited good tumour localisation over normal 
tissue and bound to the immobilised extracellular domain of HER 2 with a KD of 16 nM and to 
native antigen expressed on SKOV-3 with a KD of 20 nM. For reference Herceptin
TM is stated as 
having a KD of 5 nM in a cell based assay (Herceptin
TM packet insert). Later work from this lab 
produced a range of higher affinity versions of C6.5 which were used to answer some 
fundamental questions on antibody targeting, see 1.5.2.2. The mutated version of C6.5 used 
within the lab of M.P.Deonarain at Imperial College , and for this thesis; (C6.5-k), shows binding 
affinity to the immobilised extracellular domain or HER2 with a KD of 3.1nM (Kon = 1.4 x106 M-1s-1 
and Koff = 4.3x10-3 s-1) as measured by surface plasmon resonance (Biacore), see 2.1.5.1 for a 
comparison for the sequence to the original C6.5. 
 
5.1.2 Conjugation techniques  
 
There has been significant development in the technology for antibody-drug conjugate 
(ADC) production over the years, and this has applied directly to the field of 
photoimmunoconjugates (PIC). As the photo efficiency of PS has improved with second 
generation PS, the field generally moved in the direction of the low level specific and direct 
conjugation of one or two PS to each antibody molecule, however as the solubility of PS has 
been improved some, including ourselves, are returning to more highly loaded less specific direct 
conjugations techniques. Other choices include conjugation via a spacer or pre conjugation of PS 
to a polymer that is then subsequently attached to the Ab. See 5.1.4. for more details. 
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There are many techniques for potential bioconjugate reactions, enough to fill a 1200 page 
book by Hermanson (Hermanson, 2008). The amino acids that make up protein provide a range 
of key reactive groups that can be specifically manipulated to provide a tailorable approach to 
protein-drug conjugation. Although the amino acids are often the most common providers of 
reactive groups, lipids, glycans and nucleic acids are also possible bioconjugation partners. The 
easily disrupted 3D tertiary protein structure however adds a level of complexity and sensitivity 
to chemical bond formation, a field traditionally carried out in a myriad of solvent and 
environmental conditions. The ideal reaction will go to near completion without any side 
products or damage to the protein resulting in the production of a pure and well described 
product. It is also important to consider how the linker will react in an in vivo environment, 
linkers can be designed to have independent functionality alongside the two molecules being 
conjugated. The most commonly manipulated linker functionality is the predicted breakage of 
this bond in a chosen physiological environment. In the case of PIC however the reasons for 
introducing an antibody are primarily to reduce the side effects of free PS so a stable, essentially 
irreversible, bond is usually preferred. 
 
For PIC production the bioconjugation methods that have been used in the field so far 
include direct conjugations via carbodiimide coupling, activated esters, reductive amination, 
conjugations via isothiocyanate, maleimide or acryloyl moieties, and indirect conjugation of PS 
onto polymeric linkers such as dextran, polylysine, polyvinyl acetate (PVA), polyglutamic acid 
(PGA), fullerene or HPMA before subsequent conjugation of this PS/linker to the antibody. The 
use of all these different techniques and their use over the development of the field has been well 
discussed recently (Bullous et al., 2011; Giuntini et al., 2011). The use of specifically targeted 
endogenous thiols within the antibody fragment has attracted particular attention recently as a 
method for exquisite specificity of both conjugation (Junutula et al., 2008), and controlled 
release of the drug (Shen et al., 2012). Investigation into different conjugation chemistries has 
already shown to, and will further help prevent, common problems encountered with PS 
conjugation.  
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5.1.3 Chosen conjugation technique for our system 
 
The reaction most commonly carried out in the context of PIC formation is the reaction 
between an NHS (N-hydroxysuccinimide) ester reactive group and the ε-amine found on the 
amino acid lysine. This same reaction was used in work preceding this project, see 1.6. The 
reaction provides an easy one step method to make highly loaded covalent conjugates with very 
little manipulation of the antibody itself. The antibody used in this thesis was itself partially 
chosen because of its high number of well spaced and solvent exposed lysine residues, see 5.2.2. 
A reaction mechanism for this reaction is shown in Figure 41. 
 
Before conjugation the PS have to be chemically modified with the NHS ester group, this is 
formed away from the central ring by modification of the carboxylate group on the propionic 
acid side chain of each PS (Stamati et al., 2010). NHS ester derivatives of the PS to be 
investigated were isolated as purified dry solids to be later reconstituted into DMSO and added 
to the conjugation reaction as opposed to generation of the NHS in situ during the reaction. An 
NHS ester will react with nucleophiles with the release of the NHS leaving group to form an 
acylated product. Its reaction with primary (RNH2) and secondary (R2NH) amines creates stable 
amide and imide linkages respectively. In respect to protein; the reactive groups for an NHS ester 
are the primary α-amine at the N terminus and the primary ε-amine in the side chain of lysine 
residues. The amide bonds formed from this reaction are very stable, it is amide bonds that link 
the individual amino acids together in endogenous protein. (Hermanson, 2008) 
 
It is worth noting that the NHS ester can also react with other nucleophiles on the protein 
surface including the nucleophiles found within sulfhydryl (SH) or hydroxyl (OH) groups, 
however this will not yield stable conjugates as the bonds formed are thioesters or ester linkages 
respectively both of which are hydrolysed and broken down in aqueous environments or 
exchanged in the presence of reactive amine nucleophiles. It is also possible for the ring 
nitrogens on histidine and tryptophan to react with an NHS ester but again the linkages are 
predicted to hydrolyse very rapidly in an aqueous solution. Of all the nucleophiles found in 
proteins a list of the strongest and most reactive nucleophiles to the weakest is as follows; the 
sulfhydryl group of cysteine, particularly in the ionised, thiolate form, the lysines ε amine and N 
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terminal α amine groups in their uncharged, un-protonated forms, the secondary amines in the 
histidine imidazolyl groups or tryptophan indol rings, then the guanidino amines of arginine 
residues and finally the oxygen containing ionisable groups including the α-carboxylate at the C-
terminal, the β-carboxyl of aspartic acid, the γ-carboxyl of glutamic acid, and the phenolate of 
tyrosine residues (Hermanson, 2008). The ionisation state of these groups is very important and 
will change NHS reactivity dramatically. In respect to lysine, it is the un-protonated / un- ionised 
form that is reactive and as pH increases toward and over the pKa of this group this reactive un-
protonated form becomes more prevalent. The pKa of the ε-amine of lysine is stated as being 9.3-
9.5 and so increasing the pH of the conjugation reaction toward or above this should he lp drive it 
forward, although the micro-environmental effects occurring within the proteins can effect lysine 
pKa, meaning even at neutral pH this reaction can, and has been shown to, progress effectively. 
In terms of competing reactions from other more or similarly reactive nucleophiles for the NHS 
ester, histidines imidazolyl nitrogen has a predicted pKa. of 6.7-7.1 so will be more reactive at 
pH above this, cysteines sulfhydryl has a predicted pKa. of 8.8-9.1 so will also be more reactive 
at pH above this, and the Tryptophan indole ring isn’t ionisationable at physiological pH so is 
always in its reactive uncharged form. (Hermanson, 2008) 
 
Multiple factors other than the pKa must be considered when predicting the reactivity and 
selectivity of the reaction, in the case of the NHS ester this has been studied and discussed 
elsewhere (Anjaneyulu and Staros, 1987; Cuatrecasas and Parikh, 1972; Mädler et al., 2009). 
However it could be of interest to carry out competition experiments with the isolated reactive 
groups as done by Alonso and colleagues with a similar reactive group the maleimide group 
(Alonso et al., 2010). This reactive group can also used in PIC preparation, and can exhibit 
potential conjugation to both protein thiol and amine groups, the experiments carried out by this 
lab ensured they could redirect antibody conjugation to the preferred sites, in this case the thiols. 
Another issue also worth consideration is the spontaneous hydrolysis of the NHS ester and its 
subsequent inactivation. In aqueous physiological conditions the half life of an NHS ester group 
is predicted to be in the order of hours and will decreases as the pH increases, at pH 8.6 the half 
life could be as short as 10 minutes (Hermanson, 2008). Therefore the pH of the conjugation 
mixture has to balance NHS ester hydrolysis and lysine de-protonation. 
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Figure 41 : Chosen conjugation technique for our system. 
 
 
Anticipated mechanism for the formation of an amide bond between an NHS ester on a PPa 
molecule and a primary amine on a lysine amino acid side chain. The lysine is de-protonated 
and acts as the nucleophiles for the NHS ester forming a tetrahedral intermediate state. The de-
protonation of the nitrogen in this intermediate state catalyses the formation of an amide bond 
and release of the leaving group NHS. Adapted and re-produced with the permission of Dr. 
Ioanna Stamati (Imperial College London). 
 
 
5.1.4 Photo-immunoconjugates; progression of the field. 
 
As discussed in the introduction (1.5.3), despite the initial development of photo-
immunoconjugates (PICs) thirty years ago, not one has undergone clinical evaluation. Some of 
the problems seen with PIC preparation are detailed below through a description of how various 
labs have progressed PIC production and the problems they each encountered.  
 
The high loading of hydrophobic PS can cause an antibody to aggregate and become 
insoluble in aqueous solution. This was shown in initial work carried out under Van Dongen 
(Vrouenraets et al., 2002, 2001, 2000, 1999) in which they produced direct amide linkage 
conjugations between various internalising and non internalising IgG antibodies and various PS 
of different solubilities; including the hydrophobic chlorin mTHPC (the active drug in the 
commercial product FoscanTM) and the hydrophilic tetrasulfonated aluminium phthalocyanine 
AIPcS4. For all the PS used they found conjugation efficiencies above 2-3 molecules of PS per 
Ab was limited by aggregation of the IgG and a subsequent loss during purification. When tested 
in vitro the results showed that generally the more hydrophobic PS showed lower or equal uptake 
and toxicity when conjugated compared to its comparable free PS and the more hydrophilic PS 
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showed equal or higher uptake and toxicity conjugated than their comparable free PS. In vivo 
results showed selective tumour localisation of the PICs but for nearly all the conjugate 
combinations a higher coupling ratio would clear faster and/or was taken up into the tumour less, 
liver accumulation of PS was also seen to increase, especially with hydrophobic PS.  
 
The changes seen above in in vivo antibody bio-distribution upon conjugation of PS was also 
seen by other labs: PIC production carried out under Pèlegrin (Carcenac et al., 2001, 1999; Folli 
et al., 1994, 1992; Pèlegrin et al., 1991) achieved much greater conjugation efficiencies between 
the same hydrophilic PS AIPcS4 Van Dongen used above, and IgG antibodies against either 
CEA (non internalising) or HER2 (internalising), again the linker was via an amide bond. With a 
FITC conjugate to the same anti CEA IgG (non internalising) they tested ratios of between 0 and 
19 FITC per IgG and showed when conjugation was below 10 FITC per IgG it affected neither 
tumour localisation or tissue bio-distribution but when above 10 both half life and tumour 
localisation fell dramatically. When the same antibody was conjugated to PS, they produced 
conjugates with ratios of 5, 12 and 16 PS per IgG and showed that compared to the free IgG all  
conjugates retained their tumour retention and specificity in vivo. However when studied by in 
vitro assay, they showed no enhanced cytotoxicity over a similar conjugate with an irrelevant 
antigen. In vitro they also compared uptake and toxicity of both the non- internalising (CEA) and 
internalizing (HER 2) antigen with similar PS conjugates of between 6-9 PS per IgG. They 
engineered a cell line to express equimolar amounts of each antigen on the surface and showed 
much higher toxicities could be obtained with the internalising conjugate against the non-
internalising conjugate. Both groups mentioned above have subsequently moved onto different 
ADCs with payloads other than PS. 
 
In the ideal PIC PS will acquire targeting and macromolecular blood clearance and the 
antibody will acquire cytotoxicity. However there can be other changes in the PS caused by the 
proximity of antibody and changes in the antibody by the proximity of PS. These changes are in 
particular seen with highly hydrophobic PS and/or smaller Ab fragments, these changes are what 
drive the balance between highly loaded highly toxic Ab fragments and the loading of only a few 
well spaced PS to ensure more effective retention of antibody and PS functionality. Overloading 
of PS onto an antibody will cause a loss of PIC toxicity, most often caused by a loss of Ab 
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binding to antigen, however it can also be caused by a loss of PS photo efficiency due to 
quenching by the Ab or the other conjugated PS molecules. 
 
The very first conjugates produced under the group of Levy (Mew et al., 1985, 1983; Steele 
et al., 1988) between HPD (PhotofrinTM) and various IgG molecules produced conjugates of high 
loading ratios, although this was difficult to confirm accurately because HPD is a mixture of 
oligomers, but if the oligomer is assumed to be on average 5 units long the ratios would be 
around 5 – 27 PS per IgG. Interestingly even in this very first paper they predicted they may 
have high levels of non-covalently bound PS within the conjugate, the group later stated that 
these conjugates made with HPD suffered from poor reproducibility and significant loss of 
antibody binding before changing to preloading of a PVA carrier molecules with the PS 
benzoporphyrin derivative monoacid (BPD-MA / Verteporfin / VisudyneTM). Using this 
technique they could load up to 25 PS molecules per carrier and could load 1 carrier per IgG 
(Jiang et al., 1992, 1991, 1990). Unfortunately they also showed these conjugates included 
significant levels of non-covalently bound PS and conjugation of more than one carrier was 
limited due to extensive cross linking of the Ab under the conjugation conditions used. In vitro 
testing of the compounds showed killing of cells not expressing the target antigens, a sign of 
non-covalently bound PS, and when a conjugated irrelevant IgG was used in the same cell line, 
although toxicity was lower it was too significant to disregard.  
 
Even in these early papers the problem of hydrophobic PS forming non-covalent interactions 
with the antibody or itself meant a pure PIC was hard to obtain. This is a problem for the future 
application of any successful therapies if success is in part more due to this non-covalent PS 
dissociating in vivo and less due to the PIC itself.  
 
The Hasan group initially studied the conjugation of the PS chlorin e6 to a shedable non-
internalising IgG against CA 125, a glycoprotein over expressed on 85% of non-mucinous 
epithelial ovarian carcinomas. The conjugation was carried out via pre loading of a PGA linker.  
Loading ratios were high with 1-2 linkers per IgG and so 24-40 PS per IgG in total. (Goff et al., 
1996, 1994, 1991). However with these conjugates there was evidence of cross linking and the 
formation of a mixture of products, along with evidence for significant levels of non-covalently 
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bound PS. Additionally some loss of binding was seen when compared to IgG alone, despite this 
they did show some specificity and improved toxicity over free PS in vitro and when tested in 
vivo they showed lower toxicity and higher specificity for tumour accumulation than for that of 
the free PS. Higher dosage levels however induced fatal side effects but use of a fractionated 
light delivery did something to improve survival rates without having to increase PIC dose.  
 
Their work then moved on to try and increase tumour uptake by the use of a smaller fragment 
version of the same antibody (OC125), a F(ab’)2 fragment. The chlorin e6 was now conjugated 
to a new poly-L- lysine linker prior to its conjugation to the antibody. Conjugation ratios 
achieved were around 15-20 PS per Ab. An additional factor was introduced in that the linker 
could be modified to bear a positive or negative charge, shown to affect intracellular localisation 
(cationic was vesicular and anionic was diffuse) and cellular uptake (up to 17 times more for 
cationic vs. anionic and un-conjugated antibody). (Duska et al., 1997; Hamblin et al., 1996; 
Molpus et al., 2000). In vitro the cationic conjugates showed good specificity and higher uptake 
than all other PICs and controls, cytotoxicity was also respectively higher even when compared 
to the cationic conjugate of the full IgG molecule. Binding to cells expressing antigen was also 
maintained relative to unmodified Ab. In vivo although they did show some improvement in 
survival times, and despite the fact difficulties such as reticulo-endothelial uptake and 
extravasation were removed because the PIC was injected intraperitoneally rather than 
intravenously, these PICs still had a problem with non specific tissue toxicity. Despite this 
cationic PIC were seen to deliver more PS to the tumour than any other species at both time 
points, overall tumour to normal tissue ratios however were similar to PS conjugated to a non 
specific IgG, alongside a marked separation of Ab and PS post injection this suggests high levels 
of non-covalently bound PS.  
 
They then changed the antigen they were targeting to epCAM, this time an internalising 
antigen. They conjugated chlorin e6 against this full IgG molecule but limited it to an extent of 
4-5 PS per lysine linker molecules (anionic or cationic) and only 1 (cationic) or 2 (anionic) 
linkers per IgG. (Del Governatore et al., 2000a, 2000b; Hamblin et al., 2000). Again the cationic 
conjugate showed greater uptake in vitro but there was evidence for a loss in native antigen 
binding and evidence for it not being antigen-dependent uptake. Internal localisation showed 
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similar but not identical patterns between un-conjugated IgG, anionic PIC and cationic PIC, and 
data this time suggested the Ab and PS stayed bound together. In vitro toxicity was shown to be 
greatest in cationic PIC but still significant toxicity was still seen with irrelevant antigen PICs. In 
vivo intravenous injection showed greatest tumour uptake was seen with the anionic PS, the 
cationic PS accumulating highly in the lungs, both accumulated highly in the liver. Treatment 
experiments showed only a small increase in survival over free alongside significant evidence for 
collateral liver damage.  
 
More recent work from this group has focused back on the direct coupling of the PS to the 
Ab and a move back to full size IgG (Savellano and Hasan, 2005, 2003; Soukos et al., 2001) 
(Soukos et al., 2001). More recently they conjugated chlorin e6 and the non toxic dye Cy5.5 to 
Cetuximab (ErbituxTM); a chimeric anti-EGFR IgG licensed for the treatment of metastatic 
colorectal and head and neck cancer. The initial work with chlorin e6 and Cy5.5 was designed to 
be used as non invasive pre-diagnostic treatment that could be used for detection (Cy5.5) and 
subsequent removal (chlorin e6) of pre cancerous cells for oral squamous cell carcinoma. They 
used the same conjugation reaction as used in this thesis and created conjugates with 4.8 chlorin 
e6 per IgG and 2.1 Cy5.5 per IgG, stating that for chlorin e6 if the ratio was carried beyond 5 the 
molecules aggregated and could not be used. When tested in a hamster pouch cheek model 
fluorescent levels of Cy5.5 dye correlated with disease stage when an irrelevant conjugate (BSA 
Cy5.5) did not, they then went in with the PDT PIC and irradiated, when re probed with the 
Cy5.5 PIC they saw lower levels in the irradiated area compared to both dark and normal control 
areas. This work shows despite relatively low level PS conjugation, levels were sufficient for 
both detection and induction of cell damage, although they did have to wait significant amounts 
of time (days) for the highest tumour to normal tissue retention levels.  
 
Later work (Savellano and Hasan, 2005, 2003) used a different PS, verteporfin, with the 
same Ab and the emphasis of this work was to create water soluble PICs that are free of any 
aggregates and non covalently bound material. They made a few adaptations to the conjugation 
method but as before it was NHS ester/lysine ε-amine mediated as in this thesis, they first 
PEGylated the Ab with 2 PEG chains (via the same method) to improve PIC solubility, if not 
PEGylated then when they tried to transfer the conjugated PICs to 100% aqueous solution they 
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would precipitate out of solution. The Ab was stated as stable in up to 50% DMSO but it 
aggregated and denatured at 60%. At 40% DMSO verteporfin was shown to be primarily 
monomeric via spectral methods, because of this they carried out the conjugation and 
purification in a 50% DMSO in aqueous solvent system to prevent aggregation and NCB. The 
PIC conjugation ratios achieved by this method were 7-10 verteporfin with 2 PEG per Ab, if they 
achieved more than 11 they lost Ab binding and yields dropped during purification, less than 7 
saw a loss in toxicity. They achieved <5% non covalently bound PS and an in vitro toxicity assay 
showed specificity for the target antigen and cell death that could be almost completely 
competed with free IgG showing its reliance on antigen dependant up take. However the light 
dose needed was much higher than that needed for free un-conjugated PS (PIC needed around 
20J/cm2) and to obtain equivalent uptake levels to free PS the PIC had to be incubated for 
40hours (vs. 4hrs for the free PS). They showed this was due to loss of photophysical efficiency 
with the PIC when compared to predicted levels of free verteporfin.  
 
The success of PIC therapy when non-covalently bound PS is deliberately minimised and 
when PS loading is reduced to a level that ensures almost complete Ab binding retention, is 
shown best by the work of Boyle and Neri, this work shows that a PIC need not be excessively 
conjugated or internalising to produce some impressive results.  
 
The Boyle labs first PIC paper; (Sutton et al., 2002), put primary focus on the development 
of synthetic PS specifically for PIC production, they synthesised a panel of porphyrin based PS, 
all with an isothiocyanate reactive group for conjugation. Like an NHS ester, isothiocyanate also 
reacts with protein nucleophiles such as ε-amine on lysine but creates a stable isothiourea linkage 
instead of an amide bond. They tried to identify structural features that would minimise non-
covalent binding and studied its effect on not just SDS PAGE gel but also with preferential 
binding experiments, like those carried out with BSA within our own lab by Kuimova (Kuimova 
et al., 2007). Of particular relevance is that they saw free PS transfer from the antibody was 
especially rapid and efficient onto whole HeLa cells, reinforcing the emphasis of why the non-
covalently bound PS should be as low as possible in the final PIC, if present at  all. One of the 
results in this paper also supports the hypothesis of the work in this thesis in that the PS that were 
more water soluble showed a higher % removal of unbound PS by size exclusion 
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chromatography making the final PIC purer. After this study they chose a few different PS, many 
with 1 or 3 positively charged Methyl-pyridinium groups, to create and test a number of different 
PICs (Hudson et al., 2005; Malatesti et al., 2006; Smith et al., 2011; Staneloudi et al., 2007). 
Two PS frequently under investigation were a PS with 3 dihydroxyl phenyl groups and a PS with 
3 positively charged Methyl-pyridinium groups. With IgG, Ab conjugation ratios were similar 
for both PS, around 1.5-2.5 PS per IgG, although during conjugation if the amount of PS used in 
excess with the dihydroxyl PS (the more hydrophobic PS) was increased, it would cause a 
decrease in the final conjugation ratios - thought to be due to a loss in solubility of the more 
highly conjugated PIC and its loss upon purification. Increased ratios of the pyridinium PS to Ab 
(the more hydrophillic PS)  increased conjugation efficiencies as expected. No loss of antigen 
binding on immobilised sepharose was seen for these PICs however a small loss for all PICs was 
seen with native cell expressed antigen on flow cytometry. In vivo all dihydroxyl IgG PIC 
showed equivalent tumour retention to the free IgG, whereas the pyridinium PS showed that PIC 
with increased conjugation ratios caused a correlated decrease in tumour uptake, though to be 
due to increased blood clearance. The same PS were also conjugated to scFv antibody fragments 
and the conjugation ratio increased for the hydroxyl PS; 4-20 PS were found per scFv but all PIC 
completely lost their binding affinity to antigen. For the pyridinium PS ratios were 0.67-1.2, 
lower in a molar sense than for IgG but in terms of mass, higher. These conjugates all retained 
effective binding efficiency. Nevertheless, despite some success in in vitro cell kills they saw 
significant non specific toxicity with both IgG and scFv conjugates with va rious IgG both 
internalising and non internalising. 
 
The Neri group were also independently working on PICs, (Birchler et al., 1999; Fabbrini et 
al., 2006; Trachsel et al., 2007) They were using a successful and well studied, high affinity 
antibody in its SIP or scFv fragment formats. The antibody is called L-19 and it is a vascular 
targeted non internalising Ab which targets EDB fibronectin, a splice variant expressed during 
angiogenesis. They were conjugating the non toxic but fluorescent Cy3 or the toxic but weakly 
fluorescent Sn-chlorin e6. Conjugation ratios were around 1.5 PS per scFv or 2 PS per SIP 
monomer (4 per SIP dimer), conjugations above these ratios was claimed to cause a loss in 
binding efficiency. For these PIC conjugation was carried out at a ratio so that antigen binding 
was maintained above 80%, all conjugates were purified via size exclusion column and 
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specifically shown to be free of any non-covalently bound material. Experiments carried out in 
models of ocular vascular growth (scFv PIC) and cancer (SIP PIC) both showed specific 
targeting, in the case of ocular vascular growth they showed effective vessel occlusion and in the 
case of the tumour models they showed significant tumour growth delay and even cures in a 
number of the mice. However in both models when mice were allowed to live past the treatments 
end, the blood vessels or the cancer would grow back. 
 
The two labs under Neri and Boyle came together for their most recent work on PICs, 
(Alonso et al., 2010; Palumbo et al., 2011) in which they created PICs using the L-19 SIP 
antibody from the Neri lab and the PS with 3 Methyl-pyridinium groups from the Boyle lab. 
These conjugates were made in two different ways but both showed promising results when 
tested in vitro or in vivo: 
 
Alonso and colleagues (Alonso et al., 2010) used a site specific conjugation of the PS, in this 
case derived with a maleimide group, to two C terminal cystines res idues, one genetically 
engineered onto the end of each SIP monomer. Tertiary folding of the antibody means these two 
groups are close together in space in the final molecule so an awareness of any possible PS 
quenching was important. As a tool to investigate this they changed the length of linker between 
the porphyrin and maleimide. One PS was linked directly, another had a short hydrocarbon 
spacer (CH2)4, and another had a longer hydrocarbon spacer (OCH2CH2)7, this longest linker was 
also designed like a PEG to increase hydrophilicity a bit further. Conjugation was shown to go to 
completion by mass spectrometry analysis i.e. one PS per SIP monomer, they also showed 
conjugation did not affect SIP dimerisation or its ability binding to antigen. The conjugates were 
clean and showed no non-covalently bound PS on SDS PAGE. Photo-toxicity in vitro showed 
the PIC with the longest linker was significantly more toxic (factor of 10) then the mid length 
linker and this in turn was more toxic then the direct PS. Specificity was maintained and there 
was lack of any killing in a cell line not expressing the antigen. Interestingly, and an argument 
for the influence of quenching affecting spectral conjugation ratios, despite all PS showing on 
mass spectrometry that a conjugation ratio of 2 was obtained, spectral quantification results give 
ratios 0.76, 0.9, and 1.75 increasing with linker length, re-enforcing the idea of quenching 
between the PS with smaller linkers. 
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Palumbo and colleagues (Palumbo et al., 2011) also used L-19 SIP and a 3 Methyl-
pyridinium group PS, but instead used the same conjugation technique as presented in this thesis, 
via an NHS ester (no spacer) to lysine ε-amines. Their conjugates were shown by mass 
spectrometry to present as a poisson distribution over a number of molecular masses with an 
average of 3 PS per monomeric SIP (6 per dimer). The PIC could still form dimers, had no free 
PS, and binding to immobilised antigen on sepharose was over 90% retained. In vivo 
experiments showed the PIC retained its highly selective tumour vascular targeting compared to 
the free Ab. And in therapy experiments (in which they added 10 fold less PS within the PIC 
compared to the standard treatment dose for free PS), PICs showed a very strong anti-cancer 
response: Complete tumour eradication was shown alongside complete and prolonged cures in 
4/4 mice treated. Comparatively an irrelevant SIP-PIC, un-irradiated PIC or un-conjugated L19 
showed no impairment in tumour growth. Upon closer inspection tumour histology showed 
disruption of tumour blood vessels, extensive haemorrhage, oedema and widespread cell death. 
Of additional interest is that when they carried this out in mice deficient in NK cells; only 
transient tumour growth arrest was seen, implying an immune element was important to the 
complete cures.  
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5.2 Results 
5.2.1 Expression of antibody fragment C6.5-k 
 
The full length scFv antibody fragment C6.5-k with N terminal secretion sequence and C 
terminal His and Myc tags was expressed in HB2151 E.Coli bacterial cells and purified from 
bacterial supernatant via its Myc Tag. See 2.1.5.1. Wash and elution fractions from this 
purification process separated via SDS PAGE are shown in Figure 42. A single band of the 
predicted size (29185 Da), with a small amount of what is thought to be degradation products, is 
shown in both coomassie stained gels and in gels transferred to nitrocellulose and blotted with a 
peroxidase-conjugated anti-poly Histidine IgG. 
 
 
 
 
Figure 42 : Expression of antibody fragment C6.5-k 
 
 
 
C6.5-k with C-terminal His and Myc tag was expressed in HB2151 E.Coli bacterial cells and 
purified from bacterial supernatant via its Myc Tag. Wash and elution fractions from this 
purification process are shown separated via SDS PAGE. One gel (LEFT) is stained with 
coomassie and another (RIGHT) is transferred to nitrocellulose and blotted against the His Tag. 
Flow = flow-through from purification column, W = washes with PBS, E1-3 = glycine washes 
with decreasing pH for elution of antibody.  
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5.2.1.1 Binding of antibody fragment to native antigen 
 
To test the ability of the C6.5-k antibody fragment to specifically recognise native cell 
surface expressed antigen, in this case HER2, a binding titration experiment was carried out. 
This experiment was also required to identify the concentration of C6.5-k needed to show a 
significant but not saturated fluorescent shift upon binding, important when carrying out later 
flow cytometry (FC) experiments to investigate PIC binding. Two cell lines SKOV-3 and U-87, 
were chosen to act as a positive and negative control for HER2 expression respectively. 
Suspension preparations of these cells were incubated with C6.5-k over a range of concentrations 
chosen considering published expression levels, cell number and staining volume. It is 
commonly stated in the literature that breast cancers can have up to 2 million receptors expressed 
at the tumour cell surface, the reference trail for this figure normally leads back to a paper by 
Kallioniemi et al (Kallioniemi et al., 1992) however that figure is not contained within this paper, 
which doesn’t even look at protein expression level but gene copy number. Despite this and for 
the purpose of setting up this experiment it gave a figure to start from, from this a average 
maximum number of receptors expressed from all the cells in the sample could be calculated and 
therefore roughly the number of scFv molecules to have in the primary solution to create a 
suitable range that should cover receptor saturation.  
 
Figure 43 shows the data from this flow cytometry experiment and the calculated genomic 
mean of each result is plotted in a graph over initial C6.5-k concentration. The data shows our 
C6.5-k binds specifically to SKOV-3 cells and not U-87. In this system saturation of signal 
occurs around 60nM (SKOV-3) with low levels of non specific binding (U-87). This dose will be 
used for all further work with secondary and tertiary at 3 time molar excess over each other 
respectively.  
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Figure 43 : C6.5-k binding titration assay. 
 
 
SKOV-3 
U-87 
 
Two cell lines SKOV-3 and U-87 were chosen to act as a positive and negative control for HER 
2 expression respectively. Suspension preparations of these cells were incubated with a range of  
C6.5-k concentrations and then relevant secondary and tertiary antibodies to allow detection of 
binding via flow cytometry , see 2.1.5.5 for method. (C6.5-k shortened to C6 in figure). 
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5.2.2 Homology modelling of C6.5-k. 
 
Antibodies are made up of linked immunoglobulin- like domains see 1.5.1. High levels of 
homology between the amino acid sequence of the various antibody domain families and 
isotypes allows the reliable modelling of the tertiary structure of our antibody (Ab) fragment 
against the known structure of other antibodies. It is clear that certain areas of the antibody will 
have less successful modelling, in particular the CDR loops. For one; these are the areas that will 
exhibit most structural differences from other Ab and for two; even in a similar Ab these are 
solvent accessible flexible loop domains so would be harder to get reliable crystal structures for. 
However the modelling carried out for this thesis did aim to look at changes in atom orientation 
but more generally at the spacing of lysines around the whole structure, for this it should be 
reliable. For the prediction of the three-dimensional (3D) structure of C6.5-k from its amino acid 
sequence a protein fold recognition server called PHYRE was used, see 2.1.3.4 for an overview 
of the process and PDB files used to align the final model. Alignment to an experimentally 
solved endogenous IgG antibody structure ensured the orientation of the final model was 
optimal; however scFv molecules are expressed independent of the rest of the IgG that might 
provide some structural influence on domain orientation as well as the additional structural 
influence of an amino acid linker. Maintained antigen binding can be a good indication that the 
variable light and heavy chain are interacting correctly as the binding site for antigen recognition 
is formed by a mixing of CDR loops from both domains. 
 
5.2.2.1 Prediction of spacial orientation and reactivity of lysines on C6.5-k  
 
The images shown in Figure 44 show the modelled C6.5-k antibody, presented as a space fill 
model from 4 angles as well as a ribbon and stick model. The model has been coloured to show; 
Red = heavy chain framework regions,  Pink = light chain framework regions, orange = CDR for 
both heavy and light chains, yellow = lysines from both heavy and light chains. From this model 
the lysines residues seem well-spaced around the molecule, this should help avoid PS self 
quenching. It should be noted however that one of the Lysine residues is within the canter of the 
CDR region (Lysine 59) and this could cause problems with steric hindrance of antigen 
recognition if it gets conjugated by a PS. 
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To further investigate this model, Figure 45 shows the results for all the Lysine residues when 
the 3D model was put through the PROPKA server, see 2.1.3.4. Alongside is a simple annotated 
amino acid sequence with all lysines labelled in red and numbered in the order they appear in the 
amino acid sequence (N to C). PROPKA calculates the predicted pKa. values of ionisationable 
residues (including lysines) taking into consideration extra information from the 3D structure file 
such as spatially neighbouring residues and solvent exposure (Bas et al., 2008). The data 
presented here confirms most of the lysines are 100% solvent accessible, a good sign for 
effective conjugation reactions. Three of the lysines however are predicted to be partially buried 
in the protein core, including the one in the CDR (underlined) hopefully this will be energetically 
less likely to get conjugated, particularly with our more water soluble PS. In terms of pKa. 
prediction the ε-amine of lysine side chain is usually stated as having a pKa. of 9.3-9.5 
(Hermanson, 2008). When pH = pKa 50% of the groups will be ionised and 50% will be 
unionised, the nature of the Log unit means that 1 pH unit above or below the pKa. 91% of the 
groups will be un-protonated or protonated respectively, (in lysines case unionised or ionised 
respectively). The prediction by PROPKA that average antibody lysine pKa. is a pH unit higher 
(average value of 10.3) could have implications on conjugation efficiency. 
 
5.2.2.2 Model Images of a fully conjugated fragment 
 
Figure 46 models each PS in stick format next to the modelled C6.5-k, this gives an idea of 
the relative size and contribution to surface cover/character each PS will make. C6.5-k is shown 
in blue with lysine residues highlighted in pink. PPa is in Green, PS4 in orange and PS1 in red. 
In Figure 47 PPa molecules as shown as if conjugated to the antibody. C6.5-k is shown in space 
fill (orange with yellow = lysine, white = reactive ε-amine), where as PPa molecules are in stick 
format, PPa molecules ‘conjugated’ to exposed lysines are shown in red, and those that would be 
conjugated to the hypothetically buried lysines are in pink. Although orientation of PS is likely to 
change upon interaction with protein surface this diagram does give us an idea to how possible 
distribution of hydrophobic character on one side of the fully conjugated molecule could occur 
and how the face containing the CDR could be spared as all PPa here are shown in pink not red.  
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Figure 44 : Homology modelling of C6.5-k. 
The prediction of the 3D structure of a C6.5-k from its amino acid sequence using a protein fold 
recognition server was used called PHYRE, see 2.1.3.4 Red = heavy chain framework regions, 
Pink = light chain framework regions, orange = CDR for both heavy and light chains, yellow = 
lysines from both heavy and light chains. 
 
Front view (space fill view) Back view(space fill view) 
Top view(space fill view) 
Bottom view(space fill view) 
Back view (ribbon view)  
Back view (stick view)  
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Figure 45 : Prediction of pKa. for lysines in 3D model of C6.5-k. 
 
3D model of C6.5-k was put through the PROPKA server, see 2.1.3.4 (The underlined lysine falls 
in the CDR loop region). PROPKA calculates the predicted pKa. values of ionisationable 
residues (including lysines) taking into consideration extra information from the 3D structure 
file such as spatially neighbouring residues and solvent exposure. 
 
 
A annotated amino acid sequence of C6.5-k with all lysines labelled in red and numbered in the 
order they appear in the amino acid sequence (N to C). 
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Figure 46 : Model images of PPa, PS1 and PS4 in relation to C6.5-k 
 
Each PS next to the modelled C6.5-k, all in stick format. C6.5-k is shown in blue with lysine 
residues highlighted in pink. PPa is in Green, PS4 in orange and PS1 in red. 
 
Figure 47 : Model images of a fully conjugated fragment 
 
Front view
 
Back view
 
PPa molecules lined up next to each ε-amine of Lysines on the model of C6.5-k (yellow = lysine, 
white = reactive ε-amine), C6.5-k is shown in space fill (orange) where as PPa molecules are in 
stick format, PPa molecules corresponding to exposed lysines are shown in red, and 
corresponding to the predicted buried lysines are in pink  
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5.2.3 Introduction of a new dye to establish a model conjugation system. 
 
Previous work within this laboratory had found the level of C6.5-k conjugation with 
activated PPa to be inadequate, this was hypothesised to be due to the insolubility of activated 
PPa in the conjugation reaction. In order to see if higher levels of conjugation of the C6.5-k was 
possible and if it could be improved by more water soluble dyes, a commercial dye was used; a 
highly water soluble cyanine dye Cy5.5 derivatised with a mono-activated NHS ester group 
(2.1.6.3). As with the PS previously (3.2.3.1) Cy5.5 was dissolved in different solvents and the 
extent of any shifts in absorption spectra examined, this work is shown in Figure 48 and reflects 
the high water solubility of this dye. 
 
The reaction conditions previously used within this lab (Stamati et al., 2010) were changed 
slightly for the Cy 5.5 conjugations (see 2.1.6.5) in that concentration of C6.5-k was increased to 
145µM, the buffer C6.5-k was dissolved in was also changed from PBS pH8 to a carbonate 
buffer made from 0.1M Na2CO3 and 0.1M NaHCO3 to a pH of 9.4.(Delory and King, 1945) The 
Dye to Ab ratio was maintained at 16:1 but the addition of DMSO was increased to 10% of final 
volume and no additional MeCN was added to the mixture. Mixtures were added immediately 
and reaction was left shaking and protected from light at room temperature for 2-3 hours then left 
overnight at 4oC before purification. 
 
Figure 48 : Absorbance spectra of Cy5.5 dissolved in various solvents 
 
Absorbance spectrums over 300nm to 900nm of Cy5.5 dissolved in de-ionised water (red), 
PBS(purple), DMEM media with phenol red and 10% FCS (blue) and 100% DMSO (green). 
Cy5.5 is at a final concentration of 5.52µM. Spectrums of absorbance read over a blank of the 
relevant solvent and normalised to absorption at 900nm.   
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5.2.3.1 C6.5-k conjugates with Cy5.5 
 
Two sets of conjugation reactions were carried out between C6.5-k and Cy5.5. The first 
‘conjugation one’ was a small scale experiment carried out as above and the second ‘conjugatio n 
two’ was of a larger scale in which 3 reactions were carried out in parallel with Cy5.5 at 16:1, 
8:1 and 4:1 molar excess over C6.5-k. All conjugations were carried out as above and 
purification was achieved via repetitive washing with PBS through a 5000 MWCO 
polyethersulfone membrane using centrifugal pressure, progression was followed by examination 
of absorbance of dye at 674nm in the filtrate and was continued until level of Cy5.5 in the wash 
was undetectable, the final product was then concentrated back to the original volume.  
 
Figure 49 shows the photoimmunoconjugates (PIC) before and after purification separated 
via SDS page gel. In the pre stained gels the light blue from the Cy5.5 can already be seen in two 
places, running around the predicted height for the antibody and at the dye front, the band at the 
dye front corresponding to unconjugated Cy5.5 is removed in the purified sample. When imaged 
under UV light to visualise fluorescence from the Cy5.5 and compared to the intensity of the 
blue in the unstained gel images it seems free dye fluoresces more than bound dye, and bound 
dye fluorescence can be quenched at higher conjugation ratios. When stained for protein (dark 
blue) the gels now show the unconjugated C6.5-k which runs at a similar place in the gel to the 
PIC. Interestingly the coomassie dye does not bind the PIC as effectively as free C6.5-k, perhaps 
due to steric hindrance of the binding site for coomassie. The PIC in ‘conjugation one’ seems to 
have conjugated better than the equivalent 16:1 PIC in ‘conjugation two’ and can be seen to run 
higher in the gel. The conditions were similar for both conjugations and this loss in efficiency 
could be due to hydrolysis of the Cy5.5 NHS ester, even though it was stored for only a short 
time at -20oC and in anhydrous DMSO. NB: during staining with coomassie free Cy5.5 leaches 
out of the gel, the coomassie staining solution contains acetic acid and methanol which will fix 
the protein by causing it to precipitate out of solution and get stuck within the gel. The same 
must not happen with the free dye. 
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Figure 49 : C6.5-k conjugates with Cy5.5. 
 
 
 
Two sets of conjugation reactions carried out with C6.5-k and Cy5.5. The first ‘conjugation one’ 
was a small scale experiment carried out at 16:1 Cy5.5 to C6.5-k molar ratio. The second 
‘conjugation two’ was of a larger scale and 3 conjugations were carried out in parallel with 
Cy5.5 at 16:1, 8:1 and 4:1 over C6.5-k. SDS PAGE gels are presented showing separation of 
PIC samples before and after purification alongside the predicted equivalent level of un-
conjugated protein if no protein was lost during the conjugation procedure. The gels are shown 
un-stained, unstained and imaged under UV light and stained with coomassie. (C6.5-k shortened 
to C6 in figure) 
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5.2.3.2 Quantification of Cy5.5 conjugates with C6.5-k 
 
In order to quantify the conjugation efficiency of the PICs the UV spectra of the conjugate 
was used, see 2.1.6.6. This method to calculate conjugation ratios is seen frequently in the 
literature, however within our system the standard method was compromised and had to be 
modified: In the spectra of the PIC the dye peak had a different ratio between the maxima and its 
shoulder peak when compared to the free dye. This shift was hypothesised to be due to 
interactions between the protein and the Cy5.5 dyes now conjugated to its surface. To 
circumvent this PIC was denatured with urea and spectras were re read. Figure 50 shows that 
PIC dissolution in urea induces a return of the PIC dye spectra to that of a free dye.  
 
Using extinction coefficients of Cy5.5 at 280nm and 674nm in urea, shown in Figure 51. 
Final concentration ratios of purified PIC could now be calculated by a spectral method; 
Conjugation one produced an average molar ratio of 10:1 (dye: protein), whereas the 
conjugations in Conjugation two produced final conjugation ratios of 4:1. 2:1 and 1: 1 for initial 
conjugation ratios of 16:1, 8:1 and 4:1 respectively.  
 
As discussed above conjugation can quench the photophysical properties of the Cy5.5. It can 
also affect the absorbance of residues within a protein responsible for its absorbance at 280nm; 
tryptophan (contribution of one residue to ε at 280nm = 5500), tyrosine (1490) and cysteine 
(125) (Thermo Scientific, 2008) so an alternative method of protein quantification was 
investigated. Figure 52 shows an experiment carried out to look at interference of Cy5.5 with 
two other methods of protein concentration determination, the Bradford assay and the BCA assay 
see 2.1.4.7. The BCA assay was unusable as the absorption spectra of Cy5.5 directly interferes 
with the spectra from the BCA. The Bradford assay spectra was also affected but would be fine if 
the reading was taken at a shorter wavelength. However, as was seen with coomassie staining of 
the SDS page gels, Bradford staining may be also be inhibited by extensive conjugation. This is 
because the Bradford assay and coomassie staining utilise different forms of the same protein. 
Different forms of coomassie exist; an cationic (red), anionic (blue) and neutral (green) form, the 
neutral (Bradford) and the anionic (Gel stain) species can both bind proteins but do so in 
different ways (Georgiou et al., 2008).  
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Figure 50: Spectral quantification of Cy5.5 conjugates with C6.5-k 
 
 
The spectra of the conjugates in their either 8M Urea or Carbonate buffer pH 9.4 overlaid with 
dilutions of free Cy5.5 in the same buffer. NB concentration unknown in conjugate so not 
directly comparable with any dilution of free Cy5.5 (C6.5-k shortened to C6 in figure) 
 
Figure 51 : Extinction coefficients of Cy5.5 and C6.5-k in carbonate buffer or 8M urea. 
 
 
Extinction coefficients for Cy5.5 were calculated by measuring different molar solutions of C6.5-
k or Cy5.5 in either carbonate buffer ay pH 9.4 or 8M Urea solution. (C6.5-k shortened to C6 in 
figure). 
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Figure 52 : The interference of Cy5.5 with the BCA or Bradford assay 
 
 
Cy5.5 diluted into either BSA in H2O or H2O alone. Cy5.5 was at 10 times molar excess over the 
protein. BCA or Bradford assay were used on these solutions as normal and absorbance spectra 
were read alongside solutions with no Cy5.5.  
 
5.2.4 Binding of purified conjugates to native antigen 
 
From ‘conjugation two’ presented above, three conjugates were produced with different final 
Cy5.5 to C6.5-k conjugation ratios: 1:1, 2:1 and 4:1. In order to see if changes in conjugation 
level affect the ability of the PIC to bind to antigen two cell lines SKOV-3 and U-87 were used 
as a positive and negative control for HER2 expression respectively and binding of PIC to these 
cells analysed by flow cytometry. PIC from ‘conjugation one’ could not be tested due to lack of 
material. Figure 53 presents this experiment. Fluorescent shifts that would indicate binding were 
monitored in two channels; the FL-1 channel (for the C6.5-k) and FL-4 channel (for Cy5.5). To 
the HER2 negative U-87 cells all PIC showed no binding in either channel. To the HER2 
positive SKOV-3 cells all three conjugates show the same shift in the FL-1 channel as the C6.5-k 
only control indicating there is no loss in binding affinity for the PICs. In the FL-4 channel 
positive shifts are also seen but this time only for the Cy5.5 conjugated C6.5-k and not the C6.5-
k alone. All shifts are similar despite the differences in the number of Cy5.5 conjugated per 
C6.5-k, this suggests fluorescence emission from the fluorophore is quenched above a certain 
conjugation level and all PIC conjugates have the same fluorescent efficiency, this was also seen 
on the SDS page gels.   
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Figure 53 : Binding of purified Cy5.5 / C6.5-k conjugates to native antigen. 
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SAMPLE  Primary  Secondary   Tertiary  
A   None  None None 
B   None  180nM anti His mouse  540nM anti mouse FITC 
C   60nM C6.5-k alone  180nM anti His mouse  540nM anti mouse FITC 
D   60nM C6.5-k Cy (4:1)  180nM anti His mouse  540nM anti mouse FITC 
E   60nM C6.5-k Cy (2:1)  180nM anti His mouse  540nM anti mouse FITC 
F   60nM C6.5-k Cy (1:1)  180nM anti His mouse  540nM anti mouse FITC 
 
 
Three Cy5.5 / C6.5-k  PICs with final conjugation ratios as follows : 1:1 , 2:1 and 4:1 (dye: 
protein) were tested for native antigen binding. SKOV-3 and U-87 were used as a positive and 
negative controls for HER2 expression respectively. Cells were incubated with 60nM of each of 
the PICs and then relevant secondary and tertiary antibodies to allow detection of binding via 
flow cytometry, fluorescence was measured in two channels. FL- 1 to detect the C6.5-k and FL-4 
to detect the Cy5.5.  
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5.2.5 Cellular uptake and localization of conjugates. 
 
Confocal experiments were carried out with Cy.5.5/C6.5-k PIC and HER2 positive SKOV-3 
cells to investigate PIC intracellular localisation. The PIC with a final Cy5.5 to C6.5-k 
conjugation ratio of 10:1 (dye: protein) from the reaction ‘conjugation one’ above was used in 
this experiment and incubated with SKOV-3 cells at 2µM PIC for 2-3 hours, after this time cell 
were imaged directly without fixation see 2.1.4.5. Presented in Figure 54 are the images of 
intracellular localisation visualised by Cy5.5 fluorescence, the PIC localisation is punctuate and 
spread throughout the cytosol.  
 
Further experiments to study cellular uptake of the Cy.5.5/C6.5-k PIC at different time points 
as well as the leaching/degradation of the PIC over time were carried out with the PIC with a 
final Cy5.5 to C6.5-k conjugation ratio of 4:1 (dye: protein) from the reaction ‘conjugation two’ 
above. The results are presented in Figure 55 and the data shows a slow uptake of conjugate over 
2-3 hours, after washing the PIC remains inside the cell with no evidence of any extensive 
leaching or degradation over the 3 hours studied. A matching dose of free Cy5.5 dye alone over 
4 hours didn’t show any uptake. This matches data presented with the same antibody but 
conjugated to verteporfin by Kuimova and colleagues (Kuimova et al., 2007).  
 
5.2.6 Summary of work with model conjugation  
 
Introduction of a commercial aqueous dye to establish a model conjugation system was 
carried out in order to see if extensive conjugation of the C6.5-k was possible, data has shown 
that it is possible to conjugate 10 Cy5.5 molecules to C6.5-k, the upper limit predicted by 
homology modelling of the availability of reactive lysine residues on the proteins surface. PICs 
could be successfully purified and successfully used in assay designed to look at native antigen 
binding and cellular uptake and localisation.  
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Figure 54 : Cellular localisation of Cy5.5 / C6.5-k conjugates. 
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SKOV-3 cells exposed to supplemented cell culture media containing 2µM C6.5-k (within a 
Cy5.5 / C6.5-k PIC), after 2-3 hours cells washed once in PBS and media re-added and imaged. 
Confocal fluorescent microscopy imaging carried out under irradiation of 633nm laser at 28%, 
through a X20 dry objective or X53 water objective with detection channels for brightfield and 
fluorescence between 640-780nm.  
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Figure 55 : Cellular uptake and leaching of Cy5.5 / C6.5-k conjugates 
 
UPTAKE 
over 4hrs
 
UPTAKE  
over 3hrs
 
UPTAKE 
over 2hrs
 
UPTAKE 
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2hr uptake then LEACHED for 
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CONTROL  
(4hrs Cy5.5 only)
 
CONTROL 
(4hrs Media only)
 
UPTAKE = SKOV-3 cells exposed to supplemented cell culture media containing 2µM C6.5-k (within a Cy5.5 / C6.5-k PIC) for varying 
times before cells were imaged. LEACHING = SKOV-3 were incubated for 2 hours in supplemented cell culture media containing 2µM 
C6.5-k (within a Cy5.5 / C6.5-k PIC) then exchanged to media alone for varying times before being imaged.Confocal fluorescent microscopy 
imaging carried out under irradiation of 633nm laser at 20%, through a X40 dry objective with detection channels for brightfield and 
fluorescence between 660-770nm. 
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5.2.7 Activation of PPa, PS1 and PS4 for conjugation. 
 
In order to conjugate the free PPa, PS1 and PS4 they first had to be converted into their 
active form; synthetic chemists within the laboratory (Dr G. Yahioglu and Dr. I. Stamati) 
converted the carboxylic acid group on the propionic acid side chain of the PS to an activated 
NHS ester. See 2.1.6.4 to see the change in structure of the activated PS along with the relevant 
molecular weight changes. Unfortunately PS4 proved a harder conversion and it was not 
optimised in the time frame of this work.  
 
Figure 56 shows the absorbance spectra of PS acid vs. PS active ester (AE) in DMSO for PPa 
and PS1. No shifts were seen in any of the peaks upon PS activation but a slight loss in intensity 
is seen in both PPa and PS1 between acid and AE.  
 
Figure 57 looks at the difference between the acid and AE of PPa and PS1 in more detail, 
presented is comparative spectra of all four PS at the same concentration in 4 different solutions, 
PBS, Water, supplemented cell culture media and DMSO. As it may have been required for 
quantification of conjugates later, the extinction coefficients at the peak of Q band 1 and 280nm 
were calculated and recorded and are shown alongside. NB. for PS in supplemented media 
extinction coefficient at 280 nm cannot be calculated as the FCS in the solution also contains 
proteins that absorb at 280nm. The difference between PPa acid and PPa AE in aqueous buffers 
is striking, for all aqueous solutions some or extensive precipitate was seen and the spectra 
flattened considerably. This meant no extinction coefficients could be calculated. Comparatively 
PS1 AE easily dissolved into solution with no precipitate for any of the solvents. In fact it 
showed a better retention of spectral shifts than the PS1 acid form in water and PBS, but slightly 
worse in media. Both PS AE retained the characteristic red shift upon dissolution in aqueous 
solution over DMSO. 
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Figure 56 :Absorbance spectra of PS acid vs. PS AE in DMSO for PPa and PS1 
 
 
Absorbance spectrums over 300nm to 800nm of PS dissolved in de-ionised 100% DMSO at a 
final concentration of 29.63µM. Spectrums of absorbance read over a blank of the relevant 
solvent and normalised to absorption at 900nm.  
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Figure 57 : Absorbance spectra of PPa and PS1 acid and AE forms in various solvents. 
 
 
 
 
Absorbance spectrums over 300nm to 750nm of PS dissolved in de-ionised water (red), 
PBS(green), DMEM media with phenol red and 10% FCS (yellow) and 100% DMSO (blue). PS 
is at a final concentration of 29.63µM. Spectrums of absorbance read over a blank of the 
relevant solvent and normalised to absorption at 900nm. Extinction coefficients for Q band 1 
and 280nm calculated over a range of concentrations of PS in the same solvents are shown 
below. 
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PPa AE in media* 677 280 PS1 AE in media 682 12127 280
PPa AE in PBS** 681 280 PS1 AE in PBS 686 25090 280 13449
PPA AE in dmso 667 21057 280 10447 PS1 AE in dmso 672 22462 280 9583
(*slight precipitate visable, **definate precipitate visable)
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5.2.8 Conjugation of C6.5-k with PS1 AE and PPa AE. 
 
The first conjugation between C6.5-k and either PPa AE or PS1 AE was carried out at a 16:1 
PS to C6.5-k molar ratio under the same conditions as for the cyanine dye in 5.2.3. After the 
reaction samples were collected and subjected to centrifugal force. The PPa conjugation reaction 
produced a large pellet where as the PS1 conjugation reaction had no pellet at all. Equivalent 
amounts of the supernatants were separated on an SDS PAGE gel and are shown in Figure 58. 
The PS1-PIC shows a greater intensity of fluorescence and so it seems evident that the PS1 AE 
has reacted more extensively with the antibody than PPa AE. Both PS1 and PPa fluoresces to a 
similar efficiency in the gel environment, see 5.2.10.2. However both reactions show the 
majority of PS is in an unconjugated form and runs at the dye front. 
 
To try and improve conjugation efficiency some small scale conjugations were carried out in 
which the conditions of conjugation were adjusted. The DMSO was increased to 20% and the pH 
of the carbonate buffer was increased to 10.6. These conjugate trials were ran directly on a gel 
and compared to a band of the equivalent amount of un-conjugated C6.5-k. The SDS PAGE gels 
of these PIC are shown in Figure 59. For PPa AE the increase of pH to 10.6 caused a big 
improvement in conjugation efficiency, this was less evident with PS1 AE. Increased DMSO had 
no obvious effect for either PS. A reaction like this will typically produce a range of PIC 
conjugated to different extents, these will be normally distributed around a mean (Palumbo et al., 
2011). The PS1-PIC that migrated highest in the gel, so hypothetically most highly conjugated,  
were not stained at all by coomassie. This mirrors what was seen with the highly conjugated 
Cy5.5 PICs see 5.2.3. The different levels of conjugated PS1-PIC are separated more effectively 
by the gel than PPa-PIC, this is most likely due to the gel retardation effect of PEG chains 
(Savellano and Hasan, 2003). All future conjugations were carried out in carbonate buffer pH 
10.6 and 16.67% final DMSO, all other conditions were maintained as previously. 
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Prior to this study, experiments were carried out to check the effect of increased pH and 
organic solvent on C6.5-k stability and PS absorbance spectra.  
 
Figure 60 shows a native antigen binding experiment for C6.5-k that has been exposed to 
different proposed conjugation solvents for the same time and temperatures as a typical 
conjugation reaction. Results showed C6.5-k binding to SKOV-3 is maintained in all pH 
conditions (9.4, 10.2 and 10.7) when compared to  C6.5-k that was in PBS pH 7.4. However 
exposure to different levels of DMSO showed that binding was only maintained with DMSO 
levels of 10% or 20% but not 50% or 80%.  
 
Figure 61 shows the absorbance spectra of PPa AE or PS1 AE in the same proposed 
conjugation solvents. For PPa AE changing the pH of the carbonate buffer does not improve 
spectra at all but with increasing DMSO small spectral changes are seen at lower wavelengths 
with 10% and 20% DMSO, 50% shows a slight improvement in Q band spectra but it requires 
80% to see a significant recovery of absorbance. In terms of PS1 AE, the changes in pH exhibit 
only slight spectral shifts, and with increasing DMSO the pattern is similar to PPa AE in that 
increasing DMSO increases absorbance efficiency albeit any improvements are of a smaller 
extent.  
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Figure 58 : First conjugation of PPa and PS1 with C6.5-k 
 
Conjugation reactions carried out with C6.5-k and PPa AE or PS1 AE, experiment was carried out at 16:1 PS to 
C6.5-k molar ratio with conditions used as in 5.2.3. SDS PAGE gels are presented showing the supernatant taken 
from a PIC conjugation mixture in which insoluble material was removed via centrifugal force. Alongside un-
conjugated C6.5-k has been ran (not equivalent amount). The gels are shown un-stained and imaged under UV light 
and stained with coomassie. . (C6.5-k shortened to C6 in figure). 
 
Figure 59 : Trials of modified conjugation buffers on conjugation efficiency. 
 
Conjugation reactions carried out with C6.5-k and PPa AE or PS1 AE, experiment was carried out in varying 
conditions explained in (5.2.8). SDS PAGE gels are presented showing separation of a direct sample of the PIC 
conjugation mixture alongside the equivalent level of un-conjugated protein. The gels are shown un-stained, un-
stained and imaged under UV light and stained with coomassie. (C6.5-k shortened to C6 in figure).  
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Figure 60 : C6 stability in modified conjugation conditions 
 
C6 exposed to varying carbonate solution pH  C6 exposed to varying levels of DMSO0 
A native antigen binding experiment (see 2.1.5.5) for C6.5-k that had been exposed to the 
various possible conjugation solvents. . (C6.5-k shortened to C6 in figure). 
 
Figure 61 : PS solubility in modified conjugation conditions 
 
 
The absorbance spectra of PPa AE or PS1 AE in the various possible conjugation solvents. . 
(C6.5-k shortened to C6 in figure). 
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5.2.9 TLC plates to determine PS state after conjugation  
It was of interest to work out if the free PS left after conjugation was of an acid or AE form. 
A sample of PS1 PIC and PPa PIC, (the PPa conjugate was separated into pellet and 
supernatant), was ran on a TLC plate alongside free PPa or PS1 in its acid or AE form.  Only free 
PS is expected to run. Separation between acid and ester was obtained by using Silica 60 TLC 
plates in a 10% Methanol in DCM solvent system see 2.1.6.8. Images of the plates and calculated 
RF values are presented in Figure 62. Results provide evidence that in the PS1 conjugate 
mixture, the free PS is in the acid form, in the PPa conjugate supernatant the free PS is present in 
both the acid and the ester form and in PPa conjugate pellet all the free PS is present in the ester 
form. The presence of the ester form suggests not all the PPa AE was in solution and therefore 
not available for conjugation.  
 
Figure 62 :  TLC plates to determine PS state after conjugation 
 
PS1 PIC, PPa PIC supernatant and PPa PIC pellet were ran alongside free PPa or PS1 in its 
acid or AE form. Separation between acid and ester was obtained by using Silica gel 60 glass 
TLC plates in a 10% Methanol in DCM solvent system see 2.1.6.8. Identification of RF values for 
each moiety listed in the table alongside. Attempted purification of PICs 
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There was a significant amount of unconjugated PS that ran at the dye front, with the 
Cy5.5 conjugate this could be removed in aqueous solution via a semi permeable membrane. But 
when samples of the PPa or PS1 PIC were washed with PBS against a 5000 MWCO 
polyethersulfone membrane none of the free or conjugated PS was able to pass through the 
membrane, this was seen by both spectral and gel analysis of the samples from both sides of the 
membrane (data not shown). Small losses seen could be due to non specific binding to plastic 
surfaces, loss upon liquid transfer or insoluble PS AE being trapped in the membrane. PICs were 
also clarified through a 0.2µm PVDF syringe driven membrane which would remove any large 
aggregated PIC or PS, and again only small loses are seen (data not shown). The inability to 
purify the free PS could be due to a number of factors, including the possible complete non 
covalent association of all of the free PS with the antibody or that the free PS is unable to interact 
with the semi permeable membrane and/or traverse it, even with its concentration gradient or 
under centrifugal force. 
 
5.2.9.1 The introduction of n-Octyl-β-D-Glucopyranoside to promote purification. 
 
Experiments were carried out in order to see if free unconjugated PS were able to cross a 
semi permeable membrane. To help solubilise the free PS the inclusion of a dialysable non ionic 
alkyl-glucoside detergent called n-Octyl-β-D-Glucopyranoside (OG) (Sigma 08001) was used. 
CMC for OG is around 0.73% solution in water (24-26mM) and micellar molecular weights of 
8000-29000 have been reported.  
Figure 63 shows PPa and PS1 diluted with varying concentrations of OG. All four PS were 
tested and the AE forms showed similar behaviour to their acid forms (acid forms not shown). 
Spectral shifts are evident as OG concentration increases. When compared to spectra of PS as 
seen in Figure 57, PS at low OG concentrations matched the spectra of PS in PBS and at high 
OG the spectra of PS in DMSO. For future work it was decided to use 2% OG as for both PS this 
was sufficient to return the spectra to a more ‘DMSO like’ spectra. 
 
To see if the presence of 2% OG can aid semi-permeable membrane transition. Free PPa AE 
or PS1 AE were made up as mock solutions, i.e. up to a similar concentration with co-solvent as 
would be found in a conjugation reaction, and then diluted into buffer with or without 2% OG 
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and passed through the 5000 MWCO polyethersulfone membrane. Results are shown in Figure 
64; both with and without OG, no PS was able to flow through the membrane. NB the PPa AE 
mock solution was not submitted to centrifugal force before being used in the experiment and 
over half of the PPa AE got stuck in the membrane. Although large OG micelles predicted to 
contain free PS could not have passed through the membrane themselves it was hoped that as 
micelle formation is in equilibrium and its presence would help encourage PS interaction with 
the membrane or co-transport with OG monomers. 
 
To extend this work a small scale dialysis experiment in which free PPa AE or free PS1 AE 
were diluted in and dialysed into different solvents through a 8000 MWCO Cellulose Dialysis 
Tubing. These solvents included; PBS, Tris pH8, Tris pH 9, Carb pH 10 and Glycine pH 2, in 
combinations with different supplements: 0.6% OG (below CMC) 1% OG (above CMC) and 
20% DMSO. None of the samples in any of the supplemented solvent systems equilibrated 
across the membrane. Many of the samples, especially those with PPa AE showed evidence of 
significant precipitation. Example data for the supplemented PBS solvents in shown in Figure 
65. Other solvents systems showed very similar data (data not shown). 
 
5.2.9.2 A solvent exchange system for purification of PIC. 
 
Another idea to purify the un-conjugated PS from the mixture was by solvent extraction. A 
trial using free PS and free BSA was carried out with a chloroform / PBS two-solvent system in 
which BSA or PS were dissolved in PBS, a layer of chloroform added over the top and both 
gently mixed overnight before spectral analysis of the two layers for evidence of transition 
between them. A similar experiment but with compound containing PBS mixed with activated 
charcoal, mixed overnight and then separated by centrifugation was also tested. For the 
chloroform / PBS solvent system the BSA remained entirely in the PBS (top fraction) where as 
the PS transitioned entirely into the chloroform. For the activated charcoal experiment the 
charcoal extracted both BSA and PS from the solution.  When the chloroform extraction 
technique was attempted with PIC samples, the PS showed no transition into the chloroform to 
any extent, when this was extended over a further day, PS partially transitioned but so did the 
PIC. (data not shown)  
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Figure 63: Absorbance spectra of PS at various concentrations of OG. 
 
Absorbance spectrums over 250nm to 750nm of PS dissolved in aqueous solution supplemented 
with varying concentrations of n-Octyl-β-D-Glucopyranoside. PS is at the same final 
concentration. Spectrums of absorbance read over a blank of the relevant solvent and 
normalised to absorption at 900nm.  
 
Figure 64: PS transition through a semi permeable membrane. 
 
Free PPa AE or PS1 AE were made up as mock solutions, i.e. up to a similar concentration with 
co-solvent as would be found in a conjugation reaction, and then diluted 1:3 into buffer with or 
without 2% OG. Absorbance spectra was taken before and after the mixtures were passed 
through a 5000 MWCO polyethersulfone membrane, remaining solutions were then made up to 
the original volume and re analysed against the flow through.  
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Figure 65 : Dialysis of free PS in a number of different supplemented solvent systems. 
 
 
 
Small scale dialysis experiment with a number of different 500ul PS AE solutions (either PPa AE 
or PS1 AE) were dialysed into 30ml of the same solution minus the PS through a 8000 MWCO 
Cellulose Dialysis Tubing. All solvents PBS, Tris pH8, Tris pH 9, Carb pH 10 and Glycine pH 2, 
were tested in combinations with all solvent supplements 0.6% OG (below CMC) 1% OG (above 
CMC) and 20% DMSO alongside un-supplemented solvent. Dialysis was carried out over 4 days 
in the dark at RT. Samples from inside and outside the dialysis tubing were recovered, all 
insoluble material was removed and discarded before UV spectrums were ran of the samples. 
Only data from the PBS system is shown, similar data was obtained for all other solvent systems. 
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5.2.9.3 Ion exchange columns to aid purification of PICs. 
 
The next step was to use a column based system to specifically retain the antibody while 
washing with supplemented solvents to remove free PS, before buffer exchange and release of 
the now purified antibody. Centrifugal Ion Exchange Spin Columns coated with a quaternary 
ammonium (R-CH2-N
+-(CH3)3Cl
-) strong basic anion exchanger, are designed to reversibly bind 
to negatively charged molecules, i.e. molecules at a pH above their pI value, and elute at 
increased salt concentrations or by lowering the pH below the PI. The pI of C6.5-k was predicted 
at 6.52, although this could have changed upon PS conjugation. 
 
The ion exchange columns were shown to bind and release un-conjugated C6.5-k as 
predicted. However when PPa and PS1 PICs were tested samples became stuck on the column. 
Columns were washed with increasing amounts of OG in 0.02M Tris pH 8.5. Initial washes of 
0.6% were increased to 0.9% then 1% over 13 washes, during these washes free PS was 
observed in the wash fractions by both spectral analysis and SDS PAGE. Elutions steps were 
with 1M NaCl + 0.65% OG in 0.02M Tris. Small amount of un-conjugated C6.5-k were eluted 
but none showed any fluorescence under UV light on SDS PAGE. Despite various harsh elution 
techniques; i.e. decreasing the pH from 7 to 5 over the elution period, using 5M NaCl, or 0.2M 
Glycine pH 2 or 2% OG (in 0.02MTrispH8.5) still no release of the PIC was observed. Upon 
dissection of the spin column it was clear the conjugate was stuck in the upper few layers of the 
column system, this is shown in Figure 66. UV spectra and SDS PAGE separation of all the 
fractions from this attempted purification are shown in Figure 67.  
 
The same idea was applied with further conjugates but with Ion exchange columns based on 
a chromatography system made of high flow agarose with a dextran surface extender containing 
anion N+(CH3)3 the idea being that for these if the conjugate didn’t bind they would remain in 
the bulk flow and not be trapped. However, the same trapping in the top layers of the column 
was observed, see Figure 66, extreme denaturing washes in a range of solvents were not able to 
remove it. 
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Figure 66 : Images of PICs stuck within ion exchange chromatography columns. 
 
Centrifugal Ion Exchange Spin Columns coated with a quaternary ammonium (R-CH2-N
+-
(CH3)3Cl
-) strong basic anion exchanger: layers separated from the column show PIC stuck in 
the top few layers. 
 
 
Chromatography system made of High flow agarose with a dextran surface extender containing 
anion N+(CH3)3 : PIC stuck visibly in the top of the column. 
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Figure 67 : Ion exchange chromatography for PICs 
Insoluble material was removed from PPa PIC and PS1 PIC and the remaining solution dialysed into 0.02M Tris pH 8.5 before addition to 
the Ion Exchange Spin column. NB: the amount of un-conjugated C6.5-k ran as a control is much lower than the amount contained within 
the conjugates. Samples were added to the column and washed with increasing amounts of OG in 0.02M Tris pH 8.5. Initial washes of 0.6% 
were increased to 0.9% then 1% over 13 washes; initial elutions were with 1M NaCl and 0.65% OG in 0.02M Tris solutions decreasing the 
pH from 7 to 5 over the elution period. UV spectra and SDS PAGE separation of samples of the fractions was monitored. (C6.5-k shortened 
to C6 in figure). 
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5.2.10 Quantification of the extent of PS conjugation  
 
Despite the problems with purification shown above, work was carried out toward 
development of a method to ensure reliable analysis of the PIC. The extinction coefficients can 
change when PS is activated, this was shown in Figure 57, and the PS that has conjugated will 
not either of these two forms, instead it will have formed an amide bond in position of the NHS 
ester or carboxylic acid group on the propionic acid side chain. This position is far from the 
central ring and so changes to it are unlikely to alter the absorption spectra directly but via its 
effect on PS aggregation and/or solubility.  
 
5.2.10.1 Spectral methods to calculate conjugation ratios 
 
Extinction coefficients of the four PS in water were determined and are shown in Figure 57.  
Extinction coefficients were also calculated for the PS in 8M Urea and in 2% OG in Carbonate 
buffer pH10, these solvents were used to dissolve PIC in an attempt to circumvent possible 
protein-PS interactions interfering with PS spectra like for Cy5.5 See 5.2.3.2. The extinction 
coefficients for PS in these buffers are shown in Figure 68 alongside a graph that plots the 
predicted relationship of C6.5-k and absorbance at 280nm using the extinction coefficient 
predicted by ProtParam (ε=65235) (See 2.1.5.3), and actual readings taken diluting C6.5-k into 
carbonate pH10, carbonate pH10 + 2% OG and 8M Urea. For C6.5-k all diluted curves matched 
that of the predicted value, and so it was used for all subsequent calculations.  
 
An additional complication is the inability to remove free PS from the PIC mixture, the 
spectra produced will therefore be a mixture of PS acid, PS ester (in the case of PPa) and 
conjugated PS forms. For all the following work on spectral and gel quantification Figure 69 
shows the SDS Page analysis of the PIC that were used. Conjugation reactions carried out with 
C6.5-k and PPa AE or PS1 AE at a 16:1 PS to C6.5-k molar ratio along the conditions detailed in 
2.1.6.5. PIC were subjected to centrifugal force to separate any insoluble PIC/PS then dialysed 
extensively into PBS.  
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Figure 68: Extinction coefficients of PS and C6.5-k in 8M urea and in 2% OG. 
 
 
Extinction coefficients of PS in 8M Urea and in 2% OG in Carbonate buffer pH10, alongside a 
graph that plots the predicted relationship of C6.5-k and absorbance at 280nm using the 
extinction coefficient predicted by ProtParam (ε=65235) See 2.1.5.3, and actual readings taken 
diluting C6.5-k into carbonate pH10, carbonate pH10 + 2% OG and 8M Urea. . (C6.5-k 
shortened to C6 in figure). 
 
Figure 69 : Conjugation of PPa and PS1 with C6.5-k for quantification experiments 
 
Conjugation reactions carried out with C6.5-k and PPa AE or PS1 AE, experiment was carried 
out at 16:1 PS to C6.5-k molar ratio with conditions used in 2.1.6.5. insoluble material was 
removed and is shown alongside as ‘pellet’, dialysed into PBS and subsequently separated via 
SDS page gel. Final PIC samples are shown alongside an equivalent amount of un-conjugated 
C6.5-k. The Gel was imaged under UV light before staining with coomassie. . (C6.5-k shortened 
to C6 in figure).  
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The absorbance spectra of the final PPa PIC and PS1 PIC samples were analysed a fter dilution in 
either water, 8M Urea or 2% OG in carbonate buffer. Spectra are shown in Figure 70 and Figure 
71 alongside tables showing the actual vs. predicted Q band 1 peak for free PS in the same 
solution. NB; around twice as much PIC was used for the OG vs. water dilutions (1 in 20) in 
Figure 71 compared to the Urea vs. water dilutions (1 in 40) in Figure 70, and OG solutions have 
some absorbance at 280nm so it was important to produce accurate blanks including the 5µl or 
10µl of PBS that would be added alongside PIC. 
 
When Comparing PIC dissolved in water or 8M Urea; PIC spectra doesn’t change and PS 
peaks still match the peak expected for free PS. This could mean that there is no change of PS 
spectra upon conjugation, that any changes that do occur urea can’t reverse, or that the free PS is 
at too high a concentration compared to bound that any effects are masked. When Comparing 
PIC dissolved in water or 2%OG; the PIC spectra changes significantly when dissolved in 2% 
OG and peaks match what would be expected for free PS in those solutions. However, for both 
systems when absorbance values were taken and respective concentrations of PS and C6.5-k 
calculated via extinction coefficients the following was observed. 
 
 For PPa Conjugates; even though PS is in both an acid and AE form (see 5.2.9), 
acid PS coefficients had to be used for water and urea as AE coefficients couldn’t be 
calculated due to extensive precipitation. This caused a large underestimation of PS in all 
urea and water calculations. For example the results in the 1 in 20 dilution into water 
predicted the total PS (pellet + supernatant) was 10µM as it is known none or very little 
PS has been removed from the sample since conjugation (completely in-effective 
purification) the total PS split between pellet and conjugate should be around 72µM. This 
was improved with dissolution in 2%OG and total PS was calculated at a more believable 
60μM (predicted around 72μM). However; for the OG dilutions PPa AE coefficients 
could also now be used as dissolution produced no precipitate, but use of this extinction 
coefficient calculated impossible values for total PPa at 119 μM. The mixture of AE and 
Acid would need to be resolved or quantified for future accurate quantification. 
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 For PS1 conjugates; acid coefficients could be used with confidence (see 5.2.9), but when 
the calculations were carried out predictions in all three solutions, (water, 8M Urea and 
2%OG), all predicted the contribution to the absorbance at 280nm from C6.5-k to be 
unusually low. For example for the 1:40 dilutions into water or urea the absorbance at 
280nm for protein was calculated at less than 0.06 units, almost undetectable. This 
seemed unlikely because if no C6.5-k was lost the sample should contain around 2.5µM 
C6.5-k, which would produce absorbance at 280nm of 0.16 units. Perhaps the conjugated 
PS has quenched not its own absorbance but that of C6.5-k. Because of this PS:C6.5-k 
ratios predicted by these calculations were 43:1 for water and 74:1 for urea - impossible 
values as only 16:1 was added. Even when C6.5-k concentration was increased to a 1 in 
20 dilutions they again predicted C6.5-k to be unusually low with impossibly high ratios 
of PS 30:1 (Water) and 71:1 (2% OG).  
 
Despite seeing very little C6.5-k is lost on coomassie and knowing PS can’t escape during 
the dialysis process having manipulated the samples above significantly post conjugation the 
levels of PS or C6.5-k that one would predict to be contained within the samples couldn’t be 
guaranteed. For this reason a sample was taken directly from the conjugation mixture and 
analysed in the same way; this sample had undergone no manipulation since the conjugation was 
set up so the exact concentration of PS and C6.5-k added was known. If the spectral method 
showed agreement with this ‘known’ sample then the spectral method for quantification of PIC 
could be deemed accurate. Known amounts of C6.5-k and PS in these solutions were 3.3µM 
C6.5-k and 53.3µM PS. When absorbance values were taken and respective concentrations of PS 
and C6.5-k calculated via extinction coefficients the sampled diluted in 2% OG coefficients 
again underestimated the amount of C6.5-k, at 2µM or 1.3µM for PPa and PS1 respectively, 
predicting PS:C6.5-k  ratios of 22:1 and 34:1, again impossible as the mixture only contains 
16:1.  
 
None of the spectral analyses presented above are reliable and there is still a lot of 
contaminating un-conjugated PS effecting readings and possibly masking any shifts of PS upon 
conjugation. Purification of the conjugates should be addressed before this is investigated any 
further.   
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Figure 70 : Absorbance spectra of PPa PIC and PS1 PIC samples in water or 8M urea. 
 
 
 
The absorbance spectra of the final PPa PIC and PS1 PIC samples were analysed after dilution 
in either water or 8M Urea, alongside a table showing the predicted Q band 1 peak for free PS 
in the same solution and the actual peak nm at Q band I of the PIC. 
 
Figure 71 : Absorbance spectra of PPa PIC and PS1 PIC samples in water or 2% OG 
 
 
 
The absorbance spectra of 10ul the final PPa PIC and PS1 PIC samples were analysed after 
dilution in either 190ul water or 2% OG in Carbonate buffer pH10.6, alongside a table showing 
the predicted Q band 1 peak for free PS in the same solution and the actual peak nm at Q band I 
of the PIC.  
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5.2.10.2 Quantification of PS by UV imaging of SDS PAGE gels.  
 
Although PIC and free PS cannot yet be separated in their native form, separation is seen in a 
denatured form on the SDS Page gels. The images of these taken under UV light show us the 
relative distribution of PS between the protein-conjugated and free forms of PS. To further 
investigate if this was quantifiable at the same time as conjugate gels were ran gels with a 
dilution series of free PS AE was also ran, they were then imaged at the same time.  The PIC gel 
as presented in Figure 69 is shown again in Figure 72 but shown in red is any camera saturation 
in terms of its pixels. Exposure times was adjusted until none of the bands were saturated on 
either the gel containing PIC or the gels containing free PS. These images are shown in the larger 
image in Figure 72 and were taken under the same camera settings.  
 
Gel band intensity was quantified using Image J software, see 2.1.6.6. Figure 73 shows the 
PS ‘standard curve’ gels and a graph of PS concentration over band intensity. In this graph PPa 
and PS1 show similar fluorescent efficiency in the gel environment but even though the image 
pixels are not saturated only band intensities below around 8000 show any linearity. Figure 74 
presents the gel containing the PICs, and from the calculated band intensity values the amount of 
PS conjugated compared to the amount free at the dye front could be predicted. Values were 
normalised for the increased intensity from dye front alone and any endogenous C6.5-k 
fluorescence. The PS1 PIC shows twice as much PS1 is free than is conjugated. For the PPa 
supernatant there is 25 times more free PPa than is conjugated. For the PPa PIC when you 
calculate a ratio of the distribution of PS between conjugated, free and pelleted, free PPa in pellet 
is (36), free PPa in supernatant is (25) and PPa in conjugate is (1).  
 
If it is assumed no PS has been lost and PS at the dye front is not saturated (as suggested may 
be possible by the free PS gels), the amount of conjugated PS out of the total PS added to 
conjugation mixture is 1 part out of 3 for PS1 and 1 part out of 62 for PPa. If it is assumed no 
C6.5-k is lost from these conjugates this would provide PS:C6 molar ratios of 0.3:1 for PPa and 
5:1 for PS1, but too many assumption are made to take these values reliably; for example 
conjugated PS is assumed to have similar fluorescent properties to free PS in a gel environment, 
and it is unknown if any free PS could have diffused out of the gel over time.  
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Figure 72 : PIC gel re-imaged for no saturation alongside free PS AE standard curves. 
 
The PIC gel as presented in Figure 69 is shown again but in red is any camera saturation in 
terms of its pixels: 
.  
 
Gels were ran with a dilution series of free PS AE and were imaged at the same time as the gel 
containing the PICs. Exposure times were adjusted until none of the bands were saturated on 
either the gel containing PIC or the gels containing free PS and all images recorded under the 
same camera settings: 
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Figure 73 : Quantification of band intensity of free PS AE standard curve gels  
 
 
 
A graphical version of each gel is shown below actual image of the gel with the X axis of 
each well representing the distance travelled down the gel, and the Y axis for the fluorescent 
intensity of that distance down the well. The areas of these curves shown below correspond to 
the total intensity of each band. These figures are plotted against PS concentration in the graph 
below. 
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Figure 74 : Quantification of band intensity of PICs gel. 
A graphical version of the PIC gel : 
 
 
From the band intensity values the amount of PS conjugated compared to the amount free at the 
dye front has been calculated and in shown in the graph below, values at the dye front have been 
normalized for the increased intensity from dye front alone (seen above as number 7 in the C6.5-
k only well) and the conjugate band normalised against the endogenous C6.5-k fluorescence 
(seen as number 6 in the C6.5-k only well) 
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5.2.10.3 Evidence for the quenching of endogenous protein absorbance by PS. 
 
A continual issue encountered throughout this chapter has been the possibility that PS can 
quench the endogenous absorbance of protein at 280nm, to investigate this possibility BSA was 
incubated at different concentrations in water with a constant concentration of PS over molar 
ratios relevant to conjugation efficiencies. The spectra are shown in Figure 75 alongside the 
spectra produced by the 20µM PS alone. The Q band 1 of all PS is unaffected by an increase in 
concentration of BSA. However results show inclusion of PS in its AE form do affect the 
absorbance at 280nm possibly due to conjugation reactions between the active ester and the 
protein. The change in A280 (minus the contribution of the relevant 20µM PS) is shown plotted 
over protein concentration and compared to a protein only control (shown in red), this graph 
shows significant deviations from the normal relationship with all PS, even the acid forms.  
 
5.2.10.4 Interference of PS with the Bradford and BCA assays. 
 
As with Cy5.5 an alternative way to measure protein could be via BCA or Bradford assay, 
(see 5.2.3.2)Figure 52. The interference of PS with these assays is presented in Figure 76. It is 
shown, as with Cy5.5, the BCA assay is unusable due to absorption spectral overlap whereas the 
Bradford assay is less affected but again ineffective coomassie binding (seen in gel formats) has 
been shown for highly conjugated PIC.  
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Figure 75 : Evidence for the quenching of endogenous protein absorbance by PS. 
 
 
BSA was incubated at different concentrations in water with a constant concentration of PS over 
molar ratios relevant to conjugation efficiencies. The absorbance spectra of each mixture was 
read alongside the spectra produced by the 20µM PS alone -shown by a black dotted line.  
 
 
Data above plotted as the absorbance at 280nm (minus the contribution of the relevant 20µM 
PS) over BSA concentration. In red is the same dilutions of BSA with no PS present. 
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Figure 76 : Interference of PS with the Bradford and BCA assays. 
 
 
 
PPa acid or PS1 acid diluted into either BSA in H2O or H2O alone. PS was at 10 times molar 
excess over the protein. BCA or Bradford assay were used on these solutions as normal and 
absorbance spectra were read alongside solutions with no PS.  
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5.2.11 Evaluating conjugate binding on native antigen. 
 
Despite the conjugate not being pure, it can be used to look at native HER 2 binding as any 
free PS not attached to the bound antibody should be washed away before analysis. As some free 
PS could be taken up into the cell non-specifically, an in-direct method against an antibody tag 
and not endogenous PS fluorescence was used to study binding. For these experiments new 
conjugations were set up at PS:C6.5-k ratios of 16:1, 8:1 and 4:1, after reaction the mixtures 
were dialysed into PBS then subjected to centrifugal force to remove any insoluble material in a 
pellet. The SDS Page gels of the PIC are shown in Figure 77. 
 
Figure 78 shows the results from the native antigen binding experiment set up as in 2.1.5.5. 
All the same samples were also incubated with U-87 cells that do not express any antigen and 
were all negative for any shifts (data not shown). All conjugates were incubated at levels 
predicted to be 60nM if no protein was lost in the conjugation and dialysis procedure. Each 
conjugate was separately investigated with either a secondary antibody against the His or the 
Myc tag on C6.5-k. Samples assayed against the C6.5-k His tag shows all three PPa PIC bind as 
well as un-conjugated C6.5-k but PS1 PIC show a decreased binding efficiency with increased 
conjugation efficiency, with the 16:1 PSI-PIC showing a considerable loss. The same samples 
assayed against the C6.5-k Myc tag show a similar pattern for PPa-PIC but a different pattern for 
the PS1-PIC; here it is only the 16:1 PS1-PIC conjugate that shows a loss in binding and the 
extent of the loss is greatly reduced. There could be a number of reasons for a loss in PIC 
binding; PS conjugation may be interfering with tag recognition and/or antigen recognition, this 
could be either via a steric interaction or PS quenching when brought into close contact with the 
FITC on the tertiary antibody. The change in binding patterns between the different tags does 
suggest a loss of tag rather than antigen recognition. The Myc tag contains a Lysine residue and 
the Histidines that make up the His tag are both possible PS conjugation sites. Native tag 
availability could be tested by retention on anti Myc or anti HIS columns similar to those used 
for purification. A purified PIC would allow use of the PS endogenous fluorescence to visualise 
binding more directly.   
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Figure 77 : PPa/C6.5-k and PS1/C6.5-k PICs used for native anitgen binding experiment. 
 
  
 
Two sets of conjugation reactions carried under conditions mentioned in 2.1.6.5 with C6.5-k and 
either PS1 AE or PPa AE. For each set 3 conjugations were carried out in parallel with PS at 
16:1, 8:1 and 4:1 over C6.5-k. SDS PAGE gels are presented showing separation of PIC 
samples alongside the predicted equivalent level of un-conjugated protein. The gels are shown 
un-stained and imaged under UV light and subsequently stained with coomassie. . (C6.5-k 
shortened to C6 in figure). 
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Figure 78 : Native antigen binding experiment of PPa / C6.5-k and PS1 / C6.5-k PICs. 
 
 
All PIC from Figure 77 were incubated at levels predicted to be 60nM if no protein was lost in 
the conjugation and dialysis procedure, and followed by secondary mouse anti His and tertiary 
FITC anti mouse as described in 2.1.5.5. . (C6.5-k shortened to C6 in figure). 
 
 
 
All PIC from Figure 77 were incubated at levels predicted to be 60nM if no protein was lost in 
the conjugation and dialysis procedure, and followed by secondary mouse anti Myc and tertiary 
FITC anti mouse as described in 2.1.5.5. . (C6.5-k shortened to C6 in figure).  
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5.3 Discussion 
 
This chapter presented work on the detailed analysis and optimisation of the conjugation of 
photosensitisers to the antibody fragment C6.5-k. The chosen conjugation strategy makes use of 
the numerous endogenous reactive ε-amines exposed on the antibodies surface, for this reason in 
silico modelling was carried out to get an idea of the 3D arrangement of these reactive groups. 
From this model, the lysines residues were seen to be well spaced around the molecule, this 
should help the final photo- immunoconjugates (PICs) avoid PS quenching upon high loading. It 
was noted at this point however that one of the lysine residues was to be found within the centre 
of the CDR region – a region important for antigen recognition. This 3D model was also 
analysed within the PROPKA server which predicts the pKa and solvent accessibility of amino 
acids of interest, and also therefore their reactivity. PROPKA predicted that 9 of the 12 lysines 
were almost entirely solvent accessible and 3 were ~30% buried in the proteins core, including 
the lysine in the CDR, hopefully discouraging its conjugation. The prediction that the pKa. of the 
lysines was a pH unit higher than free lysine also had implications on the optimisation of the 
conjugation procedure and the pH used. (NB: The model did not include linker or tags,  therefore 
it didn’t consider the lysine found inside the Myc tag which brings the total lysines in the 
sequence to 13). 
 
To help develop and understand the conjugation reaction the extent to which a n optimal 
highly water soluble dye could be conjugated to C6.5-k was investigated. Conjugates were 
produced and successfully purified through a semi-permeable membrane. Conjugation ratios 
were obtained of up to 10 dye molecules per C6.5-k when quantified in a modified solvent 
system (8M Urea) that was able to reduce the dye spectra shifts induced by conjugation. C6.5-
k/Cy5.5 conjugations of final efficiencies 4:1, 2:1 and 1:1 (ratio of PS to Ab), were shown to all 
retain their ability to bind native antigen expressed on cells, and intracellular conjugate showed a 
widely distributed punctuate pattern that corresponds to the endosomal pattern seen with other 
anti-HER2 antibodies or similar PICs (Carcenac et al., 2001; Savellano and Hasan, 2005). In 
addition, after media containing the PIC was removed from the cells there was a prolonged high 
level retention of the PIC many hours after removal of solution. A hopeful sign toward 
successful PIC tumour retention in vivo.  
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In cultured cells expressing low or moderate levels of HER2, the  internalisation half- life (t½) 
(time it takes to internalise half of the molecules) is reported to be in the range of 6–10 hrs, 
whereas in cells highly over-expressing HER2 the t½ could be 24 hrs or longer (Sorkin and Goh, 
2009). As cell surface expression levels of HER2 have been shown not to be affected by binding, 
uptake levels of the antibody after antibody binding to HER2 are likely to be similar to that of 
the endogenous HER2 internalisation. This has already been seen with Trastuzumab and C6.5-
k(IgG) where upon binding of HER2 uptake rate was similar to that of naked HER2 (Austin et 
al., 2004; Rudnick et al., 2011). This matches the uptake rates seen with our C6.5-k/Cy5.5 PIC as 
well as other anti-HER2 or similar PIC data in the literature (Kuimova et al., 2007; Savellano 
and Hasan, 2003). 
 
Conversion of the new water-soluble PS to the active form could only be carried out with 
PS1 as the synthesis of PS4 active ester (AE) was more complicated and could not be completed 
in the time frame of this work. When the active ester forms of PPa and PS1 were compared to 
their acid forms differences were seen; PPa AE was a lot less soluble than its acid form and 
showed visible precipitate in all aqueous solution. PS1 AE dissolved well and was comparable to 
the acid form, if anything it showed shifted but more preferable spectra in physiological solution 
than its acid form. The difference between PPa AE and PS1 AE is now even greater in terms of 
aqueous solubility. Under all conjugation conditions investigated,  C6.5-k was more highly 
conjugated when reacted with PS1 than with PPa, validating the initial idea behind the 
development of more water soluble PS for conjugation. This was shown via SDS PAGE gel 
analysis, both free PPa and PS1 were shown to fluoresce to a similar extent in the gel 
environment but the band corresponding to PIC fluoresced much more brightly for PS1-PIC than 
for PPa-PIC, in addition it migrated more slowly in the gel but this could be over-enhanced by 
the PEG chains ability to attract water molecules. However without further analysis, for example 
mass spec of the purified product, it is still possible that both PIC are conjugated to the same 
extent but there is significantly more quenching of PPa than fo r PS1 once conjugated, whether 
between itself or by interaction with the proteins surface, the larger PEG chains on PS1 possibly 
keeping the PS away from the proteins surface. It has already been seen that for C6.5-k/Cy5.5 
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PIC fluorescence intensity as seen on a gel was more effected by quenching than the PICs 
absorbance profile.  
 
There is a lot of work presented in this chapter on the attempted removal of free PS from PIC 
solution, no reliable method was found during the short period of study presented here. It was 
shown that in the case of semi permeable membrane purification it is not just non-covalent 
interactions between PS and protein but the inherent inability of the PS on its own to cross a semi 
permeable membrane that causes a purification problem. When purification was changed to a 
ion-exchange  based system a lot of the free PS was successfully removed but the PIC became 
trapped in the matrix of the column. In future size or affinity based chromatography along with a 
supplemented solvent system with a different matrix could be the solution. 
 
Lack of purification of the PICs hampered any further work that could be done on 
development of a quantification method as results from spectral analysis or in-gel fluorescence 
quantification were shown to be unreliable. Purification of the conjugate would allow more 
reliable analysis and even the possibility for mass spectrometry experiments which would 
resolutely show the conjugation efficiency without any bias of spectral quenching. Many of the 
experiments performed hinted that bound PS could be quenching the endogenous protein 
absorption, compromising any spectral quantification of the protein concentration. Two other 
options for protein quantification were studied; the BCA assay and the Bradford assay. The BCA 
unfortunately was affected by PS spectral interference. The spectral interference of PS with the 
Bradford assay was lower but it is a low sensitivity assay and SDS Page gels have already shown 
there may be a problem with high level PS conjugation inhibiting binding sites for coomassie. 
For quantification of PIC most published articles, see 5.1.4, use a similar spectral method to the 
one described herein but other published options include use radio-labelling of the antibody, 
(Carcenac et al., 1999; Vrouenraets et al., 2002) or the use of the Lowry method of protein 
detection (cupric ion reaction with peptide bond) (Goff et al., 1991).  
 
Many published PIC papers show spectral changes associated with the PS upon PIC 
formation; Savellano and Hassan showed a red shift of PIC over free PS after direct conjugation 
to the antibody  (Savellano and Hasan, 2003), Goff and colleagues showed blue spectral shifts of 
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5nm from the PIC compared to free PS (Goff et al., 1991) and Del Governatore and colleagues 
showed that once conjugated PS Soret band is reduced and Q band is red shifted by ~12nm (Del 
Governatore et al., 2000b). Interestingly these last two papers used the same PS and the same 
antibody but conjugation occurred via a different linker. The spectral changes can not only affect 
quantification but PIC potency, many papers show a direct loss in PS photophysics when 
conjugated, see 5.1.4, including Savellano and Hasan (Savellano and Hasan, 2003) who looked 
at fluorescence decay signal as an indication of a PS’ ability to intersystem cross, they showed a 
reduction in maximal intensity as well as a longer lived decay signal in PIC vs. free PS, which 
became more exaggerated as PS loading increased. 
 
Despite being impure, some PPa PICs and PS1 PICs were produced of varying but unknown 
conjugation ratios and were tested for native antigen binding. The PPa conjugates all exhibited 
retention of binding compared to the un-conjugated Ab, but PS1 conjugates showed a loss of 
antigen binding as conjugation ratio increased. There were some questions remaining over this 
experiment and whether it was actually loss of tag recognition. The purification and accurate 
determination of C6.5-k content in the sample is required before any reliable conclusions can be 
drawn. An alternative binding experiment independent on tag recognition or fluorescent 
detection, for example by surface plasmon resonance (Biacore) would be preferable but that also 
requires accurate protein concentration determination. 
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5.3.1 Chapter conclusions 
 
Key proposition put forward from work; 
Activated PS1 (PS1 in its NHS ester form) shows further increased aqueous solubility 
compared to the activated form of PPa, and as hoped, PS1 greatly improve conjugation 
efficiency to the antibody fragment C6.5-k. There remain problems with purification of the un-
conjugated PS from the mixture and hence attempts at quantification of the conjugation 
efficiency were hampered. Using a water soluble activated mode l dye it was to be possible to 
conjugate around 10 molecules of dye onto each C6.5-k molecule with retained antigen binding, 
but this needs to be confirmed by non-spectroscopic methods. Any further increases in solubility 
of the PS may provide these high conjugation ratios seen with Cy5.5 alongside more effective 
purification, for this reason the successful activation of PS4 for use in this work would be of 
interest. 
 
Main question raised from this work;  
If the cellular uptake of PS1 and PS4 were re-established on a similar level to PPa, for 
example by conjugation to an antibody fragment and subsequent manipulation of different 
uptake pathways (antibody internalisation), would this make them significantly more toxic than 
PPa? Other questions will arise over whether the PS or the antibody would provide the dominant 
determinants in uptake and localisation. Once internalised would conjugation be retained or will 
PS and antibody return to their independent pathways? Successful purification of the PICs and 
application into many of the assays developed in previous chapters will help answer these 
questions.  
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6 General Discussion.  
6.1 Original aims and objectives 
 
Targeted PDT is an emerging treatment area that promises to overcome the limitations of 
current, non-targeted PDT. Most photosensitisers (PS) for PDT are poorly soluble and could be 
improved if made more compatible with an aqueous protein environment. The work presented in 
this thesis showed that PPa-based photosensitisers could be chemically modified to increase their 
solubility and this in turn could facilitate bio-conjugation with a view to their use as antibody 
targeted drugs. Increasing PS solubility can also alter PS potency and intracellular localisation; 
this must therefore be taken into account when assessing their utility as conjugates. The 
objectives of this work were to establish systems to characterise the free PS (potency, 
localisation, etc.) and measure these properties in the context of targeting to learn what the 
important attributes are. These objectives were not fully met during the work presented because 
pure photo- immunoconjugates were never obtained. Both PPa and PS1 derived PICs contained a 
high amount of non-covalently bound material which meant any comparison with the free PS 
was compromised. However, much was learnt about how manipulating the chemical properties 
of the free PS affects it solubility in physiological solutions and therefore its potency as a free 
PDT agent. 
 
6.2 Photosensitiser solubility and potency 
 
PPa is an excellent PS and serves as a good building block for improved derivatives. It is 
often stated as being a very effective photosensitiser, and although not an absolute indication of 
efficiency, the singlet oxygen quantum yield for PPa was measured to be 0.5 (Stamati et al., 
2010). Compared to other photosensitisers this is at the higher end of the range, the range  being 
stated as ∼0.3 to 0.5 (Plaetzer et al., 2009) or  0.009 – 0.83 (Bonnett, 2000). By no means does 
this exclusively predict PS potency, efficient Type I reactions can also occur with PS, for 
example Ding and colleagues (Ding et al., 2011) presented some work in which the micelle 
carrying the PS could manipulate the tendency for either Type I (radicals or electron transfer) or 
Type II (singlet oxygen) reactions to occur. They showed similar potencies in three cell lines 
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under air but increased potency for the type I preferable PS in cells under argon, they suggest 
such manipulation of the PS would make it more effective in a hypoxic tumour environment.  
 
The considerable influence of multiple systemic and pharmacokinetic factors, see 1.3, will 
always play a role in PS potency. For this reason direct comparison of potency of a PS is 
difficult, numerical physical measurements of a PS are the most often used but there is a lack of 
any single comparable model for photosensitiser clinical efficacy, especially as manipulation of 
clinical application factors such as laser dose, see 1.3, can also enhance or diminish potency 
dramatically. Berlanda and colleagues (Berlanda et al., 2010)  tried to compare a series of 
clinically relevant PS including Hypericin, Foscan, AIPcS4 and ALA  in the same in vitro PDT 
model in the same cell line (A431 cells). Multiple factors were investigated including cellular 
uptake, caspase activation and calculation of an IC50 both for dark cytotoxicity and cytotoxicity 
with laser activation. The results for the IC50 values range from 0.03µM to 393µM. The IC50 
values presented in this thesis (see 3.2.2.3) for PPa range from 1.97µM (at 0.33J/cm2) to 0.06µM 
(at 23.22J/cm2) with no observed dark toxicity at any light dose at PS up to 100µM. Compared to 
the values presented in Berlanda et al (Berlanda et al., 2010) dark toxicity is greatly improved for 
PPa over these PS and at higher laser doses PPa is nearly as potent as the best PS they studied 
especially considering the laser dose used by Berlanda et al was 1.5 J/cm2 and PS were incubated 
with the cells for 20 hours in serum free media. Despite this comparing the data presented in this 
thesis to that presented in (Berlanda et al., 2010) is flawed. As discussed for SKOV-3 in 3.1.1.2 
all cell lines are inherently biased. It may also be worth remembering that in this in vitro 
situation, one has removed some of the more complicated but highly influential effecting 
mechanisms, and it can be misleading to set certain variables at set levels. The question remains 
what parameters really would be important for when PDT is chosen for use in the clinic? What 
would a clinician need to know? One may have to resort back to more comparable ‘optimum 
physiochemical factors’ as an indication of the potential of a PS that can be brought out with 
clinical optimisation. These  ‘optimum physiochemical factors’  could then be presented 
alongside some thorough  pharmacokinetic dosimetry data for PS blood clearance and tissue 
distribution in humans. 
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The work presented in this thesis showed the novel PS1 and PS4 to be more water soluble 
than their parent compound (PPa), the molecules showed less spectral shifts in a range of 
physiological environments which suggests improved photo-physical characteristics for effective 
traditional PDT. However in an in vitro non-targeted PDT cancer cell model, initial data 
suggested these new more soluble PS became less potent. In 3.1.3 and 5.1.4 ways in which other 
researchers have approached the creation of more water soluble PS was discussed, both the 
addition of a positive charge (PS4) and PEG chains (PS1) are well supported methods to improve 
solubility, however the literature results on overall potency from more water soluble PS like 
these are variable. Unfortunately our new PS lost some potency, significant amounts in the case 
of PS4. However this may change in vivo and work studying blood clearance and tumour uptake 
in an in vivo mouse transplanted tumour model has been carried out by other members of this lab 
(unpublished data) and did show despite lower tumour uptake PS4 had improved specificity over 
PPa and PS1 and increased blood clearance times, PPa exhibited the highest tumour uptake but it 
was equally specific to PS1 which cleared from the system twice as fast. Free PS have not yet 
been tested against each other for their potency in this model. 
 
Despite showing increased solubility in aqueous solutions the new PS presented some 
fluorescent spectra that could suggest aggregation. Aggregation is normally associated with a 
loss in photophysical efficiency, and work investigating a polymer carrying a number of closely 
linked PPa molecules did show a decreases of the fluorescence, intersystem crossing, and singlet 
oxygen quantum yields (Helmreich et al., 2005), however other work carried out by Dairou and 
colleagues (Dairou et al., 2002) showed in-fact in aqueous solution the dimers formed by PPa, 
although exhibiting shifted and loses in intensity of their fluorescent spectra, maintained their 
singlet oxygen quantum yield and therefore are still effective photosensitisers. This work also 
has implications for the spacial arrangement of PS over a protein surface upon antibody 
conjugation.  
 
6.3 Photosensitiser uptake and cell kill mechanisms 
 
Investigation into the mechanism of cellular uptake and localisation of the modified PS 
showed that despite being as potent as PPa, PS1 intracellular concentrations were much lower 
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suggesting PS1 actually exhibits improved death per dose over PPa, this was hypothesised to be 
due to its enhanced intracellular photophysics. Despite showing significantly different uptake 
kinetics, PPa and PS1 at lethal doses seem to be able to initiate similar mechanisms of action, 
likely due to their similar intracellular localisations. The reduced potency of PS4 over PPa seems 
to be driven by both the substantially reduced cellular uptake, and an altered cellular localisation, 
although the potential for PS4 upon antibody conjugation still remains high.  
 
There is a lot of evidence to support increased water solubility reducing cellular uptake, see 
3.1.3, but one is reminded of the importance of other factors for potency, by Henderson and 
colleagues (Henderson et al., 1997), who showed that in vivo PS with decreased solubility would 
show increased absolute tumour uptake, however this potency would only increase alongside 
decreased solubility up to a point despite further increased tumour uptake. After a point the 
potency was limited by other more influential factors like internal localisation and photophysical 
efficiency. In relationship to the work presented herein the addition of a PEG or a cationic charge 
could manipulate internalised PS efficiency in a number of ways, for example cationic PS have 
been shown to more likely localise in the mitochondria (Dummin et al., 1997; Woodburn et al., 
1991), although in our case this seems to not be the case. PEG chains can speed up intracellular 
diffusion (Suh et al., 2007) or as Hamblin and colleagues (Hamblin et al., 2001) showed, when 
they PEGylated of a series of Chlorin e6 photosensitisers, the mechanism of PS can be changed 
from majority type II (singlet oxygen) to majority type I (radicals or electron transfer), when they 
tested these PS in vivo PEGylated PS were more potent than the non PEGylated controls. 
 
Cell death mechanisms activated upon illumination presented mixed results for the novel PS. 
From the limited work carried out, it suggested the multiple cell death mechanisms that were 
activated for PPa and PS1 were similar but the balance between these could be changing. In 
terms of clinical PDT the type of cell death required for effective therapy is not a lways clear. It is 
also very likely that throughout the tumour and its microenvironment cell death mechanisms will 
be different due to changes in local PS dose, light dose, and tumour environmental factors. 
Despite this however various rules are often stated for example Mikes and colleagues (Mikes et 
al., 2007) say that “Oxygen-conserving low fluence rate protocols favouring apoptosis and 
should be recommended when PDT is applied for the curative treatment of in situ neoplasia 
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or/and as a palliative de-obstructing treatment modality. In both cases, a rapid shrinking of the 
tumour mass is expected and apoptosis without accompanying inflammatory reaction and 
swelling should be favoured above complete tumour eradication. On the other hand, when the 
goal of PDT is to cure an infiltrative tumour that is possibly already micro-spreading beyond the 
margins of the illumination spot, necrosis with its accompanying inflammatory reaction may be 
recommended. However, the protocols employing high fluence rates should be finely tuned, since 
oxygen-depleting regimens may significantly limit treatment outcome.”  
 
There exist factors that can be brought up to dispute this idea but as a generalisation it may 
be worth bearing in mind. It is now understood that apoptosis can manipulate the immune system 
just as necrotic cells can be cleared away quietly via phagocytosis, phagocytosis itself is a 
complicated process that can also manipulate the immune system (Galluzzi et al., 2012; Krysko 
and Vandenabeele, 2010; van der Most et al., 2008; Zitvogel et al., 2010). So although the 
preference of apoptosis vs. necrosis isn’t always clear - recently the interest in the recruitment of 
immunogenic mediators to improve long term PDT efficiency, see 1.2.4, has revitalised the area. 
One unifying factor seen frequently with PDT is the idea of soluble attraction and danger signals 
(Damage-Associated Molecular Patterns, DAMPs) being released and/or secreted by both 
apoptotic cells and primary and secondary necrotic cells. There is also a body of work to back up 
theories that PDT process can induce photo-oxidative changes that provide new antigens for 
recognition and therefore make the cells more immunogenic (Galluzzi et al., 2012; Korbelik, 
2011). The requirement of an antigen for recognition in this process was shown to be important 
in mouse models transplanted with tumours with or without engineered expression of the foreign 
jellyfish GFP protein, a difference in cure rate was seen in that the tumours that GFP were much 
more effectively cured (A P Castano et al., 2006).  
 
6.4 Soluble PPa for bio-conjugation 
 
Activated PS1 (PS1 in its NHS ester form) showed further increased aqueous solubility 
compared to the activated form of PPa, and as designed, PS1 greatly improve conjugation 
efficiency to the antibody fragment (C6.5-k). There remain problems however with purification 
of the un-conjugated PS from the mixture and hence attempts at quantification of the conjugation 
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efficiency were hampered. Using a water soluble activated model dye it was shown to be 
possible to conjugate around 10 molecules of dye onto each C6.5-k molecule with retained 
antigen binding, but this should be confirmed by non-spectroscopic methods. It would be 
interesting to see, once pure, the ratios achieved with the PS1 conjugates which may now be 
providing these same high conjugation ratios due to PS1s enhanced solubility, however a yet 
further increase in solubility may be required for effective purification, for this reason the 
successful activation of PS4 for use in this work would be of interest.  
 
The problem of PIC purity is evident throughout the progression of PIC development. 
Different approaches to address this include attempts to pre conjugate the PS to a polymer which 
can then be treated to more harsh solvent conditions to facilitate purification before conjugation, 
or the adaptation of the conjugation method and the antibody itself to take the antibody to the 
limits of its solubility in organic solvents, see 5.1.4. In terms of purification both PEGylation and 
the introduction of positive charges have been used as tools to improve this. The PEG chains on 
PS1 are hypothesised to increase solubility as well as sterically hinder binding to any 
hydrophobic patches on the protein, in (Savellano and Hasan, 2003) PEG were indeed shown to 
help effective PIC production. Reports also cite cationic PS as providing less contamination with 
non-covalently bound PS (Sutton et al., 2002) and in recent PIC work presenting very successful 
and pure PIC; it was cationic PS that were used (Palumbo et al., 2011).  
 
Adaption of the purification techniques to manipulate the free PS and PIC into an 
environment where their differences, for example in size, could be used for purification purposes 
is still an alive and viable option. Although of course, as was the initial theory of this work, the 
re-design of PS themselves to make them even more water soluble is also a possible solution. 
When structures were analysed with computer software to predict lowest energy conformers 
(data not shown) , all showed one group projecting either above or below the ring.  Perhaps 
redesigning PS1 to include a top and bottom PEG extending above and below the plane of the 
molecule as suggested by Dr G. Yahioglu would be worth consideration. 
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6.5 Summary of work 
 
Introduction of chemical factors to increase the aqueous solubility of a photosensitiser can 
change both the cellular uptake and localisation and hence alter the modality and efficiency of 
cell death in cancer cells treated with PDT. Despite significant reductions in cellular uptake of 
more soluble photosensitisers a more effective retention of photophysical efficiency of the more 
soluble photosensitiser (PS1) could more than compensate for reduced uptake. However when 
final intracellular localisation was changed alongside the significant reduction in cellular uptake 
(PS4) possible retention of photophysics could no longer provide any potency of the 
administered PS. The introduction of increased water solubility to the photosensitiser was also 
able to improve conjugation to an antibody fragment. Once purified if antibody driven uptake of 
the PIC will help override the loss in cellular uptake seen with the free PS the potential for 
selective and highly effective PDT is a real possibility. 
 
6.6 Future work  
 
During this project the aims were to investigate the effect of increased solubility on 
photosensitiser efficiency with an emphasis on antibody conjugation for targeted-PDT. Previous 
work had already shown targeted PDT exhibits enhanced specificity and cell kill over 
conventional, non-targeted PDT. This project therefore had a focus on elucidating the molecular 
mechanisms behind this improvement, particularly in respect to the processes of intracellular 
trafficking and the mechanism of the cell death. Increased solubility of the free PS was shown to 
have significant effects on these properties and so once pure conjugates can be made, it will be of 
interest to test the PIC in the same experiments as the free to find out what further differences or 
similarities are seen upon antibody conjugation. It is likely if the cellular uptake of PS1 and PS4 
were re-established on a similar level to PPa this would make PS1 and PS4 significantly more 
toxic than PPa.  
 
The hypothesis that antibody conjugation can be used to control and override natural uptake 
and localisation patterns of any photosensitiser could be of particular interest for the greater 
acceptance of PDT in the clinic. Once an understanding of the respective contribution of PS and 
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antibody to the cellular localisation and cell death pathways initiated by a photo-
immunoconjugate has been improved, knowledge could be utilised for a more predictable and 
controllable PDT experience, i.e. a more intelligent modulation of PDT efficiency via the 
effective combination of antibody, targeted cell surface receptor, conjugation technique and 
synthetically optimised photosensitisers.  
 
The drug discovery field is currently thriving with interest in antibody drug conjugates in 
general. It was over a half a century ago that the first antibody drug conjugates were used and 
radio- labelled antibodies showed their exquisite potential for targeting specific tissues within the 
human body. However the delivery of successful antibody drug conjugates as clinically approved 
drugs has taken a long time and alongside advances in linker technology and increased drug 
potencies, only now in the last few years a successful class of biopharmaceuticals with an 
exciting and growing pipeline of candidates has been seen; there have been numerous reviews on 
this subject over the last few years three of which with specific emphasis on the history of the 
ADC field and it recent explosion are detailed here (Adair et al., 2012; Goldenberg and Sharkey, 
2012; Hughes, 2010). 
 
Personally an area of particular potential is the use of photosensitisers in contexts out of the 
restriction of the localised laser light, as discussed in 1.2.6, the use of ultrasound in Sonodynamic 
therapy (SDT). (Kuroki et al., 2007; Ma et al., 2009; Mitragotri, 2005; Yamaguchi et al., 2011). 
The development of quantum dots or other nanomaterials that act as energy transfer molecule so 
systems can use ionising radiation for example X-rays or gamma rays which can penetrate much 
deeper in to tissue in order to activate the photosensitiser. (Juzenas et al., 2008; Liu et al., 2008; 
Samia et al., 2006). Or PS conjugates that can convert the energy from radiotherapy (Chen and 
Zhang, 2006), or magnetic resonance imaging scans (Huang et al., 2011; Vaidya et al., 2008). 
After all porphyrin molecules are incredible machines for the conversion and delivery of packets 
of energy with possibly unlimited potential, as well as curing our cancer they could be found in 
our computers as molecular electronic components (Jurow et al., 2010) or provide our energy in 
solar panels  (Campbell et al., 2007). 
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